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Abstract
Assessing prognosis and prediction of treatment response in
early rheumatoid arthritis: systematic reviews
Rachel Archer,* Emma Hock, Jean Hamilton, John Stevens,
Munira Essat, Edith Poku, Mark Clowes, Abdullah Pandor
and Matt Stevenson
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author r.archer@sheffield.ac.uk
Background: Rheumatoid arthritis (RA) is a chronic, debilitating disease associated with reduced quality
of life and substantial costs. It is unclear which tests and assessment tools allow the best assessment
of prognosis in people with early RA and whether or not variables predict the response of patients to
different drug treatments.
Objective: To systematically review evidence on the use of selected tests and assessment tools in patients
with early RA (1) in the evaluation of a prognosis (review 1) and (2) as predictive markers of treatment
response (review 2).
Data sources: Electronic databases (e.g. MEDLINE, EMBASE, The Cochrane Library, Web of Science
Conference Proceedings; searched to September 2016), registers, key websites, hand-searching of
reference lists of included studies and key systematic reviews and contact with experts.
Study selection: Review 1 – primary studies on the development, external validation and impact of
clinical prediction models for selected outcomes in adult early RA patients. Review 2 – primary studies
on the interaction between selected baseline covariates and treatment (conventional and biological
disease-modifying antirheumatic drugs) on salient outcomes in adult early RA patients.
Results: Review 1 – 22 model development studies and one combined model development/external validation
study reporting 39 clinical prediction models were included. Five external validation studies evaluating eight
clinical prediction models for radiographic joint damage were also included. c-statistics from internal validation
ranged from 0.63 to 0.87 for radiographic progression (different definitions, six studies) and 0.78 to 0.82 for
the Health Assessment Questionnaire (HAQ). Predictive performance in external validations varied considerably.
Three models [(1) Active controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid
arthritis of Early onset (ASPIRE) C-reactive protein (ASPIRE CRP), (2) ASPIRE erythrocyte sedimentation rate
(ASPIRE ESR) and (3) Behandelings Strategie (BeSt)] were externally validated using the same outcome definition
in more than one population. Results of the random-effects meta-analysis suggested substantial uncertainty
in the expected predictive performance of models in a new sample of patients. Review 2 – 12 studies were
identified. Covariates examined included anti-citrullinated protein/peptide anti-body (ACPA) status, smoking
status, erosions, rheumatoid factor status, C-reactive protein level, erythrocyte sedimentation rate, swollen joint
count (SJC), body mass index and vascularity of synovium on power Doppler ultrasound (PDUS). Outcomes
examined included erosions/radiographic progression, disease activity, physical function and Disease Activity
Score-28 remission. There was statistical evidence to suggest that ACPA status, SJC and PDUS status at baseline
may be treatment effect modifiers, but not necessarily that they are prognostic of response for all treatments.
Most of the results were subject to considerable uncertainty and were not statistically significant.
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Limitations: The meta-analysis in review 1 was limited by the availability of only a small number of
external validation studies. Studies rarely investigated the interaction between predictors and treatment.
Suggested research priorities: Collaborative research (including the use of individual participant data)
is needed to further develop and externally validate the clinical prediction models. The clinical prediction
models should be validated with respect to individual treatments. Future assessments of treatment by
covariate interactions should follow good statistical practice.
Conclusions: Review 1 – uncertainty remains over the optimal prediction model(s) for use in clinical
practice. Review 2 – in general, there was insufficient evidence that the effect of treatment depended on
baseline characteristics.
Study registration: This study is registered as PROSPERO CRD42016042402.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Accuracy The degree to which a measurement or estimate agrees with the true value.
Apparent validation A form of internal validation using exactly the same population as that used for the
model development.
Area under the curve An alternative term used to describe the c-statistic. In a logistic regression analysis,
the c-statistic can be interpreted as the area under the receiver operating characteristic curve.
Calibration This describes the extent to which the expected outcomes (predicted by the model) and
observed outcomes agree.
Clinical prediction model A formal combination of multiple predictors, from which the probability of
occurrence of a specific clinical outcome can be estimated for individual patients. Commonly developed to
aid health-care providers in their decision-making.
Correlation A measure of the statistical relationship, whether or not causal, between two random variables.
Cross-validation A statistical technique commonly used for the internal validation of a clinical prediction
model, which aims to limit overfitting. As with data splitting, separate partitions of the data set are
used for deriving the model and evaluating the model performance. Cross-validation extends the simple
data-splitting approach by iterating the procedure over several partitions of the data set. The performance
results are averaged to provide an overall measure.
Data splitting A statistical technique commonly used for the internal validation of a clinical prediction
model, which aims to limit overfitting. Data are divided into a training data set (used to derive the model)
and a validation data set that is used to evaluate the model’s performance.
Discrimination Describes the ability of the clinical prediction model to distinguish between individuals
who do and do not experience the outcome of interest.
Effect modifier A covariate that alters the relative effect of treatments on outcomes, so that the
treatment is more or less effective in different subgroups formed by levels of the effect modifier. Effect
modifiers are not necessarily also prognostic variables. The effect modifier status is specific to a given scale:
the positive status of a covariate as an effect modifier on one scale does not necessarily imply, either
positively or negatively, an effect modifier status on another scale; however, a covariate that is not an
effect modifier on one scale is guaranteed to be an effect modifier on another.
External validation This is used to quantify the performance of a clinical prediction model in a
population that is external to that which was used for the model development.
Interaction An interaction arises between two or more variables when their joint impact on a dependent
variable is greater than the sum of their individual contributions.
Internal validation Used to quantify the performance of a clinical prediction model in the population
used to develop the model.
Logistic regression A statistical technique used to model the relationship between a binary outcome
variable and one or more covariates of interest.
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Main effect The effect of an independent variable on a dependent variable averaging across the levels of
any other independent variables.
Meta-analysis A statistical method by which the results of a number of studies are aggregated to provide
a combined summary statistic.
Negative predictive value For individuals who are not expected to experience the outcome of interest
(as predicted by the model), the proportion who do not experience the outcome.
Overfitting Occurs when a model is optimally designed to fit the development data set and performs less
favourably in more general situations.
Positive predictive value For individuals who are expected to experience the outcome of interest
(as predicted by the model), the proportion who experience the outcome.
Prognostic variable A covariate that affects (or is prognostic of) the outcome. We make the distinction
between prognostic variables and effect modifiers; effect modifiers are not necessarily also prognostic variables.
R2 A measurement of overall model performance that describes the proportion of explained variation.
Sensitivity For individuals who are known to experience the outcome of interest, the proportion that
were correctly predicted (using the clinical prediction model) to experience the outcome.
Shrinkage A statistical estimation procedure that preshrinks regression coefficients towards zero, so that
the clinical prediction model will not need to be recalibrated in a new data set. Also linked to the shrinkage
factor of a calibration plot, which will be less than one when a clinical prediction model is applied to a new
data set, if overfitting has occurred during the model development.
Specificity For individuals who are known not to experience the outcome of interest, this is the proportion
that was correctly predicted (using the clinical prediction model) not to experience the outcome.
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ABT abatacept
ACPA anticitrullinated protein/peptide
anti-body
ACR American College of Rheumatology
ADA adalimumab
ADL Activities of Daily Living
AhFibA anti-human citrullinated fibrinogen
anti-body
ANOVA analysis of variance
anti-CCP anticyclic citrullinated peptide
anti-MCV antimutated citrullinated vimentin
ASPIRE Active controlled Study of Patients
receiving Infliximab for the
treatment of Rheumatoid arthritis
of Early onset
ATTRACT anti-TNF trial in rheumatoid arthritis
with concomitant therapy
AUC area under the curve
bDMARD biologic disease-modifying
antirheumatic drug
BeSt Behandel Strategieen
BMI body mass index
cDMARD conventional disease-modifying
antirheumatic drug
CG79 Clinical Guidance number 79
CHARMS CHecklist for critical Appraisal and
data extraction for systematic Reviews
of prediction Modelling Studies
CI confidence interval
CRP C-reactive protein
CsA ciclosporin A
DARE Database of Abstracts of Reviews
of Effects
DAS Disease Activity Score
DAS28 Disease Activity Score-28
DMARD disease-modifying antirheumatic drug
ERO erosive
ESPOIR Étude et suivi des polyarthrites
indifférenciées récentes
ESR erythrocyte sedimentation rate
ETN etanercept
EULAR European League Against
Rheumatism
FE fixed effects
GSTM gold sodium thiomalate
HAQ Health Assessment Questionnaire
HAQ-DI Health Assessment Questionnaire –
disability index
HCQ hydroxychloroquine
HLA human leucocyte antigen
HTA Health Technology Assessment
IFX infliximab
IMPROVED Induction therapy with MTX and
Prednisone in Rheumatoid Or Very
Early arthritis Disease
IPD individual participant data
IQR interquartile range
LEF leflunomide
MBDA multibiomarker disease activity
MHAQ modified Health Assessment
Questionnaire
MMP matrix metalloproteinase
MTX methotrexate
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NPV negative predictive value
NSAID non-steroidal anti-inflammatory
drug
O : E observed to expected (ratio)
OR odds ratio
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PDUS power Doppler ultrasound
PPV positive predictive value
PR predicted risk
PRISMA Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses
PROBAST Prediction model study Risk Of Bias
Assessment Tool
PROGRESS PROGnosis RESearch Strategy
QUIPS Quality in Prognosis Studies
RA rheumatoid arthritis
RCT randomised controlled trial
RE random effects
RF rheumatoid factor
RRP rapid radiographic progression
ScHARR School of Health and Related
Research
SD standard deviation
SE shared epitope
SHS Sharp–van der Heijde score
SJC swollen joint count
SJC28 28 swollen joint count
SONORA Study Of New-Onset Rheumatoid
Arthritis
SSZ sulfasalazine
SWEFOT Swedish Farmacotherapy
TAR Technology Assessment Review
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TRIPOD Transparent Reporting of a
multivariable prediction model for
Individual Prognosis Or Diagnosis
TSS total Sharp score
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Plain English summary
Rheumatoid arthritis (RA) is a chronic disease that can cause disability and pain. Health professionalsneed to be able to judge at an early stage of disease which patients may experience more severe RA or
respond better to different treatments. This assessment aimed to (1) study tools that identify, at an early
stage of disease, the disease course and (2) determine whether or not there are any patient characteristics
that predict which patients are likely to respond best to particular treatments.
Twenty-three studies were found that tried to predict the severity of disease using patient characteristics.
Six studies assessed how well these predictions performed in different groups of patients. Results were
mixed, showing that a tool that performs well for one group of patients may not perform well for others.
Further research is needed to understand which combinations of patient characteristics best predict the
severity of disease in patients with early RA.
Twelve studies were found that allowed us to find out whether or not different patient characteristics
can predict different treatment effects. Ten characteristics were assessed. The results were inconclusive,
although the benefit of some treatments seemed to differ according to different patient characteristics.
Further research is needed to understand how treatment benefit varies by patient characteristics.
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Scientific summary
Background
Rheumatoid arthritis (RA) is a chronic and debilitating disease that can lead to increasing disability, pain
and irreversible joint damage. Symptoms include pain, morning stiffness, swelling and tenderness of joints,
loss of mobility, warmth of the peripheral joints and fatigue. RA is associated with a reduced quality of life
and substantial direct and indirect costs resulting from treatment and reductions in productivity. Treatments
for RA include conventional disease-modifying antirheumatic drugs (cDMARDs) and biologic disease-
modifying antirheumatic drugs (bDMARDs). Key outcomes in RA include measures of joint destruction
(e.g. radiographic progression), disease activity [as assessed via, for example, the Disease Activity Score-28
(DAS28)] and disability [as assessed via, for example, the Health Assessment Questionnaire (HAQ) scores].
Health-care professionals need to be able to determine at an early stage of disease which patients may
experience a worse prognosis in order to inform effective disease management and avoid pharmacological
overtreatment of patients. There is currently no clear consensus on which of the available tests and
assessment tools used in RA provide the best assessment of prognosis in people newly diagnosed with
RA and whether or not patient or disease characteristics can predict how well patients will respond to
different drug treatments.
This report was commissioned by the National Institute for Health Research Health Technology Assessment
programme as project number 14/151/08.
Objectives
The objectives of this work were to undertake systematic reviews to determine the:
l use of selected tests and assessment tools in the evaluation of prognosis in patients with early RA
l potential of selected tests and assessment tools as predictive markers of treatment response in patients
with early RA.
Methods
Two related systematic reviews were undertaken. The systematic reviews were informed by the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (www.prisma-statement.org/)
and current good practice in prognostic reviews advocated by the Cochrane Prognosis Methods Group
(http://methods.cochrane.org/prognosis/). A final protocol for this assessment was registered on PROSPERO
(CRD42016042402).
Review 1 (clinical prediction models)
Prognostic research involves the study of the relationship between future outcomes among people with
a given baseline health state in order to improve health. A prognostic model is a formal combination of
multiple predictors from which the probability of a specific event can be estimated for individual patients.
Searches of electronic databases (e.g. MEDLINE, EMBASE, The Cochrane Library, Web of Science Conference
Proceedings; searched to September 2016), registers, relevant websites, hand-searching of reference lists of
included studies and key systematic reviews were conducted and contact was made with experts.
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Primary studies describing the development, external validation and impact of eligible clinical prediction
models in adult patients with early RA (defined as being within 2 years of the onset of symptoms) were
eligible for inclusion. The prognostic variables considered in the assessment were informed by the phase 1
scoping searches and agreed following discussion between the review team and clinical advisors. The
prognostic variables selected for inclusion in review 1 were anticitrullinated protein/peptide anti-bodies
(ACPAs), rheumatoid factor, erosions/joint damage assessed via X-ray, C-reactive protein (CRP) levels,
erythrocyte sedimentation rate (ESR), swollen joint count (SJC), DAS28, early RA untreated for ≥ 12 weeks
following the onset of symptoms, smoking status and HAQ scores. Eligible outcomes were joint damage as
assessed on radiographs, DAS28 and HAQ scores.
Data extraction was informed by the CHecklist for critical Appraisal and data extraction for systematic
Reviews of prediction Modelling Studies (CHARMS). Assessment of the study quality characteristics of
clinical prediction modelling studies was informed by criteria included in the Prediction model study Risk
Of Bias Assessment Tool (PROBAST).
Data on the predictive performance of included clinical prediction models were described in a narrative
synthesis, presented separately for internal and external validation studies. Evidence synthesis using
meta-analysis was considered for external validation studies.
Review 2 (prediction of treatment response)
Searches for evidence were undertaken using data sources, as described for review 1.
Review 2 included evidence on the interaction between baseline covariates and treatment on salient
outcomes in adult patients with early RA. The response to cDMARDs and bDMARDs was studied. Eligible
studies involved at least 6 months’ treatment duration (with the exception of 12 weeks for certolizumab
pegol). Eligible predictive variables were the same as for review 1, with the addition of body mass index
(BMI) and vascularity of synovium assessed using power Doppler ultrasound (PDUS). The outcomes selected
for inclusion were the same as for review 1, with the addition of selected definitions of response/remission
[European League Against Rheumatism (EULAR) response; remission as a DAS28 of < 2.6, a Disease
Activity Score of < 1.6 and/or American College of Rheumatology/EULAR remission].
Studies of predictive variables were assessed by criteria informed by the Quality in Prognosis Studies
(QUIPS) tool.
A formal meta-analysis was not performed as, for specific outcome measures and potential treatment
effect modifiers, there were no studies that shared any treatments in common. Results were presented
with regard to assessing the predictive ability of baseline patient and/or disease characteristics according
to different treatments by study.
Results
Review 1 (clinical prediction models)
Twenty-eight studies that investigated the use of assessment tools and tests in the evaluation of a prognosis
in early RA patients were identified. These included 22 model development studies and one combined
model development/external validation study that reported a total of 39 clinical prediction models for the
outcomes of radiographic joint damage, DAS28 and HAQ score. An additional five external validation
studies, which tested the performance of eight clinical prediction models for radiographic joint damage
outcomes, were also included.
Included studies varied in terms of the methods applied to develop the clinical prediction models, for
example, in the strategies used to select or reject candidate predictors from the final model and in the
handling of continuous predictors. Several studies presented a ‘matrix model’, and continuous variables
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were frequently categorised to allow this presentation format. For models developed using randomised
controlled trial data with patients assigned to alternative treatment strategies, the model development
generally failed to assess interactions between predictors and treatment group and so did not generate
truly treatment-specific models.
Model development studies varied in the reporting of predictive performance. A key measure of model
predictive performance, the c-statistic, was presented from internal validation in 8 of the 23 model
development studies; sensitivity and specificity (eight studies), accuracy (seven studies), positive predictive
value and/or negative predictive value (12 studies) were also reported. Of the eight studies that reported
c-statistics from internal validations, c-statistics for radiographic progression outcomes ranged between 0.63
[with Degboé et al. (Degboé Y, Constantin A, Nigon D, Tobon G, Cornillet M, Schaeverbeke T, et al. Predictive
value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early
rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort.
RMD Open 2015;1:e000180) predicting a Δ Sharp/van der Heijde score (SHS) of ≥ 5 at 1 year] and 0.87
[with Houseman et al. (Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, et al. Baseline
serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic
progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012;14:R30)
predicting a Δ SHS of ≥ 10.5 at 8.2 years]. Two studies predicting HAQ also generated c-statistics from
internal validation {0.78 [Dirven et al. (Dirven L, Visser K, Klarenbeek NB, Ewals JA, Han KH, Peeters AJ, et al.
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid
arthritis are different from predictors of rapid radiological progression. Scand J Rheumatol 2012;41:15–19)
HAQ ≥ 1 at 3 months] to 0.82 [Bansback et al. (Bansback N, Young A, Brennan A, Dixey J. A prognostic
model for functional outcome in early rheumatoid arthritis. J Rheumatol 2006;33:1503–10) HAQ ≥ 1.5
at 5 years]}. However, even if consistent approaches had been used for internal validation, comparing the
performance of clinical prediction models that have been internally validated in different populations would
still be limited, because good discriminative ability in the population used to develop the model would be
expected. External validation is required to provide an objective comparison.
For the eight models that were externally validated, predictive performance varied considerably. Five
clinical prediction models [Syversen, Swedish Farmacotherapy (SWEFOT), Étude et suivi des polyarthrites
indifférenciées récentes (ESPOIR), multibiomarker disease activity and Study Of New-Onset Rheumatoid
Arthritis (SONORA)] were externally validated only in one population per outcome definition. Three clinical
prediction models [Active controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid
arthritis of Early onset (ASPIRE) CRP, ASPIRE ESR and Behandelings Strategie (BeSt)] were externally validated
using the same outcome definition in more than one population. The results of the random-effects meta-
analysis indicated that the most favourable performance across external validations was for the BeSt model
[c-statistic 0.72, 95% confidence interval (CI) 0.20 to 0.96], followed by ASPIRE ESR (c-statistic 0.62, 95% CI
0.44 to 0.78) and ASPIRE CRP (c-statistic 0.55, 95% CI 0.13 to 0.91). However, there is considerable
heterogeneity for all three models, with the wide CIs suggesting substantial uncertainty in the expected
predictive performance in a new sample of patients. The 95% CIs of the pooled estimates contain 0.5 for
all three clinical prediction models, indicating that there is limited confidence that the performance of the
models is better than would be expected by chance.
The inconsistent results generated by the clinical prediction models on external validation indicate that
there is heterogeneity in the populations in which the models are being tested that is not explained by
the currently proposed models. However, the meta-analysis was limited by the small number of available
external validation studies. The synthesised estimates are indicative of performance in the observed studies,
but cannot be used to provide a definitive conclusion about the performance in future studies or to explore
the reasons for the heterogeneity between studies.
Despite the identification of 23 model development studies and six external validations (including the
combined model development/external validation study), uncertainty remains over the optimal prediction
model(s) for use in clinical practice. There were limitations identified in the methods used to develop the
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clinical prediction models in many of the development studies, including the handling of continuous
predictors and failure to assess interactions. It is therefore likely that the most clinically useful prediction
model may contain predictors from across more than one of the reviewed clinical prediction models and/or
consider alternative handling of key predictive variables.
Review 2 (prediction of treatment response)
Review 2 identified 12 primary studies with which to assess the prediction of treatment response according
to baseline covariates. The covariates examined included ACPA status, smoking status, erosions, rheumatoid
factor status, CRP levels, ESR, SJC, BMI and vascularity of synovium on PDUS. The outcomes examined
included erosions/radiographic progression, disease activity, physical function and DAS28 remission.
There was statistical evidence to suggest that ACPA status, SJC 28 and PDUS status at baseline may be
treatment effect modifiers, but not necessarily that they are prognostic of response for all treatments.
Most of the results were subject to considerable uncertainty and were not statistically significant. In general,
there was insufficient evidence that the effect of treatment depended on baseline characteristics.
Conclusions
Review 1 (prognostic models)
No single clinical prediction model can currently be recommended in preference to any other for use
in clinical practice on the basis of uncertainties and limitations in the available evidence. The optimal
prediction model(s) may include variables (e.g. biomarkers/genetic tests) that are not routinely or currently
available. Any practical and cost implications associated with their use would need to be evaluated before
future implementation.
Review 2 (prediction of treatment response)
There was limited evidence with which to assess whether or not specific baseline variables can predict
differential effects according to the treatment administered. Nevertheless, the available evidence suggested
that some baseline variables do affect relative treatment effects and that not all baseline variables may be
prognostic of response for all treatments.
The effects of covariates were rarely assessed in single models adjusting for all covariates and with the
inclusion of interaction terms with treatment. Although there was statistical evidence to suggest that
some baseline covariates affect treatment response differentially, the results were subject to considerable
uncertainty and there was generally insufficient evidence that the effect of treatment depended on
baseline characteristics. This may be a real effect or may be because studies lacked statistical power to
detect interaction effects. In future analyses, the true effect of baseline variables should be evaluated in
single multivariable models, adjusting for all relevant covariates and interactions with treatment.
Suggested research priorities
Review 1 (prognostic models)
Recommendations for further research include:
l collaborative research, including the use of individual participant data, for further (1) development/
internal validation and (2) external validation of optimal clinical prediction model(s) to demonstrate
predictive performance and generalisability
l adherence to good model development and reporting standards of future clinical prediction model studies
l research to investigate the effects on patient outcomes (and the cost-effectiveness) of the use in clinical
practice of optimal internally and externally validated model(s).
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Review 2 (prediction of treatment response)
Recommendations for further research include the following:
l Clinical prediction models should be developed and validated with respect to individual treatments.
l The assessment of treatment by covariate interactions should follow good statistical practice: subgroup
analyses should be avoided, categorising continuous baseline covariates should be avoided and the
interactions between treatments and baseline variables should be specifically modelled.
l The results of multivariable analyses presented in published reports should include estimates of the
main effects of covariates and any interaction effects together with their standard errors and
covariances for secondary research purposes.
Study registration
This study is registered as PROSPERO CRD42016042402.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Clinical features of rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic disease characterised by progressive, irreversible joint damage, impaired
joint function, pain, swelling and tenderness of joints.1 RA is associated with increasing disability and reduced
quality of life.1 Symptoms of RA include pain, morning stiffness, joint swelling, joint tenderness, loss of
movement, warmth of the peripheral joints and fatigue.2,3 RA is associated with substantial costs, both directly
(in terms of drug acquisition and hospitalisation) and indirectly, because of reduced productivity.4 RA has long
been linked with increased mortality,5,6 in particular because of cardiovascular events.7
Epidemiology
It has been estimated that there are approximately 400,000 people in the UK with RA.8 RA has been
reported to have a greater incidence in females (3.6 per 100,000 per year) than in males (1.5 per 100,000
per year).9 Although the peak age of incidence in the UK is in the eighth decade of life, people of all ages
may develop RA.9
Aetiology
A range of contributing factors, such as genetic and environmental influences, have been implicated as
potential causes of RA. The heritability of RA is estimated to be between 53% and 65%,10 with a family
history of RA carrying a corresponding risk ratio of 1.6 compared with the general population.11 Many
genes linked with RA susceptibility are concerned with immune regulation. Although infectious agents
have been suspected, no consistent relationship with an infective agent has been demonstrated. Sex
hormones have also been implicated because of the higher prevalence of RA in women and a tendency
for RA to improve during pregnancy. There is no proof of any causal link with lifestyle factors, such as diet,
smoking or occupation (but lifestyle factors may increase the risk of developing RA).
Management of rheumatoid arthritis
There are a range of treatment options available for the management of RA, with the aim of alleviating
symptoms and of minimising irreversible joint damage that may occur as a result of the disease process.8
Traditionally, patients have been treated with conventional disease-modifying antirheumatic drugs
[(cDMARDs) also known as conventional synthetic disease-modifying antirheumatic drugs], including
methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), leflunomide (LEF) and gold injections,
as well as corticosteroids, analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). However, more
recently, a group of biologic immunosuppressant drugs have been developed that specifically modify
the disease process by blocking key protein messenger molecules (such as cytokines) or cells (such as
B-lymphocytes).8 These treatments have been termed as biologic disease-modifying antirheumatic drugs
(bDMARDs); of these, certolizumab pegol, adalimumab (ADA), etanercept (ETN), golimumab and infliximab
(IFX) are tumour necrosis factor (TNF) inhibitors (or antagonists). Of the remaining bDMARDs, tocilizumab
is a cytokine interleukin-6 inhibitor, abatacept (ABT) is a selective modulator of the T-lymphocyte activation
pathway and rituximab is a monoclonal anti-body against the cluster of differentiation 20 (CD20) protein.
For patients who have exhausted all National Institute for Health and Care Excellence (NICE)-recommended
treatments, non-biologic final treatment options may be used.
Prompt diagnosis of RA is important in ensuring the appropriate clinical management of patients early in
the course of the disease. The 2013 European League Against Rheumatism (EULAR) recommendations
for the management of RA state that treatment with disease-modifying antirheumatic drugs (DMARDs)
should begin as soon as RA is diagnosed.12 The lack of sensitivity of the 1987 American College of
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Rheumatology [(ACR) previously known as the American Rheumatism Association] classification criteria in
early disease has been acknowledged and led to the development of the 2010 RA classification criteria.13
The 2010 criteria for RA require (for classification as definite RA) the confirmed presence of synovitis in at
least one joint, the absence of an alternative diagnosis to better explain the synovitis and scoring ≥ 6
(of a maximum of 10) from individual scores across four domains: (1) number and site of affected joints
(score range 0–5), (2) serological abnormality (score range 0–3), (3) elevated acute-phase response
(score range 0–1) and (4) symptom duration (range 0–1).13
The EULAR recommended that, if a treatment target is not reached, the use of a bDMARD should be
considered in the presence of poor prognostic factors [e.g. high disease activity, positivity to rheumatoid
factor (RF) and/or anti-bodies to citrullinated proteins and the early presence of joint damage].14
Rheumatoid arthritis is a heterogeneous disease and the disease course can vary considerably between
patients. The guideline development group for the NICE guidance on RA [i.e. Clinical Guidance number
79 (CG79)] suggested that it would be useful to clinicians if they could identify at an early stage those
RA patients who are most likely to suffer a worse course of disease (or prognosis).8 These patients could
then be closely monitored to ensure that they can receive appropriate treatment to minimise the health
problems and joint damage caused by RA. Patients who are considered to be less likely to experience a
poor prognosis may require a less intensive follow-up and treatment strategy. The provision of clearer
information on the prognosis and prediction of treatment response would be useful to inform the optimal
clinical management of patients and to avoid pharmacological overtreatment of patients.
The NICE guidance on RA (i.e. CG79) indicated the potential role of a range of factors in determining the
prognosis of patients with early RA.8 These included RF, anticyclic citrullinated peptide (anti-CCP) positivity,
baseline radiological damage, nodules, acute-phase markers, Health Assessment Questionnaire (HAQ)
score, grip strength and swollen joint counts (SJCs).
Although there is a large amount of evidence available on the use of tests and assessment tools in
determining the prognosis and prediction of treatment response, a recent good-quality evidence synthesis
was considered to be lacking. Therefore, there is no clear consensus on which of the available tests and
assessment tools used for RA could allow the best assessment of prognosis in people newly diagnosed
with RA and whether or not variables, if identified, also predict how well patients respond to different
drug treatments.
Measurement of key outcomes in rheumatoid arthritis
Major outcomes in RA include measures of joint destruction (e.g. radiographic progression), disease
activity [as assessed via, for example, Disease Activity Score-28 (DAS28)] and disability (as assessed via,
for example, HAQ scores).
Radiographic progression is frequently measured in clinical trials and observational research.15 The two
main scoring systems available for measuring radiographic progression are the Larsen et al.16 system and
the Sharp et al.17 system. The van der Heijde18 modification of the Sharp system includes both hands and
feet, erosions, joint-space narrowing and a range of joints.
In the UK, monitoring the progression of RA is often undertaken using the DAS28 in terms of swelling
(SW28) and of tenderness to the touch (TEN28). The DAS28 also incorporates erythrocyte sedimentation
rate (ESR) and a subjective assessment on a scale of 0–100 made by the patient regarding disease activity
in the previous week.
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The equation for calculating DAS28 is as follows:19
DAS28 = 0.56 × TEN280.5 + 28 × SW280.5 + 0.70 × ln(ESR) + 0.014 × subjective assessment. (1)
A second version of the DAS28 using C-reactive protein (CRP) levels instead of ESR exists. The DAS28 can be
used to classify both the disease activity of the patient and the level of improvement. Patients with a DAS28
of ≤ 3.2 are classed as having inactive disease, patients with a DAS28 of > 3.2 and ≤ 5.1 are regarded as
having moderate disease and those with a DAS28 of > 5.1 are regarded as having very active disease.19
The HAQ is a key measure of patient functional disability.20 It is a patient-completed assessment resulting
in scores ranging from 0 to 3 (with higher scores indicating greater disability).
Background to prognosis research
Key concepts in prognosis research
Prognosis research describes the investigation of the relationship between future outcomes among people
with a given baseline health state in order to improve health.21,22
The PROGnosis RESearch Strategy (PROGRESS) partnership outlined a framework for prognostic research,
with the aim of enhancing the quality and translational impact of prognosis research findings. The
framework has four key elements, as outlined below:
1. Fundamental prognosis research – examining the average prognosis of patients (natural course of a
disease or condition) with current clinical practice.21,22
2. Prognostic factor research – studying individual factors that, for patients with a given disease or
condition, are associated with the clinical outcome of interest.21,22
3. Prognostic model research – the use of multiple prognostic factors in combination to provide a clinical
prediction model, from which the probability of the outcome can be predicted for individuals. This research
theme includes model development, validation and assessing the clinical impact of these models.23
4. Stratified medicine research – the use of prognostic information to predict an individual’s response to
treatment, and hence make treatment decisions that are tailored to individuals.24
The current assessment focuses on prognostic model research (theme 3) and stratified medicine (theme 4).
Briefly, prognostic model research seeks to estimate the absolute response of an outcome for an individual,
whereas stratified medicine seeks to target therapy and make the best decisions for groups of similar
patients.23 One approach to stratifying the use of treatments is to consider the absolute response of
each individual (as estimated using a prognostic model). Those people with the most severe prognosis
are likely to derive the largest absolute benefit from a treatment and may be targeted for intervention.
For example, lipid-lowering therapy may be recommended to individuals above a certain threshold for
the risk of developing cardiovascular disease.25 The results from prognostic model research are therefore
relevant for guiding stratified medicine research, and the two themes are related.
Clinicians may also stratify medicine because the relative treatment effect is inconsistent across patients. In
statistical terms, this means that the patient or disease characteristic is a treatment effect modifier (i.e. there
is an interaction between the patient or disease characteristic and the effect of treatment on the outcome).
Assessing the presence of these differential treatment effects is important in predicting individual treatment
response. Examples include the use of trastuzumab for the treatment of breast cancer in individuals with
a positive human epidermal growth factor receptor-2 status. The prediction of treatment response is
considered in review 2, and further background on the development of treatment-specific clinical prediction
models is given in Background to stratified medicine research. Further examples of stratified treatment
decisions in clinical practice, based on the prediction of absolute risks, or differential treatment effects across
different subgroups of the population are provided by Hingorani et al.24
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Definition of a prognostic model
Prognostic models are developed to aid health-care providers in their decision-making by estimating the
probability that a specific event will occur in the future.23,26
Moons et al.27 stated that, because of the complexities in patients and diseases, prognostic studies require a
multivariable approach. Indeed, Collins et al.26 noted that, in practice, the prediction of an individual’s
response is not typically based on a single predictor and that clinicians integrate a range of patient
characteristics and symptoms in their own estimation of prognosis.26 We further acknowledge that clinical
prediction models would simplify to only one variable if this were the only significant predictor of prognosis.
A prognostic model is a formal combination of multiple predictors from which the probability of a specific
outcome can be estimated for individual patients.23,27 For an individual with a given set of baseline
characteristics and assuming that the outcome is binary (e.g. progression/no progression), a prognostic
model provides an estimate of the probability of experiencing the outcome within a specific period of time
(i.e. an estimate of absolute risk). Measures of relative risk [e.g. odds ratios (ORs), relative risks, hazard
ratios] are not relevant when evaluating the performance of prognostic models, other than to obtain an
estimate of the absolute risk in conjunction with a baseline response.28
Clinical prediction model development
Prediction model studies may be classed as model development,29 model validation30 or comprise a
combination of both. There are many important statistical considerations to the development process,
which we summarise here briefly to aid interpretation of the results. More comprehensive descriptions
of model development and validation procedures are given in the provided references.
Clinical prediction models are developed using data from cohorts of patients or clinical trials. The
development procedure starts with a preselected set of candidate predictors, and suitable procedures
should be used to identify the most important predictors and assign relative weights to the predictors
to form the combined clinical prediction model.31 Important considerations include the following:
l The selection of candidate predictors. Candidate predictors are variables that are chosen to be studied
for their prognostic performance.31 They should be selected based on subject knowledge and
availability in practice, with consideration to the size of the data set.32 Selection based on univariable
analyses could lead to the omission of important predictors and so should be avoided.33
l The handling of missing values. It is generally recommended that some form of imputation should be
used to account for missing data, because an analysis including only the individuals with completely
observed data may lead to biased results.34 A complete-case analysis may be appropriate, provided that
the proportion of missing values is small (i.e. typically < 5%).33
l Continuous predictors. Simple transformations of continuous variables to account for non-linearity may
be appropriate.31 The creation of artificial categories leads to a loss of information and power and
should therefore be avoided.35,36
l Final variable selection. Clinical prediction models are usually developed using multivariable regression.
If a full-model approach (containing all candidate variables) is not appropriate, then backwards
selection is the preferred method for statistical selection. Selection based purely on statistical
significance in univariable analysis should not be used.31,37,38
l Interactions between variables should also be considered. Interactions between variables and treatment
(treatment effect modification) are considered in review 2.
After a model has been developed, validation is conducted to quantify the performance of the model in
the population used to develop the model (internal validation). This is described as apparent validation if
the validation is conducted in exactly the same sample as that used for model development. This usually
produces the best-possible estimate of model performance, because the model was optimally designed to
fit the development data set (described as overfitting) and performs less favourably when applied generally
to similar samples of patients.31 Overfitting is of particular concern when the development data set is small
and/or the number of candidate predictors is high.31
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Alternatives to apparent validation should ideally be used. Data splitting involves dividing the development
sample into a training data set (used to derive the model) and a validation data set that is used to evaluate
model performance. However, this approach is considered to be statistically inefficient, as not all available
data are used to formulate the model.31 Therefore, either bootstrapping or cross-validation is recommended
as the preferred method of internal validation.26 Cross-validation extends the simple data-splitting approach
by iterating the procedure over several partitions of the data set. The performance results are averaged to
provide an overall measure.
Overfitting can also be avoided or minimised using a procedure called shrinkage. This is a statistical
estimation method that preshrinks the model regression coefficients towards zero.33
Measures of predictive model performance (binary outcomes)
There are several summary measures used to quantify the predictive performance of clinical prediction
models in internal and external validation. The following key measures of predictive model performance
are considered in the assessment.
Overall model performance statistics
Overall model performance statistics include R2 and the mean-squared error/Brier score. R2 ranges from
zero to one and describes the proportion of explained variation in the data. There are several methods
for calculating R2, with Nagelkerke’s39 R2 commonly being reported for logistic regression models. The
mean-squared error is defined as the average-squared difference between the observed outcome (0 or 1)
and the predicted probability of the outcome.
Calibration
Calibration indicates the extent to which expected outcomes (predicted from the clinical prediction model)
and observed outcomes agree. Summarising the estimates of calibration performance is challenging,
because studies may quantify calibration using different summary statistics.40 In a recently published guide to
systematic review and meta-analysis of prediction model performance, Debray et al.40 based their assessment
of calibration on the total number of observed (O) events compared with the expected number of events (E)
predicted by the model. The observed-to-expected (O : E) ratio provides a rough indication of the overall
model calibration across the entire range of predicted probabilities. An O : E ratio of close to one would
indicate good calibration, whereas values that are < 1 or > 1 indicate a model that either overestimates or
underestimates the number of events.
Discrimination
Discrimination refers to the ability of a prediction model to distinguish between patients who do and
those who do not experience the outcome of interest. For binary outcomes, discrimination is frequently
quantified using the concordance statistic (c-statistic), and it is also known as the area under the receiver
operating characteristic curve. For categorical outcomes, Harrell’s c-statistic for ordinal data37 can be used.
The c-statistic is also relevant for other outcome measures (e.g. time to event) and is sometimes termed the
c-index. A c-statistic of 0.5 indicates no discriminative ability over that that would be expected because of
chance, whereas a c-statistic of 1 indicates perfect discriminative ability.
External validation
Demonstrating that a clinical prediction model can successfully predict the outcome of interest in the
sample used to derive the model is not, by itself, sufficient to confirm its value.23,28 A more objective
measure of model performance is obtained using external validation, in which the model performance is
assessed in a sample of patients who are external to those who were used for the model development.
Model updating or recalibration can be considered if a particular model does not calibrate well in external
populations. This is considered to be a better alternative to redeveloping new models in each patient
sample as a result of poor performance of existing models.31 Despite this recommendation, a recent
systematic review shows that recalibration is not commonly undertaken.41
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The c-statistic of a clinical prediction model may vary substantially between different validation studies, and a
common cause for this heterogeneity is because of differences in the distribution of patient characteristcs.40
Vergouwe et al.42 demonstrated in a simulation study that a more heterogeneous sample was related to a
higher discriminative ability. It is therefore important to consider the distribution of patient characteristics
(case mix) of the included validation studies. This could be done by considering the standard deviation (SD)
of key variables or of the combined linear predictor (the weighted sum of regression weights and covariate
values in the validation sample).
Background to stratified medicine research
Developing treatment-specific clinical prediction models
Stratified medicine research is concerned with the use of prognostic information to predict an individual’s
response (i.e. clinical benefit or adverse events) according to different treatments. The prediction of
absolute treatment effects according to different patient and/or disease characteristics for different
treatments is based on an analysis of relative treatment effects. The development of treatment-specific
clinical prediction models should follow the same process as described in Clinical prediction model
development; an assessment of differential treatment effects should be conducted formally, including
the use of interaction tests, and not through subgroup analyses.
Issues associated with subgroup analyses
Although it is common for an assessment of differential treatment effects to be based on a series of
subgroup analyses, this is not generally recommended. Constructing subgroups based on patient and/or
disease characteristics that are continuous (e.g. ESRs of < 25mm/hour, 25–50mm/hour and > 50 mm/hour)
assumes that treatment effects are constant within categories and have a discontinuity according to
each category; in practice, such categorisation is often subjective and not supported by evidence. Some
subgroups, including definitions such as early disease, involve other patient and/or disease characteristics
that are correlated with such definitions of subgroup, and the resulting estimates of treatment effects may
have a more complex interpretation. Absence of evidence is not evidence of absence, and a statistically
significant treatment effect in one subgroup but not in another should not be interpreted as there being a
true effect in one subgroup but not in another; the result may reflect different degrees of uncertainty or
different magnitudes of treatment effect in the subgroups. Assessing the statistical significance of treatment
effects in different subgroups does not incorporate an adjustment for other covariates that may be important
and assumes that there is no residual differential treatment effect within the subgroup. Treatment effects
may be misleading when treatments interact with covariates that were not used to form subgroups, and
when the subgrouping variable interacts with a patient and/or disease characteristic that was ignored.43
Assessing treatment by covariate interactions
Ideally, patient and/or disease characteristics that may affect relative treatment effects should be
prespecified. All covariates believed to be prognostic or treatment effect modifiers should be included in
the analysis and should be used consistently across data sets irrespective of the statistical significance of
the covariates. The main effects should be modelled flexibly and should not assume linearity of response
with a change in the value of a covariate; interaction effects should be modelled using the same approach.
The statistical significance of all interaction effects included in a model should be assessed using a single
test; this controls for multiplicity and will not be affected by potential treatment effect modifiers that are
colinear with each other. The absence of a statistically significant interaction effect should not necessarily
be interpreted to mean that this is evidence of the absence of an interaction effect. Studies are not typically
designed to assess interaction effects, and a lack of statistical significance may simply reflect a lack of
power of the test. Similarly, some interaction tests may be statistically significant by chance. Furthermore,
it is important when interpreting interaction effects to distinguish between qualitative interactions,
whereby the effect of treatment is reversed for some value(s) of the covariate, and quantitative interactions,
whereby the treatment effect is in the same direction for different values of the covariate, but the magnitude
of the treatment effect is different and may be clinically irrelevant. Finally, in non-linear models, such as the
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use of logistic regression for binary outcomes, any omitted covariates will result in biased estimates of
treatment effect.
Assessing treatment by covariate interactions in this review
Studies used in this assessment to evaluate whether or not different patient and/or disease characteristics are
prognostic according to different treatments will include those used in the development of treatment-specific
clinical prediction models, as well as randomised controlled trials (RCTs) and observational studies that
include patients with differential treatment use at entry. The use of RCTs and observational studies is to
acknowledge the evidence that these studies provide about differential treatment effects in the absence of
treatment-specific clinical prediction models. Studies that provide information only about the prognostic
effect of patient and/or disease characteristics are excluded; nevertheless, studies meeting the inclusion
criteria do provide some, albeit selective, information about the prognostic effect of covariates according to
treatment. However, the results should be treated with caution for the reasons given above.
The primary parameter of interest is that representing the interaction between treatment and baseline
covariate; it is this parameter that quantifies whether or not the response to treatment varies according to
the value of the covariate. In practice, such interactions should be assessed in a single regression model
incorporating main effects and interaction terms.
As discussed previously, studies may lack sufficient power to detect interaction terms as being statistically
significant [i.e. 95% confidence intervals (CIs) not including the null value] and it should not be assumed
that absence of evidence is equivalent to evidence of absence. Similarly, in the event that a statistically
significant treatment effect modifier is identified, it may not be clinically relevant. In addition, the results
should be considered as hypothesis-generating, because studies were generally not designed to detect
interaction effects; the potential treatment effect modifiers are assessed univariately in this review,
although their relevance may be different when the correlation between multiple covariates is taken
into consideration in clinical prediction models, and spurious results may occur by chance given the
number of multiple comparisons being performed.
Interpretation of the evidence regarding patient and/or disease characteristics
There are four scenarios that may arise depending on whether a covariate is (or is not) prognostic for at
least one treatment and whether a covariate is (or is not) a treatment effect modifier: these are illustrated
below for a comparison of two treatments with respect to a single covariate, which may be discrete
or continuous.
Scenario 1: prognostic variable for both treatments, but not a treatment effect modifier
(Figure 1)
Given two treatments coded such that t1 = 0 and t2 = 1, the mean response (i.e. expected value) for a
person with a baseline value of xj who receives treatment t1 is:
E½y i j = β0 + β1x j + β2t i. (2)
For treatment t1 this is:
E½y1 j = β0 + β1x j, (3)
and for treatment t2 this is:
E½y2 j = (β0 + β2) + β1x j. (4)
In this scenario, the treatment effect is β2, which is constant at each value of the predictor; it is also
possible for a baseline variable to be a prognostic and for there to be no treatment effect (in which case,
the two regression lines would be superimposed).
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Scenario 2: prognostic variable for both treatments and a treatment effect modifier
(Figure 2)
Given two treatments coded such that t1 = 0 and t2 = 1, the mean response (i.e. expected value) for a
person with a baseline value of xj who receives treatment t1 is:
E½y i j = β0 + β1x j + β2t i + β12t i.x j. (5)
For treatment t1 this is:
E½y1 j = β0 + β1x j, (6)
and for treatment t2 this is:
E½y2 j = (β0 + β2) + (β1 + β12)x j. (7)
In this scenario, the treatment effect at xj is β2 + β12xj, which depends on the value of the baseline variable;
it is also possible that β2 = 0.
t2
t1
xj
yij
FIGURE 1 Scenario 1: prognostic variable for both treatments but not a treatment effect modifier.
t2
t1
xj
yij
FIGURE 2 Scenario 2: prognostic variable for both treatments and a treatment effect modifier.
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Scenario 3: not a prognostic variable for one treatment, but a treatment effect modifier
(Figure 3)
Given two treatments coded such that t1 = 0 and t2 = 1, the mean response (i.e. expected value) for a
person with a baseline value of xj who receives treatment t1 is:
E½y i j = β0 + β1x j + β2t1 + β12t i.x j. (8)
For treatment t1 this is:
E½y1 j = β0, (9)
and for treatment t2 this is:
E½y2 j = (β0 + β2) + β12x j. (10)
In this scenario, the treatment effect at xj is β2 + β2xj, which depends on the value of the baseline variable;
it is also possible that β2 = 0.
Scenario 4: not a prognostic variable for either treatment and not a treatment effect
modifier (Figure 4)
Given two treatments coded such that t1 = 0 and t2 = 1, the mean response (i.e. expected value) for a
person with a baseline value of xj who receives treatment t1 is:
E½y i j = β0 + β1x j + β2t i + β12t i.x j. (11)
For treatment t1 this is:
E½y1 j = β0, (12)
and for treatment t2 this is:
E½y2 j = β0 + β2. (13)
t2
t1: β = 0
xj
yij
FIGURE 3 Scenario 3: not a prognostic variable for one treatment, but a treatment effect modifier.
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In this scenario, the treatment effect at xj is β2, which is independent of the baseline variable; it is also
possible for there to be no treatment effect (in which case, the two regression lines would be superimposed).
Stratified medicine research is concerned with identifying treatment effect modifiers, as illustrated by
scenarios 2 and 3.
t2: β2 = 0
t1: β1 = 0
xj
yij
FIGURE 4 Scenario 4: not a prognostic variable for either treatment and not a treatment effect modifier.
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Chapter 2 Review question and objectives
Review question
The review question as outlined in the Health Technology Assessment (HTA) commissioning brief and final
protocol was as follows: what test or combination of clinical, laboratory and imaging tests gives the best
assessment of prognosis in RA, and how well do they predict response to treatment?
Assessment structure
The assessment structure consisted of systematic reviews with appropriate predefined subgroup analyses.
It was anticipated in the final protocol that the factors most likely to be of use for prognosis and prediction
of treatment response would be assessed through meta-analysis of available aggregate-level data. The de
novo development of a specific prediction model and the use of individual participant data (IPD) were
outside the remit of this assessment.
Overall objectives of the assessment
The objectives of this work were to undertake systematic reviews to determine the:
l use of selected tests and assessment tools in the evaluation of prognosis in patients with early RA
l potential of selected tests and assessment tools as predictive markers of treatment response in patients
with early RA.
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Chapter 3 Methods for the assessment of
prognosis and prediction of treatment response in
early rheumatoid arthritis
Assessment structure
This assessment consisted of two related systematic reviews. The first systematic review (review 1, clinical
prediction models) investigated the use of assessment tools and tests in the evaluation of prognosis in early
RA patients. The second systematic review (review 2, prediction of treatment response) determined the
ability of selected assessment tools and tests to predict the response to specific treatments.
The systematic reviews were informed by the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (www.prisma-statement.org/) and current good practice in prognostic
reviews, as advocated by the Cochrane Prognosis Methods Group (http://methods.cochrane.org/
prognosis/).
A final protocol for this assessment was registered on PROSPERO (as record CRD42016042402).
Scoping of the assessment
The searches for reviews in this assessment were structured in two phases. The phase 1 scoping searches
were performed to determine the approximate extent of the evidence base relevant to the assessment and
to inform the discussion of prognostic and predictive variables for inclusion in conjunction with clinical
advisors (full details are provided in Appendix 1).
Following discussions with two expert clinical advisors who manage patients with early RA in the UK
(as described in Acknowledgements), the review team selected variables for inclusion. The selection of
prognostic and predictive variables was based on:
l tests and assessment tools (e.g. selected laboratory tests, imaging tests and clinical assessment
measures) the variables being readily available and used in UK clinical practice (and, therefore, genetic
markers were not included by the review team)
l the clinical experience of advisors in evaluating prognosis/treatment response in patients
l the initial scoping of literature in the area by the review team.
The selected prognostic and predictive variables were used in the development of the full searches for
reviews 1 and 2.
Justification of review approach
In view of the anticipated large number of search results, it was necessary for the review team to revise
the intended review approach in order to maintain the feasibility of the assessment within the available
resources and time scales. Additional details of protocol deviations are provided in Appendix 2.
Therefore, the two related systematic reviews were planned as detailed in the following sections.
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Review 1: clinical prediction models
A systematic review of studies that describe the development, external validation or impact of eligible clinical
prediction models in early RA was performed. As outlined in Background to prognosis research, prediction
model research requires a multivariable analysis approach and, therefore, it was considered methodologically
appropriate to restrict review 1 to the study of prognostic variables analysed in combination.
Review 2: prediction of treatment response
A systematic review of primary studies that describe the development, external validation or impact of
eligible outcome models to predict treatment response in early RA patients was undertaken. Given that it
was anticipated (based on earlier scoping searches) that the availability of outcome models and external
validation studies relevant to review 2 would be limited, it was decided that review 2 would also include a
review of studies to predict treatment response in patients with early RA. This approach would provide
information for researchers who wish to develop outcome models for the prediction of treatment response
based on a summary of the key evidence for the variables/tests and assessment tools selected following
discussions with our clinical experts.
Methods for review 1 (clinical prediction models)
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases and research registers:
l MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations and Epub ahead of print (via Ovid;
1947 to September 2016)
l EMBASE (via Ovid; 1974 to September 2016)
l The Cochrane Library (via Wiley Online Library), including Cochrane Database of Systematic Reviews
(CDSR), Cochrane Central Register of Controlled Trials (CENTRAL) and Database of Abstracts of
Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED), HTA databases (inception
to September 2016, or 2015 in the case of DARE/NHS EED, which are no longer being updated)
l Web of Science Conference Proceedings (1990 to September 2016).
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators
and database-specific syntax were developed to search the electronic databases. Synonyms relating to
disease (e.g. Arthritis, Rheumatoid/) and prognostic variables were combined with a highly sensitive search
filter aimed at restricting results to prognostic studies.44
No date restrictions were used on any database. However, all searches were restricted to the English
language because of time and resource constraints for translation services.
All resources were initially searched from inception to 27 September 2016. An example of the MEDLINE
search strategy is provided in Appendix 3.
Research registers and other websites
The following resources were also searched for relevant evidence:
l The World Health Organization’s trial search portal (http://apps.who.int/trialsearch) and ClinicalTrials.gov
[(https://clinicaltrials.gov) records added since 2010 up to the date of the search on 27 September 2016].
l Arthritis Research UK; British Society for Rheumatology; National Rheumatoid Arthritis Society;
Outcome Measures in Rheumatology (OMERACT) Task Force; Royal College of Pathologists; Royal
College of Physicians; Royal College of Surgeons; EULAR, American College of Rheumatology; the US
Food and Drug Administration (FDA); and the European Medicines Agency (EMA) (no date restrictions).
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Results were manually added to EndNote Version X7 [Clarivate Analytics (formerly Thomson Reuters),
Philadelphia, PA, USA] for sifting.
Other resources
To identify additional studies, the reference lists of all included studies and key systematic reviews were
checked. In addition, key experts in the field were contacted.
Results from the phase 2 full searches were imported into reference management software EndNote and
duplicates were removed.
Study selection
Studies were assessed for eligibility for review based on the following criteria.
Inclusion criteria
Population
Adult patients (aged ≥ 18 years) diagnosed with early RA. The final protocol stated that patients would be
diagnosed with RA according to established criteria. Patients with early RA were defined in consultation
with clinical advisors as being within 2 years of the onset of symptoms. It was noted that studies may
report the duration of symptoms or the duration of disease at baseline and so the definitions applied in
included studies were noted and tabulated. In the absence of any further information, disease duration at
baseline was considered to be equivalent to symptom duration.
Studies investigating mixed populations were included only if ≥ 80% of the study population were early
RA patients or if subgroup data were presented for this population.
Externally validated clinical prediction models were included if the external validation population met the
inclusion criteria, even if the original development population did not meet the inclusion criteria. The rationale
for this was that a clinical prediction model might perform well for the decision problem and it is not important
that it was originally developed in a different population. In this case, the study that developed the original
clinical prediction model was included even if it did not meet the criteria stated above. In addition, studies
proposing clinical prediction models that did not present internal validation were included if they had been
externally validated in another study. External validations in populations outside the scope of the assessment
were not included in the review, but were referred to in the discussion as appropriate.
Technology
Blood tests, imaging modalities and clinical assessment scores used in the evaluation of prognosis in
patients with early RA were included. Specific tests and assessment tools to be included were determined
following the phase 1 scoping searches and agreed with clinical advisors. Tests and assessment tools were
for the measurement of prognostic variables as described below.
Prognostic variables
Prognostic variables considered in the assessment were informed by the phase 1 scoping searches and
agreed following discussion between the review team and clinical advisors. The prognostic variables
selected for inclusion for review 1 were:
l anticitrullinated protein/peptide anti-bodies (ACPAs) status; RF status
l erosions/joint damage as assessed on radiographs
l C-reactive protein levels
l erythrocyte sedimentation rate
l SJC
l DAS28
l early RA untreated for ≥ 12 weeks following the onset of symptoms
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l smoking
l HAQ scores.
Genetic markers were discussed in the assessment only when these were included in a final clinical prediction
model alongside other eligible prognostic factors as selected by the review team in collaboration with the
clinical advisors. This was decided on the basis that genetic testing is not currently used in routine UK
clinical practice.
Included clinical prediction models contained at least one eligible prognostic variable. Results were
presented based on all prognostic variables included in each multivariable model (including those not
included in this review).
Outcomes
The selected outcomes considered in this assessment were agreed following discussions between the
review team and the clinical advisors. The outcomes below were considered by the review team and the
clinical advisors to have clinical relevance and to be important to patients, and are widely reported in RA
research. The outcomes selected for inclusion in review 1 were:
l disease activity as measured by the DAS28
l physical function as measured by the HAQ
l joint damage as assessed on radiographs.
Study types
It was anticipated in the final protocol that the study types included in review 1 would be likely to include
published reports of cohort studies (and potentially case–control studies), which report the associations
between individual prognostic variables and outcomes. However, as described above, in order to maintain
the feasibility of the assessment, review 1 was restricted to the inclusion of studies that describe the
development, external validation or the impact of eligible clinical prediction models in early RA.
Included studies were categorised in accordance with the Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis (TRIPOD) classification, which groups studies
according to their methods of determination of performance.
Studies developing clinical prediction models that had not been validated in one of the included external
validation studies were included if they presented some form of internal validation to quantify predictive
performance [e.g. calibration and discrimination measures, such as the c-statistic or area under the curve
(AUC)]. For clinical prediction models that were not externally validated and did not report the c-statistic
or AUC or calibration, a study reporting at least two alternative measures of predictive performance
[e.g. sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy] was
considered to be eligible on the basis of being sufficiently informative to the review. When a study
reported only R2 (a measure of the model goodness-of-fit), this was not considered to provide sufficient
information regarding predictive performance, and the study was not included (but recorded in the table
of excluded full-text studies in Appendix 4).
Exclusion criteria
The following criteria were applied to exclude studies:
l non-English-language papers
l reports published as meeting abstracts only, in which insufficient methodological/results details
are reported
l animal models
l preclinical and biological studies
l narrative reviews, editorials and opinions.
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It was necessary, because of resource and time constraints, to deviate from the final protocol in the
applied screening approach (see Appendix 1). An iterative approach to the screening of evidence was
undertaken (adapted from Archer et al.45). Titles and abstracts of search records were examined by one
reviewer. Titles and abstracts were searched for terms relating to clinical prediction models. Key terms
were identified by consulting publications relating to prediction model research (e.g. Moons et al.,31
Debray et al.40). Terms used were risk model*, prognostic model*, prediction model*, predictive model*,
risk assessment model*, prediction score*, algorithm*, matrix/matrices, assessment tool*, prediction rule*,
decision rule*, and risk score* in order to identify potentially relevant studies for screening at the full-text
stage. As described previously, this method was supplemented by the hand-searching of reference lists
of included studies, existing key systematic reviews (e.g. Bombardier et al.,46 Navarro-Compán et al.47),
contact with clinical experts and the searching of grey literature.
Full texts of remaining articles were screened for eligibility before inclusion. Study inclusion based on
full-text articles was performed by one reviewer and queries were discussed with a second reviewer. Any
discrepancies were resolved by discussion, with the involvement of a third team member when required.
Data extraction
A data extraction form was designed and piloted before use on a minimum of two studies.
Data were extracted by one reviewer. Extracted data were checked for accuracy by a second reviewer.
Any discrepancies were discussed and resolved, with reference to a third team member when required.
The CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling
Studies (CHARMS)48 includes guidance on the relevant items for extraction from reports of prediction
modelling studies. Data extraction was guided by CHARMS.48 Predictive performance measures relating to
each clinical prediction model’s overall performance, calibration and discriminative ability were extracted
from each clinical prediction model development and external validation study. Following advice in Debray
et al.,40 the c-statistic was used as the primary measure of discrimination and the O : E ratio used as the
primary measure of calibration. If these measures or the associated variance estimates were not reported
for a particular study, they were computed from other information when possible. The results of the
Hosmer–Lemeshow test (a measure of model calibration) were also extracted, along with measures of
model overall goodness of fit (such as R2). Information regarding the case mix of the development/
validation population, which may help to explain the heterogeneity in the results, was also summarised
from the available information when possible. Further details relating to the data extraction and associated
calculations are provided in Appendix 5.
Quality assessment strategy
The assessment of the study quality characteristics of clinical prediction modelling studies was informed by
criteria included in an unpublished draft version of the Prediction model study Risk Of Bias Assessment
Tool (PROBAST).49 The risks of bias for participant selection, predictors and outcomes were discussed
narratively and tabulated. Potential key sources of bias in the model development and validation were
discussed narratively.
The methodological quality of each included study was assessed by one reviewer and checked with a
second reviewer. Disagreements were resolved by discussion between the two reviewers and if agreement
could not be reached, a third reviewer was consulted.
Synthesis methods
Data relating to clinical prediction model performance were described in a narrative synthesis, presented
separately for internal and external validation studies. An evidence synthesis using meta-analysis was
considered for external validation studies.
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Variation in predictive performance is expected because of differences in the design and execution of
alternative external validation studies and, hence, a random-effects (RE) model that accounts for between-
study heterogeneity was used.40 Results using a fixed-effects (FE) model (i.e. a condition inference given
the observed studies) are also presented for comparison.
Results are presented in terms of the summary c-statistic (and 95% CIs) that quantifies the average
performance across the included studies. For RE models, it was anticipated that an estimate of the
between-study SD (that quantifies the extent of heterogeneity between studies), as well as the 95%
prediction intervals (which provide a range for the potential model performance in a new study), would
also be provided. However, this was not possible on account of the limited number of studies that
validated each prediction model, thereby providing limited information with which to estimate the
between-study heterogeneity.
All analyses were conducted in R50 (The R Foundation for Statistical Computing, Vienna, Austria)
using the metafor package.51 A restricted maximum likelihood estimation was used with the Hartung–Knapp–
Sidik–Jonkman method (which accounts for uncertainty in the estimated between-study heterogeneity) to
estimate the CIs for the pooled estimate and the 95% prediction intervals.40,52 Analysis was conducted on
the logit scale as previously recommended and back-transformed to the original scale for the presentation
of results.40,52
It was stated in the review protocol that meta-analyses would be conducted using a Bayesian RE model.
However, this was modified for the final analysis, because there were very few studies that validated each
clinical prediction model, thereby providing limited information with which to estimate the between-study
heterogeneity. Although it would be possible to implement a Bayesian RE analysis using a weakly
informative prior, this was not implemented, because there was a lack of empirical evidence to inform the
prior distribution for the heterogeneity parameter and eliciting experts’ beliefs was beyond the scope of this
project. Although the analysis deviated slightly from the protocol, the implemented RE model accounts for
uncertainty in the between-study heterogeneity and is consistent with methodological recommendations.40
Given the limited number of studies available, it was not possible to explore heterogeneity in prognostic/
predictive effects using metaregression. However, subgroup analyses based on baseline DAS28 were
considered in the narrative synthesis of evidence for review 1 and review 2.
Methods for review 2 (prediction of treatment response)
Identification of studies
Electronic databases
Electronic databases, research registers and other websites searched were identical to those for review 1
(see Identification of studies). Sensitive keyword strategies using free text and, when available, thesaurus
terms using Boolean operators and database-specific syntax were developed to search the electronic
databases. The disease and candidate variable terms used in review 1 were combined with the appropriate
search filter for review 2.53
Research registers and other websites
The resources searched were identical to those used in review 1. The results were manually added to
EndNote for sifting.
Other resources
To identify additional studies, the reference lists of all included studies were checked. Hand-searching of
key systematic reviews and narrative reviews was also performed. A citation search of included articles
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[using Google Scholar (Google Inc., Mountain View, CA, USA)] was undertaken. In addition, key experts in
the field were contacted.
Results from the phase 2 full searches were imported into reference management software EndNote
(version X8) and duplicates were removed.
Study selection
Studies were assessed for eligibility for review 2 based on the following criteria.
Inclusion criteria
Population
Adult RA patients (aged ≥ 18 years) who have:
l received treatment with cDMARDs/bDMARDs for RA
l baseline/early disease and follow-up data for selected variables (as defined below).
For the review for the prediction of treatment response (review 2), response to cDMARDs and bDMARDs
was studied. It was planned in the final protocol for review 2 that, if data allowed, treatment would be
subdivided into cDMARDs and bDMARDs. Response to any other treatments (e.g. steroids) was not
assessed for reasons of feasibility. Predictors of treatment response to individual drugs (e.g. specific
biologics) would be explored if feasible and if sufficient evidence was available.
Studies were eligible for inclusion in review 2 if they involved at least 6 months’ treatment duration (with
the exception of certolizumab pegol, for which the response is largely known at 12 weeks and, therefore,
a 12-week treatment duration was considered to be more acceptable by clinical advisors and was applied
for this drug).
Technology
The tests and assessment tools for the measurement of predictive variables are as described below.
Predictive variables
The predictive variables considered in the assessment were also informed by phase 1 scoping searches
and selected following discussion between the review team and clinical advisors. The predictive variables
selected for inclusion in review 2 were the same as those for review 1, with the addition of two variables:
1. body mass index (BMI)
2. vascularity of synovium assessed using power Doppler ultrasound (PDUS).
Outcomes
The outcomes selected for inclusion were the same as for review 1, with the addition of:
l definitions of response/remission selected in conjunction with clinical advisors (EULAR response;
remission: a DAS28 of < 2.6, a Disease Activity Score (DAS) of < 1.6 or ACR/EULAR remission).
Study types
It was anticipated in the protocol that the included study types in review 2 would be cohort studies and
RCTs. Following a protocol amendment, in order to maintain the feasibility of the assessment within the
available time and resources, review 2 consisted of:
l a systematic review of studies that describe the development, external validation or impact of eligible
clinical prediction models to predict the response to individual treatments in patients with early RA
(developed/validated in observational cohorts or experimental data sets)
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l a review of primary studies (experimental or observational) to identify patient characteristics that affect
the response to individual treatments in patients with early RA.
The exclusion criteria were as described for review 1.
The titles and abstracts of search records were examined by one reviewer and irrelevant evidence was
excluded. The full texts of remaining articles were screened for eligibility before inclusion. Study inclusion
based on full-text articles was performed by one reviewer and queries were discussed with a second
reviewer. Any discrepancies were resolved by discussion, with the involvement of a third team member
when required.
Data extraction
A data extraction form was designed and piloted before use on a minimum of two studies.
Data were extracted by one reviewer. Extracted data were checked for accuracy by a second reviewer.
Any discrepancies were discussed and resolved, with reference to a third team member when required.
Quality assessment strategy
Any identified clinical prediction model studies were to be critically appraised, guided by the items included
in the PROBAST.49 Studies of prognostic variables were assessed by criteria informed by the Quality in
Prognosis Studies (QUIPS) tool (see Hayden et al.54), as stated in the final protocol.
Critical appraisal was performed by one reviewer and double-checked by a second reviewer. Discrepancies
were resolved by discussion, with the involvement of a third team member if necessary.
Synthesis methods
In the protocol, it was envisaged that a formal meta-analysis comparing all treatments across all studies
would be performed with respect to the predictive ability of treatments. However, for specific outcome
measures and potential treatment effect modifiers, there were no studies that shared any treatments in
common. Consequently, a formal meta-analysis was not performed and the results are presented assessing
the predictive ability of treatments by study.
Some authors fitted single regression models to the data from all treatment groups and included only
the main effects of treatment and baseline covariates; these models do not allow an assessment of the
interaction between treatments and baseline covariates. Other authors fitted separate regression models to
the data from each treatment group and presented estimates of treatment effects by covariate; it is these
estimates that are used to quantify the extent to which the treatment effect varies by covariate.
For continuous outcomes, the interaction effect is estimated by calculating the difference (and 95% CI
for the difference, when possible) in the mean between treatments; departures from zero are indicative
of the covariate being a treatment effect modifier. For binary outcomes, the interaction is estimated by
calculating the ratio (and 95% CI for the ratio when possible) of the ORs between treatments; departures
from one are indicative of the covariate being a treatment effect modifier.
Results indicating that a covariate is not a treatment effect modifier should not be interpreted to mean
that a covariate is prognostic, only that the relationship between covariate and response may be the same
for both treatments subject to a treatment effect (i.e. the covariate may be prognostic for both treatments
or not prognostic for both treatments).
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Chapter 4 Results: review 1
Quantity of research available
Searches for evidence (Figure 5) identified 22 model development studies and one combined model
development/external validation study, reporting a total of 39 clinical prediction models for the prediction
of major outcomes, including radiographically assessed joint damage, the HAQ score and the DAS28 (note
that one publication56 considered the development of models for multiple outcomes; however, because of
unclear reporting, the individual models could not be summarised and so have been counted as a single
entry for the purposes of the assessment). The study by Bombardier et al.57 was available as a conference
abstract only and a full-text publication was not available. Six external validation studies (including the
combined model development/external validation study) of eight previously proposed clinical prediction
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models for radiographically assessed joint damage outcomes were identified. No studies assessing the
impact of the use of clinical prediction models in the clinical management of early RA were identified.
Quality of the research available
Potential sources of bias in participant selection, predictors, outcomes, model development and validation
are discussed in the following sections and tabulated in Appendix 6.
Types of included prediction model studies
The TRIPOD statement26 was developed with the aim of improving the quality of reporting of prediction
model studies. Collins et al.26 described six categories (listed below) that can be used to classify studies
according to their aim (development or/and validation) and the methodology used.
The inclusion criteria for review 1 required that studies developing clinical prediction models apply some
form of internal validation to quantify the predictive performance of the developed model (e.g. calibration
and discrimination), with the exception of cases in which the clinical prediction model had been subsequently
externally validated. In these cases, the external validation results may be considered to be more informative
than the omitted internal validation results and it was deemed necessary to include the original development
paper for completeness. These studies did not have a category according to the TRIPOD statement, and
it was therefore necessary to introduce a new TRIPOD category (Type 0) to allow the description of these
studies.
The tailored TRIPOD classification categories used in this review (based on Collins et al.26) are as follows:
l Type 0 – development of a clinical prediction model in which the predictive performance is not
evaluated in the development paper, but an evaluation of the predictive performance has been
considered in a separate publication.
l Type 1a – development of a clinical prediction model with an evaluation of the predictive performance
using the same data set (apparent performance).
l Type 1b – development of a clinical prediction model using the whole data set and an evaluation of
the predictive performance using resampling (e.g. bootstrapping or cross-validation).
l Type 2a – random splitting of data into two groups, the first for clinical prediction model development
and the second for the testing of its predictive performance.
l Type 2 – non-random splitting of data into two groups, the first for clinical prediction model
development and the second for the testing of its predictive performance.
l Type 3 – development of a clinical prediction model in one data set and an evaluation of the predictive
performance on separate data (e.g. from a different study).
l Type 4 – the evaluation of the predictive performance of an existing clinical prediction model using
separate data (external validation).
The TRIPOD classification categories of the 28 included studies are presented in Table 1. The PROBAST49
study-type classifications of the included studies are also presented in Table 1.
Of the 23 clinical prediction model development studies, the vast majority (n = 16) were TRIPOD type 1a
{i.e. Berglin et al.,59 Visser et al.79 [Behandelings Strategie (BeSt)], Combe et al.62 (Combe A), Combe et al.63
(Combe B), de Vries-Bouwstra et al.,65 Degboé et al.,66 Dirven et al.,67 Drossaers-Bakker et al.,56 Fautrel
et al.69 [Études et suivi des polyarthrites indifférenciées récentes (ESPOIR)], Forslind et al.,70 Graell et al.,71
Houseman et al.,72 Saevarsdottir et al.73,74 [Swedish Farmacotherapy (SWEFOT)], Sanmartí et al.,75 Syversen
et al.76 and van Steenbergen et al.77}, with validation conducted in exactly the same data as those used for
clinical prediction model development. Fewer studies were categorised as type 1b (n= 1; i.e. Bansback et al.58),
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TABLE 1 The TRIPOD classification of included studies
First author (year of
publication)
Name of clinical
prediction
modela
Externally
validated?
(Y/N)
Model
presented
in useable
format?
Category
PROBAST TRIPODb
Clinical prediction model development studies
Bansback (2006)58 Bansback N Y Development only 1b
Berglin (2006)59 Berglin N N Development only 1a
Bombardier (2009)57 SONORA Y N Development only 0
Brennan (1996)60 Brennan N Y Development only 2a
Centola (2013)61 Centola Y Y Development only 0
Combe (2001)62 Combe (A) N Y Development only 1a
Combe (2003)63 Combe (B) N N Development only 1a
de Punder (2015)64 de Punder N Y Development/external
validation
1b/4
de Vries-Bouwstra (2006)65 de Vries-Bouwstra N N Development only 1a
Degboé (2015)66 Degboé N N Development only 1a
Dirven (2012)67 Dirven N Y Development only 1a
Dixey (2004)68 Dixey N N Development only 2a
Drossaers-Bakker (2002)56 Drossaers-Bakker N N Development only 1a
Fautrel (2012)69 ESPOIR Y Y Development only 1a
Forslind (2004)70 Forslind N Y Development only 1a
Graell (2009)71 Graell N Y Development only 1a
Houseman (2012)72 Houseman N N Development only 1a
Saevarsdottir (2015)73,74 SWEFOT Y N Development/external
validation
1a/4
Sanmartí (2007)75 Sanmartí N Y Development only 1a
Syversen (2008)76 Syversen Y Y Development only 1a
van Steenbergen (2015)77 van Steenbergen N N Development only 1a
Vastesaeger (2009)78 ASPIRE Y Y Development and external
validation
3c
Visser (2010)79 BeSt Y Y Development only 1a
External validation studies
De Cock (2014)80 External validation only 4
Granger (2016)82 External validation only 4
Hambardzumyan (2015)83 External validation only 4
Heimans (2015)84 External validation only 4
Markusse (2014)85 External validation only 4
ASPIRE, Active controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset;
BeSt, Behandelings Strategie; ESPOIR; European Clinical Study for the Application of Regenerative Heart Valves; N, no;
SONORA, Study Of New-Onset Rheumatoid Arthritis; SWEFOT, Swedish Farmacotherapy; Y, yes.
a Selected studies presented multiple alternative models. These are described in Table 8.
b The TRIPOD categories are as described in Types of included prediction model studies.
c The validation population (established RA) was outside the scope of the assessment.
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using techniques to evaluate performance and optimism of the developed model, type 2a (n= 2; i.e.
Brennan et al.60 and Dixey et al.68), using a data-splitting approach for development and validation, or type 0
{n = 2; i.e. Bombardier et al.57 [Study Of New-Onset Rheumatoid Arthritis (SONORA)] and Centola et al.61},
with no internal validation presented for Bombardier et al.57 Although internal validation was conducted for
Centola et al.,61 it was developed for a different outcome measure and so the study is categorised as type 0
for the purpose of the current review. One study {n = 1; i.e. Vastesaeger et al.78 [Active controlled Study of
Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset (ASPIRE)]} considered
validation in an external population in addition to model development (type 3); however, the external
validation population comprised patients with established RA and, therefore, was outside the scope of this
assessment. The methods of internal validation and reporting of models in the included development studies
are described in greater detail in Model development.
Five additional included studies were external validations of clinical prediction models (TRIPOD class 4).
Three of these studies (i.e. De Cock et al.,80 Granger et al.82 and Heimans et al.84) externally validated a
total of seven clinical prediction models (i.e. ASPIRE CRP,78 ASPIRE ESR,78 BeSt,79 ESPOIR,69 SONORA,57
SWEFOT73 and Syversen76). The remaining two external validation studies (Hambardzumyan et al.83
and Markusse et al.85) evaluated the use of a multibiomarker disease activity (MBDA) test61 (developed
as a measure of disease activity) in the prediction of eligible clinical outcomes. In addition to the seven
purely external validation studies, the de Punder model development paper64 (TRIPOD category 1b/4) also
externally validated the BeSt79 and ESPOIR69 models.
Two additional external validation studies were identified but not included.73,86 The study reported by
Durnez et al.86 is considered to be a precursor study to the work by De Cock et al.,80 and so the work by
De Cock et al.80 is utilised in this assessment as being more recent and comprehensive in the coverage of
validated models. The application of the BeSt model79 was considered by Saevarsdottir et al.73 (TRIPOD
category 1a/4) using the SWEFOT data set. However, the presented results did not provide sufficient data
to be considered as informative to the current review, as no summary statistic of overall performance
(e.g. c-statistic) was reported. Saevarsdottir et al.73 presented the allocation of individuals to risk matrix
categories, combined for the whole validation sample rather than separately by treatment group.
Description of data sources for the development of clinical prediction
models and external validation
Moons et al.31 advocated the use of cohort study data in the development of clinical prediction models,
which are preferably prospective in design to allow for the greater completeness of data collection.31 Trial
data are also an appropriate data source, although it has been noted that trial eligibility criteria may result
in more restricted and less generalisable data than registry cohort studies.31 All identified clinical prediction
models for review 1 were developed in either observational cohort or registry data or in existing cohorts
from intervention trials in early RA populations and, therefore, can be considered to have been developed
in appropriate data sources. Studies were longitudinal in design, with potential predictors measured in
an early RA population at baseline or in an early disease stage before the measurement of a specified
outcome at a subsequent time point. There was one main exception to this, Houseman et al.,72 which
is discussed further in Description of predictors. The characteristics of the data sources used in the
development and external validation of the included clinical prediction models are tabulated in Table 2.
Four included clinical prediction model development studies used RCT data.67,73,78,79 The models by
Vastesaeger et al.78 were developed in the ASPIRE RCT.87 Both the models by Visser et al.79 and Dirven
et al.67 were generated using data from the BeSt RCT.89 Data from the SWEFOT RCT90 were used by
Saevarsdottir et al.73 to build the SWEFOT clinical prediction model.
The Leiden Early Arthritis Clinic cohort was a common data source, being used in the development of models
by de Vries-Bouwstra et al.,65 Drossaers-Bakker et al.56 and van Steenbergen et al.77 The ESPOIR cohort was
RESULTS: REVIEW 1
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TABLE 2 Data sources used in the development and external validation of the included risk prediction models
Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
Clinical prediction model development studies
ASPIRE78 Active-controlled study of patients receiving
infliximab for the treatment of rheumatoid
arthritis of early onset (ASPIRE) RCT87
Internally validated in the anti-TNF trial in
rheumatoid arthritis with concomitant therapy
(ATTRACT)88 [median disease duration,
8.4 years (IQR 4.3–14.7 years); established RA
outside scope of assessment]
Multicentre, multinational study (122 sites in North
America and Europe)
Patients recruited between 2000 and 2002
Aged 18–75 years, met the 1987 revised ACR
criteria, persistent synovitis for 3 months to
3 years, ≥ 10 swollen joints and ≥ 12 tender
joints. Plus one or more of positive serum RF,
radiographically detected erosions of hands/feet
or CRP level of ≥ 2.0 mg/dl. Patients excluded if
any prior MTX (three or fewer pre-study doses
permitted), received other DMARDs within
4 weeks of entry (or LEF within past 6 months)
or treated with IFX, ETN, ADA or other anti-TNF
Subjects were excluded if they were infected with
HIV, hepatitis B or hepatitis C, they had a history
of active or past TB, congestive heart failure,
lymphoma or other malignancy within the past
5 years (excluding excised skin cancers)
Bansback58 Early Rheumatoid Arthritis Study (ERAS)
inception cohort
Unspecified regions of England (nine centres)
Cohort established in 1986
All consecutive RA patients seen within 2 years of
initial symptoms and before second-line drug use.
Patients completing 5 years of follow-up included
in the analysis
Berglin59 Cohort data Department of Rheumatology, University Hospital,
Umeå, Sweden, co-analysed with Northern
Sweden Health and Disease Study (NSHDS) cohort
and maternity cohort of northern Sweden (Medical
Biobank), Umeå, Sweden (number of centres and
period of data collection NR)
Department of Rheumatology, University Hospital,
Umeå register: early RA (duration of < 1 year)
meeting the 1987 revised ACR criteria for RA,
with a known date of the onset of symptoms
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TABLE 2 Data sources used in the development and external validation of the included risk prediction models (continued )
Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
BeSt79 Behandelings Strategie (BeSt) RCT89 18 peripheral and two university hospitals in the
western Netherlands
Patients recruited between 2000 and 2002
Early RA defined by the 1987 revised ACR criteria,
disease duration of ≤ 2 years, aged ≥ 18 years,
active disease with ≥ 6 of 66 swollen joints,
≥ 6 of 68 tender joints and either an ESR of
≥ 28mm/hour or a global health score of ≥ 20mm
on a 0- to 100-mm VAS (0 = best, 100 =worst)
Subjects were excluded if they had previous
DMARD treatment other than antimalarials,
concomitant treatment with an experimental drug,
malignancy within the past 5 years, bone marrow
hypoplasia, serum aspartate aminotransferase or
alanine aminotransferase (ALT) levels of > 3 times
the upper limit of normal level, serum creatinine
levels of > 150 µm/l or estimated creatinine
clearance of < 75ml/minute, diabetes mellitus,
alcohol or drug abuse, concurrent pregnancy,
wish to conceive during study period or
inadequate contraception
Brennan60 Prospective cohort All primary care general practices in Norwich
Health Authority, Norfolk, UK (number of
centres NR)
Recruited between 1990 and 1993
Satisfied any subset of the revised 1987 ACR RA
criteria and were recruited within 180 days of
the onset of symptoms, with complete baseline
and 1-year follow-up measurements (and having
provided blood for RF testing at baseline)
Centola61 Feasibility studies (stage 2): Oklahoma City
cohort and Brigham and Women’s
Rheumatoid Arthritis Sequential Study (BRASS)
cohort
Algorithm training study (stage 3): Brigham
and Women’s Rheumatoid Arthritis Sequential
Study (BRASS) cohort and Index for
Rheumatoid Arthritis Measurement (InFoRM)
study
NR All patients met ≥ 4 of 7 of the 1987 revised ACR
criteria for RA
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Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
Combe (A)62 Prospective cohort France (four centres: Montpellier, Paris-Cochin,
Toulouse and Tours)
Included March 1993 to October 1994
All consecutive outpatients referred from primary
care, disease duration of < 1 year, met ACR criteria
for RA, DMARD-naive
Combe (B)63 Prospective cohort France (four centres: Montpellier, Paris-Cochin,
Toulouse, Tours)
Included March 1993 to October 1994
All consecutive outpatients referred from primary
care, disease duration of < 1 year, met ACR criteria
for RA and were DMARD naive
de Punder64 Nijmegen early RA inception cohort Radboud University Medical Centre, Nijmegen,
the Netherlands
Included from 1985 to 2008
Satisfied the 1987 ACR criteria for RA, disease
duration of ≤ 1 year, no previous DMARD use
and aged ≥ 18 years. Patients with radiographs
available at inclusion and after 2 or 3 years’
follow-up included in analysis
Patients treated with biologic DMARDs within first
3 years were excluded from analysis
de Vries-Bouwstra65 Leiden Early Arthritis Clinic cohort Early Arthritis Clinic (EAC), Department of
Rheumatology, Leiden University Medical Centre,
the Netherlands
Sample from patients included from 1993 to 1999
Arthritis confirmed by rheumatologist, duration of
symptoms of < 2 years and patient had not seen
another rheumatologist for the same symptoms.
All patients presenting with RA/probable RA
and in whom a diagnosis of RA was confirmed at
3 months after presentation. Follow-up of ≥ 1-year
and radiographs of hands and feet at baseline
and after 1 year included in analysis. Definite RA
according to the 1987 revised ACR criteria but
without the criterion that symptoms must be of
6 weeks’ duration and observed by a physician
Degboé66 ESPOIR cohort 14 regional centres, France
Period of data collection NR
Suspected or confirmed RA diagnosis, aged
18–70 years, ≥ 2 swollen joints for > 6 weeks and
< 6 months, no receipt of DMARDs or steroids
except for < 2 weeks prior to entry. Included in
analysis if satisfied the 2010 ACR/EULAR criteria
and with complete radiographs at baseline and
year 1 and complete ACPA measurements
continued
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TABLE 2 Data sources used in the development and external validation of the included risk prediction models (continued )
Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
Dirven67 Behandelings Strategie (BeSt) RCT89 The Netherlands
Number of centres and period of data
collection NR
DMARD-naive patients, with RA as defined by the
1987 revised ACR criteria
Dixey68 Inception cohort Rheumatology departments of nine hospitals,
country NR, but assumed to be the UK
Recruitment of patients from 1986
Patients with RA according to the 1987 revised
ACR criteria, duration of symptoms of ≤ 2 years, no
use of second-line medication. Patients completing
3 years’ follow-up with adequate-quality
radiographs for scoring were included in the
analysis
Drossaers-Bakker56 Prospective inception cohort
Leiden Early Arthritis Clinic cohort
Rheumatology outpatient clinic of Leiden
University Medical Centre, the Netherlands
Patients attending from 1982 to 1986
All consecutive female RA patients, with symptoms
of < 5 years’ duration, aged 20–50 years at first
visit
ESPOIR69 ESPOIR cohort 14 regional centres in France (16 university
hospital rheumatology departments)
Patients referred and included from
December 2002 to March 2005
Patients recruited from the community, with early
arthritis for < 6 months, aged 18–70 years, two or
more swollen joints for > 6 weeks and < 6 months,
suspected/confirmed RA diagnosis, not receiving
any DMARDs or steroids except for < 2 weeks
before entry. Current study included ESPOIR
patients with RA diagnosis according to the
rheumatologist and receipt of first cDMARD with
demonstrated efficacy for ≥ 3 months of the first
year of follow-up
Forslind70 BARFOT (Better Anti-Rheumatic
Farmacotherapy) prospective cohort
Sweden (multicentre observational study, number
of centres NR)
Cohort recruited from July 1993 to June 1997
RA satisfying the 1987 revised ACR criteria, with a
disease duration of ≤ 1 year
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Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
Graell71 Prospective cohort Rheumatology units of Hospital Clinical of
Barcelona and Hospital Parc Tauli of Sabadell,
Spain
Patients recruited from 1998 to 2003
Patients met the 1987 revised ACR criteria;
symptoms for < 24 months, patients previously
treated with DMARDs or > 10mg/day of
prednisone were excluded
Houseman72 Prospective cohort Geographical setting and number of centres NR
(general rheumatology clinics)
Cohort established between 1998 and 2000
Consecutive early RA patients recruited from
general rheumatology clinics and from among
patients referred for early synovitis. Satisfied the
1987 revised ACR criteria for RA with the onset of
persistent symptoms for < 2 years
Sanmartí75 Prospective cohort Rheumatology units of Hospital Clinical of
Barcelona and Hospital Parc Tauli of Sabadell,
Spain
Patients recruited from 1998 to 2003
Patients met the 1987 revised ACR criteria;
symptoms for < 24 months, patients previously
treated with DMARDs or > 10mg/day of
prednisone were excluded
SONORA57 SONORA cohort North America Patients diagnosed by rheumatologist with early
RA (i.e. a symptom duration ≥ 3 and ≤ 12 months)
SWEFOT73 SWEFOT RCT 15 rheumatology units in Sweden90
Patients screened for inclusion from 2002 to
200590
RA according to the 1987 revised ACR criteria,
aged ≥ 18 years, with symptom duration for
< 1 year, a DAS28 of > 3.2, no previous DMARDs
and stable prednisolone dose if present for
≥ 4 weeks before entry and throughout the study
at ≤ 10mg/day
Syversen76 Prospective cohort
European Research on Incapacitating Disease
and Social Support (EURIDISS) project
Geographical setting, number of centres NR
EURIDISS began in 1992
Clinical diagnosis of RA (1987 ACR criteria), aged
20–70 years, with a disease duration of 0–4 years
at baseline
Patients with Steinbrocker function class IV
excluded
van Steenbergen77 Prospective cohort
Leiden Early Arthritis Clinic cohort
Leiden Early Arthritis Clinic
Recruited from 1993 to 2006
Patients meeting the 1987 ACR criteria and
symptom duration of ≤ 2 years
continued
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TABLE 2 Data sources used in the development and external validation of the included risk prediction models (continued )
Name of clinical prediction
model/external validation Name and study design of data source
Setting (number of centres) and period of
data collection Key eligibility criteria
External validation studies
De Cock80 Part of observational cohort
(Verschueren et al. 200881)
Department of Rheumatology at University
Hospitals of Leuven, Leuven, Belgium
Enrolled from 2001 to 2007
Consecutive DMARD-naive early RA patients.
Patients with radiographs of hands and feet at
baseline, year 1 and year 2 included in study
Patients in parallel RCTs excluded
Granger82 ESPOIR cohort France (14 regional centres)
Recruited from 2002 to 2005
Aged 18–70 years, with two or more swollen
joints for > 6 weeks and < 6 months, not taking
any DMARDs/steroids except for < 2 weeks
before entry. Patients with RA diagnosis from
rheumatologist and initiation of first cDMARD
Hambardzumyan83 SWEFOT RCT90 15 centres, Sweden
Patients screened for inclusion from 2002 to 2005
Aged > 18 years, DMARD naive, early RA meeting
the 1987 revised ACR criteria, with a symptom
duration of < 1 year
Heimans84 IMPROVED (Induction therapy with MTX and
Prednisone in Rheumatoid Or Very Early
arthritis Disease) randomised trial
Multicentre trial; 12 hospitals in the Netherlands
Recruited from 2007 to 2010
Patients with early RA (ACR/EULAR 2010 criteria,
a symptom duration of ≤ 2 years) and UA initially
treated with MTX and prednisone
Markusse85 Behandelings Strategie (BeSt) RCT89 18 peripheral and two university hospitals in the
western Netherlands
Patients recruited from 2000 to 2002
As for BeSt89
ATTRACT, anti-TNF trial in rheumatoid arthritis with concomitant therapy; DMARD, disease-modifying antirheumatic drug; HIV, human immunodeficiency virus; IQR, interquartile range;
NR, not reported; TB, tuberculosis; UA, undifferentiated arthritis; VAS, visual analogue scale.
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used to build models by Degboé et al.66 and Fautrel et al.69 Combe et al. developed models for the prediction
of radiographic damage/progression (Combe A)62 and HAQ score (Combe B)63 in French cohort data. The
Graell71 and Sanmartí75 clinical prediction model development studies used the same Spanish cohort data
source. The models by Bansback et al.,58 Berglin et al.,59 Brennan et al.,60 Centola et al.,61 de Punder et al.,64
Bombardier et al.57 (SONORA), Dixey et al.,68 Forslind et al.,70 Houseman et al.72 and Syversen et al.76 were
developed in cohort study data sets.
The five included external validation studies were also performed in appropriate data sources, being either
intervention trials {i.e. Hambardzumyan et al.83 (SWEFOT), Heimans et al.84 [Induction therapy with MTX
and Prednisone in Rheumatoid Or Very Early arthritis Disease (IMPROVED)], Markusse et al.85 (BeSt)} or
cohort study data [i.e. De Cock et al.80 (Verschueren cohort), Granger et al.82 (ESPOIR)].
Description of population characteristics
As outlined in Table 3, the majority of clinical prediction models were developed in populations that had
satisfied the 1987 ACR criteria for the diagnosis of RA (i.e. ASPIRE,78 Bansback et al.,58 Berglin et al.,59 BeSt,79
Brennan et al.,60 Centola et al.,61 Combe (A),62 Combe (B),63 de Punder et al.,64 de Vries-Bouwstra et al.,65
Dixey et al.,68 Dirven et al.,67 Forslind et al.,70 Graell et al.,71 Houseman et al.,72 Sanmartí et al.,75 SWEFOT,73
Syversen et al.76 and van Steenbergen et al.77). Degboé et al.66 used the 2010 ACR/EULAR criteria in their
diagnosis of patients, whereas in the ESPOIR model data source, patients had received a RA diagnosis from
their rheumatologist (and the proportion of patients meeting the ACR/EULAR 2010 criteria was reported).
The RA diagnosis method used by Drossaers-Bakker et al.56 was not specified. However, all patients were
described as having RA, and two other included studies (i.e. de Vries-Bouwstra et al.65 and van Steenbergen
et al.77), which were also developed using data from the Leiden Early Arthritis Clinic, both had used the
1987 ACR criteria (and, therefore, the review group has assumed a similar use of the 1987 ACR criteria by
Drossaers-Bakker et al.56). The amount of information available in the conference abstract by Bombardier
et al.57 describing the development of the SONORA clinical prediction model was limited. It was stated that
patients included in the SONORA study were diagnosed with RA by a rheumatologist. The populations used
in the external validation studies by Hambardzumyan et al.83 and Markusse et al.85 were diagnosed with
RA according to the 1987 revised ACR criteria. The patients of the ESPOIR cohort, included in the Granger
et al.82 external validation study, were diagnosed with RA by their rheumatologist (and the proportion
meeting the ACR/EULAR 2010 criteria was reported). Heimans et al.84 reported that the ACR/EULAR 2010
criteria were used for the diagnosis of RA in the mixed RA/undifferentiated arthritis population used for their
external validation study.84 In the De Cock et al.80 external validation study, all patients (in the Verschueren
cohort) were described as being newly diagnosed with early RA.
As stated in Study selection, early RA was defined in conjunction with clinical experts as being within
2 years of the onset of symptoms. Included studies reported either the duration of symptoms or the duration
of disease at baseline (with disease duration at baseline considered by the review team to be equivalent to
symptom duration in the absence of further information). The studies set an upper threshold of symptom/
disease duration for study eligibility and/or reported the median/mean symptom/disease duration at baseline,
as presented in Table 3. Compared across studies, the baseline median/mean symptom/disease duration for
included populations was typically approximately 5–6 months. The ESPOIR,69 Combe (A)62 and Combe (B)63
models were derived from patients with earlier RA (mean duration of disease of 15 weeks, 3.3 months and
3.6 months, respectively). The populations in the models by Drossaers-Bakker et al.56 (median symptom
duration of 1 year) and Syversen et al.76 (mean disease duration of 2.3 years) had disease of a longer
duration. It is noted that the population used to develop the Syversen et al.76 clinical prediction model was
outside the 2-year limit used to define early RA. However, this study was eligible for inclusion because it was
externally validated in a population that did meet the inclusion criteria (i.e. De Cock et al.80). The populations
in the data sources used for the six included external validation studies were all of ≤ 2-year symptom/disease
duration at baseline.
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TABLE 3 Key population characteristics of the included risk prediction model development and external validation studies
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Clinical prediction model development studies
ASPIRE78 Satisfied the 1987 revised ACR
criteria
Persistent synovitis for
3 months to 3 years
Median disease duration =
0.6 years (IQR 0.4–1.1 years)
DAS28 NR MTX-naive patients (three or fewer pre-study
doses of MTX permitted) randomised to receive
MTX monotherapy or MTX in combination with
3 or 6 mg/kg of infliximab through 46 weeks. IFX
and MTX groups were combined in each study
Bansback58 Patients meeting the 1987 revised
ACR criteria for RA included in the
main analysis. Patients not meeting
the 1987 ACR criteria followed and
considered in the subgroup analysis
Patients seen within 2 years of
initial symptoms
The median duration of
symptoms (months) reported
for patients with none/mild and
moderate/severe functional
impairment at 5 years was:
Mild group = 6 months
(IQR 4–11 months)
Severe group = 6 months
(IQR 4–12 months)
The median DAS28 reported
for patients with none/mild
and moderate/severe
functional impairment at
5 years was:
Mild group = 5.4 (IQR
3.5–7.9)
Severe= 6.2 (IQR 3.6–8.1)
DMARDs used based on physician preference
using standard practice of the late 1980s/1990s
(i.e. sequential monotherapy and ‘step-up’
combination treatment for more severe RA).
A total of 801 patients (81%) received ≥ 1
DMARDs starting at a median of 2 months
(68% by 3 months and 87% by 12 months).
The remaining 19% of patients received NSAIDs
and/or low-dose steroids. 54% of patients
received SSZ, 18% received MTX, 13% received
intramuscular gold, 9% received D-penicillamine,
4% received antimalarials and 2% received
unspecified treatments. A total of 55% of
DMARD-treated patients received ≥ 1 drugs.
A total of 17% (n= 164) received steroids at
≥ 7.5 mg daily for ≥ 12 months
Berglin59 Patients met the 1987 revised ACR
classification criteria for RA
Baseline median time after the
onset of symptoms =
7.0 months (IQR 5.0–9.0 months)
NR During the study, 92% of patients were treated
with DMARDs for > 6 months (68% received
MTX, 30% received SSZ, 14% received oral/
parenteral gold, 12% received antimalarials,
0.7% received anti-TNF agents, 12% received
other unspecified DMARDs and 30% received
combination therapy). A total of 48% of patients
received low-dose prednisolone (at ≤ 10mg/day)
for > 6 months during study
R
E
S
U
L
T
S
:
R
E
V
IE
W
1
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
3
2
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
BeSt79 The 1987 revised ACR criteria Symptom duration of ≤ 2 years
Baseline symptom duration,
median number of weeks:
MTX monotherapy = 25 weeks
(IQR 14–55 weeks)
Combination with
prednisone = 24 weeks
(IQR 15–56 weeks)
Combination with
IFX = 22 weeks
(IQR 13–44 weeks)
NR
A DAS of 4.3–4.5 across
groups
All patients were DMARD naive and met the
1987 ACR criteria for RA. Patients receiving
dynamic treatment strategies (aimed at a low
level of disease activity, shown by a DAS of
≤ 2.4). Group 1 (n= 126) and group 2 (n = 121)
patients began initial MTX monotherapy which
could be switched/extended with other
DMARDs. Group 3 (n= 133) patients began
combination MTX, SSZ, HCQ and tapered
high-dose prednisone. Group 4 (n= 128)
patients began a combination of MTX and IFX.
Treatment was adjusted every 3 months in
accordance with the fixed protocol with the
aim of achieving a DAS of ≤ 2.4. Groups 1
and 2 were combined for the current analysis.
Used data from patients randomised to initial
monotherapy or combination therapy
Brennan60 Satisfied any subset of the
American Rheumatism Association
1987 revised RA criteria
Patients were recruited within
180 days of the onset of
symptoms
Baseline disease duration
[(days) length of time between
patient-reported onset of
symptoms and first
examination by a metrologist
from the study]:
0–90 days, n = 91 (52%)
91–180 days, n= 84 (48%)
NR 83 out of 175 patients (47%) were treated with
second-line drugs at baseline (SSZ, 66/83 patients)
Treated with steroids at baseline, n= 35 (20%)
continued
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TABLE 3 Key population characteristics of the included risk prediction model development and external validation studies (continued )
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Centola61 Feasibility studies (stage 2 I–V): all
patients met four or more of the
seven 1987 revised ACR criteria
for RA
Algorithm training study (stage 3):
all patients met four or more of the
seven 1987 revised ACR criteria
for RA
Feasibility studies (stage 2 I–V):
NR
Algorithm training study
(stage 3): NR
Feasibility studies (stage 2 I–V):
DAS28-CRP median= 3.8 (IQR
2.7–5.0) to 5.8 (IQR 4.7–6.5)
Algorithm training study
(stage 3): DAS28-CRP
median = 3.8 (IQR1.6–6.4)
Feasibility studies (stage 2 I–V): MTX, 48–64%;
non-biologic DMARDs, 64–81%; biologics,
43–65%; and corticosteroids, 24–33%
Algorithm training study (stage 3) NR
Combe (A)62 Patients met the ACR criteria for RA Disease duration of < 1 year
Mean duration of disease
at baseline = 3.3 months
(SD 2.6 months)
NR
Mean DAS: 4.1 (SD 0.8)
Patients were DMARD naive at entry, treated
with DMARDs (typically MTX or SSZ, modifiable
based on efficacy/side effects). During 3-year
study, mean of 1.7 DMARDs used (range 1–5;
MTX, n = 166 patients; SSZ, n= 146 patients;
gold, n = 32 patients; HCQ, n= 20 patients;
D-penicillamine, n= 13 patients; and CsA, n= 1
patients). A total of 63 patients received
low-dose prednisone (5–15 mg/day) on more
than one occasion during follow-up
Combe (B)63 Patients met the ACR criteria for RA Disease duration of < 1 year
Mean duration of disease at
baseline = 3.6 months
(SD 2.6 months)
NR
Mean DAS: 4.1 (SD 0.8)
Patients were DMARD naive at entry, treated
with DMARDs (typically MTX or SSZ, modifiable
based on efficacy/side effects). During the 5-year
study, a mean of 1.95 DMARDs was used
(range 1–5; MTX, n= 175 patients; SSZ, n= 147
patients; gold, n= 41 patients; HCQ, n = 25
patients; D-penicillamine, n= 14 patients; and
CsA, n= 1 patient). A total of 63 patients
received low-dose prednisone (5–15mg/day) on
more than one occasion during follow-up
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Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
de Punder64 Satisfied the 1987 ACR criteria
for RA
Disease duration of ≤ 1 year Mean baseline DAS28
reported for groups with:
1. joint damage progression
[DAS28= 5.5 (SD 1.3)]
2. no joint damage
progression
[DAS28= 4.9 (1.4)]
Joint damage progression group:
l Combination of DMARDs (unspecified),
n= 37 (21%)
l Monotherapy DMARDs (unspecified),
n= 132 (75%)
l Oral prednisone, n= 107 (61%)
No joint damage progression group:
l Combination DMARDs (unspecified),
n= 51 (20%)
l Monotherapy DMARDs (unspecified),
n= 181 (72%)
l Oral prednisone, n= 152 (61%)
de Vries-Bouwstra65 Definite RA in accordance with the
1987 revised ACR criteria, but
without the criterion that symptoms
must be of 6 weeks’ duration and
observed by a physician
Duration of symptoms:
< 2 years
Median symptom duration
at first visit = 22 weeks
(IQR 11–45 weeks)
NR A total of 85% of included patients who received
DMARDs during the first year after diagnosis
(starting with HCQ for 40% of patients, SSZ for
30% of patients or unspecified other drugs for
30% of patients). A total of 14 patients (9.2%)
received combination DMARDs in the first year,
nine patients received a combination of
antimalarial drugs with other DMARDs (n= 3
patients received antimalarial drugs and MTX;
n= 5 patients received antimalarial drugs and
ciclosporin; and n= 1 patient received
antimalarial drugs and experimental peptide
vaccination strategy). Other combinations: SSZ
and low-dose prednisone (n= 2); MTX and
low-dose prednisone (n= 2); and SSZ and
interferon-beta (n= 1). DMARD combination
commenced after a mean of 24 weeks after
presentation. No patient was treated with
combination drugs directly after presentation
continued
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TABLE 3 Key population characteristics of the included risk prediction model development and external validation studies (continued )
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Degboé66 RA according to the 2010 ACR/
EULAR criteria
Two or more swollen joints for
> 6 weeks and < 6 months
Median disease duration =
5.0 months (IQR 3.1–
7.4 months)
NR Baseline treatment: steroids, n= 71 patients
(12.5%)
Year 1 treatment: steroids, n= 259 patients
(45.8%)
Any DMARDs, n= 436 patients (82.4). Biologic
DMARDs, n = 40 patients (7.1%)
Dirven67 RA according to the 1987 revised
ACR criteria
Median symptom duration
(weeks) at baseline:
MTX monotherapy group =
25 weeks (IQR 14–55 weeks)
Combination + prednisone =
23 weeks (IQR 15–53 weeks)
Combination + IFX = 23 weeks
(IQR 13–46 weeks)
Mean DAS at baseline:
MTX monotherapy group =
4.5 (SD 0.9)
Combination+ prednisone =
4.4 (SD 0.9)
Combination+ IFX =
4.3 (SD 0.9)
For analysis, strategy groups 1 and 2 combined
as patients achieved a HAQ score at 3 months
on the same initial treatment, i.e. MTX
monotherapy. In strategy 3, patients started on
combination MTX, SSZ and tapered high-dose
prednisone. In strategy 4, patients started on a
combination of MTX and IFX
Dixey68 RA according to the 1987 revised
ACR criteria
Duration of symptoms for
≤ 2 years
Median duration of RA
symptoms prior to presentation
to the rheumatologist and
study entry was 6 months
(4–11 months)
NR DMARD selected according to physician
preference. A total of 80% of patients received
at least one DMARD at a median of 7 weeks
from first presentation to a rheumatology clinic.
First DMARD:
l SSZ, 73%
l Intramuscular gold, 10%
l D-penicillamine, 7%
l Oral gold, 3%
l Antimalarials, 3%
l MTX, 3%
l Various others (azathioprine, ciclosporin,
cyclophosphamide)
A total of 16% of patients used steroids at a
dose of ≥ 7.5 mg daily for ≥ 12 months
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Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Drossaers-Bakker56 NR (all RA), but de Vries-Bouwstra
et al. (2006)65 and van Steenbergen
et al. (2015)77 samples from the
Leiden Early Arthritis Clinic both
used the 1987 revised ACR criteria
(therefore assumed a similar use of
the 1987 revised ACR criteria)
Symptoms of < 5 years’
duration (median 1 year)
Median baseline DAS = 2.8
(IQR NR)
NR
ESPOIR69 RA diagnosis according to the
rheumatologist; n= 316 patients
(85.4%) met the ACR/EULAR
criteria at baseline
Early arthritis for < 6 months,
two or more swollen joints for
> 6 weeks and < 6 months
Mean disease duration of
15.2 weeks (SD 15.4 weeks)
Mean DAS28 = 5.4 (SD 1.2) One hundred per cent of patients received MTX
or LEF as a first-line agent
Treatment based on usual care by
rheumatologist. A total of 370 patients started
MTX (n = 335, mean dose of 17.5 mg/week) or
LEF (n = 35, mean dose of 20 mg/week). A total
of 302 patients still receiving MTX at 1 year,
19 patients switched to another cDMARD and
11 patients switched to a bDMARD. Two
patients receiving LEF switched to a bDMARD
at 1 year
Forslind70 RA satisfying the 1987 revised
ACR criteria
Disease duration of ≤ 1 year
Median disease duration
at baseline = 6 months
(IQR 4–8 months)
Median DAS28 at
baseline= 5.10
(IQR 4.22–5.85)
Patients were DMARD naive and corticosteroid
naive at entry. At baseline, patients were given:
MTX, 36%; SSZ, 51%; other unspecified
DMARDs, 13%; and MTX and SSZ, n= 1.
At study end, 254 patients received DMARD
treatment (MTX, 49%; SSZ, 22%; other
unspecified DMARD, 19%; 10% combination
therapy). At the start, 167 patients received
low-dose prednisolone (mean) at a daily dose
of 8.30 mg (SD 2.45 mg) and by study end,
155 patients were receiving prednisolone at a
dose of 5.90 mg/day (SD 2.70 mg/day)
continued
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TABLE 3 Key population characteristics of the included risk prediction model development and external validation studies (continued )
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Graell71 Patients met the 1987 revised ACR
criteria
Symptoms for < 24 months,
Baseline mean disease
duration = 10 months
(SD 6.7 months)
Mean DAS28 5.66 (SD 0.91) Patients treated with therapeutic protocol with
the early use of DMARDs using a step-up
approach. 50 mg/week of intramuscular sodium
aurothiomalate prescribed as first-choice DMARD
plus 4 mg/day of methylprednisolone. NSAIDs
and intra-articular steroids were given at clinical
discretion. Introduction of MTX at a dose of
7.5–30mg if adverse events/lack of efficacy at
6 months (or according to clinical discretion for a
high level of disease activity before 6 months).
ACR50 responders at 6 months received gold
salts every 2 or 3 weeks. ACR20 criteria
responders (but not ACR50 criteria responders)
at 6 months received a combination of sodium
aurothiomalate and MTX. Tapering of oral
steroids was done according to clinical
judgement. After 1 year, patients were treated
using an aggressive approach informed by clinical
judgement (with initiation of other DMARDs/
bDMARDs when required)
Houseman72 Satisfied the 1987 revised ACR
criteria for RA
Onset of persistent symptoms
of < 2 years before entry
Median disease duration:
l Low-progressors group =
260 (IQR 169–412) days
l High-progressors group =
242 (IQR 146–384)
Median baseline DAS28:
l Low-progressors
group = 5.1 (IQR 4.0–6.1)
l High-progressors
group = 6.2 (IQR 4.8–6.8)
Treatment according to local practice with
sequential DMARD monotherapy or combination
therapy. Five patients subsequently received
anti-TNF therapy
Sanmartí75 Patients met the 1987 revised ACR
criteria
Disease duration of < 2 years
Baseline mean disease
duration = 10 months
(SD 6.7 months)
Mean DAS28 of 5.7 (SD 0.9);
75.7% of patients had a
DAS28 of > 5.1
Patients treated with therapeutic protocol (as for
Graell et al.71) of gold salts and MTX in a step-up
approach plus methylprednisolone (4 mg/day)
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Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
SONORA57 Patients diagnosed with RA by a
rheumatologist (method NR)
Symptom duration of ≥ 3 and
≤ 12 months
Mean disease duration
170 days (SD 180 days)
NR NR
SWEFOT73 RA according to the 1987 revised
ACR criteria
Symptom duration of < 1 year
Median symptom duration =
5 months (IQR 4–8 months)
Median baseline DAS28 = 5.8
(IQR 5.0–6.4)
Baseline concurrent prednisolone, n= 42
patients (14%)
Baseline concurrent NSAIDs, n= 192 patients
(62%)
MTX monotherapy, combination with IFX,
combination with SSZ and HCQ
Syversen76 Clinical diagnosis of RA according
to the 1987 ACR criteria
Mean disease duration at
baseline = 2.3 years
(SD 1.2 years)
DAS28 NR Patients treated according to rheumatologist
preference
Baseline (10-year follow-up) treatments:
l DMARDs, 52.1% (48%)
l NSAIDs, 52% (44%)
l Prednisolone, 25% (36%)
l Anti-TNFs, 0% (12%)
A total of 14.1% of patients received no
DMARDs or anti-TNFs during the study
van Steenbergen77 Patients meeting the 1987 ACR
criteria
Symptom duration of ≤ 2 years NR Initial treatment differed based on the inclusion
time period:
l 1993–5, initial NSAIDs
l 1996–8, initial HCQ or SSZ
l Since 1999, initial MTX
continued
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TABLE 3 Key population characteristics of the included risk prediction model development and external validation studies (continued )
Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
External validation studies
De Cock80 All newly diagnosed early RA
patients (method NR)
Mean symptom duration:
8 months (SD 7 months)
Mean disease duration:
1 month (SD 1 month)
Mean DAS28-CR: 4.91
(SD1.22)
ICTS (n= 32 patients) or IMT (n = 42 patients)
received based on patient RA severity according
to rheumatologist opinion. Evaluated at least
every 4 months
Granger82 Patients with RA diagnosis from
their rheumatologist (n= 316,
85.4% met the 2010 ACR/EULAR
criteria)
Disease duration of 15.2 weeks
(SD 8.2 weeks)
DAS28: 5.3 (SD 1.2) ESPOIR treatment strategies were not protocol
based. Included patients in this study received
MTX or LEF for at least 3 months within the first
year of follow-up. Duration of DMARD treatment
during the first year of 9.06 months (SD 3.07
months), 26% of patients received concomitant
glucocorticoids. Some patients received an
‘insufficient dosage’ of another treatment
(cDMARD or bDMARD); this not considered in
the analysis
Hambardzumyan83 RA in accordance with the 1987
revised ACR criteria
Mean symptom duration:
6.2 months (SD 4.57 months)
Baseline mean DAS28-ESR:
5.7 (SD 1.01)
Baseline mean DAS28-CRP:
6.5 (SD 1.22)
As for the SWEFOT RCT
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Name of clinical
prediction
model/external
validation study
Diagnosis (and proportion)
of RA
Duration of
symptoms/disease
at baseline DAS28 at baseline Treatment
Heimans91 Mixed RA/UA population (80.3% of
the population for the matrix model
had RA)
[Patients with early RA (ACR/EULAR
2010 criteria)]
Symptom duration of ≤ 2 years
(Heimans et al. 2014)
Median symptom duration:
18 weeks (IQR 9–34 weeks)
DAS28 NR
Mean baseline DAS: 3.34
(SD 0.9)
IMPROVED study patients initially treated with
MTX at a dose of 25 mg/week and prednisone
at a dose of 60 mg/day tapered to 7.5 mg/day in
7 weeks. Medication tapered in patients
reaching early remission (a DAS of < 1.6 after
4 months). Patients not in early remission after
4 months randomised to either MTX at a dose of
25 mg/week and HCQ at a dose of 400mg/day
and SSZ at a dose of 2000mg/day and
prednisone at a dose of 7.5 mg/day (study arm 1)
or to MTX at a dose of 25 mg/week and ADA
at a dose of 40 mg/2 weeks (study arm 2). During
follow-up, medication was increased or switched
in the case of no remission and tapered or
stopped in the case of remission
Markusse85 1987 revised ACR criteria NR, but disease duration of
≤ 2 years in BeSt RCT
Mean baseline DAS28 ranged
from 5.82 (SD 1.03) to 5.98
(SD 1.00)
As for BeSt
CsA, ciclosporin A; DMARD, disease-modifying antirheumatic drug; ICTS, initial DMARD combination therapy with steroids; IMT, DMARD monotherapy; IQR, interquartile range; NR, not
reported; UA, undifferentiated arthritis.
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The DAS28 disease severity score at baseline was tabulated when available. A DAS28 of ≥ 5.1 is classed
as severe disease, whereas a DAS28 of 3.2–5.1 is regarded as moderate disease severity.19 Unfortunately,
the DAS28 at baseline was not available for the majority of studies. Five clinical prediction models (i.e.
ESPOIR,69 Forslind et al.,70 Graell et al.,71 Sanmartí et al.75 and SWEFOT73) were developed in populations
that were defined as having severe disease activity based on the DAS28. Two external validation studies
were performed in populations with severe DAS28 (i.e. Granger et al.82 and Hambardzumyan et al.83).
In some studies, the DAS28 at baseline was reported only for subgroups (rather than for the total
population), but indicated a severe DAS28. The cohort used in the De Cock et al.80 external validation was
borderline between the moderate and severe DAS28 categories [mean DAS28-CRP of 4.91 (SD 1.22)].80
Therefore, unfortunately, sufficient data were not available to evaluate the performance of predictors
across moderate and severe DAS28 populations.
The treatment histories and concurrent treatments in included studies are described in Table 3. Additional
population characteristics at baseline are presented in Appendix 7, Table 30.
The data sources and participant selection in the included studies were assessed using domain 1 of the
PROBAST tool49 (see Appendix 6).
Appropriate data sources were considered to have been used for all model development and external validation
studies. Inclusions and exclusions of participants were considered by the review authors to be acceptable
overall. However, it was noted that the Drossaers-Bakker model56 included only female participants, which
may affect the generalisability of the model. As explained previously, the Syversen model76 was developed in
a population with a longer mean disease duration [mean 2.3 years (SD 1.2 years)]. Although the Syversen
model76 has been externally validated in a relevant population, this may affect the performance of the model.
It was stated in the final protocol that, for review 1, patients should have been diagnosed with early RA
according to established criteria. The methods used for RA diagnosis in included studies are presented
in Table 3. The lack of clarity around the method of RA diagnosis used in the populations in the
Drossaers-Bakker56 and SONORA57 clinical prediction models and the De Cock external validation study80
may contribute to a potential source of bias. The De Cock external validation study80 was based on a
cohort recruited at the University of Leuven, Belgium. The original report for this study cohort described
patients as being ‘newly diagnosed with RA.’ Although the specific method used for diagnosis was not
reported, the entire cohort was described as having a diagnosis of RA and the duration of symptoms
meets our definition of early RA. Therefore, in light of the fact that the De Cock external validation study80
presents key informative evidence comparing the performance of multiple clinical prediction models and is
described as being based on an early RA cohort, this study has been included.80
Three model development studies were rated as having an unclear risk of participant selection bias on
PROBAST domain 1 [i.e. Drossaers-Bakker et al.,56 Bombardier et al. (SONORA)57 and Syversen et al.76].
All other remaining model development studies were rated as being at a low risk of participant selection
bias. Two external validation studies were rated as having an unclear risk of bias for participant selection
(i.e. De Cock et al.80 and Heimans et al.84). All other external validation studies were categorised as having
a low risk of bias for participant selection.
Description of predictors
The candidate predictors considered in the development of clinical prediction models are presented
in Table 4. The candidate predictors were interpreted by the review team to be all predictors considered in
the model development process (and were not limited to those included in the multivariable analysis) in
line with the definition applied in CHARMS (i.e. Moons et al.48).
RESULTS: REVIEW 1
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TABLE 4 Characteristics of the candidate predictors studied in the included clinical prediction model
development studies
Name of the clinical
prediction model
development study Definition and measurement of candidate predictors Timing of measurement
ASPIRE78 TJC, SJC, ESR (Westergren method), CRP level (nephelometry), IgM
RF and radiographs of hands and feet. Association tested between
‘all available baseline variables’ from the ASPIRE data set and
radiographic progression
Baseline
Bansback58 Model development involved the removal of predictors from the
full 35-predictor model. Nineteen individual candidate predictors
reported: sex, age at onset, months of RA symptoms prior to
diagnosis, RF, presence of nodules, Carstairs deprivation index, ACR
criteria, number of DMARDs used in the first year, functional grades
I–IV, morning stiffness (hours), SJC, TJC, grip strength (0–300mm),
HAQ score, pain score (VAS 0–100), haemoglobin level, ESR, DAS28
and radiographic damage, scored using the Larsen Damage and
Erosion Scores
Baseline and 1 year
Berglin59 NR, but the multivariable analysis included anti-CCP, IgG, IgM, IgA
RF by ELISA, SE via HLA-DRB1 genotyping, ESR (mm/hour), SJC28,
Larsen score, therapeutic EULAR response at 6 months
Baseline and therapeutic
response at 6 months
BeSt79 Age, sex, BMI, symptom duration, smoking, SJC, TJC, DAS, CRP
(mg/l), ESR (mm/hour), HAQ score, total SHS, erosion score, IgM RF
positivity (measured in participating hospitals according to cut-off
point of each laboratory) and ACPA positivity (EuroDiagnostica,
Arnhem, the Netherlands and Axis-Shield Diagnostics, Dundee, UK)
Baseline
Brennan60 A total of 11 individual candidate predictors reported as being
measured at baseline (assumed all were entered into modelling):
RF titre (from tube latex test, 1 : 80 cut-off point for positive result),
swelling of specific joint areas, number of swollen joints, duration
of morning stiffness, presence of rheumatoid nodules, disability
score, age, sex, disease duration (length of time between symptom
onset and first presentation to register metrologist: < 90 days or
90–180 days), time between onset of disease and radiography and
HAQ score
Baseline
Centola61 Candidate predictors selected using a multistage approach. A total
of 130 candidate biomarkers were tested in feasibility studies and
25 were tested in algorithm development, training and selection
Unclear (assumed
baseline for subset of
patients)
Combe (A)62 Age, sex, BMI, disease duration, duration of morning stiffness,
patient VAS pain, SJC, TJC, Ritchie Articular Index, DAS, presence/
absence of nodules and extra-articular manifestations, HAQ score,
ESR, CRP level, IgA and IgM RF positivity by enzyme-linked
immunosorbent assay (ELISA), antikeratin anti-body positivity,
antiperinuclear anti-body positivity, antiRA33 anti-body positivity,
antiheat shock protein positivity, anticalpastatin anti-body positivity,
YKL-40 positivity, antinuclear anti-body positivity, HLA-DRB1 and
DQB1 genotyping, SHS
Baseline
Combe (B)63 Age, sex, BMI, disease duration, duration of morning stiffness,
patient VAS pain, swollen and tender joint counts, Ritchie Articular
Index, DAS, presence/absence of nodules and extra-articular
manifestations, HAQ score, ESR, CRP level, IgA and IgM RF positivity
by ELISA, antikeratin anti-body positivity, antiperinuclear anti-body
positivity, antiRA33 anti-body positivity, antiheat shock protein-90
positivity, anticalpastatin anti-body positivity, YKL-40 positivity,
antinuclear anti-body positivity, HLA-DRB1 and DQB1 genotyping
and radiographic score
Baseline
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TABLE 4 Characteristics of the candidate predictors studied in the included clinical prediction model
development studies (continued )
Name of the clinical
prediction model
development study Definition and measurement of candidate predictors Timing of measurement
de Punder64 Anti-CCP and/or RF (0, 1 or 2 positive) (positive anti-CCP level of
> 25 U/ml, ELISA immunoscan RA mark 2, > 10 U/l for frozen
samples, EliA™ CCP (Thermo Fisher Scientific, Waltham, MA, USA;
positive RF of > 10 U/ml), SE (positive/negative), smoking status (ever
or never), ESR (< 25 , 25–50 or > 50mm/hour), CRP level (≤ 5, 6–10,
≥ 11 mg/dl), SJC28 (0–5, 6–10, 11–15, > 15), TJC28 (0–5, 6–10,
11–15, > 15), VAS general health (0–29, 30–60, 61–100), VAS pain
(0–29, 30–60, 61–100), erosions (0, 1–5, 6–10, > 10 Ratingen
points), DAS28 (≤ 3.2, 3.3–5.1, ≥ 5.2), age and sex
Baseline
de Vries-Bouwstra65 Age (continuous), sex, duration of symptoms at presentation
(> 6 weeks or ≤ 6 weeks), duration of morning stiffness
(continuous), patient’s global assessment of disease activity
(continuous), HAQ score (continuous), total SJC [maximum
22 (continuous)], Ritchie Articular Index score (continuous), bilateral
compression pain in metatarsophalangeals (categorical), IgM RF
positivity (≥ 5 U) by ELISA (categorical), ESR (continuous), SE hetero-
or homozygosity (categorical), presence of erosions on radiographs
(categorical), SHS (continuous) and DMARD therapy received
Baseline
Degboé66 Anti-CCPs [anti-CCP2 (DiaSorin, Saluggia, Italy], anti-mutated
citrullinated vimentin [positivity of > 20 UA/ml (Orgentec, Mainz,
Germany)], anticitrullinated fibrinogen (positivity of > 0.056 AU,
in-house ELISA). Categorised as negative, low titre, high titre, IgM RF
[(Menarini Diagnostics, Winnersh, UK) positivity of > 9 UI/ml],
presence of HLA-DRB1 SE (typing and subtyping using PCR), ESR,
CRP level, age, sex, duration of disease course before inclusion,
smoking consumption, clinical centre, presence of erosions at
baseline and treatment (use of steroids, synthetic or biologic
DMARDs within the first year tested in the model)
Baseline
Dirven67 Age, sex, symptom duration, DAS, HAQ, pain, Ritchie Articular
Index, SJC, TJC, treatment group, presence of RF, anti-CCP,
radiological damage (total SHS, erosion score, narrowing score,
erosions), SE, smoking status, VAS disease activity, VAS pain,
VAS morning stiffness, VAS global health, BMI, CRP level and ESR
Baseline
Dixey68 Larsen erosion score, RF, ESR, haemoglobin level, nodules, SJC, grip
strength, duration of symptoms, presence of HLA-DR SE, HAQ, DAS.
All continuous variables were categorised into quartiles
Baseline and 1 year
Drossaers-Bakker56 Disease duration, RF, HLA-DQ and HLA-DR SEs, RA protected,
percentage agalactosyl IgG, SJC, Ritchie score, presence of erosions
and HAQ score
Baseline
ESPOIR69 Age, sex, SJC28 (< 14, 14–20 or ≥ 20), TJC28, ESR, CRP (mg/l,
< 4, 4–35 or ≥ 35), elevated ESR or CRP level, DAS28-ESR, ACPA
positivity, RF positivity, ACPA or RF positivity, HAQ score, typical RA
erosion, disease duration, prednisone at a dose of ≥ 7.5 mg/g, delay
before first DMARD initiation for ≥ 6 months after the onset of RA,
satisfaction of the 2010 ACR/EULAR criteria. Combe 2007 ESPOIR
description: clinical and biological variables recorded at baseline and
each visit. Baseline CRP level (number of < 10mg/l), IgM and IgA RF
[ELISA (Menarini, Rungis, France), positive at > 9 U/ml], anti-CCP2
anti-bodies [ELISA (DiaSorin, Antony, France), positive at > 5 U/ml]
measured for all patients using the same method in a central
laboratory
Baseline
RESULTS: REVIEW 1
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TABLE 4 Characteristics of the candidate predictors studied in the included clinical prediction model
development studies (continued )
Name of the clinical
prediction model
development study Definition and measurement of candidate predictors Timing of measurement
Forslind70 Anti-CCP1 [ELISA (EuroDiagnostica, Malmö, Sweden)], positive result
titre of ≥ 25 U/ml), RF [Serodia agglutination test (Fujirebio Inc.,
Tokyo, Japan)], positive result titre of 20 IU/ml), HLA-DRB104
genotyping, DAS28, ESR (mm/hour), CRP (mg/l), VAS global health,
VAS pain, HAQ score and Larsen score
Baseline
Graell71 Sex, age, disease duration, marital status (widowed), handworkers,
education, active work, HLA-DRB104, SE, RF (> 25 U/l), anti-CCP
(> 50 U/l), ESR (mm/hour), CRP (mg/dl), haemoglobin level, TJC28,
SJC28, patient’s global assessment, physician’s global assessment,
VAS pain, DAS28, a DAS28 of > 5.1, MHAQ and Larsen score
Baseline
Houseman72 Anti-CCP positivity [titre of > 6 U/ml (Axis-Shield Diagnostics, Dundee,
UK)], RF (> 40 U/ml), elevated MMP-3 levels (i.e. > 85.79 ng/ml),
C-telopeptide of type II collagen level (> 20 µg/mmol), cartilage
oligomeric matrix protein level (> 11.20 U/l), tissue inhibitor of
metalloproteinase 1 level(> 688.68 ng/ml,) ESR (> 20mm/hour),
CRP level (> 5mg/l), radiographic damage (i.e. a SHS of > 7)
and a physician’s global assessment on the VAS (> 49.00mm)
Baseline, anti-CCP taken
at the 8.2-year follow-up
Sanmartí75 NR, but univariable analysis reported to include significant factors:
haemoglobin level, ESR, sex, SE, SE homozygosity, HLA-DRB1*04
genotype, anti-CCP, RF and MHAQ
Baseline
SONORA57 Limited reporting of candidate predictors Baseline
SWEFOT73 Sex, age, symptom duration, anti-CCP positivity [Immunoscan-RA
mark 2 (ELISA test, EuroDiagnostica, Malmö, Sweden)], RF positivity,
(determined using routine methods), RF and/or anti-CCP positivity,
smoking status (current, past or never), radiographic erosions,
concurrent prednisolone use, DAS28 (per unit increase), SJC
(< 10, 10–17 or > 17), TJC (per increase of 10), CRP level
(< 10mg/dl, 10–35mg/dl, > 35mg/dl), ESR (< 21mm/hour,
21–50mm/hour or > 50mm/hour), VAS-global health (per increase
of 10), HAQ score (per unit increase) and HLA-DRB1 SE
Baseline
Syversen76 CRP [positive at > 10mg/l; phyCardioPhase hsCRP (Dade Behring
Inc., Deerfield, IL, USA)], ESR (positive at > 20mm/hour; Westergren
method range 0–140mm/hour), anti-CCP [negative at < 25 U/ml,
25–200 U/ml (low to moderate) or > 200 U/ml (high), as assessed via
second-generation ELISA (Inova Diagnostics, San Diego, CA, USA)],
IgA RF and IgM RF (positive at > 25 U/l, in-house ELISA), sex, HAQ
score, age and radiographic progression rate
Baseline
van Steenbergen77 Age, sex, symptom duration at first visit, localisation of initial joint
symptoms, SJC66, ACPA status, RF, ESR, SE, selected SNPs located
in/nearby gene(s) (i.e. CD40, IL-15, DKK-1, IL2RA, GRZB, IL4R,
SPAG16, C5orf30, MMP-9, rs1465788 and OPG)
Baseline
AhFibA, anti-human citrullinated fibrinogen anti-body; anti-CCP2, anti-cyclic citrullinated peptide-2; AU, arbitrary units;
C5orf30, chromosome 5 open reading frame 30; CCP, cyclic citrullinated peptide; CD40, cluster of differentiation 40;
DMARD, disease-modifying antirheumatic drug; ELISA, enzyme-linked immunosorbent assay; GRZB, granzyme B;
HLA, human leucocyte antigen; hsCRP, high-sensitivity CRP; IgA, immunoglobulin A; IgG, immunoglobulin G;
IgM, immunoglobulin M; IL-15, interleukin 15; IL2RA, interleukin 2 receptor alpha chain; IL4R, interleukin 4 receptor;
MHAQ, modified Health Assessment Questionnaire; MMP-3, matrix metalloproteinase 3;MMP-9, matrix metalloproteinase 9;
NR, not reported; OPG, osteoprotegerin; PCR, polymerase chain reaction; rs, reference SNP cluster ID; SE, shared epitope;
SHS, Sharp–van der Heijde score; SJC28, 28 swollen joint count; SNP, single nucleotide polymorphism; SPAG16,
sperm-associated antigen 16; TJC28, 28 tender joint count; VAS, visual analogue scale.
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The timings of the measurement of candidate predictors in the included model development studies were
noted. Measurement was at baseline for all studies, although some studies (i.e. Bansback et al.,58 Berglin
et al.,59 Dixey et al.68 and Houseman et al.72) also measured predictors at later time points. Anti-CCP
positivity was measured at the extension visit (at 8.2 years of follow-up) in the Houseman et al. study72
and was also included in the final clinical prediction models. The inclusion of predictors measured at
substantially later time points is potentially problematic to the validity of the resulting clinical prediction
model. Variables measured at later time points are problematic: they cannot be used to make predictions
about outcomes in patients with newly diagnosed RA in clinical practice because the observation will not
be available until after the decision has been made to treat the patient. The outcome will depend on the
specific sequence of treatments administered, and such observations will bias the model relative to models
that use only baseline information. None of these models has been externally validated, which highlights
the difficulty in their application.
Given the incomplete reporting in the conference abstract, it was unclear which candidate predictors were
considered in the SONORA model.57
We considered whether or not all relevant candidate predictors were analysed (i.e. whether or not all
variables selected for inclusion in conjunction with clinical advisors were considered in the model
development studies as candidate predictors). When selected variables of interest were not examined as
candidate predictors, these studies were rated as being at an unclear risk of bias (as it was not clear what
potential contribution the untested predictors may have had).
Description of outcomes
The outcomes assessed by the included studies are presented in Table 5 for the model development
studies and in Table 6 for the external validation studies.
Among the clinical prediction model development studies, the majority assessed radiographic joint damage
as an outcome. Six models were developed to predict radiographic progression [modified Sharp–van der
Heijde score (SHS)] at 1 year: ASPIRE,78 BeSt,79 de Vries-Bouwstra,65 Degboé,66 ESPOIR69 and SWEFOT.73
The SONORA model57 assessed radiographic progression (original Sharp score) at 1 and 2 years. Combe (A)62
predicted radiographic score and radiographic progression (modified SHS) at 3 years. Van Steenbergen et al.77
and Houseman et al.72 studied radiographic progression (modified SHS) at 6 and 8.2 years, respectively.
The Syversen model76 predicted radiographic progression (modified SHS) over the longest follow-up period
(i.e. 10 years). Five studies evaluated radiographic joint damage/progression, measured using the Larsen score
(i.e. Brennan et al.60 at 1 year; Berglin et al.,59 Forslind et al.70 and Sanmartí et al.75 at 2 years; and Dixey
et al.68 at 3 years). De Punder et al.64 assessed radiographic progression (according to the Ratingen score)
at 3 years.
Five other clinical prediction models were designed for the prediction of other eligible outcomes. Dirven
et al.67 assessed short-term functional disability (HAQ score of ≥ 1) after 3 months of treatment. The
outcome used in the Graell model71 was the modified HAQ (MHAQ) at 2 years. Bansback et al.58 and
Combe (B)63 both modelled the HAQ score at 5 years [with Combe (B)63 also modelling the 3-year HAQ
score]. Drossaers-Bakker et al.56 included a broad range of outcomes, categorised as (1) body functions and
structure (impairment), (2) activities at the individual level (disability), (3) participation in society (handicap)
and (4) disease course. However, because of unclear reporting, the performance of the individual models
could not be summarised, and so this study was counted as a single model in the combined total of
39 included models.
RESULTS: REVIEW 1
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TABLE 5 Definition of the outcomes in the included model development studies
Name of clinical
prediction model Outcome category Outcome definition and measurement
Predicted time
point
ASPIRE78 Radiographic progression (modified SHS)a Radiographs of hands and feet obtained and scored using the van der
Heijde modification of the SHS. RRP was defined as a threshold change in
the modified Sharp/van der Heijde (SHS) of ≥ 5 U/year
1 year
Bansback58 HAQ score A HAQ score of ≥ 1.5 was defined as moderate to severe disease. Patients
completed the disability index of the modified Stanford HAQ (range 0–3)
5 years
Berglin59 Radiographic progression (Larsen) Radiographic progression defined as present if the difference in Larsen
score at baseline and 2 years was greater than the median value.
Posteroanterior radiographs of hands, wrists and feet
2 years
BeSt79 Radiographic progression (SHS)a Radiographs of hands and feet taken at baseline and after 1 year. RRP
(increase in SHS of ≥ 5 after 1 year)
1 year
Brennan60 Presence of radiological erosions (Larsen) Presence of radiological erosions in hands or feet, or both, at least
12 months after the onset of symptoms. Radiographs scored using the
Larsen method and patients dichotomised according to the radiographic
evidence of erosions in any joints of the hands/feet (Larsen’s grade ≥ 2)
1 year
Centola61 DAS28 Low level of disease activity/moderate to high level of disease activity
(using cut-off points of DAS28-CRP of 2.67 or median DAS28-CRP)
NR
Combe (A)62 Radiographic score and radiographic
progression (SHS)
Hand, wrist and foot radiographs taken at baseline and 3 years, scored
using the SHS method. Radiographic progression defined by a change in
radiographic scores that are greater than the upper boundary of 95% CI
of differences (i.e. change of at least 3.2, 2.9 and 3.4 in erosions score,
narrowing score and total damage score, respectively)
3 years
Combe (B)63 HAQ score Functional disability according to the HAQ score (as a continuous variable) 3 and 5 years
de Punder (extended)64
de Punder (simplified)64
Radiographic progression (Ratingen) Radiographs at baseline and after 3 years of follow-up scored using the
Ratingen method. Modelled change in Ratingen score between baseline
and 3 years. Joint damage progression defined as the difference in ≥ 5
Ratingen points between baseline and 36 months’ follow-up
3 years
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D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
6
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
8
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
A
rch
er
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
4
7
TABLE 5 Definition of the outcomes in the included model development studies (continued )
Name of clinical
prediction model Outcome category Outcome definition and measurement
Predicted time
point
de Vries-Bouwstra65 Radiographic progression (SHS) Radiographic progression during the first year, measured as the difference
between the SHS score at baseline and 1 year (SHS of > 0). Patients
classed as:
1. patients with severe disease – patients with progression of radiological
damage (progression score of > 0)
2. patients with mild disease – patients without progression of
radiological damage (progression score of 0)
1 year
Degboé66 Radiographic progression (modified SHS)a Radiographs scored using modified Sharp/van der Heijde method.
RRP defined as an increase in a total modified SHS of ≥ 5 per year
1 year
Dirven67 HAQ score Short-term functional disability (i.e. a HAQ score of ≥ 1) after 3 months of
treatment
3 months
Dixey68 Radiographic assessment of joint damage
(Larsen)
Radiographs of hands and feet taken at baseline and annually, and scored
using the Larsen method. Radiographs digitised and scored randomly by
one observer using the Larsen method. Larsen’s erosion score used as
outcome
3 years
Drossaers-Bakker56 Outcomes categorised as:
1. body functions and structure (impairment)
2. activities at the individual level (disability)
3. participation in society (handicap)
4. disease course
Radiographs of hands and feet scored using modified Sharp/van der
Heijde method. Radiographs of large joints scored using the Larsen large
joint score (0–60). Disease activity measured using the DAS (pooled ESR,
SJC and Ritchie Articular Index). Cumulative disease activity measured
using the AUC of all DAS assessments during 12 years’ follow-up. A panel
of five experienced rheumatologists jointly defined the criteria and classed
patients as having a mild or severe RA course. Measured tertiles of
radiographic damage (modified Sharp/van der Heijde method), disability
(measured using the HAQ) and severe disease course defined as patients
with either 33% highest cumulative disease activity (AUC of all observed
disease activity scores) or highest tertile of radiographic damage. Identified
patients in lowest (mild) and highest (severe) tertiles of each outcome
measure
12 years
ESPOIR69 Radiographic progression (modified SHS)a RRP defined as an increase of ≥ 5 on the modified SHS 1 year
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Name of clinical
prediction model Outcome category Outcome definition and measurement
Predicted time
point
Forslind70 Joint damage and radiological progression
(Larsen score)
Posteroanterior radiographs taken of hands, wrists and forefeet at
baseline and after 2 years. Radiographs read by one reader. Joint damage
defined as present if the end point Larsen score was ≥ 10 (median).
Radiological progression was defined as present if the difference between
the end point and baseline Larsen score was ≥ 8 (median)
2 years
Graell71 Functional disability measured using the
MHAQ (MHAQ score of > 0)
MHAQ (eight questions on activities of daily living, scored 0–3) Final score
was the mean score of all eight items. Disability =MHAQ score of > 0
2 years
Houseman72 Radiographic progression (modified SHS) Posteroanterior radiographs of hands/wrists and feet taken at baseline and
8.2 years. Radiographic progression measured using the van der Heijde/
modified Sharp method. Based on median SHS change from baseline to
8.2 years, patients categorised into low or high progression groups.
Additional analyses performed using only total SHS at 8.2 years for
‘absolute’ radiographic outcome and cohort categorised into non-
progressors and progressors using the lower quartile value (value = 6)
from the distribution of total SHS (median value= 26.5)
8.2 years
Sanmartí75 Radiographic progression (Larsen) Radiographs obtained of hands and feet scored using the modified Larsen
method. Radiographic progression defined as a change of > 4 Larsen units
between baseline and 24 months
2 years
SONORA57 Radiographic progression (original Sharp
method)
Hand radiographs at baseline, year 1 and year 2 scored using the original
Sharp method (range 0–280). Radiographic progression defined as a
change of ≥ 3.54 in the TSS (as reported in the Granger et al.82 external
validation)
1 and 2 years
SWEFOT73 Radiographic progression (modified SHS
method)a
Radiographs of hands and feet at baseline and 1 year scored using the
modified SHS method. Radiographic progression defined as an increase in
total SHS of ≥ 5 at 1 year
1 year
Syversen76 Radiographic progression (van der Heijde/
modified Sharp score)
Anteroposterior radiographs of hands obtained. Radiographs scored using
the van der Heijde/modified Sharp score. Radiographic progression
defined as a change in the SHS of hands from baseline to 10 years of
> 10 and dichotomised as the presence or absence of radiographic
progression in the analyses
10 years
van Steenbergen77 Radiographic progression (SHS) Radiographs of hands and feet obtained. Progression in SHS over 6 years
(as a continuous outcome or categorised as no/little progression (ΔSHS of
≤ 6), moderate (ΔSHS of 7–30) or severe (ΔSHS of > 30) progression)
6 years
MHAQ, modified Health Assessment Questionnaire; NR, not reported; RRP, rapid radiographic progression; SHS, Sharp–van der Heijde score; TSS, total Sharp score.
a Studies applying the standard rapid radiographic progression definition of an increase in van der Heijde/modified Sharp score of ≥ 5 over 1 year.
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TABLE 6 Definition of outcomes in the included external validation studies
Name of
external
validation
Outcome definition and
measurement
Outcome
time point
(years)
Externally
validated
clinical
prediction
model(s)
Does the outcome
definition in the
external validation
match the outcome
definition in the
model development?
(Y/N)
De Cock80 RRP defined as TSS progression of
≥ 5 units per yeara
1, 2 ASPIRE CRP Y (two validations)
ASPIRE ESR Y (two validations)
BeSt Y (two validations)
ESPOIR Y (two validations)
SWEFOT Y (two validations)
Syversen Nb (two validations)
De Cock80 TSS progression of ≥ 10 units from
baseline to year 2 also defined as RRP.
Radiographs scored using the modified
Sharp/van der Heijde method
(van der Heijde, 199918)
> 2 ASPIRE CRP Na
ASPIRE ESR Na
BeSt Na
ESPOIR Na
SWEFOT Na
Syversen Nb
de Punder64 See Table 5 3 BeSt Na
ESPOIR Na
Granger82 Radiographs scored using van der Heijde/
modified Sharp score at 1 year
RRP defined as an increase in van der
Heijde/modified Sharp score of ≥ 5 in the
first yeara
1 ASPIRE CRP Y
ASPIRE ESR Y
BeSt Y
ESPOIR Y
SONORA Nc
Hambardzumyan83 Radiographic progression (increase in
van der Heijde/modified Sharp score of
≥ 5 over 1 year)a
1 MBDA Nd
Heimans84 Radiographs of hands and feet (blinded
for patient identity) scored for the
presence of erosions and JSN. c-statistic
reported for the ability of the model
to predict radiological progression
(≥ 0.5-point increase in the SHS)
1 BeSt Ne
Markusse85 Radiographic progression (increase in van
der Heijde/modified Sharp score of ≥ 0.5)
Radiographic progression (increase in van
der Heijde/modified Sharp score of ≥ 5)a
1, 2 MBDA Nd (four validations)
JSN, joint-space narrowing; N, no; RRP, rapid radiographic progression; SHS, Sharp–van der Heijde score; TSS, total Sharp
score; Y, yes.
a Studies applying the standard RRP definition of an increase in van der Heijde/modified Sharp score of ≥ 5 over 1 year.
b Radiographic progression defined as a change in the SHS of hands from baseline to 10 years of > 10 and dichotomised
as the presence or absence of radiographic progression in analyses.
c Radiographic progression defined as a change of ≥ 3.52 in total Sharp score (Bombardier et al.57). Granger et al.82 stated
that the SONORA RRP definition was an increase in the SHS of 3.54.
d MBDA developed in Centola et al.61 as a disease activity test.
e BeSt (developed to predict the RRP (increase in the SHS of ≥ 5 after 1 year) used to predict radiological progression
(≥ 0.5-point increase in the SHS).
RESULTS: REVIEW 1
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As summarised above, the majority of studies considered binary outcomes, based on dichotomising an
observed continuous variable. Although these outcomes are considered to be standard practice, it is worth
noting that dichotomising continuous variables has previously described disadvantages.92,93 The magnitude
of the association will depend on the cut-off point used to dichotomise the variable.
As described in Table 6, all five external validation studies and the study by de Punder et al.,64 which
considered development and external validation, considered radiographic progression at 1 and/or 2 years
as the outcome variable.
The external validation studies considered a total of eight previously developed clinical risk prediction
models, and conducted a total of 31 external validations. In addition to describing the outcome considered
in the external validation study, Table 6 lists which clinical prediction models were considered and whether
or not the outcome considered by the external validation study was consistent with that in the original
model development paper.
For 17 of the 31 external validations that were conducted, the outcome considered by the external
validation was different to that used for the model development. Five of these studies (labelled as Nd in
Table 6) externally validated the MBDA clinical prediction model (originally developed to predict the
DAS28) for the prediction of radiographic progression outcomes. Ten external validations (labelled as Na
and Nb in Table 6) externally validated risk models using the outcomes at a different time point than that
defined in the original model development paper. Two external validations (labelled as Nc and Ne in Table 6)
externally validated risk models using different thresholds to define events, compared with that used in the
original model development study.
The handling of outcomes in included studies was critically appraised using domain 3 of the PROBAST tool
(see Appendix 6). The included studies were rated as being at a low or unclear risk of bias.
Model development
The methods used in the development of the included clinical prediction models are summarised in Table 7.
Clinical prediction models were typically developed in the included studies using data from patients with
complete cases only [i.e. having complete predictor and outcome data (e.g. Bansback,58 Brennan,60 Combe A,62
Combe B,63 de Punder,64 de Vries-Bouwstra,65 Degboé,66 Dirven,67 Dixey,68 Drossaers-Bakker,56 Forslind,70 Graell,71
Sanmartí,75 SWEFOT73 and Syversen76)].
Continuous variables were frequently converted to dichotomous/trichotomous variables during the clinical
prediction model development process. This was the case for seven of the externally validated models
developed for the prediction of radiographic progression (all externally validated models, with the exception
of MBDA). This conversion is not considered to be good practice.31 The categorisations used for the variables
included in the final models are described in Table 8.
Clinical prediction models were developed using multivariable regression, with the majority of studies using
logistic regression [i.e. ASPIRE78, Bansback et al.,58 Berglin et al.,59 BeSt,79 Brennan et al.,60 Combe et al. (A),62
de Punder et al.,64 Degboé et al.,66 Dixey et al.,68 Dirven et al.,67 Drossaers-Bakker et al.,56 ESPOIR,69 Forslind
et al.,70 Graell et al.,71 Houseman et al.,72 Sanmartí et al.,75 SWEFOT et al.73 and Syversen76], as the outcome
variables were binary. Backwards selection was reported for three models (i.e. Berglin et al.,59 de Punder
et al.64 and Dirven et al.67) as being used in the selection of the final variables in the model, whereas forwards
selection was used in four model development studies (i.e. Drossaers-Bakker et al.,56 Forslind et al.,70 Graell
et al.71 and Houseman et al.72). There were variations in how the selection was implemented (e.g. levels of
statistical significance and combination with other techniques, such as bootstrapping, see Table 7).
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TABLE 7 Development of the individual clinical prediction models
Name of clinical prediction
model
Method of
Presentation of modelModel development Internal validation
ASPIRE78
Two models: ESR and CRP
Correlations of all baseline factors with RRP were
explored. Selected factors (selection unclear) included
in multivariable logistic regression
None Risk matrices with predicted probabilities
stratified by treatment
Bansback58 Logistic regression (multivariable, removal of predictors
from full model, including covariables with a p-value
of < 0.2)
Bootstrapping resampling to estimate
slope shrinkage
Full model regression coefficients, nomogram
Berglin59
Two models
Candidate predictors selected using univariable
regression or clinical assumptions (description unclear).
Logistic multivariable regression (backward stepwise)
Apparent performance in development
cohort
OR only
BeSt79
Two models: ESR and CRP
Logistic regression. Univariable and multivariable with
backwards selection using a p-value of > 0.1.
Interactions with treatment explored
Apparent performance in development
cohort
OR presented for ESR and CRP models. Risk
matrices with predicted probabilities presented
for CRP model only, stratified by treatment
Brennan60 Logistic regression (multivariable, stepwise removal of
predictors with a p-value of > 0.05, model checked
by sequential addition of removed variables and
sequential removal of remaining variables)
Randomly selected sample (prediction
sample 60%, n= 105; validation sample
40%, n= 70)
Tabulation of PR for each risk category
Centola61 Stage 1: candidate predictors prioritised based on
univariable and multivariable regression
Stage 2: multivariable modelling with forward stepwise
selection using three methods (OLS, LASSO, elastic net
modelling)
Stage 3: multivariable modelling using OLS, LASSO,
elastic net method. Curds and whey multivariable
response method with OLS or LASSO
Performance compared in 70/30 cross-
validation (repeat training in randomly
selected 70% of data and testing in
remaining 30%)
Full model regression coefficients
Combe (A)62 Univariable analysis of all baseline variables. Logistic
regression (stepwise, multivariable, selection from
univariable analysis a p-value of ≤ 0.15). Results
confirmed with stepwise multilinear model (with
continuous random variables instead of dichotomous
variables)
Apparent performance in development
cohort
Full model regression coefficients
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Name of clinical prediction
model
Method of
Presentation of modelModel development Internal validation
Combe (B)63 Prediction of HAQ score (continuous outcome)
considered separately at 3 and 5 years. Univariable
analysis of all baseline variables. Multivariable linear
regression model with continuous and categorical
candidate predictors
Apparent performance in development
cohort
Coefficients only
de Punder64
Simplified and extended
models
Logistic regression (univariable multivariable,
backwards selection with a p-value of < 0.20, as well
as consideration of previously identified factors)
Bootstrapping using 300 samples for
each of the five imputed data sets
Full model regression coefficients
de Vries-Bouwstra65,a Model considers prediction of ΔSHS (continuous
outcome). Developed using linear regression
(univariable and multivariable) with categorical and
continuous outcomes. Resulting predicted progression
score and SD then used to calculate the probability of
severe disease (ΔSHS of > 0, binary outcome) for
which PPV is reported
Apparent performance in development
cohort
OR only
Degboé66
Four models
Logistic regression (univariable and multivariable) Apparent performance in development
cohort
OR only
Dirven67 Logistic regression. Potential confounders and
candidate predictors with a p-value of < 0.1
considered in multivariable model. Backward selection
process with a p-value of 0.10. Final regression model
then fitted with variables categorised based on tertiles
to allow matrix construction
Apparent performance in development
cohort
Three matrices according to treatment group:
1. initial monotherapy
2. initial combination therapy with prednisone
3. initial combination therapy with IFX
Dixey68
Three models
Logistic regression (univariable and multivariable) Randomly selected sample (prediction
sample 60%; validation sample 40%)
OR only
Drossaers-Bakker56
Five outcomes with two
models for each
Logistic regression (multivariable stepwise forward
method)
Apparent performance in development
cohort
OR only. Basic decision tree for one model
ESPOIR69 Logistic regression (univariable, variables with a p-value
of ≥ 0.1 included in multivariable forwards and
backwards selection procedure with a p-value of < 0.05)
Apparent performance in development
cohort
Full model regression coefficients and
prediction matrix
continued
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TABLE 7 Development of the individual clinical prediction models (continued )
Name of clinical prediction
model
Method of
Presentation of modelModel development Internal validation
Forslind70 Logistic regression (univariable analysis used to select
candidate predictors a p-value of < 0.05, then forward
stepwise selection for final model)
Apparent performance in development
cohort
Full model regression coefficients
Graell71 Univariable analysis, multivariable logistic regression
(forward, stepwise). Clinically relevant interactions
were considered
Apparent performance in development
cohort
Full model regression coefficients
Houseman72 Logistic regression [univariable and multivariable,
forward stepwise (entry probability = 0.05, removal
probability = 0.1)]
Apparent performance in development
cohort
Selected multivariable OR provided in text. Full
clinical prediction model regression coefficients
not provided
Sanmartí75 Univariable analysis used to identify significant
(p< 0.25) variables for inclusion in multivariable logistic
regression (stepwise)
Apparent performance in development
cohort
Full model regression coefficients
SONORA57 Univariable models to identify factors, general
estimation equation model used for the multivariable
model
NR OR only
SWEFOT73
Four matrices
Logistic regression (univariable and multivariable.
Parameters showing ‘strongest association’ chosen to
make three parameter risk matrices)
None Risk matrices show observed proportions of
events rather than predicted probabilities.
De Cock external validation80 based on related
conference abstract
Syversen76
Three models
Logistic regression (variables with a p-value of< 0.15 in
univariable analysis included in multivariable model)
Apparent performance in development
cohort
Full model regression coefficients provided for
model 1, OR only for models 2 and 3.
Histogram
van Steenbergen77 Linear mixed-model analysis and linear regression
analysis, with continuous and categorical outcomes
considered for model development
Apparent performance in development
cohort
Presents performance measures only
LASSO, least absolute shrinkage and selection operator; NR, not reported; OLS, ordinary least squares; PR, predicted risk; RRP, rapid radiographic progression; SHS, Sharp score.
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TABLE 8 Predictors included in individual final modelsa
Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
ASPIRE78
CRP/ESR models
SJC28 (< 10, 10–17 or
> 17)
CRP level (< 0.6 mg/dl,
0.6–3 mg/dl, > 3mg/dl) or ESR
(< 21mm/hour, 21–50mm/hour
or > 50mm/hour)
RF (< 80 U/ml, 80–200 U/ml or
> 200 U/ml)
– – MTX monotherapy or
MTX and IFX
Berglin59
Two models
Model 1: SJC28
Models 1 and 2:
therapeutic response
(yes/no) (EULAR response
criteria no vs. good/
moderate response)
Model 1: anti-CCP (yes/no)
Model 2: ESR
Model 2: IgA RF (yes/no)
– – – –
BeSt79 – ACPA and/or RF 0, 1 or 2
positive, a CRP level of < 10mg/l,
10–35mg/l or ≥ 35mg/l
Erosion score of 0, 1–4
or ≥ 4
– – Treatment strategy
(initial monotherapy,
initial combination with
prednisone, initial
combination with IFX)
Brennan60 Involvement of ≥ 2 large
joints
Disease duration of
> 90 days (i.e. 12.9 weeks)
at first presentation
RF positive (titre of ≥ 1 : 80) – – – –
continued
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TABLE 8 Predictors included in individual final modelsa (continued )
Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
Combe (A)62 Model 2 (high > 4 Sharp
score): pain at ≥ 59mm
(median value at baseline
on a VAS scale of 0–100)
Model 1 (radiographic
progression): an ESR of
≥ 33mm/hour (median value at
baseline)
Models 1 (radiographic
progression) and 2 (high
> 4 Sharp score): IgM RF
positivity (≥ 20 IU/ml)
(categorical low/absent or
high/present)
Model 1 (radiographic
progression): erosions
score of ≥ 1 (categorical
low/absent or high/
present)
Model 2 (high > 4 Sharp
score): initial Sharp score
(categorical low/absent
or high/present)
– Models 1 (radiographic
progression) and 2 (high
> 4 SHS): HLA-DRB1*04
positivity
–
de Punder64
Simplified and
extended
models
– Extended: anti-CCP and/or RF
(0, 1 or 2 positive), an ESR of
< 25mm/hour, 25–50mm/hour
or > 50mm/hour
Simplified: dichotomised
anti-CCP level of > 25 U/ml
(> 10 U/l in frozen samples)
and a dichotomised ESR of
> 25mm/hour
Extended: erosions
(0 Ratingen points,
1–5 Ratingen points,
6–10 Ratingen points or
> 10 Ratingen points)
Simplified: dichotomised
baseline Ratingen score
of ≥ 1 point
Aged < 45 years,
45–64 years,
> 64 years at
diagnosis and
female sex
– –
de Vries-
Bouwstra65,b
Bilateral compression pain
in metatarsophalangeal
joints (categorical),
duration of symptoms at
presentation (> or
≤ 6 weeks), HAQ score
(continuous), morning
stiffness duration
(continuous), Ritchie
Articular Index score
(continuous), total SJC
(max 22) (continuous), VAS
disease activity (continuous)
ESR (continuous), IgM RF
positivity [≥ 5 U (categorical)]
Presence of erosions
on radiographs
(categorical), SHS
(continuous)
Age (continuous)
and sex
SE hetero- or
homozygosity
(categorical)
–
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Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
Degboé66,c
Four models
– Model 1: anti-CCP-2 positivity
and a CRP level of > 10mg/l
Model 2: anti-MCV positivity,
a CRP level of > 10mg/l and RF
positivity
Model 3: AhFibA positivity,
a CRP level of > 10mg/l
Model 4: high anti-CCP2 or
AhFibA titres, high anti-MCV
titres and a CRP level of
> 10mg/l
Model 2: RF positivity
Models 1 and 4:
erosions at baseline
Model 3: age at
RA onset
– –
Dixey68
Three models
All continuous variables
categorised into quartiles
Model 2: SJC
Model 2: nodules
Models 1 and 3: ESR
Model 1: RF positivity
Model 2: joint score
Models 2 and 3: Larsen
score
– – –
Drossaers-
Bakker56
Mild radiographic damage
(all): SJC
Mild radiographic damage
(selected): SJC
Severe radiographic
damage (all): SJC
Severe radiographic
damage (selected): SJC
Mild radiographic damage (all):
RF positivity
Mild radiographic damage
(selected): RF positivity
Severe radiographic damage
(all): RF positivity
Severe radiographic damage
(selected): RF positivity
Mild radiographic
damage (all): erosive at
study start
Mild radiographic
damage (selected):
erosive at study start
Severe radiographic
damage (all): erosive at
study start
Severe radiographic
damage (selected):
erosive at study start
– Mild radiographic
damage (all): SE
Mild radiographic
damage (selected): –
Severe radiographic
damage (all): RAP
Severe radiographic
damage (selected): –
–
continued
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TABLE 8 Predictors included in individual final modelsa (continued )
Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
ESPOIR69 SJC28 (< 14, 14–20 or ≥ 20) ACPA positive/negative
CRP ≥ 35mg/l, 4 mg/l ≤ CRP
< 35mg/l, CRP < 4mg/l
Presence/absence of
typical RA erosions on
radiographs
– – –
Forslind70
Two models
– (Continuous variables
categorised by median baseline
value as cut-off point; anti-CCP
and RF positivity)
Model 1 (radiological damage)
and model 2 (radiological
progression): anti-CCP positivity
Models 1 (radiological damage)
and 2 (radiological progression):
ESR
Models 1 (radiological
damage) and 2
(radiological
progression): Larsen
score
– – –
Houseman72
Two models
– Radiographic progression
model: anti-CCP positivity
(titre of > 6 U/ml) (taken at the
8.2-year follow-up visit) and
baseline MMP-3 elevation
(> 85.79 ng/ml)
Absolute radiographic outcome
model: anti-CCP positivity
(titre of > 6 U/ml) (taken at the
8.2-year follow-up visit) and
baseline MMP-3 level
(> 85.79 ng/ml)
Radiographic
progression model:
baseline SHS (SHS
of > 7)
– – –
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Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
Sanmartí75 – Anti-CCP positive – Sex HLA-DRB1*04 positive –
SONORA57 DAS28 (≤ 3.2 or > 3.2) Anti-CCP (≤ 20 UI/l or > 20 UI/l) SHS (0, 1–5 or 6–10) – – –
SWEFOT73
Original, sex
and treatment
models
– Original, sex and treatment
models: CRP level (< 10mg/dl,
10–35mg/dl or > 35mg/dl)
Original, sex and
treatment models:
presence of erosions
Original, sex and
treatment
models: current
smoking
Sex model
– Treatment model
(treatment month 3–12):
whole group, MTX
monotherapy,
combination with IFX,
combination with SSZ
and HCQ
Syversen76 – Anti-CCP positivity (> 25 U/ml),
ESR (> 20mm/hour) and
IgM RF positivity (> 25 U/ml)
– Sex – –
van
Steenbergen77
Traditional factors,
including localisation of
initial joint symptoms,
SJC66
Traditional factors, including
presence of ACPA, presence of
ESR and presence of RF
– Traditional
factors, including
age, sex and
symptom
duration at first
visit
Single nucleotide
polymorphisms/genetic
variants as listed in table
footnotesd
Treatment effects (initial
treatment with NSAIDs;
initial treatment with
HCZ or SSZ; initial
treatment with MTX)
Models predicting HAQ score or disease course
Bansback58 DAS28 year 1
HAQ score at baseline and
year 1
Functional grade at
baseline (I, II, III and IV) and
year 1 (I, II, III and IV)
Haemoglobin level at baseline Larsen score at baseline Carstairs
deprivation index
(1, 2, 3, 4 or 5)
– –
continued
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TABLE 8 Predictors included in individual final modelsa (continued )
Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
Combe (B)63
Model 1: 5-year
HAQ score
Model 2: 3-year
HAQ score
Model 1 and 2: HAQ score
Model 1: Ritchie Articular
Index
Model 1: CRP
Model 1: ESR
– – – –
Dirven67 HAQ score of < 1.38,
1.38–2.00 or > 2.00
Ritchie Articular Index score
of < 10, 10–16 or > 16
VAS pain score of < 40,
40–60 or > 60
– – – – Monotherapy,
combination therapy
with prednisone,
combination therapy
with IFX
Drossaers-
Bakker56
Mild HAQ (all): HAQ score
Mild HAQ (selected):
HAQ score
Severe HAQ (all):
HAQ score
Severe HAQ (selected):
HAQ score
Severe disease course (all):
SJC and HAQ score
Severe disease course
(selected): SJC and Ritchie
score
– Mild HAQ (all): erosive
at study start
Mild HAQ (selected):
erosive at study start
Severe HAQ (all): –
Severe HAQ (selected): –
Severe disease course
(all): –
Severe disease course
(selected): –
– Mild HAQ (all): –
Mild HAQ (selected): –
Severe HAQ (all): –
Severe HAQ (selected): –
Severe disease course
(all): SE
Severe disease course
(selected): –
–
Graell71 Baseline MHAQ score
(> 0.5)
RF positivity – Age – –
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Name of
clinical
prediction
model
Clinical prediction model variables
Clinical Biomarkers Radiography Demographic Genetic Treatment
Models developed as a measure of disease activity
Centola61 – 12 biomarker model:
1. TNF receptor I
2. interleukin 6
3. vascular cell adhesion
molecule I
4. epidermal growth factor
5. VEGF-A
6. cartilage glycoprotein 39
7. MMP-1
8. MMP-3
9. serum amyloid A
10. leptin
11. resistin
12. CRP
– – – –
A, adenine; AhFibA, anti-human citrullinated fibrinogen anti-body; C, cytosine; CD40, cluster of differentiation 40; DKK-1, dickkopf WNT signalling pathway inhibitor 1; G, guanine;
GrzB, granzyme B; HCZ, hydrochlorothiazide; IgA, immunoglobulin A; IgM, immunoglobulin M; IL-15, interleukin 15; IL2RA, interleukin 2 receptor alpha chain; IL4R, interleukin 4 receptor;
HLA, human leucocyte antigen; MMP, matrix metalloproteinase; NR, not reported; OPG, osteoprotegerin; RAP, rheumatoid arthritis protected; rs, reference SNP cluster ID; SE, shared
epitope; SPAG16, sperm-associated antigen 16; T, thymine; VAS, visual analogue scale; VEGF, vascular endothelial growth factor.
a Details of the handling of continuous and categorical variables are reported when available.
b All available and potentially prognostic baseline variables used without any selection of variables.
c Anti-CCP, positive ≥ 40 U/ml; antimutated citrullinated vimentin, positive > 35 UA/ml; and AhFibA, positive > 0.119 AU.
d Generic variants located in/near gene(s) HLA-DRB1, CD40, IL-15, DKK-1, IL2RA, GRZB, IL-4R, SPAG16, C5orf30, MMP-9, rs1465788, OPG.
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The BeSt model development (by Visser et al.79) and the model by Graell et al.71 were the only two model
development studies to specifically describe having considered the presence of interactions between
variables. As Visser et al.79 also considered the effect of treatment, this is of relevance to review 2 and is
discussed in further detail in Results: synthesis of primary studies.
The majority of the included clinical prediction model development studies used a limited form of internal
validation, with apparent predictive performance tested within the original development data set (TRIPOD
statement type 1a). Testing the apparent performance of a clinical prediction model using the same data
in which the model was developed can lead to optimistic estimates of performance.26 This is attributed to
‘overfitting’, whereby there are too few outcome events in relation to the number of candidate predictors.
Therefore, the performance estimates derived from the included TRIPOD statement type 1a studies should
be viewed with caution in the absence of more robust validation.
Ideally, clinical prediction model development studies should include a method of internal validation to
quantify any optimism in the predictive performance. Two studies (i.e. Bansback et al.58 and de Punder
et al.64) used bootstrapping for estimating model performance (i.e. TRIPOD statement type 1b). A further
two studies (i.e. Brennan et al.60 and Dixey et al.68) used a data-splitting approach.
One study tested the performance of its developed clinical prediction models on separate data from a
different study (TRIPOD statement type 3). Vastesaeger et al.78 tested the performance of their ASPIRE
model for the prediction of radiographic progression in data from ATTRACT (Anti-TNF trial in rheumatoid
arthritis with concomitant therapy). As stated previously, as the ATTRACT trial was conducted in patients
with established RA, this validation is outside the scope of this assessment and so is not considered further.
The form in which the clinical prediction models were presented determines the ease with which they
may be used in clinical practice, and not all of the model development studies presented their models
in sufficient detail for them to be applied to other populations. In order for clinicians to directly apply a
model, one option is to present the full model regression coefficients (including the intercept term), which
allows the model to be used to generate absolute risks. Alternatively, the absolute risks for each individual
combination of variables (e.g. in a risk matrix format) could be presented. Of the 39 clinical prediction
models, 18 were presented in a useable format.
Of the eight externally validated risk models, the majority were presented as risk matrices in the published
report: ASPIRE78 (ESR and CRP), BeSt,79 Dirven et al.67 and ESPOIR.69 Two externally validated clinical
prediction models (MBDA61 and Syversen et al.76) presented the full model regression coefficients. Syversen
et al.76 also presented the final model graphically using a histogram. The SWEFOT73 models were not
presented in a useable format in the model development publication, and for this reason they were not
tested in the Granger et al.82 external validation. However, the main SWEFOT model was considered in the
De Cock et al.80 external validation, based on results that are available in conference proceedings.73
Some studies were noted as reporting ‘OR only’ in Table 7, indicating that the coefficient of the intercept
term in the regression was not provided and, therefore, the model would not be able to be used to
provide absolute risks.
The final predictors selected for use in the included clinical prediction models are presented in Table 8.
The prognostic variables selected for consideration in the assessment in conjunction with clinical advisors
were very commonly incorporated as predictors in the final clinical prediction models. However, the
continuous variables were generally categorised, with the models applying a range of differing thresholds
in their construction.
RESULTS: REVIEW 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
Additional clinical predictors
The clinical prediction models also included the following additional clinical predictors:
l bilateral compression pain (i.e. de Vries-Bouwstra et al.65)
l functional grade (i.e. Bansback et al.58)
l localisation of initial joint symptoms (i.e. van Steenbergen et al.77)
l morning stiffness (i.e. de Vries-Bouwstra et al.65)
l nodules [i.e. Dixey et al. (2)68]
l Ritchie Articular Index [i.e. de Vries-Bouwstra et al.,65 Combe et al. (B1),63 Dirven et al.,67
Drossaers-Bakker et al.56 (severe disease course, selected)]
l therapeutic response [EULAR response criteria: no vs. good/moderate response; i.e. Berglin et al. (1),59
Berglin et al. (2)59]
l visual analogue scale disease activity (i.e. de Vries-Bouwstra et al.65)
l visual analogue scale pain [i.e. Dirven et al.,67 Combe et al. (A2)62].
Additional biomarkers
The following biomarkers were also included in the two final clinical prediction models:
l haemoglobin level (i.e. Bansback et al.58)
l matrix metalloproteinase (MMP)-3 [i.e. Houseman et al. (radiographic progression model)72]
l additional biomarkers included in MBDA [i.e. Centola et al.61 (see Table 8)].
Additional demographic predictors
Demographic variables were included in the following final clinical prediction models:
l age [i.e. de Punder et al. (extended),64 de Vries-Bouwstra et al.,65 Degboé et al. (3),66 Graell et al.71 and
van Steenbergen et al.77]
l Carstairs Deprivation Index (i.e. Bansback et al.58)
l sex [i.e. de Vries-Bouwstra et al.,65 Sanmartí et al.,75 SWEFOT et al. (sex),73 Syversen et al.,76
van Steenbergen et al.77].
Genetic predictors
A minority of clinical prediction models also integrated genetic predictors:
l RA protected [i.e. Drossaers-Bakker et al. (severe radiographic damage, all)56]
l shared epitope (SE) [i.e. de Vries-Bouwstra et al.,65 Drossaers-Bakker et al. (mild radiographic damage,
all),56 Drossaers-Bakker et al. (severe disease course, all)56]
l HLA-DRB1*04 positivity [i.e. Combe et al. (A1),62 Combe et al. (A2),62 Sanmartí et al.75]
l single nucleotide polymorphisms located in/near human leucocyte antigen (HLA)-DRB1 (SE), CD40 (cluster
of differentiation 40), IL-15 (interleukin 15), DKK-1 (dickkopf WNT signalling pathway inhibitor 1), IL2RA
(interleukin 2 receptor alpha chain), GRZB (granzyme B), IL4R (interleukin 4 receptor), SPAG16 (sperm-
associated antigen 16), C5orf30 (chromosome 5 open reading frame 30), MMP-9, rs (reference single
nucleotide polymorphisms cluster ID) 1465788 and OPG (osteoprotegerin) (i.e. van Steenbergen et al.77).
Treatment
The ASPIRE CRP,78 ASPIRE ESR,78 BeSt,79 Dirven67 and SWEFOT (treatment)73 clinical prediction models were
developed using RCT data and included treatment as a variable in the final model. For all of these studies,
the final clinical prediction model was presented using separate risk matrices according to treatment group.
Although separate matrices by treatment were presented, the final models did not include treatment by
predictor interaction terms (as is considered in review 2). This assumes that all predictors are prognostic for all
treatments, and that the magnitude of the prognostic effect of each predictor does not vary by treatment,
which is unlikely to be true in practice. As noted inModel development, Visser et al.79 assessed the interaction
between predictors, but found these to be not statistically significant and, therefore, did not include
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interactions in the final model. It should be noted that the absence of evidence for interaction effects is not
evidence of the absence of interaction effects, and such terms should be retained in a model if there is reason
to believe them to be real effects, irrespective of their statistical significance.
It was considered in PROBAST domain 2 whether or not all (final) predictors would be available at the time
at which the model was intended to be used. The majority of predictors were considered to be widely
available. Data for the Carstairs Deprivation Index, SE, HLA-DRB1*04 testing, RA protected, MMP-3 and
genetic tests may be less accessible.
The majority of the model development studies were rated as having an unclear risk of bias for domain 2.
All external validation studies were classed as being at a low risk of bias.
Performance results: clinical prediction model development studies
The performance of the included clinical prediction models, as reported in the original model development
studies, is presented in Table 9. Discrimination (using the c-statistic) was recorded when available, in addition
to information relating to the model calibration and overall model goodness of fit. Additional performance
measures presented by the studies are shown in Appendix 7. Unless otherwise indicated, sample sizes and
the number of events refer to the sample used for the final multivariable prediction models.
As previously discussed, good discriminative ability in the population used to develop the model would be
expected. The external validation of all models in the same data set or multiple data sets is required to
objectively compare the reported c-statistics. The results of these external validations are presented in
Results: external validation studies.
Models predicting radiographic joint damage
Discrimination was reported using the c-statistic by six of the studies,64,66,69,72,77,79 which considered a total of
13 clinical prediction models. c-statistics for models predicting radiographic joint damage are summarised in
a forest plot in Figure 6.
The BeSt model79 for the prediction of radiographic progression at 1 year demonstrated reasonably good
discrimination, which was broadly comparable between the CRP and ESR models (CRP model c-statistic
0.81, 95% CI 0.77 to 0.86; ESR model c-statistic 0.80, 95% CI 0.75 to 0.85).
The de Punder extended and simplified models64 predicted radiographic progression at 3 years. The
c-statistics obtained indicated moderate predictive performance (extended c-statistic 0.77, 95% CI 0.72 to
0.81; simplified c-statistic 0.75, 95% CI 0.70 to 0.80).
Four clinical prediction models were produced by Degboé66 for the prediction of radiographic progression
at 1 year. The apparent performance (TRIPOD statement type 1a) of these models was reported. The
c-statistics were lower than for other models predicting radiographic progression over 1 year [anti-CCP
c-statistic 0.65, 95% CI 0.60 to 0.70; antimutated citrullinated vimentin (anti-MCV) c-statistic 0.63,
95% CI 0.58 to 0.68; anti-human citrullinated fibrinogen anti-body (AhFibA) c-statistic 0.65, 95% CI 0.60
to 0.71; high-level ACPA titre c-statistic 0.65, 95% CI 0.60 to 0.70].
The ESPOIR clinical prediction model69 for radiographic progression at 1 year yielded a c-statistic of 0.754
[95% CI not reported (TRIPOD statement type 1a)].
Two clinical prediction models were constructed by Houseman et al.72 The apparent performances (TRIPOD
statement type 1a) were reported. The first model (for radiographic progression at 8.2 years) showed good
performance (with a c-statistic of 0.87). The second model (for absolute radiographic outcome at 8.2
years) showed similarly good discriminatory abilities (with a c-statistic of 0.84). It was noted that anti-CCP
RESULTS: REVIEW 1
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TABLE 9 Performance results from clinical prediction model development studies
Name of clinical
prediction model(s) Outcome definition Sample size (n)
Total number of
observed events
Overall model
fit
Discrimination,
c-statistic (95% CI)
Calibration/assessment
of overfitting
Prediction of radiographic joint damage (ΔSHS ≥ 5 at 1 year)
ASPIRE78
CRP
ESR
ΔSHS of ≥ 5 at 1 year Total trial population,
n= 1049
≌ 124 (MTX
monotherapy, 22.8%;
IFX and MTX, 8.3%)
NR NR NR
BeSt79
CRP
ESR
ΔSHS of ≥ 5 at 1 year 465 102 CRP: Nagelkerke’s
R2 = 0.31
ESR: Nagelkerke’s
R2 = 0.29
CRP: 0.81
(0.77 to 0.86)
ESR: 0.80
(0.75 to 0.85)
NR
Degboé66
Anti-CCP
Anti-MCV
AhFibA
High ACPA titre
ΔSHS of ≥ 5 at 1 year 566 145 NR Anti-CCP: 0.65
(0.60 to 0.70)
Anti-MCV: 0.63
(0.58 to 0.68)
AhFibA: 0.65
(0.60 to 0.71)
High ACPA titre: 0.65
(0.60 to 0.70)
NR
ESPOIR69 ΔSHS of ≥ 5 at 1 year 370 41 (11.1%) NR 0.75 Hosmer–Lemeshow
described but not
presented
SWEFOT73
Four models
ΔSHS ≥ 5 at 1 year 269 72 NR NR NR
continued
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TABLE 9 Performance results from clinical prediction model development studies (continued )
Name of clinical
prediction model(s) Outcome definition Sample size (n)
Total number of
observed events
Overall model
fit
Discrimination,
c-statistic (95% CI)
Calibration/assessment
of overfitting
Prediction of radiographic joint damage (other outcome definitions)
de Vries-Bouwstra65 ΔSHS of > 0 at 1 year 95 69 R2 = 0.36 NR Calibration plot/table
presented
SONORA57
Year 1
Year 2
ΔSHS of ≥ 3.54a at 1 year
ΔSHS of ≥ 3.54 at 2 years
994 Year 1: 10.4%
Year 2: 11.7%
NR NR NR
Combe (A)62
Total damage
Erosions
Total damage: ΔSHS of ≥ 3.4
Erosions: ΔSHS of ≥ 3.2
at 3 years
172 Total damage: 71
Erosions: 55
NR NR NR
van Steenbergen77
Treatment and
traditional
Treatment and
traditional and geneticb
ΔSHS at 6 years
None: ΔSHS of ≤ 6
Moderate: ΔSHS of 7–30
Severe: ΔSHS of > 30
239 72, 99, 68 (none,
moderate, severe)
Treatment and
traditional:
R2 = 0.36
Treatment and
traditional and
genetic R2= 0.44
Treatment and
traditional c= 0.78
(0.73 to 0.82)
Treatment and
traditional and
genetic c= 0.82
(0.77 to 0.86)
NR
Houseman72
Change in the SHS
Absolute SHS
ΔSHS of > 10.5
Total SHS of > 6
Both at 8.2 years
58 29
44
NR
NR
0.87
0.84
NR
Syversen76 ΔSHS of > 10 at 10 years 125 74 NR NR NR
Brennan60 Based on Larsen score at 1 year 175 Prediction: 37/105
Validation: 26/70
Total: 63/175
NR NR NR
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Name of clinical
prediction model(s) Outcome definition Sample size (n)
Total number of
observed events
Overall model
fit
Discrimination,
c-statistic (95% CI)
Calibration/assessment
of overfitting
Berglin59
Model 1
Model 2
Based on Larsen score at 2 years Baseline, n= 138 NR for total sample Model 1:
Nagelkerke’s
R2 = 0.21
Model 2:
Nagelkerke’s
R2 = 0.24
NR NR
Forslind70
Joint damage
Progression
Joint damage: Larsen score
≥ 10 at 2 years
Progression: Δ Larsen score
≥ 10 at 2 years
333 NR Joint damage:
Nagelkerke’s
R2≌ 0.5
Progression:
Nagelkerke’s
R2≌ 0.4
NR NR
Sanmartí75 Based on Larsen score at 2 years 105 34 (32%) NR NR NR
Dixey68
Model 1
Model 2
Model 3
Larsen score at 3 years Overall (60%
development sample):
Model 1 – 587 (365)
Model 2 – 850 (518)
Model 3 – 649 (370)
Number in
development
population:
Model 1 – 210 erosive
Model 2 – 121 severe
Model 3 – 62 severe
NR NR NR
de Punder64
Extended
Simplified
≥ 5 Ratingen points at 3 years 425 175 NR Extended: 0.77
(0.72 to 0.81)
Simplified: 0.75
(0.70 to 0.80)
Extended:
Hosmer–Lemeshow,
p= 0.41–0.85. Shrinkage
factor: 0.90 (95% CI 0.88
to 0.92). Calibration
slope = 1.0 (95% CI 0.82
to 1.21)
Simplified model:
Hosmer–Lemeshow,
p= 0.87–0.99. Shrinkage
factor: 0.98 (95% CI 0.96
to 1.0). Calibration
slope = 1.1 (95% CI 0.89
to 1.33)
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TABLE 9 Performance results from clinical prediction model development studies (continued )
Name of clinical
prediction model(s) Outcome definition Sample size (n)
Total number of
observed events
Overall model
fit
Discrimination,
c-statistic (95% CI)
Calibration/assessment
of overfitting
Prediction of HAQ score
Dirven67 ≥ 1 at 3 months 497 199 (40%) Nagelkerke’s
R2 = 0.29
0.78 (0.74 to 0.82) NR
Bansback58 ≥ 1.5 at 5 years 985c 298 Nagelkerke’s
R2 = 0.39
0.82 Slope shrinkage of 0.89
based on 200 bootstrap
samples
Combe (B)63 Continuous variable at
5 years (3-year data not shown)
156 N/A (continuous
variable)
NR NR NR
Prediction of MHAQ score
Graell71 MHAQ score of > 0 at 2 years 105 28 NR NR NR
Prediction radiographic damage, HAQ score and severe disease course at 12 years
Drossaers-Bakker56,d Mild/severe SHS at 12 years
HAQ score and severe disease
course at 12 years
Total population,
n= 112
Unclear NR NR NR
Prediction of DAS28
MBDA (Centola et al.)61 DAS28-CRP ≥ 2.67 at 3 months 708 (stage 3
algorithm training)
NR NR NR for final MBDA
model
NR
anti-MCV, antimutated citrullinated vimentin; N/A, not applicable; NR, not reported.
a Outcome definition as reported by Granger et al.82 external validation study.
b Traditional risk factors studied were age, sex, symptom duration at first visit, localisation of initial joint symptoms (SJC66), presence of ACPA, presence of RF and ESR. The initial treatment
strategy differed for different inclusion periods [initial NSAIDs (non-steriodal anti-inflammatory drugs), initial HCQ/SSZ and initial MTX]. As the severity of progression differed for these
three groups, treatment effects were incorporated into the analyses.
c Total population size. Number contributing to the multivariable model is lower but unclear.
d Although the publication by Drossaers-Bakker et al.56 reported multiple prediction models, the reporting of these was considered to be unclear and is therefore included above as
one entry.
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positivity was measured at the 8.2-year follow-up point, as opposed to baseline or in the early stages of
disease, as discussed in Description of predictors.
c-Statistics were presented for the clinical prediction models by van Steenbergen et al.77 for predicting
radiographic progression at 6 years. For this study, an outcome variable with three categories was
considered and the reported c-statistics were computed using Harrell’s c-statistic for ordinal data.37 The
model that included treatment plus traditional (i.e. selected demographic, clinical and biomarker) variables
had a moderate performance (c-statistic 0.78, 95% CI 0.73 to 0.82). The addition of genetic factors to the
model (treatment and traditional and genetic) increased the discrimination of the model slightly (c-statistic
0.82, 95% CI 0.77 to 0.86).
The model goodness of fit (R2) was only rarely reported. Low Nagelkerke’s R2 values were obtained for
the Berglin models (model 1: 0.21; model 2: 0.24);59 Forslind model 1 (radiological damage)70 yielded a
Nagelkerke’s R2 value of 0.5, whereas the fit for model 2 (radiological progression) was slightly poorer at
0.4. For the de Vries-Bouwstra model,65 the fit (R2) was 0.36. The R2 for the van Steenbergen models77
increased when genetic factors were added to treatment plus traditional factors (0.43 from 0.36, an
increase of 0.07; p = 0.06, adjusted R2 increase = 0.03). Although Nagelkerke’s R2 was reported in several
publications and used to compare the overall model fit of competing models, it does not provide an
assessment of the models’ predictive performance. A model may have a low R2 value while still providing
a useful prediction tool.
Prediction model
Change in SHS of > 5 units at 1 year
Change in SHS of > 10.5 units at 8.2 years
Houseman (2012)72
Houseman (2012)72
de Punder extended (2015)64
de Punder simplified (2015)64
Total SHS of > 6 units at 8.2 years
Change in Ratingen score of > 5 points at 
3 years
Change in SHS at 6 years
BeSt CRP (2010)79
BeSt ESR (2010)79
ESPOIR (2012)69
Degboé anti-CCP (2015)66
Degboé anti-MCV (2015)66
Degboé AhFiba (2015)66
Degboé high level of ACPA (2015)66
van Steenbergen TT 201577
van Steenbergen TTG 201577
TRIPOD
1a
1a
1b
1b
1a
1a
1a
1a
1a
1a
1a
1a
1a
c-statistic (95% CI)
0.87
0.84
0.77 (0.72 to 0.81)
0.75 (0.70 to 0.80)
0.81 (0.77 to 0.86)
0.80 (0.75 to 0.85)
0.65 (0.60 to 0.70)
0.63 (0.58 to 0.68)
0.65 (0.60 to 0.70)
0.65 (0.60 to 0.70)
0.75
0.78 (0.73 to 0.82)
0.82 (0.77 to 0.86)
c-statistic
0.5 0.6 0.7 0.8 0.9
FIGURE 6 Forest plot of predictive performance of the included clinical prediction models for radiographic joint
damage based on internal validation. Anti-MCV, antimutated citrullinated vimentin; TT, treatment and traditional
factors; TTG, treatment, traditional and genetic factors.
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Model calibration was not frequently reported. De Punder et al.64 assessed calibration using the
Hosmer–Lemeshow test, with p-values being large (p > 0.4) for all clinical prediction models, indicating
that there was no evidence to suggest a poor model fit. Calibration slopes and shrinkage factors were also
presented for the de Punder extended model64 (shrinkage factor 0.90, 95% CI 0.88 to 0.92; calibration slope
1.0, 95% CI 0.82 to 1.21) and the de Punder simplified64 models (shrinkage factor 0.98, 95% CI 0.96 to 1.0;
calibration slope 1.1, 95% CI 0.89 to 1.33). For the ESPOIR model,69 the use of the Hosmer–Lemeshow
test was described but not presented.
Models predicting Health Assessment Questionnaire score/disease course
The Bansback model58 predicted a HAQ score of ≥ 1 at 5 years. The internal validation of the model
resulted in a c-statistic of 0.82.
The goodness of fit of the Bansback model was 0.39 (Nagelkerke’s R2).58 The reported Nagelkerke’s R2
value for the Dirven model was 0.29.67
Secondary predictive performance measures (e.g. accuracy, sensitivity, specificity, PPV, NPV) are presented
when these were available (see Tables 31 and 32). Several studies presented performance measures based
on a specific threshold to define an event, when thresholds were often defined according to the study
population, and thus differed across studies. These measures are less informative than overall performance
measures, such as the c-statistic. They are presented for completeness but are not discussed further.
Results: external validation studies
The performance results of the external validation studies are summarised in Table 10. Six external
validation studies (including one combined model development/external validation study) were identified
that tested the performance of a total of eight previously developed clinical prediction models. All studies
focused on the prediction of radiographic joint damage.
The De Cock et al.80 external validation study considered six previously developed clinical prediction models
(i.e. ASPIRE94 CRP, ASPIRE94 ESR, BeSt,79 Syversen,76 SWEFOT73 and ESPOIR69). Note that the Syversen
prediction model76 was referred to as SWEFOT 1 in the De Cock et al. external validation,80 whereas the
SWEFOT model by Saevarsdottir et al.73 was denoted as SWEFOT 2. De Cock et al.80 presented results for
three different time intervals: first year (baseline to year 1); second year (year 1 to year 2); and over 2 years
(baseline to year 2). For this final assessment, progression was defined as total Sharp score (TSS) of > 10
over 2 years, as opposed to a TSS of > 5 over 1 year and, as such, differs from the outcome definition
used in the model development studies.
The Granger external validation study82 presented results from four clinical prediction models that had
been developed in other populations. Results were also presented for the ESPOIR model69 and an updated
mESPOIR82 model; however, given that the ESPOIR model69 was initially developed in this population, this
should not be considered as an external validation. The results are presented here for completeness, but
are not used for the subsequent meta-analysis. Granger et al.82 considered two versions of each model,
with the first being based on the published model and the second recalibrated with a new estimate of the
model intercept, but fixing the regression coefficients to be the same. The models were recalibrated on a
subsample of one-third of the ESPOIR69 population and then tested on the remaining two-thirds of the
population. Details of how the calibration sample was chosen were not provided.
The BeSt79 and ESPOIR69 models were also externally validated in the report of the de Punder models.64
Heimans et al.84 externally validated the BeSt model; however, the only version of the c-statistic that was
reported was based on a different definition of the outcome (i.e. a SHS of > 0.5 rather than SHS of > 5)
than that was used to derive the model and to assess performance in the other external validation studies.
Hambardzumyan et al.83 and Markusse et al.85 externally validated MBDA.
RESULTS: REVIEW 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 10 Performance results from external validation studies
Name of external
validation study
(submodels)
Clinical prediction
model Sample size (n)
Total number of
observed events
Overall model fit
(Nagelkerke’s R2)
Discrimination
c-statistic (95% CI)
Calibration/assessment
of overfitting
Prediction of radiographic joint damage (ΔSHS of > 5 at 1 year)
De Cock first year80 ASPIRE CRP 74a 4 NR 0.68 O : E ratio:b 0.35
ASPIRE ESR 74 0.68 0.42
BeSt 73 0.60 0.27
Syversen 73 0.34 0.08
SWEFOT 74 0.52 0.20
ESPOIR 73 0.35 0.31
De Cock second year80 ASPIRE CRP 74 5 NR 0.65 NR
ASPIRE ESR 0.37
BeSt 0.50
Syversen 0.54
SWEFOT 0.44
ESPOIR 0.50
Granger82 ESPOIR 370 41 0.17 0.75 (0.70 to 0.84) Hosmer–Lemeshow test:c 0.96
mESPOIR 0.30 0.82 (0.76 to 0.89) 0.55
SONORA 0.00 0.76 (0.68 to 0.83) < 0.01
SONORA (recalculated) 0.00 0.76 (0.69 to 0.83) < 0.01
BeSt 0.00 0.73 (0.65 to 0.81) < 0.01
BeSt (recalibrated) 0.00 0.73 (0.64 to 0.80) < 0.01
ASPIRE ESR 0.00 0.54 (0.45 to 0.64) < 0.01
ASPIRE ESR (recalibrated) 0.00 0.54 (0.46 to 0.64) < 0.01
ASPIRE CRP 0.00 0.62 (0.54 to 0.69) 0.25
ASPIRE CRP (recalibrated) 0.00 0.62 (0.41 to 0.60)d < 0.01
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TABLE 10 Performance results from external validation studies (continued )
Name of external
validation study
(submodels)
Clinical prediction
model Sample size (n)
Total number of
observed events
Overall model fit
(Nagelkerke’s R2)
Discrimination
c-statistic (95% CI)
Calibration/assessment
of overfitting
Hambardzumyan83 MBDA 235 44e NR NR (sensitivity, specificity,
PPV and NPV presented in
Table 32)
NR
Markusse85 MBDA 84 NR NR 0.77 (0.64 to 0.90) NR
Prediction of radiographic joint damage (ΔSHS of > 5 at 2 years)
Markusse85 MBDA 81 NR NR 0.69 (0.453 to 0.93) NR
Prediction of radiographic joint damage (ΔSHS of > 10 at 2 years)
De Cock over 2 years80 ASPIRE CRP 74a 4 NR 0.70 O : E ratio:b 0.35
ASPIRE ESR 74 0.60 0.42
BeSt 73 0.60 0.27
Syversen 73 0.25 0.08
SWEFOT 74 0.41 0.20
ESPOIR 73 0.35 0.31
Prediction of radiographic joint damage (ΔSHS of > 0.5 at 1 year)
Heimans84 BeSt 537 (431 RA
and 106 UA)
32 NR 0.56 (0.45 to 0.68)f 1.21
Markusse MBDA 84 NR NR 0.61 (0.48 to 0.73) NR
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Name of external
validation study
(submodels)
Clinical prediction
model Sample size (n)
Total number of
observed events
Overall model fit
(Nagelkerke’s R2)
Discrimination
c-statistic (95% CI)
Calibration/assessment
of overfitting
Prediction of radiographic joint damage (ΔSHS > 0.5 at 2 years)
Markusse MBDA 81 0.69 (0.56 to 0.81)
Prediction of radiographic joint damage (≥ 5 Ratingen points at 3 years)
de Punder64 BeSt
ESPOIR
NR NR NR Range 0.76–0.79
(no further information
reported)
NR
NR, not reported; UA, undifferentiated arthritis.
a Sample sizes from the matrices supplied in the supplementary files of De Cock et al.80 N varies according to the clinical prediction model that is being validated. This is likely to be
because of missing baseline prognostic variables, whereby the included prognostic factors differ for the alternative models. Completed risk matrices were supplied for the > 2-year time
point only; however, the allocation of individuals to cells of the risk matrices was presumed to be the same for the ‘first year’ time point, given that the baseline prognostic variables for
these two evaluation periods are the same. This was confirmed with the authors in correspondence.
b Calculated from the provided risk matrices (see details in Appendix 5).
c Significant p-value indicates that the model does not fit the data.
d The reported value of 0.62 is likely to be a typographical error, as it is outside the range of the CI and is referred to in the text as being close to 0.5.
e Calculated by review authors from percentages supplied in the original report.
f Area under the curve reported for the mixed RA/undifferentiated arthritis population (80% of patients had RA).
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The application of the BeSt model79 was considered by Saevarsdottir et al.73 using the SWEFOT data set.
However, the presented results did not provide sufficient details to be considered to be informative to the
current review, as no summary statistic of overall performance (e.g. the c-statistic) was provided.
Assessment of calibration
In order to assess the calibration of the models, the expected number of events according to each clinical
prediction model was calculated in the external validation populations when possible (the De Cock et al.80
and Heimans et al.84 populations). Further details of the calculations used are provided in Appendix 5.
In the De Cock et al.80 study, four events were observed in the first year of follow-up. However, the
number of events predicted is substantially higher for all six of the considered clinical prediction models,
leading to O : E ratios that are < 1. The O : E ratio ranged from 0.42 for ASPIRE ESR to 0.08 for Syversen
et al.,76 illustrating the poor calibration of the models in this population.
The calibration of the BeSt model79 in the Heimans et al.84 population appeared to be better, with an O : E
of 1.21 (32 observed events, compared with 26.5 events predicted by the model). However, it was noted
by the review authors that this external validation study used a different outcome definition of a > 0.5-unit
increase in the SHS in order to classify the 32 events. Using the outcome definition of a SHS of > 5 (used
in the BeSt model development), only one individual experienced rapid radiographic progression (RRP),
which indicates a poor calibration (i.e. an O : E ratio of 0.04). Modification of the outcome definition by
Heimans et al.84 demonstrates that the BeSt model is not suitable for use in this population without
recalibration.
In the case of the Granger et al.82 validation study, it was not possible to compute the expected number
of events. However, the study reported p-values from the Hosmer–Lemeshow test in order to assess
calibration. This indicated that all models provided a poor fit to the data (p < 0.01) apart from the
ASPIRE CRP model (p = 0.25). Contrary to what might be expected, the recalibrated ASPIRE CRP model
provided a poorer calibration according to the Hosmer–Lemeshow test (p < 0.01) and also showed a
higher value of the Bayesian information criterion (results shown in Granger et al.82), which raises questions
as to the success of the calibration procedure.
Assessment of discrimination
The discriminatory ability of the models based on the c-statistic ranged from 0.344 to 0.675 for the
Syversen and ASPIRE models, respectively, in the De Cock et al.80 validation study assessed at 1 year.
It is worth noting that the Syversen model76 was developed in a cohort that included patients with up to
4 years’ disease duration (mean 2.3. years’ disease duration) and so was outside the 2-year limit used to
define early RA in this assessment. This may partly explain the model’s poor performance in the early RA
external validation. The observed c-statistics ranged from 0.54 to 0.76 for the ASPIRE ESR and SONORA
models, respectively, in the Granger et al. validation study.82 The discrimination of BeSt79 in the Heimans
et al. external validation84 (using a TSS of > 0.5 to define progression) was 0.56 (95% CI 0.45 to 0.68),
showing poor discrimination with the CI including 0.5, despite calibration appearing to be reasonable in
this population.
Assessment of heterogeneity
The predictive performance varied widely across the external validation populations. The two ASPIRE
models provided the highest discriminatory ability in the De Cock et al. validation;80 however, these models
demonstrated the lowest discriminatory ability in the Granger et al.82 validation. It has previously been
demonstrated that the distribution of patient characteristics could substantially affect the discriminatory
ability of a prediction model. When possible, variations in the populations that could be used to explain
heterogeneity in the observed predictive performance were quantified by calculating the case mix of the
population, using the mean and SD of the linear predictor/risk score as described in Debray et al.40 Further
details on how this was calculated are provided in Appendix 5, along with histograms of the risk scores for
the models considered in De Cock et al.80 and for the BeSt model considered in Heimans et al.84 The mean
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risk scores in the De Cock et al.80 external validation population ranged from a 12.80% (SD 8.71%)
predicted risk (PR) of progression, using the ASPIRE ESR model, to a 70.15% (SD 21.01%) PR of progression,
using the Syversen model. This shows that, when evaluated in the same external population, the alternative
risk models provide substantially different average risk predictions. The mean risk score for the BeSt model
in the Heimans et al. external validation84 population was 4.93% (SD 4.54%), compared with 20.59%
(SD 16.83%) in the De Cock et al. validation population.80 Although the De Cock et al.population had a
larger case mix (with a greater SD of the linear predictor than obtained in the Heimans population), the
observed discriminatory performance was lower. However, the calibration of the BeSt model in the De Cock
et al. population was shown to be poor (O : E ratio of 0.27).
Although consideration of the case mix is of interest to illustrate the heterogeneity between alternative
risk models, the case mix could not be computed for all of the external validation studies included in
this review. There was also a small overall number of external validations. Further consideration of
heterogeneity in discriminatory ability using metaregression was therefore not feasible.
Results of the evidence synthesis
In order to provide a comprehensive overview of the available evidence, a meta-analysis was considered for
risk models that were externally validated in more than one study. For predicting RRP (SHS of > 5 in 1 year),
three clinical prediction models (i.e. BeSt79, ASPIRE CRP78 and ASPIRE ESR78) were each externally validated in
two studies (i.e. De Cock et al.80 and Granger et al.82) that provided data in a suitable format. A meta-analysis
was conducted using the c-statistic as a measure of discrimination. Although it would also be possible to
synthesise other performance measures (e.g. the O : E ratio), other outcomes were not widely reported.
The predictive performance results are presented in Table 11 for all external validations that considered
RRP (SHS of > 5 in 1 year) as an outcome, along with the results of the FE and RE meta-analysis for the
models that were assessed in more than one external validation study.
Of the models that were externally validated in more than one population, the BeSt model79 shows
the highest overall predictive performance (overall c-statistic 0.72, 95% CI 0.20 to 0.96), followed by
ASPIRE ESR78 and then ASPIRE CRP.78 However, there is considerable uncertainty in the pooled estimates.
For all three clinical prediction models, the 95% CI of the pooled estimate from the RE model contains 0.5,
indicating that there is no confidence that the c-statistic is better than would be expected by chance.
The 95% prediction intervals are not presented for the RE model as a result of the limited number of
TABLE 11 c-statistics and meta-analysis for models predicting RRP at 1 year
Risk model
External validation, c-statistic (95% CI) Pooled estimate, mean (95%CI)
aDe Cock et al.80 Granger et al.82 Markusse et al.85 RE FE
BeSt 0.60 (0.31 to 0.83) 0.73 (0.65 to 0.81) 0.72 (0.20 to 0.96) 0.72 (0.63 to 0.79)
ASPIRE CRP 0.68 (0.38 to 0.88) 0.54 (0.45 to 0.64) 0.55 (0.13 to 0.91) 0.55 (0.46 to 0.64)
ASPIRE ESR 0.68 (0.38 to 0.88) 0.62 (0.54 to 0.69) 0.62 (0.44 to 0.78) 0.62 (0.55 to 0.69)
Syversen 0.34 (0.13 to 0.64)
SWEFOT 0.52 (0.25 to 0.78)
ESPOIR 0.35 (0.14 to 0.65)
SONORA 0.76 (0.68 to 0.83)
MBDA 0.77 (0.64 to 0.90)
a De Cock. CI approximated from other information (see Appendix 5).
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studies contributing to the analyses (therefore the prediction intervals returned by the model are the same
as the CIs). The highest predictive performance in an individual study assessing the performance of models
for the prediction of RRP at 1 year was shown by MBDA, with a c-statistic of 0.77 (95% CI 0.64 to 0.90),
followed by SONORA with a c-statistic of 0.76 (95% CI 0.68 to 0.83); however, neither of these models
were externally validated in more than one population (using the same outcome definition and presenting
a suitable performance measure).
Consideration of results according to baseline disease severity
Given the limited reporting of the DAS28 at baseline in the included model development and external
validation studies (see Table 3), it was not possible to draw conclusive inferences regarding the
development or performance of clinical prediction models in populations with moderate versus severe
disease activity based on the DAS28 at baseline.
Discussion
Twenty-two model development studies and one combined model development/external validation study
describing 39 clinical prediction models for the assessment of prognosis in early RA patients were identified
across a range of major outcomes (radiographic joint damage, HAQ score and DAS28). The large majority
of these model development studies (n = 16) tested apparent performance only (TRIPOD statement type 1a).
A total of six external validation studies (including the combined model development/external validation
study) were identified that tested the performance of a total of eight previously developed clinical prediction
models. All included external validation studies focused on radiographic joint damage outcomes.
Variation was observed in the methods used to develop the included clinical prediction models, such as
those used to select or reject candidate predictors from the final model (e.g. informed by univariable
analysis, statistical selection or clinical judgement) and handling of continuous predictors (e.g. division into
categories). Some studies presented a ‘matrix model’, and so continuous variables were categorised to
allow this presentation format, even though the categorisation of continuous covariates is generally not
recommended for prognostic model development.35,36 Model development studies also generally failed to
assess interactions between predictors, including interactions with the treatment group, and so did not
generate truly treatment-specific models. This is considered in further detail in Chapter 5.
There was also inconsistency in the measures of predictive performance reported from internal validation.
The c-statistic was reported for 8 of the 23 model development studies, although sensitivity and specificity
(eight studies), accuracy (seven studies) and PPV and/or NPV (12 studies) were also commonly reported.
However, even if consistent approaches had been used for internal validation, comparing the performance
of clinical prediction models that have been developed and internally validated in different populations
would still be limited, as good discriminative ability in the population used to develop the model would be
expected. External validation is required to provide an objective comparison.
Of the eight studies that reported predictive performance in internal validation using the c-statistic,
the results were variable. The c-statistics for radiographic progression outcomes ranged between 0.63
(i.e. Degboé et al.,66 predicting a ΔSHS of ≥ 5 at 1 year) and 0.87 (i.e. Houseman et al.,72 predicting a ΔSHS
of ≥ 10.5 at 8.2 years). The Houseman72 models were notable in that they were among the few models
that included MMP-3 in their final selection of predictors (MBDA also includes MMP-3). Unfortunately,
the Houseman models72 were assessed using apparent performance only and were not externally validated,
and so it is not possible to verify the strong apparent predictive performance suggested in the study report.
Furthermore, the Houseman model72 included anti-CCP measured at the 8.2-year follow-up visit, which
would bias the performance results relative to models that use only baseline information. Two studies
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predicting the HAQ score reported c-statistics [0.78 (i.e. Dirven et al.,67 HAQ score of ≥ 1 at 3 months) to
0.82 (i.e. Bansback et al.,58 HAQ score of ≥ 1.5 at 5 years)], which also showed promising discrimination,
albeit derived from internal validation.
Although the 39 included clinical prediction models present predictive performance results based on internal
validation, 31 of these have not been externally validated. This could be largely explained by the fact that
21 of the clinical prediction models were not published in a useable format. Of the eight clinical prediction
models that were externally validated, the majority were presented as risk matrices in the published
report,67,69,78,79 whereas two models were presented using the full model regression coefficients.61,76 The
SWEFOT73 models were not presented in a useable format in the model development publication; however,
the main SWEFOT model was considered in the De Cock et al.80 external validation based on the results that
are available in conference proceedings.73 The SONORA model was externally validated by Granger et al.,82
despite being available only in a non-useable format in abstracts.
For models that have been externally validated, predictive performance was observed to vary widely.
The highest predictive performance of a clinical prediction model for the prediction of radiographic
progression (ΔSHS of ≥ 5 at 1 year) in an individual external validation study was shown by MBDA, which
was externally validated by Markusse et al.85 (c-statistic 0.77, 95% CI 0.64 to 0.90), followed by SONORA,
which was externally validated by Granger et al.82 (c-statistic 0.76, 95% CI 0.68 to 0.83). However, neither
of these models was externally validated for the prediction of radiographic progression in more than
one population. The lowest predictive performance of a clinical prediction model for the prediction of
radiographic progression (ΔSHS of ≥ 5 at 1 year) in an individual external validation study was shown by
Syversen et al.,76 which was externally validated by De Cock et al.80 (c-statistic = 0.34) followed by ESPOIR
(c-statistic = 0.35). For both of these models, the external validation results suggest a performance that is
poorer than would be expected by chance (c-statistic < 0.5). However, the performance of ESPOIR was
much more promising when externally validated by de Punder et al.,64 in which c-statistics were reported
to range from 0.76 to 0.79 using a different outcome definition (≥ 5 Ratingen points at 3 years).
Three clinical prediction models (i.e. ASPIRE CRP, ASPIRE ESR and BeSt) were externally validated in more
than one population using the same outcome definition (ΔSHS of ≥ 5 at 1 year). The results of the RE
meta-analysis implied that the most favourable performance across external validations was observed
using the BeSt model (c-statistic 0.72, 95% CI 0.20 to 0.96), followed by ASPIRE ESR (c-statistic 0.62,
95% CI 0.44 to 0.78) and ASPIRE CRP (c-statistic 0.55, 95% CI 0.13 to 0.91). However, the favourable
performance of BeSt was largely informed by the high c-statistic observed in the Granger et al. external
validation,82 and the BeSt model performed less favourably than either of the ASPIRE models in the
De Cock et al. external validation.80 There is considerable heterogeneity for all three models, with the wide
CIs suggesting substantial uncertainty in the expected predictive performance in a new sample of patients.
The 95% CIs of the pooled estimates contain 0.5 for all three clinical prediction models, indicating that
there is limited confidence that the performance of the models is better than would be expected by chance.
Further external validations were identified in populations outside the scope of the assessment. These
external validations were in populations with established RA. Vastesaeger et al.78 tested the performance of
their ASPIRE model78 in data from the ATTRACT RCT {median disease duration of 8.4 years [interquartile
range (IQR) 4.3–14.7 years]}. Lillegraven et al.95 also tested the performance of the ASPIRE CRP,78 BeSt79
and SWEFOT73 clinical prediction models in patients with established RA [median disease duration of
12 years (IQR 4–23 years)] and reported low predictive performance (c-statistics: ASPIRE, 0.59; BeSt, 0.65;
and SWEFOT, 0.57).
No clinical prediction model performed consistently better than any other, and the current evidence therefore
does not support the recommendation of one clinical prediction model over another. The inconsistent results
generated by the clinical prediction models on external validation indicates that there is heterogeneity in the
populations in which the models are being tested that is not explained by the currently proposed models.
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However, in this assessment, it was not possible to explore the reasons for the observed heterogeneity,
because of the small number of external validations.
The external validation of a clinical prediction model may not be straightforward if the treatment regimens
used in the external validation population differ from those used in the original model development
population. The authors of the external validation studies included in this review aimed to select the
published clinical prediction matrices that provided the closest approximation to the treatment strategy
in their external validation population. The issue of treatment practices changing over time, with the
resulting differences in treatment between model development and external validation populations, was
acknowledged by Steyerberg et al.23 in their contribution to the PROGRESS series of publications. However,
these authors also noted that it was important to consider whether or not existing models could be
updated and their predictive performance improved by, for example, recalibration or the addition of new
predictor variables. Moons et al.31 also advocated the value of updating existing prediction models in order
to improve their predictive performance in new settings or populations. Recalibration was considered only
in the external validation by Granger et al.82 However, there was evidence that recalibration may not have
resulted in a better model fit.
In order to assess the comparative performance of the competing models more thoroughly, further
external validations would be required. These should be conducted in clinically appropriate populations
with early RA, previously untreated and with sufficient variation (or case mix) in the population to ensure
that the results are generalisable to the target population.
Although further external validation would help to clarify whether or not selected models are likely to
perform better than others, as previously discussed, there were limitations identified in the methods used
to develop the clinical prediction models in many of the development studies. Limitations included the
absence of potentially important candidate predictors, inconsistent selection procedures, incorrect handling
of continuous predictors and failure to test for interactions between predictors. It is therefore likely that
the most clinically useful prediction model would contain predictors from across more than one of the
reviewed clinical prediction models and/or consider alternative handling of key predictive variables. Access
to IPD would allow harmonisation (both in terms of model development and validation) beyond that
which is possible in the current assessment, which considers only aggregate-level data.96 Guidance on
IPD meta-analyses of clinical prediction modelling studies, including the advantages and challenges of
undertaking such projects, is given by Debray et al.97 Methods for assessing clinical prediction models using
IPD from multiple studies are also described by Pennells et al.98 Although the provided reference focuses
on the prediction of cardiovascular disease outcomes using time-to-event data, the key principles are
relevant for the current review.
Therefore, despite the availability of a range of clinical prediction models, uncertainty still remains over the
most appropriate clinical prediction model(s) for use in clinical practice. Future research efforts should focus
on consolidating understanding from existing clinical prediction models and external validation studies,
and ensuring that recommended practice for model development and reporting is adhered to.
The meta-analysis was limited by the small number of external validation studies available for analysis.
The synthesised estimates are indicative of performance in the observed studies, but cannot be used to
provide a definitive conclusion about the performance in future studies or to explore the reasons for the
heterogeneity between studies. A bivariate meta-analysis of calibration and discrimination has also been
proposed and could potentially be used to increase the precision of summary estimates and avoid the
exclusion of studies for which relevant estimates are missing.99 However, this was not considered in this
assessment because of the other described limitations of the evidence base.
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Review 1 conclusions
Despite the availability of a range of clinical prediction models, uncertainty still remains over the most
appropriate clinical prediction model(s) for use in clinical practice. In order to assess the comparative
performance of the competing models more thoroughly, further external validations would be required.
However, limitations were observed in the methods used to develop the clinical prediction models. It is
likely that the most clinically useful prediction model would contain predictors from across more than one
of the reviewed clinical prediction models and/or consider alternative handling of key predictive variables.
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Chapter 5 Results: review 2
Quantity of research available
Only one of the clinical prediction models involving multiple treatments that were reported in review 1
investigated potential interactions between treatments and predictor variables.79
The study selection process for review 2 is depicted in Figure 7. A total of 12 studies were included,78,100–111
two of which used the same data set.78,100
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It was stated in the final protocol that any potential overlap would be highlighted between this report and
the National Institute for Health Research (NIHR) HTA Technology Assessment Review (TAR) report number
14/16/01. One study included in review 2 (i.e. Taylor et al.101) was also included in the HTA TAR report
number 14/16/01. This study examined the effect of baseline synovial vascularity assessed by PDUS on
radiographic progression at 54 weeks by MTX versus MTX and IFX. Other studies in the NIHR HTA TAR
report number 14/16/01 were screened for relevance to the current review, but were excluded for not
examining an early RA population and/or not examining the interaction between baseline patient and/or
disease characteristics and treatments.
A summary of the 12 included studies that are used to assess the prediction of treatment response by
patient and/or disease characteristics is presented in Table 12. All included studies were post hoc subgroup
analyses of RCTs.78,100–111 The geographical locations of the studies included the Netherlands,103 the
USA,105,110 Finland,106 Italy,107 Germany108 and the UK,101,109 with three studies examining data from two
multinational trials78,100,104 and one study not reporting location.102 Sample sizes ranged from 24 to 1004
participants; most studies were funded by the pharmaceutical industry,78,100–105,107,110 two studies reported
funding from local or national health-care agencies106,109 and one study did not report the funding source.108
Overall quality of research available
All included studies were rated as being at a moderate risk of bias, according to the QUIPS assessment
tool54 (Table 13). Generally, most studies were rated as being at a moderate risk of bias for study
participation. This was mainly because most studies did not report the source of the target population and
the methods used to recruit patients to the study, with many not reporting or partially reporting whether
or not there was adequate participation in the study. Most studies reported the recruitment period,
inclusion and exclusion criteria and baseline characteristics.
The majority of studies were also rated as being at a moderate risk of bias for study attrition. This was
mainly because most studies did not report the proportion of the baseline sample that provided data for
analysis or what attempts were made to collect information on participants who dropped out. Most
studies did not report, or partially reported, the key characteristics for participants who dropped out or the
comparative characteristics of those who dropped out and those who provided follow-up data. However,
reasons for the loss of follow-up data were typically reported.
Most studies were also rated as being at a moderate risk of bias for prognostic factor measurement. This
was mainly because of a lack of clarity or reporting surrounding the proportion of data on the prognostic
factor that was available for analysis and the method used for dealing with missing data in most studies.
The method and setting of prognostic factor measurement was reported by approximately half of the
included studies, and most studies reported a definition and also valid and reliable measurement of the
prognostic factor.
Most studies were rated as being at a low risk of bias for outcome measurement. This was mainly attributable
to most of the studies reporting a clear definition of the outcome, valid and reliable measurement of the
outcome and the method and setting of the outcome being the same for all participants.
Study confounding was also rated as being at a moderate risk of bias for most studies. This was mainly
attributable to a lack of reporting or partial reporting among the majority of studies on whether or not
important confounders were measured and the definition and valid and reliable measurement of these,
and also the method and setting of confounding measurement and whether or not important confounders
were accounted for in the study design and analysis.
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TABLE 12 Characteristics of the included primary studies
First author
(year of
publication),
name of trial
or cohort
(if relevant)
Characteristics
Study design
Geographical location and
period of data collection Key eligibility criteria
Maximum
length of
follow-up
Sample size (number of
participants)
Assessment
of risk of bias
(low/moderate/
high)
a
Funding
Garnero (2002)102 Cohort study [efficacy
analyses of patients
included in a RCT
(i.e. Bathon 2000112)]
Unclear location
1997–9
Early active RA for ≤ 3 years with
≥ 10 swollen joints, ≥ 12 tender
joints, aged ≥ 18 years, diagnosed
in accordance with the 1987
revised ACR criteria, RF+, serum
CRP level of ≥ 2.0mg/dl, three or
more radiographic erosions of the
hands, wrists or feet
12 months 116 Moderate Immunex (Seattle, WA, USA)
Heimans (2013)103
BeSt
RCT (post hoc analyses) The Netherlands
2000–2 (recruitment)
Early active RA (1987 revised ACR
criteria); disease duration of
≤ 2 years; active disease (≥ 6/66
swollen joints, ≥ 6/68 tender joints,
and either an ESR of 28mm/hour
or a global health score of 20mm
on a 0- to 100-mm visual
analogue scale), aged ≥ 18 yearsb,c
10 years 484 patients (sample size
at 8 years’ follow-up;
initial cohort= 508
patients)
Moderate Dutch College of Health Insurance
Companies; Centocor Inc. (Horsham,
PA, USA); and Schering-Plough
(Kenilworth, NJ, USA)
Huizinga (2015)104
AVERT
Post hoc analysis of
RCT (phase 3b,
multicentre,
randomised, active-
controlled study)
Multicentre – 72 worldwide
sites, including North
America, South America,
Europe and the rest of the
world
NR
Adults (≥ 18 years old) with active
clinical synovitis of ≥ 2 joints for
≥ 8 weeks, persistent symptoms
for ≤ 2 years, DAS28-CRP of
≥ 3.2 and anti-CCP-2 anti-body
positivity, MTX naive or received
MTX (≤ 10mg/week) for ≤ 4
weeks with no MTX for 1 month
prior to enrolment
18 months 511 patients enrolled;
351 patients randomised
Moderate Bristol-Myers Squibb (New York
City, NY, USA)
Maska (2012)105
TEAR
RCT (subgroup
analyses)
USA
NR
Early active RA (1987 revised ACR
criteria; disease duration of < 3
years); aged > 18 years, active
disease (≥ 4 swollen joints and
≥ 4 tender joints based on DAS28-
joint count), RF+ or ACPA+, or
≥ 2 erosions on radiographs of the
hands/wrists/feet if RF– or ACPA–
2 years
(102 weeks)
A total of 412 patients
(with available serum
cotinine data at baseline,
week 48 and week 102
from study sample;
n= 755) included in the
analyses
Moderate Amgen (Thousand Oaks, CA, USA;
provided ETN and placebo); Barr
pharmaceuticals (Montvale, NJ,
USA; provided MTX); Pharmacia
(New Jersey, USA) (SSZ and
placebo); and NIH planning grant
(PI: Moreland; 1 R34 AR055122)
from NIAMS for the TEAR study
Mustila (2011)106
FIN-RACo
RCT Finland (18 centres)
1993–5 (recruitment)
Clinically active RA (1987 revised
ACR criteria), symptom duration of
< 2 years, DMARD naive
5 years 129 (of 199 randomised –
completing 5 years’
follow-up, with clinical
and radiographic data)
Moderate Competitive research funding of
the Pirkanmaa Hospital District,
Tampere University Hospital
(Tampere, Finland)
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TABLE 12 Characteristics of the included primary studies (continued )
First author
(year of
publication),
name of trial
or cohort
(if relevant)
Characteristics
Study design
Geographical location and
period of data collection Key eligibility criteria
Maximum
length of
follow-up
Sample size (number of
participants)
Assessment
of risk of bias
(low/moderate/
high)
a
Funding
Pasero (1996)107 RCT (subgroup of
patients with or
without joint erosions)
Italy
1991–3 (recruitment)
Early active RA; disease duration of
at least 6 months, but ≤ 4 years;
aged 18–65 years, fulfilling 4/7
1987 revised ACR criteria and in
Steinbrocker functional class I,
previously untreated or treated
with a maximum of only one
DMARD (an antimalarial agent or
auranofin), discontinued because
of side effects or lack of efficacy,
ESR > 30mm/hour, morning
stiffness for ≥ 45 minutes, and
three or more swollen and tender
joints, including two or more hand
joints
12 months 361 patients enrolled; 340
patients available for ITT
analysis (complete set of
radiographs, available for
n= 284 patients)
Moderate Sandoz PF (Corso Verona, Italy)
Rau (1998)108 Randomised, double-
blind, parallel-group
trial
Germany (two centres)
NR
Active disease RA (presence of
three of:
1. an ESR of > 20mm/hour in men
and > 30mm/hour in women
2. morning stiffness for ≥ 1 hour
3. six or more swollen joints
4. nine or more tender joints)
A disease duration of ≥ 4 months,
with erosive disease
Patients with advanced
radiographic changes (Larsen
stages III–V) in any joint, prior
treatment with MTX or GSTM,
treatment with any other DMARD
during the previous 3 months, and
intra-articular steroid injection
within the previous 4 weeks were
excluded
12 months 174 patients enrolled
(complete set of
radiographs, available for
n= 152 patients)
Moderate NR
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First author
(year of
publication),
name of trial
or cohort
(if relevant)
Characteristics
Study design
Geographical location and
period of data collection Key eligibility criteria
Maximum
length of
follow-up
Sample size (number of
participants)
Assessment
of risk of bias
(low/moderate/
high)
a
Funding
Seegobin (2014)109
CARDERA
RCT UK (42 centres)
2000–4d
Early active RA (1987 ACR criteria,
< 2 years’ duration), aged
≥ 18 years, with three of three or
more swollen joints, six or more
tender joints, ≥ 45 minutes’
morning stiffness, ESR of
≥ 28mm/hour
2 years 431 (from 467 recruited –
with evaluable baseline
sera)
Moderate Arthritis Research UK and NIHR
under its Research for Patient
Benefit Programme
Smolen (2006)100
Vastesaeger
(2009)78
ASPIRE
Exploratory analysis of
RCT data
Multicentre study
(122 centres in Europe –
Austria, the Netherlands,
Germany, the UK and the
USA)
2000–2 (recruitment)e
Early active RA (1987 revised
ACR criteria); age 18–75 years,
persistent synovitis for ≥ 3 months
and ≤ 3 years, ≥ 10 swollen joints,
≥ 12 tender joints, one or more of
RF, serum CRP level of ≥ 2.0mg/dl,
radiographic erosions of the hands
or feet. No prior treatment with
MTX, no other DMARDs within
4 weeks of study entry
54 weeks 1004 Moderate Centocor Inc. (Horsham, PA, USA;
subsidiary of Johnson & Johnson)
and Schering-Plough (Kenilworth,
NJ, USA)
Sokolove (2016)110
AMPLE
Exploratory analysis of
RCT
USA
2009–12
bDMARD-naive patients with
active RA (1987 revised ACR
criteria) and an inadequate
response to MTX; a DAS28-CRP of
≥ 3.2 and a history of ACPA+ or
RF+ and/or elevated ESR or CRP
levels,f aged > 18 years and
disease duration of ≤ 5 years
729 days
(2 years
approximately)
573 patients completed
2 years, with 508 who
had serum samples at
baseline
Moderate Bristol-Myers Squibb (New York
City, NY, USA)
continued
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TABLE 12 Characteristics of the included primary studies (continued )
First author
(year of
publication),
name of trial
or cohort
(if relevant)
Characteristics
Study design
Geographical location and
period of data collection Key eligibility criteria
Maximum
length of
follow-up
Sample size (number of
participants)
Assessment
of risk of bias
(low/moderate/
high)
a
Funding
Taylor (2004)101 RCT UK
NR
RA diagnosis (1987 revised ACR
criteria), symptoms for 6 months to
3 years, two or more swollen MCP
joints despite MTX, IgM RF+,
receiving MTX at a stable dose of
12.5–17.5mg/week for ≤ 4 weeks
prior to screening, either not
taking corticosteroids or receiving
a stable dose of ≥ 10mg of
prednisolone per day for
≥ 4 weeks, plus either:
1. erosion of one or fewer MCP
joints on plain radiography
of GSUS
2. erosions of two or fewer MCP
joints with a strong PDUS
vascular signal
54 weeks 24 Moderate Centocor (Horsham, PA, USA;
supplied study drug, had a role in
analysis and interpretation) and
the Rheumatoid Arthritis
Campaign
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; AMPLE, abatacept vs. adalimumab in biologic-naive RA patients with background MTX; AVERT, A Very Early
Rehabilitation Trial; CARDERA, Combination Anti-Rheumatic Drugs in Early RA; DMARD, disease-modifying antirheumatic drug; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; GSTM, gold sodium thiomalate;
GSUS, grey scale ultrasound; IgM, immunoglobulin M; MCP, metacarpophalangeal; NIAMS, National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH, National Institutes for Health; NR, not reported; PI, principal
investigator; TEAR, Treatment of Early Aggressive Rheumatoid arthritis.
a According to the QUIPS assessment tool,54 this will be summarised in more detail in Overall quality of research available and Table 13.
b From van der Kooij et al.113
c From Goekoop-Ruiterman et al.89
d From Choy et al.114
e From St Clair et al.87
f From Weinblatt et al.115
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TABLE 13 Risk of bias of included primary studies – QUIPS summary ratings
First author (year of publication),
name of trial or cohort (if relevant)
Risk of bias of
Overall risk of
bias summary
Study
participation
Study
attrition
Prognostic factor
measurement
Outcome
measurement
Study
confounding
Statistical analysis
and presentation
Garnero (2002)102 High Moderate Moderate Low Moderate High Moderate
Heimans (2013)103
BeSt
Low Moderate Low Moderate Moderate to low Moderate Moderate
Huizinga (2015)104
AVERT
Moderate Moderate Moderate Moderate Moderate Moderate Moderatea
Maska (2012)105
TEAR
Low Moderate Moderate Low Moderate to low Low Moderate
Mustila (2011)106
FIN-RACo
Moderate Moderate Low Low High Moderate Moderate
Pasero (1996)107 Moderate Moderate Moderate Moderate Moderate Moderate Moderate
Rau (1998)108 High Low Moderate Low Moderate Moderate Moderate
Seegobin (2014)109
CARDERA
Moderate Moderate Low Low Moderate Low Moderate
Smolen (2006)100
ASPIRE
Moderate High Moderate Low Moderate Moderate Moderate
Sokolove (2015)110
AMPLE
Moderate to high Moderate Moderate Moderate Moderate Moderate Moderate
Taylor (2004)101 Moderate Moderate Moderate to low Low Moderate to high Moderate Moderate
Vastesaeger (2009)78
ASPIRE
Moderate High Moderate Low Moderate High Moderate
AMPLE, abatacept vs. adalimumab in biologic-naive RA patients with background MTX; AVERT, Assessing Very Early Rheumatoid arthritis Treatment; CARDERA, Combination Anti-Rheumatic
Drugs in Early RA; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; TEAR, Treatment of Early Aggressive Rheumatoid arthritis.
a Based on Emery et al.116
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Most studies were also rated as being at a moderate risk of bias for statistical analysis. This was mainly
because of uncertainty over whether or not the presentation of the analytical strategy and model
development strategy and the avoidance of selective reporting of results were adequate, because of
a lack of a clear description in most studies.
Treatments, baseline variables and outcomes examined of the
included studies
Table 14 summarises the treatments, patient and/or disease characteristics and outcomes examined.
Numerous treatment comparisons were made, including:
l ETN versus MTX102
l sequential monotherapy with initial MTX versus step-up monotherapy with initial MTX versus MTX and
SSZ and tapered prednisone versus MTX and IFX103
l ABT (subcutaneous administration) and MTX versus ABT (subcutaneous administration) versus MTX104
l MTX and ETN immediate therapy versus MTX and SSZ and HCQ immediate therapy versus MTX and
ETN step-up therapy versus MTX and SSZ and HCQ step-up therapy105
l MTX and HCQ and SSZ in a treat-to-target (TTT) regime versus cDMARD sequential monotherapy in a
TTT regime, starting with SSZ106
l ciclosporin A (CsA) versus cDMARDs107
l MTX versus gold sodium thiomalate (GSTM)108
l MTX versus MTX and CsA versus MTX and prednisolone versus MTX and CsA and prednisolone
(in a factorial design)109
l MTX versus MTX and IFX (3 mg/kg or 6 mg/kg)78,100
l MTX and ABT (subcutaneous administration) versus MTX and ADA (subcutaneous
administration),110 and
l MTX versus MTX and IFX.101
Eligible baseline variables were ACPA status,104,106,109,110 smoking status,105 erosions,100,107 RF status,100,111
CRP level,100–102 ESR,100,108 SJC,100 BMI103 and vascularity of synovium detected using PDUS.101
Eligible outcomes were erosions/radiographic progression,100–102,106–109 disease activity,105,109 physical
function,109,110 remission103,110 and a DAS of > 2.4.103 Four studies assessed outcomes at 6 months,105,108–110
11 studies assessed outcomes at 1 year,100–103,106–110 one study assessed outcomes at 18 months,109 four
studies assessed outcomes at 2 years,105,106,109,110 and one study assessed outcomes at 3, 4 and 5 years.106
Description of population characteristics
The key population characteristics are summarised in Table 15 (and additional population characteristics
are summarised in Appendix 9, Table 34).
The majority of included studies used the 1987 revised ACR criteria for RA diagnosis.100–103,105–107,109,110 One
study did not report the diagnosis criteria104 and one study reported using the ACR case criteria.108 Five studies
defined early RA as being active RA or the presence of symptoms for a duration of < 2 years,103,104,106,109,110 four
studies defined early RA as being active RA or the presence of symptoms for a duration of < 3 years100–102,105
and two studies used other definitions (active RA for ≥ 6 months but ≤ 4 years,107 or by radiographic definition,
i.e. patients without advanced disease108); in all cases, baseline mean/median disease/symptom duration met
the inclusion criterion for early RA (i.e. being within 2 years of the onset of symptoms) for this review.
RESULTS: REVIEW 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
TABLE 14 Treatments, baseline variables and outcomes of included primary studies
First author (year
of publication),
name of trial or
cohort (if relevant) Treatment comparison Variable(s)
Measurement and timing of
variable Outcomes
Measurement and timing of
outcomes
Assessment time of
outcome measurement
Garnero (2002)102 ETN
MTX
CRP level Baseline (high levels of CRP were
defined as those in the upper tertile of
the RA population). No further details
reported
Erosion and
radiographic
progression
Change from baseline in SHS
erosion score and SHS total
score at 12 months
1 year
Heimans (2013)103
BeSt
Sequential monotherapy
(initial MTX)
Step-up combination
therapy (initial MTX)
Combination therapy
MTX and SSZ and
tapered prednisone
Combination therapy
MTX and IFX
BMI Calculated from height and weight,
as assessed at baseline by a research
nurse. Dichotomised to < 25 kg/m2
and ≥ 25 kg/m2
Treatment
response
A DAS of > 2.4, failed response
to treatment, measured in the
first 3 months of treatment and
at year 1
1 year
Huizinga (2015)104
AVERT
ABT (s.c. administration)
and MTX
ABT (s.c. administration)
and MTX
ACPA status
(anti-CCP2 status)
Measured at baseline; no further
details reported
Remission A DAS28 of < 2.6 at 12 months 1 year
Maska (2012)105
TEAR
MTX and ETN
immediate therapy
MTX and SSZ and HCQ
immediate therapy
MTX and ETN step-up
therapy
MTX and SSZ and HCQ
step-up therapy
Smoking status Measured at baseline and week 48:
smokers= detectable (serum) cotinine
level of > 5 ng/ml at both visits; non-
smokers= undetectable cotinine levels
at both baseline and week 48 visits
Disease activity Mean DAS28 at 48–102 weeks
Mean DAS28 (absolute) at
24 weeks, 48 weeks and
102 weeks
1–2 years
6 months
1 year
2 years
continued
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TABLE 14 Treatments, baseline variables and outcomes of included primary studies (continued )
First author (year
of publication),
name of trial or
cohort (if relevant) Treatment comparison Variable(s)
Measurement and timing of
variable Outcomes
Measurement and timing of
outcomes
Assessment time of
outcome measurement
Mustila (2011)106
FIN-RACo
MTX and HCQ and SSZ
in a TTT regime;
cDMARD sequential
monotherapy in a TTT
regime (starting with
SSZ)
ACPA status ACPAs were determined from a serum
sample drawn at baseline and at 1, 2
and 5 years; a cut-off value of
25 U/ml. ACPA results of < 25 U/ml
were defined as negative
Erosion by
radiographic
progression
Larsen score obtained from
once-yearly radiographs of
the hands and feet by one
experienced radiologist, blinded
to clinical data
1, 2, 3, 4 and 5 years
Pasero (1996)107 CsA
Conventional DMARDs
Erosions Presence or absence of erosions at
baseline, as determined by the
Larsen–Dale method
Erosions/
radiographic
progression
Progression in eroded joint count
(PEJC) and progression in
damage score calculated as the
difference in eroded joint count
and damage score from baseline
using the Larsen–Dale method
12 months
Rau (1998)108 MTX
GSTM
RF Baseline, after 6 and 12 months Radiographic
progression
Rau-modified Sharp/Larsen score 6 and 12 months
ESR Baseline, after 1, 3, 6, 9 and
12 months
CRP level Baseline, after 1, 3, 6, 9 and
12 months
Seegobin (2014)109
CARDERA
MTX monotherapy
MTX and CsA
MTX and prednisolone
MTX and CsA and
prednisolone (in a
factorial design)
ACPA status ACPA status (positive or negative),
evaluated using an anti-CCP2 test
with a cut-off point of > 5 units/ml
taken as positive
Radiological
progression
Onset of new erosions at
24 months and modified Larsen
scores every 6 months
6, 12, 18 and 24 months
Disease activity DAS28 every 6 months
Physical
function
HAQ score every 6 months
Smolen (2006)100
ASPIRE
MTX
MTX and IFX (3 mg/kg
or 6 mg/kg)
ESR, CRP level,
erosions, RF
status, SJC
Baseline ESR, CRP level and
radiographic erosions of hands and
feet (assessed at time of study entry)
using SHS
Radiographic
progression
Worsening of radiographic joint
damage (change in the SHS of
> 0) from baseline to week 54
Week 54
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First author (year
of publication),
name of trial or
cohort (if relevant) Treatment comparison Variable(s)
Measurement and timing of
variable Outcomes
Measurement and timing of
outcomes
Assessment time of
outcome measurement
Sokolove (2016)110
AMPLE
MTX and ABT
(s.c. administration)
MTX and ADA
(s.c. administration)
ACPA status
(anti-CCP2 status)
Baseline anti-CCP2 anti-body status
(positive/negative) was determined
using an anti-CCP2 IgG ELISA.
Patients with a baseline anti-CCP2 IgG
concentration of ≥ 25 AU/ml were
considered to be positive and were
further divided into equal quartiles
according to concentration [Q1–Q4
(highest concentration)]
Measurement assessed at various time
points up to day 729
Disease activity Adjusted mean change from
baseline in DAS28-CRP at
various time points up to
729 days (2 years) – data
extracted only for 6 months,
1 year and 2 years
Various time points up
to 729 days (2 years) –
data extracted only for
6 months, 1 year and
2 years
Physical
function
Adjusted mean change from
baseline in HAQ-DI score at
various time points up to
729 days (2 years)
Taylor (2004)101 MTX
MTX and IFX
Baseline synovial
vascularity
MCP joints scanned in PD mode
(14MHz) and images demonstrating
maximal synovial vascularity were
scored by calculating the sum of the
individual joint scores, which consisted
of the number of colour Doppler
pixels in a defined region of interest
for each joint. Taken at baseline and
week 18
Radiographic
progression
Progression in total SHS scored
by blinded, independent
observers from radiographs
taken at baseline and at week
24 (mean of the scores of the
two independent assessors).
Change from baseline to
week 54 calculated
Week 54
Vastesaeger (2009)78
ASPIRE
MTX
MTX and IFX (3 mg/kg
or 6 mg/kg)
ESR, CRP level, RF
status, SJC
ESR assessed at baseline via the
Westergren method; CRP level
measured at baseline by
nephelometry; RF status evaluated
from baseline samples evaluated at
the central laboratory; 66-joint SJC
taken at baseline (although 28-joint
SJC used)
Radiographic
progression
Differences between treatment
groups in mean van der
Waerden normal scores of the
change of ≥ 5 units/year in total
SHS
Week 54
AMPLE, abatacept vs. adalimumab in biologic-naive RA patients with background MTX; AVERT, Assessing Very Early Rheumatoid arthritis Treatment; CARDERA, Combination Anti-Rheumatic
Drugs in Early RA; CCP2, cyclic citrullinated peptide-2; CsA, ciclosporin A; ELISA, enzyme-linked immunosorbent assay; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy;
GSTM, gold sodium thiomalate; HAQ-DI, Health Assessment Questionnaire – disability index; IgG, immunoglobulin G; MCP, metacarpophalangeal; PD, power Doppler; s.c., subcutaneous;
TEAR, Treatment of Early Aggressive Rheumatoid arthritis; TTT, treat to target.
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TABLE 15 Key population characteristics of included primary studies at baseline
First author (year),
name of trial or
cohort (if relevant)
Diagnosis of
RA
Definition of
early RA Group/arm
Mean/median duration
(months) of symptoms/
disease at baseline
Mean/median DAS28
at baseline
Treatment history and current
treatments
Garnero (2002)102 1987 revised
ACR criteria
Active RA for
≤ 3 years
All participants 12 (SD 12)a NR Not previously treated with MTX.
DMARDs, including HCQ and SSZ,
were discontinued at least 4 weeks
before study entry; stable doses of
corticosteroids (≤ 10 mg of prednisone
or equivalent) and NSAIDs were
permitted. A total of 46% of
participants in the MTX arm, 39% in
the ETN (10mg) arm and 40% in the
ETN (25mg) arm had previously used
DMARDs, with the mean (SD) number
of DMARDs being 0.6 (0.7), 0.5 (0.7)
and 0.5 (0.7), respectively; 80%,
76% and 86%, respectively, using
concomitant NSAIDs at baseline; and
41%, 42% and 39%, respectively,
using concomitant glucocorticoids at
baselineb
Heimans (2013)103
BeSt
1987 revised
ACR criteria
Active RA for
≤ 2 years
All participants NR DAS: 4.4 (SD 0.9)c No prior DMARDs
A BMI of < 25 kg/m2 5.3 (IQR 3.0–13.2)d DAS: 4.4 (SD 0.8)
A BMI of ≥ 25 kg/m2 5.3 (IQR 3.0–10.8)d DAS: 4.4 (SD 0.9)
Sequential monotherapy 5.3 (IQR 3.2–12.5)d DAS: 4.5 (SD 0.9)
Step-up combination
therapy
6.0 (IQR 3.2–12.9)d DAS: 4.5 (SD 0.8)
MTX + SSZ+ tapered
prednisone
5.3 (IQR 3.5–12.2)d DAS: 4.4 (SD 0.9)
MTX + IFX 5.3 (IQR 3.0–10.6)d DAS: 4.3 (SD 0.9)
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First author (year),
name of trial or
cohort (if relevant)
Diagnosis of
RA
Definition of
early RA Group/arm
Mean/median duration
(months) of symptoms/
disease at baseline
Mean/median DAS28
at baseline
Treatment history and current
treatments
Huizinga (2015)104
AVERT
NR Onset of symptoms
for ≤ 2 years
All participants 6.72 (SD 6.0)d,e 5.4 (SD 1.2)e,f MTX naive or received MTX (≤ 10mg/
week) for ≤ 4 weeks with no MTX for
1 month prior to enrolment. Patients
receiving oral corticosteroids were
required to be on a stable dose
(i.e. ≤ 10mg/day for ≥ 4 weeks) at
initiation and to maintain that dose
until month 12
ABT (s.c. administration)
and MTX
6.96 (SD 6.0)d,e 5.5 (SD 1.3)e,f
ABT (s.c. administration) 7.08 (SD 6.24)d,e 5.5 (SD 1.1)e,f
MTX 6.0 (SD 5.88)d,e 5.3 (SD 1.3)e,f
Maska (2012)105
TEAR
1987 revised
ACR criteria
Disease duration
for < 3 years
All participants (with
serum cotinine at
baseline and week 48)
3.7 (SD 6.6)a 5.8 (1.1) bDMARD naive
g
On stable corticosteroid treatment
and < 10mg/day of prednisone or
equivalent or on a stable dose of
NSAIDs
Prior MTX use in 157 out of 755
patients (21%)
g
Current smokers 3.4 (SD 6.9)a 5.8 (SD 1.1)
Non-smokers 3.8 (SD 6.5)a 5.8 (SD 1.0)
Mustila (2011)106
FIN-RACo
1987 revised
ACR criteria
Symptom duration
for < 2 years
All participants 7.7 (SD 5.0)a,c 7.7 (SD 5.0)c DMARD naive
ACPA+ NR NR
ACPA– NR NR
MTX and HCQ and SSZ
in a TTT regime
7.3 (SD 4.7)a 5.5 (SD 1.0)
cDMARD sequential
monotherapy in a TTT
regime (starting with
SSZ)
8.2 (SD 5.2)a 5.6 (SD 1.1)
continued
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TABLE 15 Key population characteristics of included primary studies at baseline (continued )
First author (year),
name of trial or
cohort (if relevant)
Diagnosis of
RA
Definition of
early RA Group/arm
Mean/median duration
(months) of symptoms/
disease at baseline
Mean/median DAS28
at baseline
Treatment history and current
treatments
Pasero (1996)107 1987 revised
ACR criteria
Active RA, a
duration of
at least 6 months
but ≤ 4 years
All participants 1.4 (SD 1.1)a,c NR DMARD naive or treated with a
maximum of only one DMARD
(an antimalarial agent or auranofin)
94 out of 141 patients receiving CsA
and 103 out of 143 patients in the
radiologically evaluable ITT subset had
previously used NSAIDs; 56 out of 141
and 52 out of 143, respectively, for
corticosteroids; 43 out of 141 and
31 out of 143, respectively, for
antimalarial agents or auranofin
Patients with joint
erosions at baseline
NR NR
Patients without joint
erosions at baseline
NR NR
CsA arm 1.4 (SD 1.2)a NR
Other cDMARDs arm 1.3 (SD 1.1)a NR
Rau (1998)108 ACR case
criteria
By radiographic
definition: patients
with advanced
disease (higher than
Larsen grade III)
were excluded
All patients NR NR No prior treatment with MTX or
GSTM, no treatment with any other
DMARD during the previous 3 months,
no intra-articular steroid injection
within the previous 4 weeks
MTX 11.5a,h NR
GSTM 11.2a,h NR
Seegobin (2014)109
CARDERA
1987 ACR
criteria
Active RA for
< 2 years
All participants 4.0 (SD 5.1)a,c 5.8 (SD 1.3)c A total of 65 patients (14% of the
trial population) had previously
received DMARDsACPA+ 2.00 (IQR 0.00–5.00)
a 5.72 (IQR 4.91–6.73)
ACPA– 1.00 (IQR 0.00–4.00)a 5.96 (IQR 4.92–6.85)
MTX monotherapyi 2.7 (SD 3.8)a 5.8 (SD 1.2)
CsA and MTX 4.2 (SD 5.7)a 5.9 (SD 1.3)
Prednisolone and MTX 5.1 (SD 5.8)a 5.8 (SD 1.4)
Triple therapy 3.9 (SD 5.2)a 5.6 (SD 1.3)
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First author (year),
name of trial or
cohort (if relevant)
Diagnosis of
RA
Definition of
early RA Group/arm
Mean/median duration
(months) of symptoms/
disease at baseline
Mean/median DAS28
at baseline
Treatment history and current
treatments
Smolen (2006)100
Vastesaeger (2009)78
ASPIRE
1987 revised
ACR criteria
Active RA < 3 years All participants 10.4 (SD 8.8)a,c 6.7 (SD 1.0)d No prior treatment with MTX, no
other DMARDs within 4 weeks of
study entryMTX 10.8 (SD 8.4)
a 6.7 (SD 1.0)
j
IFX (all doses) 10.2 (SD 9.0)a,c 6.7 (SD 1.0)c
MTX + IFX 3mg/kg 9.6 (SD 8.4)a 6.6 (SD 1.1)
j
MTX + IFX 6mg/kg 10.8 (SD 9.6)a 6.7 (SD 1.0)
j
Sokolove (2015)110
AMPLE
1987 revised
ACR criteria
Disease duration of
≤ 2 years
All patients NR NR bDMARD-naive patients with an
inadequate response to MTX
Anti-CCP2 ABT: 12.0 (range 1.2–55.2)a,k
ADA: 15.6 (range 0.0–56.4)a,k
ABT: 5.5 (range 2.5–7.4)
j
ADA: 5.3 (range 3.0–7.3)k
Anti-CCP2+;
Q1 28–235 AU/ml
ABT: 21.6 (range 2.4–54.0)a,k
ADA: 19.2 (range 1.2–61.2)a,k
ABT: 5.0 (range 3.1–7.6)
j
ADA: 5.5 (range 3.1–7.3)k
Anti-CCP2+;
Q2 236–609 AU/ml
ABT: 20.4 (range 1.2–61.2)a,k
ADA: 14.4 (range 1.2–54.0)a,k
ABT: 5.6 (range 3.5–7.6)
j
ADA: 6.0 (range 2.8–7.4)k
Anti-CCP2+;
Q3 613–1046 AU/ml
ABT: 21.6 (range 1.2–57.6)a,k
ADA: 20.4 (range 1.2–61.2)a,k
ABT: 5.5 (range 2.8–8.1)k
ADA: 5.7 (range 3.7–7.9)k
Anti-CCP2+;
Q4 1060–4894 AU/ml
ABT: 24.0 (range 1.2–57.6)a,k
ADA: 16.8 (range 0.0–60.0)a,k
ABT: 6.0 (range 2.7–7.8)
j
ADA: 5.3 (range 1.7–7.8)
j
continued
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TABLE 15 Key population characteristics of included primary studies at baseline (continued )
First author (year),
name of trial or
cohort (if relevant)
Diagnosis of
RA
Definition of
early RA Group/arm
Mean/median duration
(months) of symptoms/
disease at baseline
Mean/median DAS28
at baseline
Treatment history and current
treatments
Taylor (2004)101 1987 revised
ACR criteria
6 months to
≤ 3 years
All 17.9 (SD 7.6)a,c 5.3 (SD 1.1)c Receiving MTX at a stable dose of
12.5–17.5 mg/week for ≤ 4 weeks
prior to screening, either not taking
corticosteroids or receiving a stable
dose of ≥ 10mg of prednisolone per
day for ≥ 4 weeks
MTX 19.7 (SD 7.6)a 5.2 (SD 1.1)
IFX and MTX 16.0 (SD 7.7)a 5.4 (SD 1.1)
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; AMPLE, abatacept vs. adalimumab in biologic-naive RA patients
with background MTX; AVERT, Assessing Very Early Rheumatoid arthritis Treatment; CARDERA, Combination Anti-Rheumatic Drugs in Early RA; DMARD, disease-modifying antirheumatic
drug; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; ITT, intention to treat; NR, not reported; Q1/Q2/Q3/Q4, quartile 1/quartile 2/quartile 3/quartile 4; s.c., subcutaneous;
TEAR, Treatment of Early Aggressive Rheumatoid arthritis.
a Disease duration.
b From Bathon et al.112
c Calculated.
d Symptom duration.
e From Emery et al.116
f DAS28-CRP.
g From Moreland et al.117
h Median.
i From Choy et al.114
j From St Clair et al.87
k Median (range).
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The duration of RA was reported in some studies as disease duration and in others as symptom duration.
Disease duration ranged from a mean of 1.4 months107 to a mean of 17.9 months,101 and from a median
of 1.0 month109 to a median of 24.0 months.110 Symptom duration ranged from a mean of 6.0 months to
a mean of 7.1 months,104 and from a median of 5.3 months to a median of 6.0 months.103 Baseline DAS28,
when reported, ranged from a mean of 5.3101,104 to a mean of 6.7,100 and one study reported DAS, with a
baseline mean of 4.4,103 indicating severe RA in all populations for which the DAS28 or the DAS at baseline
was reported. Three studies did not report the DAS28 or the DAS at baseline.102,107,108 Participants were
DMARD naive in two studies103,106 and MTX naive in three studies.100,102,108 One study reported that participants
were DMARD naive or treated with a maximum of one DMARD, which could be an antimalarial agent (30% of
the sample) or auranofin (22% of the sample).107 One study reported prior DMARD use in 14% of the
sample,109 one study reported that participants had to be bDMARD naive with an inadequate response to
MTX110 and one study reported that participants had to be receiving a stable dose of MTX.101 One study
reported that participants were bDMARD naive, with prior MTX use in 21% of the sample,105 and one study
reported that participants were MTX naive or had received a low dose of MTX previously for ≤ 4 weeks with a
1-month washout period.104
Results: synthesis of primary studies
Treatment prediction models presents the findings for clinical prediction models developed according
to specific treatments. Prediction of treatment effect by anticitrullinated protein/peptide anti-body status at
baseline: erosions presents information regarding patient and/or disease characteristics that are potential
treatment effect modifiers.
Tables 16 and 17 provide the estimates of the within-treatment responses and interaction effects by
baseline variable for continuous outcomes. Appendix 10 presents plots of the estimates of the within-
treatment responses by baseline variable. The results are presented by study because the combination of
outcomes and predictors generated no studies that shared any treatment in common, so that a formal
synthesis was not possible.
Treatment prediction models
Only one of the clinical prediction models involving multiple treatments that was reported in review 1
investigated the potential interactions between treatments and baseline variables.79 Consequently, it was
not possible to distinguish between covariates that were prognostic and those that were treatment effect
modifiers in most clinical prediction models. Visser et al.79 investigated the interaction between treatments
and baseline variables and reported that there were no statistically significant interactions between
covariates (ACPA status, RF status, CRP tertile, erosion score) and treatments (initial MTX monotherapy,
initial MTX and prednisone combination therapy and initial MTX and IFX combination therapy), although
this may be because the analysis lacked sufficient power to detect such effects as being statistically
significant.
Prediction of treatment effect by anticitrullinated protein/peptide anti-body status at
baseline: erosions
The results from Mustila et al.106 suggest that the effect of triple therapy (MTX and SSZ and HCQ) versus
sequential monotherapy on erosions at 1 (see Appendix 10, Figure 10) and 2 years (see Appendix 10,
Figure 11) was similar in patients who were ACPA positive and ACPA negative at baseline (i.e. scenario 1).
However, at 3 (see Appendix 10, Figure 12), 4 (see Appendix 10, Figure 13) and 5 years (see Appendix 10,
Figure 14), the observed effect of treatment was less in patients who were ACPA positive than the effect
of treatment in patients who were ACPA negative at baseline (i.e. scenario 2), although the results were
not statistically significant.
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be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by ACPA status at baseline: erosions
Mustila (2011)106
FIN-RACo
Larsen score (absolute
value)
ACPA+ MTX and SSZ and HCQ 1 year 46 5.91
(3.8 to 8.2)a
NR NR NR
Sequential cDMARDs 46 10.21
(6.98 to 13.46)a
NR NR NR
ACPA– MTX and SSZ and HCQ 23 3.57
(1.52 to 5.93)a
NR NR NR
Sequential cDMARDs 14 7.81
(3.21 to 12.56)a
NR NR NR
ACPA+ MTX and SSZ and HCQ 2 years 46 8.82
(6.54 to 11.52)a
NR NR NR
Sequential cDMARDs 46 14.61
(11.12 to 18.07)a
NR NR NR
ACPA– MTX and SSZ and HCQ 23 4.09
(1.82 to 6.44)a
NR NR NR
Sequential cDMARDs 14 10.87
(5.83 to 16.22)a
NR NR NR
ACPA+ MTX and SSZ and HCQ 3 years 46 12.57
(8.88 to 16.38)a
NR NR NR
Sequential cDMARDs 46 18.52
(14.84 to 22.52)a
NR NR NR
ACPA– MTX and SSZ and HCQ 23 4.96
(2.26 to 7.86)a
NR NR NR
Sequential cDMARDs 14 16.61
(8.99 to 24.34)a
NR NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
ACPA+ MTX and SSZ and HCQ 4 years 46 14.56
(11.21 to 18.15)a
NR NR NR
Sequential cDMARDs 46 22.15
(18.01 to 26.48)a
NR NR NR
ACPA– MTX and SSZ and HCQ 23 5.77
(2.9 to 9.1)a
NR NR NR
Sequential cDMARDs 14 20.31
(11.13 to 29.82)a
NR NR NR
ACPA+ MTX and SSZ and HCQ 5 years 46 19.3
(13.69 to 25.26)a
NR NR NR
Sequential cDMARDs 46 24.66
(20.22 to 29.33)a
NR NR NR
ACPA– MTX and SSZ and HCQ 23 7.62
(3.35 to 12.1)a
NR NR NR
Sequential cDMARDs 14 21.06
(11.34 to 30.83)a
NR NR NR
Seegobin (2014)109
CARDERA
Change in Larsen score
from baseline
ACPA+ MTX and CsA and
prednisolone
6 months 79 1.25 (0.28b) 0.003 NR NR
MTX 73 3.86 (0.8b) NR NR
ACPA– MTX and CsA and
prednisolone
28 0.48 (0.35b) 0.093 NR NR
MTX 34 1.6 (0.55b) NR NR NR
ACPA+ MTX and CsA and
prednisolone
12 months 79 2.41 (0.52b) < 0.001 NR NR
MTX 73 6.92 (1.1b) NR NR NR
ACPA– MTX and CsA and
prednisolone
28 1.36 (0.47b) 0.409 NR NR
MTX 34 2.03 (0.66b) NR NR NR
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
ACPA+ MTX and CsA and
prednisolone
18 months 79 3.2 (0.66b) 0.001 NR NR
MTX 73 8.52 (1.39b) NR NR NR
ACPA– MTX and CsA and
prednisolone
28 1.66 (0.64b) 0.388 NR NR
MTX 34 2.57 (0.79b) NR NR NR
ACPA+ MTX and CsA and
prednisolone
24 months 79 3.66
(0.7/2.27 to 5.05c)
< 0.001 NR NR
MTX 73 9.58
(1.41/6.76 to 12.39c)
NR NR NR
ACPA– MTX and CsA and
prednisolone
28 1.7
(0.69/0.29 to 3.10c)
0.335 NR NR
MTX 34 2.72
(0.77/1.15 to 4.29c)
NR NR NR
N/A N/A N/A N/A NR NR 7.05d < 0.001
Prediction of treatment response by ACPA status at baseline: disease activity
Seegobin (2014)109
CARDERA
Change in DAS28 from
baseline
ACPA+ MTX and CsA and
prednisolone
6 months 79 –1.98 (0.18b) < 0.001 NR NR
MTX 73 –0.99 (0.17b) NR NR NR
ACPA– MTX and CsA and
prednisolone
28 –1.43 (0.33b) 0.792 NR NR
MTX 34 –1.32 (0.22b) NR NR NR
ACPA+ MTX and CsA and
prednisolone
12 months 79 –1.48 (0.18b) 0.190 NR NR
MTX 73 –1.14 (0.19b) NR NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
ACPA– MTX and CsA and
prednisolone
28 –0.73 (0.33b) 0.186 NR NR
MTX 34 –1.36 (0.33b) NR NR NR
ACPA+ MTX and CsA and
prednisolone
18 months 79 –1.64 (0.2b) 0.356 NR NR
MTX 73 –1.37 (0.2b) NR NR NR
ACPA– MTX and CsA and
prednisolone
28 –1.27 (0.37b) 0.462 NR NR
MTX 34 –1.62 (0.3b) NR NR NR
ACPA+ MTX and CsA and
prednisolone
24 months 79 –1.84 (0.19b) 0.087 NR NR
MTX 73 –1.36 (0.22b) NR NR NR
ACPA– MTX and CsA and
prednisolone
28 –1.27 (0.32b) 0.464 NR NR
MTX 34 –1.59 (0.3b) NR NR NR
N/A N/A N/A N/A N/A N/A 3.99d 0.008
Sokolove (2015)110
AMPLE
Mean change from
baseline in DAS28-CRP
Anti-CCP2– MTX and ABT
(s.c. administration)
6 months 66 –1.9
(–1.76 to –2.2)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –1.525
(–1.375 to –1.7)a,b,e
NR NR NR
Anti-CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –2.05
(–1.8 to –2.23)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.425
(unreadable)a,b,e
NR NR NR
continued
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Anti CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –2.1
(–1.9 to –2.3)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –2.3
[–2.1 to
(unreadable)]a,b,e
NR NR NR
Anti CCP2+; Q3
613–1046 AU/ml
MTX and ABT
(s.c. administration)
46 –2.2
(–2.0 to –2.35)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.125
(–1.95 to –2.3)a,b,e
NR NR NR
Anti CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –2.6
(–2.4 to –2.8)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.5
(–2.3 to –2.675)a,b,e
NR NR NR
Anti-CCP2– MTX and ABT
(s.c. administration)
1 year 66 –1.9 [–1.75 to
(unreadable)]a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –1.65
(–1.49 to –1.85)a,b,e
NR NR NR
Anti CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –2.075 [–1.85 to
(unreadable)]a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.275
(–2.075 to –2.48)a,b,e
NR NR NR
Anti-CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –2.45
(–2.225 to –2.625)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –2.38
(–2.15 to –2.58)a,b,e
NR NR NR
Anti-CCP2+; Q3
613–104 AU/ml
MTX and ABT
(s.c. administration)
46 –2.3
(–2.15 to –2.5)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.43
(–2.25 to –2.5)a,b,e
NR NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Anti-CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –2.825
(–2.625 to –3.0)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.6
(–2.3 to –2.78)a,e
NR NR NR
Anti-CCP2– MTX and ABT
(s.c. administration)
2 years 66 –1.7
(–1.56 to –1.9)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –1.625
(–1.4 to –1.85)a,b,e
NR NR NR
Anti-CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –2.2 [–1.925 to
(unreadable)]a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.38
(–2.125 to –2.6)a,b,e
NR NR NR
Anti-CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –2.55
(–2.28 to –2.7)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –2.65
(–2. 35 to –2.83)a,b,e
NR NR NR
Anti-CCP2+; Q3
613–1046 AU/ml
MTX and ABT
(s.c. administration)
46 –2.5
(–2.25 to –2.7)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.5
(–2.275 to –2.675)a,b,e
NR NR NR
Anti-CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –3.195
(–2.975 to –3.35)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –2.75
(–2.6 to –2.83)a,b,e
NR NR NR
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by ACPA status at baseline: physical function (as assessed via the HAQ score)
Seegobin (2014)109
CARDERA
Change in HAQ score
from baseline
N/A N/A N/A N/A N/A N/A 0.48d 0.696
Sokolove (2015)110
AMPLE
Mean change from
baseline in HAQ-DI score
Anti-CCP2– MTX and ABT
(s.c. administration)
6 months 66 –0.48
(–0.4 to –0.54)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –0.25
(–0.18 to –0.32)a,b,e
NR NR NR
Anti-CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –0.49
(–0.42 to –0.575)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.63
(–0.55 to –0.71)a,b,e
NR NR NR
Anti-CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –0.7
(–0.62 to –0.78)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –0.58
(–0.49 to –0.67)a,b,e
NR NR NR
Anti-CCP2+; Q3
613–1046 AU/ml
MTX and ABT
(s.c. administration)
46 –0.72
(–0.63 to –0.815)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.59
(–0.50 to –0.67)a,b,e
NR NR NR
Anti-CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –0.83
(–0.73 to –0.93)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.75
(–0.66 to –0.84)a,b,e
NR NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Anti-CCP2– MTX and ABT
(s.c. administration)
1 year 66 –0.45
(–0.385 to –0.52)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –0.3
(–0.23 to –0.37)a,b,e
NR NR NR
Anti-CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –0.575
(–0.48 to –0.68)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.68
(–0.59 to –0.77)a,b,e
NR NR NR
Anti-CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –0.69
(–0.62 to –0.77)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –0.59
(–0.50 to –0.68)a,b,e
NR NR NR
Anti-CCP2+; Q3
613–1046 AU/ml
MTX and ABT
(s.c. administration)
46 –0.63
(–0.53 to –0.73)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.65
(–0.55 to –0.75)a,b,e
NR NR NR
Anti-CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –0.93
(–0.83 to –1.035)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.72
(–0.63 to –0.81)a,b,e
NR NR NR
Anti-CCP2– MTX and ABT
(s.c. administration)
2 years 66 –0.45
(–0.39 to –0.515)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
54 –0.32
(–0.25 to –0.38)a,b,e
NR NR NR
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Anti-CCP2+; Q1
28–235 AU/ml
MTX and ABT
(s.c. administration)
42 –0.575
(–0.485 to –0.67)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.68
(–0.59 to –0.77)a,b,e
NR NR NR
Anti-CCP2+; Q2
236–609 AU/ml
MTX and ABT
(s.c. administration)
51 –0.66
(–0.57 to –0.75)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
46 –0.67
(–0.57 to –0.77)a,b,e
NR NR NR
Anti-CCP2+; Q3
613–1046 AU/ml
MTX and ABT
(s.c. administration)
2 years 46 –0.58
(–0.50 to –0.70)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.64
(–0.54 to –0.74)a,b,e
NR NR NR
Anti-CCP2+; Q4
1060–4894 AU/ml
MTX and ABT
(s.c. administration)
46 –0.99
(–0.89 to –1.08)a,b,e
NR NR NR
MTX and ADA
(s.c. administration)
51 –0.81
(–0.71 to –0.90)a,b,e
NR NR NR
Prediction of treatment response by smoking status at baseline: disease activity
Maska (2012)105
TEAR
Mean DAS28 (absolute
value)
Non-smokers MTX and ETN IT 1–2 years
(mean)
NR 3.01 (1.3f) NR NR NR
MTX and SSZ and HCQ IT NR 3.24 (1.3f) NR NR NR
MTX and ETN SUT NR 3.31 (1.3f) NR NR NR
MTX and SSZ and HCQ
SUT
NR 3.07 (1.4f) NR NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Current smokers MTX and ETN IT NR 3.07 (1.2f) NR NR NR
MTX and SSZ and HCQ IT NR 3.15 (1.9f) NR NR NR
MTX and ETN SUT NR 3.2 (1.4f) NR NR NR
MTX and SSZ and HCQ
SUT
NR 3.2 (1.1f) NR NR NR
Non-smokers ETN and MTX (COM) 24 weeks NR 3.89 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 4.01 NR NR NR
Current smokers ETN and MTX (COM) NR 3.81 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 3.66 NR NR NR
Non-smokers ETN and MTX (COM) 48 weeks NR 3.3 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 3.33 NR NR NR
Current smokers ETN and MTX (COM) NR 3.17 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 3.33 NR NR NR
Non-smokers ETN and MTX (COM) 102 weeks NR 2.93 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 3.15 NR NR NR
Current smokers ETN and MTX (COM) NR 2.93 NR NR NR
MTX and SSZ and HCQ
(COM)
NR 3.15 NR NR NR
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by erosions at baseline: radiographic progression
Pasero (1996)107
Change from baseline in
the Larsen–Dale EJC
Erosions at
baseline
CsA 12 months 104 1.61 (0.35)a NR NR NR
Other cDMARDs 89 2.94 (0.30)a NR NR NR
No erosions at
baseline
CsA 37 0.46 (0.18)a NR NR NR
Other cDMARDs 54 1.62 (0.32)a NR NR NR
Pasero (1996)107
Change from baseline in
the Larsen–Dale damage
score
Erosions at
baseline
CsA 104 4.75 (0.89)a NR NR NR
Other cDMARDs 89 7.96 (0.93)a NR NR NR
No erosions at
baseline
CsA 37 0.48 (0.96)a NR NR NR
Other cDMARDs 54 5.14 (1.28)a NR NR NR
Smolen (2006)100
ASPIRE
Change from baseline in
the SHS
SHS of < 2.6 MTX Week 54 100 1.87 NR NR
MTX and IFX 231 0.83 < 0.05
g
NR NR
SHS of ≥ 2.6 to
< 10.5
MTX 87 4.98 NR NR
MTX and IFX 246 0.84 < 0.001
g
NR NR
SHS of ≥ 10.5 MTX 92 3.78 NR NR
MTX and IFX 238 –0.41 < 0.001
g
NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by RF status at baseline: radiographic progression
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in
the total SHS score
RF of < 80 U/ml MTX Week 54 82 Reference NR NR
MTX and IFX 201 0.38 (0.13b,h)a,i 0.0030
g
NR NR
RF of 80–200 U/ml MTX 73 Reference NR NR
MTX and IFX 783 0.38 (0.14b,h)a,i 0.0048
g
NR NR
RF of > 200 U/ml MTX 128 Reference NR NR
MTX and IFX 341 0.54 (0.11b,h)a,i < 0.0001
g
NR NR
Prediction of treatment response by CRP level at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Change from baseline
in the SHS
CRP level of
< 0.6 mg/dl
MTX Week 54 93 1.7a NR NR
MTX and IFX 232 1.15a NS NR NR
CRP level of ≥ 0.6
to < 3mg/dl
MTX 103 4.36a NR NR
MTX and IFX 242 0.84a < 0.001
g
NR NR
CRP level of
≥ 3mg/dl
MTX 86 5.99a NR NR
MTX and IFX 248 1.35a < 0.001
g
NR NR
Vastesaeger 200978
ASPIRE
Increase of ≥ 5/year
total SHS score
CRP level of
< 0.6 mg/dl
MTX 93 Reference NR NR
MTX and IFX 232 0.15 (0.08b,h)a,i 0.2172
g
NR NR
CRP level of
0.6–3.0 mg/dl
MTX 105 Reference NR NR
MTX and IFX 252 0.51 (0.26b,h)a,i < 0.0001
g
NR NR
CRP level of
> 3.0 mg/dl
MTX 84 Reference NR NR
MTX and IFX 238 0.65 (0.33b,h)a,i < 0.0001
g
NR NR
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TABLE 16 Within-treatment responses by outcome and baseline variable – continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by ESR at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Change from baseline
in the SHS
ESR of < 28mm/
hour
MTX Week 54 93 2.88a NR NR
MTX and IFX 223 (Unreadable) < 0.05
g
NR NR
ESR of ≥ 28 to
< 52mm/hour
MTX 89 2.65a NR NR
MTX and IFX 233 0.47a < 0.001
g
NR NR
ESR of ≥ 52mm/
hour
MTX 87 6.13a NR NR
MTX and IFX 234 1.64a < 0.001
g
NR NR
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in
the total SHS score
ESR of < 21mm/
hour
MTX 57 Reference NR NR
MTX and IFX 141 0.13 (0.16b,h)a,i 0.3755
g
NR NR
ESR of 21–50mm/
hour
MTX 125 Reference NR NR
MTX and IFX 313 0.45 (0.12b,h)a,i < 0.0001
g
NR NR
ESR of > 50mm/
hour
MTX 87 Reference NR NR
MTX and IFX 236 0.60 (0.12b,h)a,i < 0.0001
g
NR NR
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First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point Sample size (n)
Mean
(SD/standard
error/95% CI)
p-value for
difference
between
treatment arms
Treatment
effect statistic
(SD/standard
error/95% CI)
p-value for
treatment
effect
Prediction of treatment response by SJC at baseline: radiographic progression
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in
the total SHS score
SJC28 of < 10 MTX Week 54 50 Reference NR NR
MTX and IFX 145 0.31 (0.17b,h)a,i 0.0524
g
NR NR
SJC28 of 10–17 MTX 146 Reference NR NR
MTX and IFX 367 0.44 (0.10b,h)a,i < 0.0001
g
NR NR
SJC28 of > 17 MTX 85 Reference NR NR
MTX and IFX 210 0.51 (0.13b,h)a,i < 0.0001
g
NR NR
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; ADA, adalimumab; AMPLE, abatacept vs. adalimumab in biologic-naive
RA patients with background MTX; anti-CCP2–, anticyclic citrullinated peptide-2 negative; anti-CCP2+, anticyclic citrullinated peptide-2 positive; CARDERA, Combination Anti-Rheumatic
Drugs in Early RA; COM, combination; EJC, eroded joint count; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; HAQ-DI, Health Assessment Questionnaire – disability index;
IT, immediate therapy; N/A, not applicable; NR, not reported; NS, not significant; Q1/Q2/Q3/Q4, quartile 1/quartile 2/quartile 3/quartile 4; s.c., subcutaneous; SJC28, 28 swollen joint count;
SUT, step-up therapy; TEAR, Treatment of Early Aggressive Rheumatoid arthritis.
a Extracted from graphical data.
b Standard error.
c Standard error/95% CI.
d Analysis of variance F-statistic (ACPA × treatment interaction).
e Adjusted mean changes from baseline were determined by analysis of covariance, with treatment and DAS28 (CRP) stratification as factors and baseline values as a covariate.
f Unclear whether or not this is a SD or a standard error.
g Vs. MTX.
h Calculated.
i Difference between treatment groups in the mean van der Waerden normal scores of the change of ≥ 5/year in total SHS.
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TABLE 17 Interaction effects by outcome and baseline variable: continuous outcomes
First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
Prediction of treatment response by ACPA status at baseline: erosions
Mustila (2011)106
FIN-RACo
Erosions
Larsen score (absolute value)
ACPA+/ACPA– MTX and SSZ and HCQ vs.
sequential cDMARDs
1 year ACPA+: –4.30
ACPA–: –4.24
–0.06
(–6.68 to 6.56)
11 1
2 years ACPA+: –5.79
ACPA–: –6.78
0.99
(–6.32 to 8.30)
12 1
3 years ACPA+: –5.95
ACPA–: –11.65
5.70
(–4.23 to 15.63)
13 2a
4 years ACPA+: –7.59
ACPA–: –14.54
6.95
(–4.59 to 18.49)
14 2
5 years ACPA+: –5.36
ACPA–: –13.44
8.08
(–5.07 to 21.23)
15 2
Seegobin (2014)109
CARDERA
Erosions
Change in the Larsen score
from baseline
ACPA+/ACPA– MTX and CsA and prednisolone
vs. MTX
6 months ACPA+: –2.61
ACPA–: –1.12
–1.49
(–3.59 to 0.61)
16 2b
12 months ACPA+: –4.51
ACPA–: –0.67
–3.84
(–17.53 to 9.85)
17 2
18 months ACPA+: –5.32
ACPA–: –0.91
–4.41
(–8.02 to –0.80)
18 2, interaction effect statistically
significant
24 months ACPA+: –5.92
ACPA–: –1.02
–4.90
(–8.59 to –1.21)
19 2, interaction effect statistically
significant
Prediction of treatment response by ACPA status at baseline: disease activity
Seegobin (2014)109
CARDERA
Disease activity
Change in the DAS28
from baseline
ACPA+/ACPA– MTX and CsA and prednisolone
vs. MTX
6 months ACPA+: –0.99
ACPA–: –0.11
–0.88
(–1.80 to 0.04)
24
12 months ACPA+: –0.34
ACPA–: 0.63
–0.97
(–2.02 to 0.08)
25 Qualitative interaction,
not statistically significant
18 months ACPA+: –0.27
ACPA–: 0.35
–0.62
(–1.71 to 0.47)
26 Qualitative interaction,
not statistically significant
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First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
24 months ACPA+: –0.48
ACPA–: 0.32
–0.80
(–1.83 to 0.23)
27 Qualitative interaction, not
statistically significant
Sokolove (2015)110
AMPLE
Mean change from baseline in
DAS28-CRP
Anti-CCP2–
Anti-CCP2+; Q1
28–235AU/ml
Anti CCP2+; Q2
236–609 AU/ml
Anti-CCP2+; Q3
613–1046 AU/ml
Anti-CCP2+; Q4
1060–4894AU/ml
MTX and ABT (s.c. administration) vs.
MTX and ADA (s.c. administration)
6 months Anti-CCP2–: –0.38
Anti-CCP2+; Q1: 0.38
Anti-CCP2+; Q2: 0.20
Anti-CCP2+; Q3:
–0.08
Anti-CCP2+; Q4:
–0.10
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 0.75
(Not estimable)
Anti-CCP2+, Q2: 0.58
(–0.11 to 1.26)
Anti-CCP2+, Q3: 0.30
(–0.36 to 0.96)
Anti-CCP2+, Q4: 0.28
(–0.41 to 0.96)
32 No evidence of TE or
interaction
1 year Anti-CCP2–: –0.25
Anti-CCP2+ Q1: 0.20
Anti-CCP2+ Q2:
–0.07
Anti-CCP2+ Q3: 0.13
Anti-CCP2+ Q4:
–0.23
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 0.45
(–0.28 to 1.18)
Anti-CCP2+, Q2: 0.18
(–0.58 to 0.94)
Anti-CCP2+, Q3: 0.38
(–0.25 to 1.01)
Anti-CCP2+, Q4: 0.02
(–0.80 to 0.85)
33
2 years Anti-CCP2–: –0.08
Anti-CCP2+, Q1: 0.18
Anti-CCP2+, Q2: 0.10
Anti-CCP2+, Q3: 0.00
Anti-CCP2+, Q4:
–0.45
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 0.26
(–0.65 to 1.16)
Anti-CCP2+, Q2: 0.18
(–0.77 to 1.12)
Anti-CCP2+, Q3: 0.08
(–0.76 to 0.91)
Anti-CCP2+ Q4: –0.37
(–1.11 to 0.37)
34
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TABLE 17 Interaction effects by outcome and baseline variable: continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
Prediction of treatment response by ACPA status at baseline – physical function (as assessed via the HAQ score)
Seegobin (2014)109
CARDERA
Change in the HAQ score from
baseline
N/A N/A N/A N/A N/A
Sokolove (2015)110
AMPLE
Physical function: mean change
from baseline in the HAQ-DI
score
Anti-CCP2–
Anti-CCP2+; Q1
28–235AU/ml
Anti-CCP2+; Q2
236–609 AU/ml/ml
Anti-CCP2+; Q4
1060–4894AU/ml
MTX and ABT (s.c. administration) vs.
MTX and ADA (s.c. administration)
6 months Anti-CCP2–: –0.23
Anti-CCP2+, Q1: 0.14
Anti-CCP2+, Q2: –0.12
Anti-CCP2+, Q3: –0.13
Anti-CCP2+, Q4: –0.08
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 0.37
(0.08 to 0.66)
Anti-CCP2+, Q2: 0.11
(–0.20 to 0.42)
Anti-CCP2+, Q3: 0.10
(–0.20 to 0.42)
Anti-CCP2+, Q4: 0.15
(–0.19 to 0.49)
35 No evidence of TE or
interaction
1 year Anti-CCP2–: –0.15
Anti-CCP2+, Q1: 1.26
Anti-CCP2+, Q2: –0.10
Anti-CCP2+, Q3: 0.02
Anti-CCP2+, Q4: –0.21
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 1.41
(1.09 to 1.72)
Anti-CCP2+, Q2: 0.05
(–0.24 to 0.34)
Anti-CCP2+, Q3: 0.17
(–0.16 to 0.50)
Anti-CCP2+, Q4: –0.06
(–0.38 to 0.26)
36 No evidence of TE or
interaction
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First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
2 years Anti-CCP2–: –0.13
Anti-CCP2+, Q1: 0.11
Anti-CCP2+, Q2: 0.01
Anti-CCP2+, Q3: 0.06
Anti-CCP2+, Q4: –0.18
Interaction with
anti-CCP2–:
Anti-CCP2+, Q1: 0.24
(–0.07 to 0.54)
Anti-CCP2+, Q2: 0.14
(–0.15 to 0.43)
Anti-CCP2+, Q3: 0.19
(–0.12 to 0.50)
Anti-CCP2+, Q4: –0.05
(–0.38 to 0.28)
37 No evidence of TE or
interaction
Prediction of treatment response by smoking status at baseline: disease activity
Maska (2012)105
TEAR
Disease activity
Mean DAS28 (absolute value)
Non-smokers
Current smokers
MTX and ETN IT vs. MTX and SSZ
and HCQ IT vs. MTX and ETN SU
vs. MTX and SSZ and HCQ SU
1–2 years
(mean)
38 Cannot assess statistical
significance
ETN and MTX (COM) vs. MTX
and SSZ and HCQ (COM)
24 weeks 39 Cannot assess statistical
significance. Qualitative
interaction
48 weeks 40 3
102 weeks 41 Not prognostic for either
treatment
Prediction of treatment response by erosions at baseline: radiographic progression
Pasero (1996)107 Radiographic progression
Change from baseline in the
Larsen–Dale EJC
Erosions at
baseline: yes/no
CsA vs. other cDMARDs 12 months Erosions at baseline:
–1.33
No erosions at
baseline: –1.16
–0.17
(–1.33 to 0.99)
42 1, prognostic of response but
not a treatment effect modifier
Pasero (1996)107 Change from baseline in the
Larsen–Dale damage score
Erosions at
baseline: yes/no
CsA vs. other cDMARDs 12 months Erosions at baseline:
–3.21
No erosions at
baseline: –4.66
1.45
(–2.57 to 5.47)
43 1
Smolen (2006)100
ASPIRE
Radiographic progression
Change from baseline in the
SHS
SHS of < 2.6
SHS of ≥ 2.6 to
< 10.5
SHS of ≥ 10.5
MTX vs. IFX Week 54 44 Could not formally assess
interaction. Suggest a
treatment effect modifier
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
6
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
8
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
A
rch
er
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
1
1
5
TABLE 17 Interaction effects by outcome and baseline variable: continuous outcomes (continued )
First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
Prediction of treatment response by RF status at baseline – radiographic progression
Vastesaeger (2009)78
ASPIRE
Erosions/radiographic
progression
Increase of ≥ 5/year in
the total SHS score
RF of < 80 U/ml
RF of 80–200U/ml
RF of > 200U/ml
MTX vs. MTX and IFX Week 54 RF of < 80 U/ml: 0.38
RF of 80–200U/ml:
0.38
RF of > 200U/ml: 0.54
RF of 80–200U/ml and
RF of < 80 U/ml: 0.00
(–0.38 to 0.38)
RF of > 200U/ml and
RF of < 80 U/ml: 0.16
(–0.17 to 0.49)
Prediction of treatment response by CRP at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Change in SHS from
baseline
Radiographic progression
Change in SHS from
baseline
CRP level of
< 0.6mg/dl
CRP level of ≥ 0.6
to < 3mg/dl
CRP level of
≥ 3mg/dl
MTX vs. MTX and IFX Week 54 45 3, could not formally assess
interaction
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in
the total SHS score
CRP level of
< 0.6mg/dl
CRP level of
0.6–3.0mg/dl
CRP level of
> 3.0mg/dl
MTX vs. MTX and IFX Week 54 CRP level of
< 0.6mg/dl: 0.15
CRP level of
0.6–3.0mg/dl: 0.51
CRP level of
> 3.0mg/dl: 0.65
CRP level of
0.6–3.0mg/dl and CRP
level of < 0.6mg/dl:
0.36 (0.02 to 0.70)
CRP level of > 3.0mg/dl
and CRP level of
< 0.6mg/dl: 0.50
(0.15 to 0.85)
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First author (year),
name of trial or
cohort (if relevant) Outcome Variable Treatment
Follow-up
time point Treatment effect
Interaction effect,
mean (95% CI) Figure Scenario/summary
Prediction of treatment response by ESR at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Change in SHS from baseline ESR of < 28mm/
hour
ESR of ≥ 28 to
< 52mm/hour
ESR of ≥ 52mm/
hour
MTX vs. MTX and IFX Week 54 46 Could not formally assess
interaction. Suggest a
treatment effect modifier
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in the total
SHS score
ESR of < 21mm/
hour
ESR of 21–50mm/
hour
ESR of > 50mm/
hour
MTX vs. MTX and IFX Week 54 ESR of < 21mm/hour:
0.13
ESR of 21–50mm/
hour: 0.45
ESR of > 50mm/hour:
0.60
ESR of 21–50mm/hour
and an ESR of
< 21 mm/hour: 0.32
(–0.07 to 0.71)
ESR of > 50mm/hour
and an ESR of
< 21mm/hour: 0.47
(0.07 to 0.87)
Prediction of treatment response by SJC at baseline: radiographic progression
Vastesaeger (2009)78
ASPIRE
Increase of ≥ 5/year in the total
SHS score
SJC28 of < 10
SJC28 of 10–17
SJC28 of > 17
MTX vs. MTX and IFX Week 54 SJC28 of < 10: 0.31
SJC28 10–17: 0.44
SJC28 of > 17: 0.51
SJC28 of 10–17 and
SJC28 of < 10: 0.13
(–0.26 to 0.52)
SJC28 of > 17 and
SJC28 of < 10: 0.20
(–0.22 to 0.62)
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; AMPLE, abatacept vs. adalimumab in biologic-naive RA patients with background MTX; anti-CCP2–,
anticyclic citrullinated peptide-2 negative; anti-CCP2+, anticyclic citrullinated peptide-2 positive; CARDERA, Combination Anti-Rheumatic Drugs in Early RA; COM, combination; EJC, eroded joint count; FIN-RACo, Finnish
Rheumatoid Arthritis Combination Therapy; HAQ-DI, Health Assessment Questionnaire – disability index; IT, immediate therapy; N/A, not applicable; Q1/Q2/Q3/Q4, quartile 1/quartile 2/quartile 3/quartile 4; s.c., subcutaneous;
SJC28, 28 swollen joint count; SU, step-up; TEAR, Treatment of Early Aggresive Rheumatoid arthritis.
a Treatment effect favoured ACPA-negative patients, but was not statistically significant.
b Treatment effect favours ACPA-positive patients, but was not statistically significant.
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Results from Seegobin et al.109 (see Appendix 10, Figures 15–18) suggest that the effect of triple therapy
(MTX and CsA and prednisolone) versus MTX on erosions was greater in patients who were ACPA
positive than the effect of treatment in patients who were ACPA negative at baseline (scenario 2). At 18
(see Appendix 10, Figure 17) and 24 months (see Appendix 10, Figure 18), the interaction effect was
statistically significant (–4.41, 95% CI –8.02 to –0.80; –4.9, 95% CI –8.59 to –1.21, respectively).
Seegobin et al.109 performed a repeated-measures analysis of variance (ANOVA) examining the interaction
between treatment and ACPA status at baseline on the change from baseline in Larsen score, and
reported a significant treatment × ACPA interaction (F = 7.05; p < 0.001) when treatment was one of
the four randomised treatment arms (CsA, prednisolone, MTX monotherapy or MTX and CsA and
prednisolone triple therapy).
Prediction of treatment effect by anticitrullinated protein/peptide anti-body status at
baseline: disease activity
The results from Seegobin et al.109 (see Appendix 10, Figures 23–26) suggest that there was a qualitative
interaction between treatment and ACPA status at baseline and at 12, 18 and 24 months; patients who
were ACPA negative at baseline had a worse change from the baseline DAS28 when treated with triple
therapy (MTX and CsA and prednisolone) than the effect of being treated with MTX, whereas patients had
a better change from baseline in DAS28 when treated with triple therapy (MTX and CsA and prednisolone)
than the effect of being treated with MTX. However, these effects were not statistically significant.
Seegobin et al.109 performed a repeated measures ANOVA examining the interaction between treatment and
ACPA status at baseline on the change from the baseline DAS28, and reported a significant treatment × ACPA
interaction (F = 3.99; p = 0.008) when treatment was one of the four randomised treatment arms [(1) CsA,
(2) prednisolone, (3) MTX monotherapy or (4) MTX and CsA and prednisolone triple therapy].
Sokolove et al.110 examined the effect of treatment [MTX and ABT (subcutaneous administration) vs. MTX
and ADA (subcutaneous administration)] by anti-CCP2 status (negativity and four quartiles of anti-CCP2
positivity) on the change from baseline in DAS28-CRP at multiple time points up to 2 years (this study
examined changes at 6 months, 1 year and 2 years for consistency with other evidence, because it was not
feasible to examine all time points). There was no evidence of a difference in the effect of treatments or
that the treatment effect varied according to anti-CCP2 status at baseline and at 6 months, and at 1 and
2 years (see Appendix 10, Figures 31–33).
Prediction of treatment effect by anticitrullinated protein/peptide anti-body status at
baseline: physical function
Seegobin et al.109 performed a repeated measures ANOVA examining the interaction between treatment
and ACPA status at baseline on the change from the baseline HAQ score, but this was not statistically
significant (F = 0.48; p = 0.696) when treatment was one of the four randomised treatment arms
[(1) CsA, (2) prednisolone, (3) MTX monotherapy or (4) MTX and CsA and prednisolone triple therapy].
Sokolove et al.110 examined the effect of treatment [MTX and ABT (subcutaneous administration) vs. MTX
and ADA (subcutaneous administration)] by anti-CCP2 status (negativity and four quartiles of anti-CCP2
positivity) on the change from the baseline HAQ – disability index (HAQ-DI) score at multiple time points
up to 2 years (we examined changes at 6 months, and at 1 and 2 years for consistency with other
evidence, because it was not feasible to examine all time points). There was no evidence of a difference
in the effect of treatments or that treatment effect varied according to anti-CCP2 status at baseline at
6 months and at 1 and 2 years (see Appendix 10, Figures 34 and 35).
RESULTS: REVIEW 2
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Prediction of treatment effect by anticitrullinated protein/peptide anti-body status at
baseline: remission
Results from Huizinga et al.104 (Tables 18 and 19) suggest that the effect of ABT versus MTX on DAS28-CRP
remission at 1 year was worse for patients who were ACPA positive at baseline than for those who were
ACPA negative at baseline (ratio of ORs 0.57); however, this was not statistically significant (95% CI 0.19 to
1.69). The effect of ABT and MTX versus MTX on DAS28-CRP remission at 1 year was better in patients who
were ACPA positive at baseline than in those who were ACPA negative at baseline (ratio of odds ratios
1.33), but this was not statistically significant (95% CI 0.45 to 3.90).
Prediction of treatment effect by smoking status at baseline: disease activity
It was not possible to formally assess the interaction effect between treatment and smoking status at
baseline on DAS28 disease activity in the Maska et al.105 study because standard errors were not available.
The results of the comparison of ETN and MTX with MTX and SSZ and HCQ were inconsistent at 24, 48
and 102 weeks. At 24 weeks, there was a suggestion of a qualitative interaction between treatment and
smoking status (see Appendix 10, Figure 38); patients who were non-smokers had a lower mean response
when treated with ETN and MTX than those who were treated with MTX and SSZ and HCQ, whereas
patients who were current smokers had a higher mean response when treated with ETN and MTX than
those who were treated with MTX and SSZ and HCQ. At 48 weeks (see Appendix 10, Figure 39), the
results suggested that smoking status was not prognostic in the case of ETN and MTX, whereas patients
who were current smokers had a lower mean response when treated with ETN and MTX than non-smokers
(i.e. scenario 3). At 102 weeks (see Appendix 10, Figure 40), the results suggested that smoking status
was not a prognostic factor for both treatments.
Prediction of treatment effect by erosions at baseline: radiographic progression
The results from Pasero et al.107 suggest that the presence of erosion versus the absence of erosion
was prognostic of response but was not a treatment effect modifier for CsA versus other cDMARDs at
12 months with respect to the change from baseline in the Larsen–Dale eroded joint count (scenario 1;
see Appendix 10, Figure 41) and with respect to the change from baseline in the Larsen–Dale damage
score (scenario 1; see Appendix 10, Figure 42).
It was not possible to formally assess the interaction effect between treatment and SHS at baseline in the
Smolen et al.100 study, which reported baseline SHS in tertiles because standard errors were not available.
The observed results suggest that SHS is a treatment effect modifier of the effect of MTX and IFX versus
MTX on radiographic progression, but that SHS might not be prognostic for MTX and IFX (see Appendix 10,
Figure 43).
Smolen et al.100 reported a significant inverse correlation between erosions at baseline and change from
baseline in SHS of > 0 at week 54 for the MTX and IFX treatment arm (r = –0.19; p < 0.0001), but not for
the MTX arm (r = 0.07; p = 0.25; Table 20); this suggests that erosions may be a treatment effect modifier,
but that it is not prognostic for MTX.
Smolen et al.100 also performed separate within-treatment logistic regression analyses of worsening joint
damage at week 54, adjusting for baseline characteristics on their continuous scales. The estimated ORs
per unit change in covariate were generally small and were only statistically significant for the SHS for
patients treated with MTX and IFX. In spite of this finding, the results suggest that the SHS may have
little prognostic value in predicting the response for both MTX and IFX and MTX alone. When formally
comparing the ORs between treatments, the results suggest that there were small differences in the effect
of MTX and IFX versus MTX on worsening joint damage at week 54 by baseline SHS (ratio of ORs 0.98,
95% CI 0.96 to 1.00).
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TABLE 18 Prediction of response to treatment: dichotomous outcomes
First author (year),
name of trial or
cohort (if relevant),
measurement of
outcome Variable Treatment
Follow-up
time point
Sample
size (n) OR (SD/standard error/95% CI)
Number (%)
of cases in
category group
Prediction of treatment response by ACPA status at baseline: remission
Huizinga (2015)104
AVERT
DAS28-CRP level
of < 2.6
Anti-CCP2 IgM positive ABT (s.c. administration) and MTX 12 months 66 2.21a
Log-OR: 0.79 (variance: 0.12)
43b (65.1%)
ABT (s.c. administration) 62 0.70a
Log-OR: –0.36 (variance 0.13)
23b (37.4%)
MTX 72 Reference 33b (45.6%)
Anti-CCP2 IgM
negative
ABT (s.c. administration) and MTX 52 1.67a
Log-OR: 0.51 (variance 0.18)
30b (57.8%)
ABT (s.c. administration) 50 1.22a
Log-OR: 0.20 (variance 0.18)
25b (50.4%)
MTX 40 Reference 18b (45.0%)
Prediction of treatment response by BMI at baseline: disease activity (DAS response)
Heimans (2013)103
BeSt
DAS of > 2.4
BMI of < 25 kg/m2 MTX initial monotherapy 1 year NR Reference NR
BMI of ≥ 25 kg/m2 NR 1.04 (0.82 to 1.31)c,d
1.05 (0.84 to 1.30)d,e
Log-RR: 0.05 (standard error 0.11)e
NR
BMI of < 25 kg/m2 MTX and SSZ and tapered
prednisone
NR Reference NR
BMI of ≥ 25 kg/m2 NR 1.37 (0.63 to 2.75)c,d
1.46 (0.75 to 2.83)d,e
Log-RR: 0.38 (standard error 0.34)d
NR
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TABLE 19 Interaction effects by outcome and variable: dichotomous outcomes
First author (year), name of trial
or cohort (if relevant) Variable Comparison Follow-up time point OR
Interaction effect, ratio of
ORs (95% CI)
Prediction of treatment response by ACPA status at baseline: remission
Huizinga (2015)104
DAS28-CRP remission
ACPA status ABT vs. MTX 1 year ACPA+: 0.70
ACPA–: 1.22
0.57 (95% CI 0.19 to 1.68)
ABT and MTX vs. MTX ACPA+: 2.21
ACPA–: 1.67
1.33 (95% CI 0.45 to 3.90)
Prediction of treatment response by BMI at baseline: disease activity (DAS response)
Heimans (2013)103
BeSt
DAS of > 2.4
BMI BMI of ≥ 25 kg/m2 vs. BMI
of < 25 kg/m2
1 year MTX and SSZ and tapered
prednisone: 1.46a
MTX initial monotherapy: 1.05a
1.39b (95% CI 0.43 to 2.79)
MTX and IFX: 2.20a
MTX initial monotherapy: 1.05a
2.10b (95% CI 0.91 to 4.82)
Prediction of treatment response by erosions at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
SHS N/Ac Week 54 MTX and IFX: 0.99d
MTX: 1.01d
0.98 (95% CI 0.96 to 1.00)
Prediction of treatment response by RF status at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
RF status N/Ac Week 54 MTX and IFX: 1.00d
MTX: 1.00d
1.00 (95% CI 1.00 to 1.00)
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First author (year), name of trial
or cohort (if relevant) Variable Comparison Follow-up time point OR
Interaction effect, ratio of
ORs (95% CI)
Prediction of treatment response by CRP level at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
CRP level N/Ac Week 54 MTX and IFX: 1.03d
MTX: 1.05d
0.99 (95% CI 0.86 to 1.13)
Prediction of treatment response by ESR at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
ESR N/Ac Week 54 MTX and IFX: 1.00d
MTX: 1.02d
0.99 (95% CI 0.97 to 1.00)
Prediction of treatment response by SJC at baseline: radiographic progression
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
SJC N/Ac Week 54 MTX and IFX: 1.00d
MTX: 1.04d
0.96 (95% CI 0.93 to 1.00)
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; AVERT, Assessing Very Early Rheumatoid arthritis Treatment;
N/A, not applicable; s.c., subcutaneous.
a Relative risk.
b Ratio of relative risks.
c Within-treatment analysis.
d Within-treatment estimate of the change in the odds for a unit change in the predictor variable.
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TABLE 20 Prediction of response to treatment: correlations
First author (year), name of trial
or cohort (if relevant) Treatment
Follow-up
time point Sample size (n)
Correlation
coefficient
p-value for
correlation
coefficient
Regression
coefficient p-value for regression coefficient
Correlations between erosions at baseline and radiographic progression at follow-up
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
MTX Week 54 279 r = 0.07 0.2511 β = 0.005 0.583
MTX and IFX 715 r = –0.19 < 0.0001 β = –0.016 0.007
OR 0.99 (95% CI 0.97 to 1.0)
Correlations between RF status at baseline and radiographic progression at follow-up
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
MTX Week 54 282a r = 0.13 0.0324 β = –0.0003 0.491
MTX and IFX 722a r = 0.05 0.1906 β = 0.00 0.695
Correlations between CRP level at baseline and radiographic progression at follow-up
Garnero (2002)102
Change from baseline in the SHS
erosion score
MTX 12 months 39 r = 0.18 NR (NS) NR NR
ETN 77 r = 0.09 NR (NS) NR NR
Garnero 2002102
Change from baseline in the SHS
total score
MTX 12 months 39 r = 0.28 NR (NS) NR NR
ETN 77 r = 0.18 NR (NS) NR NR
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
MTX Week 54 282 r = 0.24 < 0.0001 β = 0.048 0.43
MTX and IFX 722 r = 0.03 0.4643 β = 0.033 0.291
Taylor (2004)101
Change from baseline in the SHS
MTX 54 weeks 12 r = 0.58 0.077 NR NR
MTX and IFX 12 r = –0.19 0.562 NR NR
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First author (year), name of trial
or cohort (if relevant) Treatment
Follow-up
time point Sample size (n)
Correlation
coefficient
p-value for
correlation
coefficient
Regression
coefficient p-value for regression coefficient
Correlations between ESR at baseline and radiographic progression at follow-up
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
MTX Week 54 269 r = 0.27 < 0.0001 β = 0.018 0.003
OR 1.02 (95% CI 1.01 to 1.03)
MTX and IFX 690 r = 0.05 0.2356 β = 0.004 0.335
Rau (1998)108
Radiographic progression (change
in the Rau-modified Larsen/Sharp
score)
MTX 6 months 87 r = 0.41 < 0.001 NR NR
GSTM 87 r = 0.24 0.04 NR NR
MTX 12 months 87 r = 0.41 < 0.001 NR NR
GSTM 87 r = 0.25 < 0.03 NR NR
Correlations between SJC at baseline and radiographic progression at follow-up
Smolen (2006)100
ASPIRE
Worsening radiographic joint
damage (change in the SHS of > 0)
MTX Week 54 282a r = 0.16 0.0088 β = 0.039 0.010
OR 1.04 (95% CI 1.01 to 1.07)
MTX and IFX 722a r = –0.01 0.7291 β = 0.002 0.866
Correlations between vascularity of synovium using PDUS at baseline and radiographic progression at follow-up
Taylor (2004)101
Change from baseline in the SHS
MTX 54 weeks 12 r = 0.78 0.005 NR NR
MTX and IFX 12 r = –0.28 0.372 NR NR
NR, not reported; NS, not significant.
a Number analysed in efficacy analyses.
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Prediction of treatment effect by rheumatoid factor status at baseline: erosions/
radiographic progression
Smolen et al.100 (see Table 20) reported a significant correlation between RF at baseline and change in the
SHS of > 0 at week 54 for the MTX treatment arm (r = 0.13; p = 0.03), but not for the MTX and IFX arm
(r = 0.05; p = 0.19). However, RF at baseline was not associated with a change in the SHS of > 0 from
baseline to week 54 in separate logistic regression analyses by treatment group, adjusting for baseline
demographic and other clinical characteristics (no further details reported) in the MTX and IFX arm
(β = 0.00; p = 0.70) or the MTX arm (β = –0.0003; p = 0.49) (see Table 20).
Vastesaeger et al.78 analysed the change from baseline in RRP (≥ 5/year in the total modified SHS score)
using an ANOVA on the van der Waerden score, and presented the results of the effect of MTX and IFX
versus MTX by RF subgroups. There was a suggestion of a treatment (i.e. MTX and IFX vs. MTX) by RF
subgroup interaction, with patients who had > 200 U/ml of RF having a greater effect when treated with
MTX and IFX versus MTX than patients with a lower RF score, although this was not statistically significant.
Rau et al.108 performed separate multivariable within-treatment linear regression analyses for MTX and
GSTM, including covariates for tender joint count, SJC, Activities of Daily Living (ADL) score, ESR, CRP level
and RF status on radiographic change between months 0–6 and 0–12. Of these, the authors found only
ESR to be statistically significant (β = 0.49, p = 0.001 for progression between 0 and 6 months; β = 0.39,
p = 0.007 for progression between 0 and 12 months) for MTX. None of the covariates was statistically
significant for GSTM. Thus, RF status was not found to be prognostic for MTX and GSTM (scenario 4).
Prediction of treatment effect by C-reactive protein level at baseline:
radiographic progression
It was not possible to formally assess the interaction between treatment and CRP level at baseline in the
Smolen et al.100 study, which reported baseline CRP level in tertiles because standard errors were not
available. The observed results suggest an increasing effect of MTX versus MTX, with higher levels of
baseline CRP. The combination of MTX and IFX seems to have an effect on radiographic progression at all
levels of CRP at baseline; this effect was not observed in the case of MTX. Baseline CRP level appears to be
a treatment modifier with respect to MTX and IFX and MTX alone, but does not appear to be prognostic
for MTX and IFX (scenario 3) (see Appendix 10, Figure 44).
Smolen et al.100 reported a significant correlation between CRP level at baseline and change in the SHS
of > 0 at week 54 for the MTX treatment arm (r = 0.24; p < 0.0001), but not for the MTX and IFX arm
(r = 0.03; p = 0.46); this supports the assertion that MTX and IFX treatment has an effect irrespective of CRP
level at baseline and that CRP level at baseline is a treatment effect modifier. However, CRP level at baseline
was not associated with a change in the SHS of > 0 from baseline to week 54 in separate logistic regression
analyses, adjusting for baseline demographic and other clinical characteristics (no further details reported) in
the MTX and IFX arm (β = 0.033; p = 0.29) or the MTX arm (β = 0.048; p = 0.43) (see Table 20).
Vastesaeger et al.78 analysed the change from baseline in RRP (≥ 5/year in the total modified SHS score)
using an ANOVA on the van der Waerden score, and presented the results of the effect of MTX and IFX
versus MTX by CRP subgroups. There was a suggestion of a treatment interaction (i.e. MTX and IFX vs.
MTX) by CRP subgroup, with the effect of MTX and IFX being greater with higher baseline CRP levels,
although the results were not statistically significant.
Garnero et al.102 (see Table 19) reported no significant correlations between CRP level at baseline and
change from baseline in the SHS erosion score in either the MTX or the ETN treatment arm at 12 months
(r = 0.18 and r = 0.09, respectively; p-values not reported). Likewise, no significant associations were
reported between CRP level at baseline and change from baseline in the SHS total score in either the MTX
or ETN arm at 12 months (r = 0.28 and r = 0.18, respectively; p-values not reported). However, in both
cases the observed association was greater for patients treated with MTX, which may indicate that CRP
level at baseline is a treatment effect modifier with respect to the effect of MTX versus ETN.
RESULTS: REVIEW 2
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Taylor et al.101 (see Table 19) reported no significant associations between CRP level at baseline and change
from baseline in the SHS score in either the MTX treatment arm or the MTX and IFX treatment arm at
54 weeks (r = 0.58, p = 0.08; and r = –0.19, p = 0.56, respectively). However, in both cases the observed
association was greater for patients treated with MTX, which may indicate that CRP level at baseline is a
treatment effect modifier with respect to the effect of MTX and IFX versus MTX.
Rau et al.108 performed separate multivariable within-treatment linear regression analyses for MTX and
GSTM, including covariates for tender joint count, SJC, ADL score, ESR, CRP level and RF status on
radiographic change between months 0–6 and 0–12. Of these, the authors found only ESR to be statistically
significant (data previously shown), with no predictive effect of CRP level for either treatment (data not
shown) for MTX. None of the covariates was statistically significant for GSTM. Thus, CRP level was not
found to be prognostic for MTX and GSTM (scenario 4).
Prediction of treatment effect by erythrocyte sedimentation rate at baseline:
radiographic progression
It was not possible to formally assess the interaction between treatment and ESR at baseline in the Smolen
et al.100 study, which reported baseline ESR in tertiles, because standard errors were not available, and it
was not possible to extract the mean from the published graph for patients treated with IFX and MTX and
with a baseline ESR of < 28 mm/hour. Nevertheless, the observed results suggest that a baseline ESR of
< 28 mm/hour and ≥ 28 to < 52 mm/hour may not be prognostic of response for MTX and IFX and MTX
alone, but that it may be a treatment effect modifier for patients with a baseline ESR of ≥ 52 mm/hour
(see Appendix 10, Figure 45).
Smolen et al.100 (see Table 20) reported a significant correlation between ESR at baseline and the change
from baseline in the SHS of > 0 for the MTX treatment arm (r = 0.27; p < 0.0001) but not for the MTX and
IFX treatment arm (r = 0.05; p = 0.24); this supports the assertion that treatment with MTX and IFX has an
effect irrespective of ESR at baseline and that ESR at baseline is a treatment effect modifier. ESR at baseline
was found to be significantly associated with a change in the SHS of > 0 from baseline to week 54 in
separate logistic regression analyses, adjusting for baseline demographic characteristics and other clinical
characteristics (no further details reported) in the MTX arm (β = 0.018; p = 0.003), with no significant
association in the MTX and IFX arm (β = 0.004; p = 0.34) (see Table 20). Again, baseline ESR may be
prognostic for MTX but not for MTX and IFX.
Vastesaeger et al.78 analysed the change from baseline in RRP (≥ 5/year in the total modified SHS score)
using an ANOVA on the van der Waerden score, and presented the results of the effect of MTX and IFX
versus MTX by ESR subgroup. There was a suggestion of a treatment (i.e. MTX + IFX vs. MTX) by ESR
subgroup interaction. The treatment effect increased with increasing baseline ESR and was statistically
significant when comparing the treatment effect in patients with baseline ESR of ≥ 52 mm/hour against
the treatment effect in patients with a baseline ESR of < 21 mm/hour (difference in the treatment effects
between subgroups 0.47 mm/hour, 95% CI 0.07 to 0.87 mm/hour).
Rau et al.108 reported a significant correlation between ESR at baseline and Rau-modified Larsen/Sharp
score for both MTX and GSTM at 6 months (r = 0.41, p < 0.0001; r = 0.24, p = 0.04, respectively) and
12 months (r = 0.41, p < 0.001; r = 0.25, p < 0.03, respectively). The association was greater in patients
treated with MTX, which may indicate that baseline ESR is a treatment effect modifier.
Rau et al.108 performed separate multivariable within-treatment linear regression analyses for MTX and
GSTM, including covariates for tender joint count, SJC, ADL score, ESR, CRP level and RF status on
radiographic change between months 0–6 and 0–12. Of these, ESR was the only statistically significant
covariate (radiographic progression over 0–6 months, regression coefficient 0.49; p = 0.001; radiographic
progression over 0–12 months, regression coefficient 0.39; p = 0.007) for MTX. None of the covariates
was statistically significant for GSTM. Thus, ESR may be a treatment effect modifier with respect to MTX
and GSTM, but it is not prognostic with respect to GSTM (scenario 3).
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Prediction of treatment effect by swollen joint count at baseline:
radiographic progression
Smolen et al.100 reported a significant correlation between SJC at baseline and the change from baseline
in SHS of > 0 for the MTX treatment arm (r = 0.16; p = 0.0088), but not for the MTX and IFX treatment
arm (r = –0.01; p = 0.73). Although the association in the case of MTX is weak, the results suggest that
baseline SJC may be a treatment effect modifier (i.e. it is prognostic for MTX but not for MTX and IFN).
SJC at baseline was found to be significantly associated with a change in the SHS of > 0 from baseline to
week 54 in separate logistic regression analyses, adjusting for baseline demographic characteristics and
other clinical characteristics (no further details reported) in the MTX treatment arm (β = 0.039; p = 0.010),
with no significant association in the MTX and IFX treatment arm (β = 0.002; p = 0.87). Again, baseline
SJC may be a treatment effect modifier (i.e. it is prognostic for MTX but not for MTX and IFX).
Vastesaeger et al.78 analysed the change from baseline in RRP (≥ 5/year in total modified SHS score) using
an ANOVA on the van der Waerden score and presented the results of the effect of MTX and IFX versus
MTX by 28 swollen joint count (SJC28) subgroups. There was a suggestion of a treatment (i.e. MTX and
IFX vs. MTX) by SJC28 subgroup interaction; the observed treatment effects increased with increasing
baseline SJC28, although these were not statistically significant.
Rau et al.108 performed separate multivariable within-treatment linear regression analyses for MTX and
GSTM, including covariates for tender joint count, SJC, ADL score, ESR, CRP level and RF on radiographic
change between months 0–6 and 0–12. Of these, ESR was the only statistically significant covariate
(radiographic progression over 0–6 months, regression-coefficient 0.49, p = 0.001; radiographic
progression over 0–12 months, regression-coefficient 0.39, p = 0.007) for MTX. None of the covariates
was statistically significant for GSTM. Thus, SJC was not found to be prognostic for MTX and GSTM
(scenario 4).
Prediction of treatment effect by body mass index at baseline: disease activity
(Disease Activity Score response)
The results from Heimans et al.103 suggest that the relative risk of MTX and SSZ and tapered prednisone
versus initial MTX monotherapy on treatment non-response (i.e. a DAS of > 2.4) at 1 year was greater for
patients with a BMI of ≥ 25 kg/m2 at baseline than for those with a BMI of < 25 kg/m2 at baseline (ratio of
relative risks 1.39); however, this was not statistically significant (95% CI 0.43 to 2.79). The relative risk
of MTX and IFX versus initial MTX monotherapy on treatment non-response (i.e. a DAS of > 2.4) at 1 year
was approximately twice that for patients with a BMI of ≥ 25 kg/m2 at baseline compared with those with
a BMI of < 25 kg/m2 at baseline (ratio of relative risks 2.10); however, this was not statistically significant
(95% CI 0.91 to 4.82).
Prediction of treatment effect by power Doppler ultrasound at baseline:
radiographic progression
Taylor et al.101 reported a significant correlation between the vascularity of synovium using PDUS at
baseline and the change from baseline in SHS score at 54 weeks for the MTX treatment arm (r = 0.78;
p = 0.005), but not for the MTX and IFX treatment arm (r = –0.28; p = 0.37). The difference in the strength
of the association suggests that baseline vascularity of synovium may be a treatment effect modifier.
Discussion
Twelve primary studies were identified with which to assess the prediction of treatment response in terms
of baseline covariates. Covariates examined included ACPA status, smoking status, erosions, RF status,
CRP level, ESR, SJC, BMI and vascularity of synovium on PDUS. Outcomes examined included erosions/
radiographic progression, disease activity, physical function and DAS28 remission.
RESULTS: REVIEW 2
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There is no evidence, from the current review, that the end point (i.e. remission or low disease activity) had
an impact on the results. One study (i.e. Huizinga et al.104) examined remission as an outcome with ACPA
status as the baseline covariate, and found no significant interaction between treatment and covariate.
Similarly, one study (i.e. Heimans et al.103) looked at low disease activity as an outcome, with BMI as the
baseline covariate, and found no significant interaction between treatment and covariate. In order to explore
the question of how end points of remission and low disease activity affect the prediction of treatment
response, further research is needed to examine both end points and the same baseline covariates, preferably
within the same treatment regime.
Considerable variation was found within the evidence examining the prediction of treatment response in
terms of baseline covariates, in terms of covariates examined, treatments compared, outcomes assessed and
statistical methodology. Most of the studies performed within-treatment analyses and examined the effects
of baseline patient and/or disease characteristics using subgroup analyses, and rarely adjusted for other
covariates. More importantly, no consideration was given to more flexible relationships between covariates
and response and their interaction effects. It was rare for studies to perform a formal assessment of any
treatment by covariate interactions; when these were performed, it is likely that the test lacked sufficient
power to detect interaction effects as being statistically significant.
We have compared treatment effects across values of baseline variables in an attempt to identify potential
treatment effect modifiers using data presented in the included papers (when possible). Given the
heterogeneity between studies in the outcomes assessed, the differences in modelling approaches and the
lack of information on the correlation between covariates, a formal quantitative synthesis of the evidence
was not conducted. The conclusions were limited to a comparison between treatments at the study level
and should be treated as hypothesis-generating for certain patient and/or disease characteristics being
modifiers of treatment effect. Such predictors should be formally evaluated in treatment-specific clinical
prediction models.
Review 2 conclusions
There was statistical evidence to suggest that ACPA status, SJC28 and PDUS status at baseline may be
treatment effect modifiers, but not necessarily that they are prognostic of response for all treatments.
Most of the results were subject to considerable uncertainty and were not statistically significant. In
general, there was insufficient evidence that the effect of treatment depended on baseline characteristics.
However, it should be noted that insufficient evidence for a covariate by treatment interaction does not
mean that there is no interaction or that baseline covariates are prognostic for both treatments. The
inability to reject the null hypothesis of no interaction effect is likely to reflect the power of the test being
low for meaningful interaction effects.
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Chapter 6 Assessment of factors relevant to the
NHS and other parties
P redictors included in the clinical prediction models identified in this assessment may be useful insupplementing clinicians’ decision-making regarding patient prognosis. However, because of
uncertainties and limitations in the evidence base, no single clinical prediction model can currently be
recommended over any other for use in clinical practice.
The prognostic factors selected for consideration in the assessment are readily available in clinical practice.
However, the optimal prediction model(s) may include other biomarkers/genetic tests that are not currently
available. The use of these tests may have associated practical and cost implications that will need to be
considered before potential future implementation.
Collaboration between professionals within the clinical and research community would facilitate further
model development and external validation research.
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Chapter 7 Discussion
Statement of principal findings
Review 1 (clinical prediction models)
A total of 28 studies were identified that investigated the use of assessment tools and tests in the
evaluation of prognosis in early RA patients. Twenty-two model development studies and one combined
model development/external validation study reported the development and/or internal validation of a total
of 39 clinical prediction models for outcomes, including radiographic joint damage, HAQ score and DAS28.
Six external validation studies (including the combined model development/external validation study) were
included, which tested the performance of eight clinical prediction models57,61,69,73,76,78,79 for radiographic
joint damage outcomes.
The predictive performance in internal validation was reported using the c-statistic in eight studies with
variable results. c-Statistics for radiographic progression ranged between 0.63 (Degboé et al.66 predicting
a ΔSHS of ≥ 5 at 1 year) and 0.87 (Houseman et al.72 predicting a ΔSHS of ≥ 10.5 at 8.2 years). However,
many of the included models had not been externally validated. For the eight models that had been externally
validated, predictive performance varied considerably. Five clinical prediction models (i.e. Syversen,76
SWEFOT,73 ESPOIR,69 MBDA61 and SONORA57) were externally validated in only one population per outcome.
Three clinical prediction models (i.e. ASPIRE CRP,78 ASPIRE ESR78 and BeSt79) were externally validated using
the same outcome definition in more than one population. The results of the RE meta-analysis indicated that
the most favourable performance across external validations was for the BeSt model79 (c-statistic 0.72, 95% CI
0.20 to 0.96), followed by ASPIRE ESR78 (c-statistic 0.62, 95% CI 0.44 to 0.78) and ASPIRE CRP78 (c-statistic
0.55, 95% CI 0.13 to 0.91). However, there is considerable heterogeneity for all three models, with the wide
CIs suggesting substantial uncertainty in the expected predictive performance in a new sample of patients.
The 95% CIs of the pooled estimates contain 0.5 for all three clinical prediction models, indicating that we
cannot be confident that the performance of the models is better than would be expected by chance.
Limitations were observed in the methods used to develop the included clinical prediction models, such
as the absence of potentially important candidate predictors and the incorrect handling of continuous
predictors. For models developed using RCT data with patients assigned to alternative treatment strategies,
the model development generally failed to assess the interactions between predictors and treatment
group, and so did not generate truly treatment-specific models.
There was no evidence to suggest that a single clinical prediction model performs well in all patients.
Further research is required to determine the optimal clinical prediction model(s) for use in clinical practice
and to determine the value of any emerging, currently untested candidate predictors in the development
of future prediction models.
Review 2 (prediction of treatment response)
Twelve primary studies were identified with which to assess the prediction of treatment response
according to baseline covariates. Covariates examined included ACPA status, smoking status, erosions,
RF status, CRP level, ESR, SJC, BMI and vascularity of synovium on PDUS. Outcomes examined included
erosions/radiographic progression, disease activity, physical function and DAS28 remission.
There was statistical evidence to suggest that ACPA status, SJC28 and PDUS status at baseline may be
treatment effect modifiers, but not necessarily that they are prognostic of response for all treatments.
Most of the results were subject to considerable uncertainty and were not statistically significant. In
general, there was insufficient evidence that the effect of treatment depended on baseline characteristics.
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Strengths and limitations of the assessment
This assessment has been undertaken according to current good practice in prognostic systematic reviews.26,48,118
A comprehensive range of predictors readily available in clinical practice and key outcomes were selected
for review. However, in order to maintain the feasibility of the assessment within the resources and time
scales available, a limited number of protocol amendments were necessary, as described in Appendix 2.
It was also necessary to limit the inclusion of studies to those published in the English language, because
resources were not available to allow for the translation of non-English-language articles.
The evaluation of prognostic models and the evidence regarding differential treatment effects according to
different values of predictor variables was limited to published aggregate data; published models typically
involved different predictor variables and did not include interaction terms with treatment. In both cases,
the ideal scenario would be to fit common models to the IPD. Access to IPD would allow harmonisation
(both in terms of model development and validation). However, analyses using IPD were beyond the scope
of this assessment.
Uncertainties
Despite the availability of a range of clinical prediction models, uncertainty remains over which (if any)
is the most appropriate for use in clinical practice. In order to assess the comparative performance of the
competing models more thoroughly, further external validations would be required. However, limitations
were observed in the methods used to develop the clinical prediction models. It is therefore likely that
the most clinically useful prediction model would contain predictors from across more than one of the
reviewed clinical prediction models and would consider alternative handling of key predictive variables.
Interactions between predictors and treatment group were rarely considered, and so there is limited
evidence regarding differential treatment effects according to different values of predictor variables.
Future research should seek to demonstrate the predictive value of existing variables that are currently
included in available clinical prediction models and should also aim to identify new, potentially valuable
variables for testing in future clinical prediction models. The development of new clinical prediction models
should conform to recommended good practice in model development and reporting (e.g. adherence to
the TRIPOD statement). Developed models should be externally validated in order to demonstrate their
usefulness. External validations should be conducted in clinically appropriate populations with previously
untreated early RA, and with sufficient variation (or case mix) in the population to ensure that the results
are generalisable to the target clinical population.
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Chapter 8 Conclusions
Implications for service provision
Review 1: clinical prediction models
No single clinical prediction model can currently be recommended in preference to any other model for
use in clinical practice because of uncertainties and limitations in the existing evidence base. The optimal
prediction model(s) may include variables (e.g. biomarkers/genetic tests) that are not routinely or currently
available. Their potential use may have associated practical and cost implications that will need to be
evaluated before future implementation.
Review 2: prediction of treatment response
There was limited evidence with which to assess whether or not specific baseline variables can predict
differential effects according to the treatment administered. Nevertheless, the available evidence suggested
that some baseline variables do affect relative treatment effects and that not all baseline variables may be
prognostic of response for all treatments.
There was statistical evidence to suggest that ACPA status, SJC28 and PDUS status at baseline may be
treatment effect modifiers, but not necessarily that these are prognostic of response for all treatments.
Most of the results were subject to considerable uncertainty and were not statistically significant.
In general, there was insufficient evidence that the effect of treatment depended on baseline
characteristics. This may be a real effect or may be because studies lacked statistical power to detect
interaction effects. The true effect of baseline variables should be evaluated in single multivariable models
adjusting for all relevant confounders.
Suggested research priorities
Review 1: clinical prediction models
l Collaborative research, including the use of IPD, for further (1) development/internal validation and
(2) external validation of clinical prediction model(s) with improved predictive performance.
l Adherence to good reporting standards of future clinical prediction model studies (e.g. in accordance
with the TRIPOD statement26).
Review 2: prediction of treatment response
l Clinical prediction models should be developed and validated with respect to individual treatments.
l The assessment of treatment by covariate interactions should follow good statistical practice: subgroup
analyses should be avoided; categorising continuous baseline covariates should be avoided; and the
interactions between treatments and baseline variables should be specifically modelled.
l The results of multivariable analyses presented in published reports should include estimates of the
main effects of covariates and any interaction effects, together with their standard errors and
covariances for secondary research purposes.
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Appendix 1 Additional details of the scoping of
the assessment
Appropriate methods for the identification of prognostic and predictive studies were considered bythe review team. Although various filters are available, published validation studies suggested that
none of these can be completely relied on.119,120 Therefore, the review team consulted the website of the
Cochrane Prognosis Methods Group [http://methods.cochrane.org/prognosis/our-publications (accessed
July 2016)] and judged that the ‘sensitivity-maximising’ search strategies, devised by the Hedges’ team at
McMaster University for identifying prognostic and clinical prediction studies, would be most suitable for
use in this assessment.44,53
The initial phase 1 scoping searches of MEDLINE were conducted to assess the size of the available
literature. The numbers of results retrieved were multiplied by 2.5 for an approximate estimate of the total
numbers to be found across other databases. The search terms for RA were initially combined with the
Hedges’ team filter to retrieve as broad as possible a set of prognostic studies. This was estimated to yield
approximately 40,000 records, if the searches were extended to all included databases.
According to a validation study by Geersing et al.,120 the Haynes’ filter results in a very low number of
missed studies; however, Geersing et al.120 recommended its use for scoping purposes only, suggesting
that, if a review is interested in only one or two specific variables, it is best to search for these without the
application of any filter.
Potential candidate prognostic and predictive variables were identified to inform discussion with
clinical experts.
A separate methodological exercise was undertaken to examine a sample of the records that were
retrieved by the Haynes’ filter but did not contain any of the terms relating to our candidate variables. The
free-data visualisation tool VOSviewer version 1.6.5 (Centre for Science and Technology Studies, Leiden
University, the Netherlands)121 was used to display frequently occurring words and phrases in a sample of
the discarded records in an attempt to reveal any emerging variables that were unknown to the team. No
new potential candidate variables for discussion were revealed through this process.
Following discussions with two expert clinical advisors who manage patients with early RA in the UK
(see Acknowledgements), the review team selected variables for inclusion based on:
l tests and assessment tools (e.g. selected laboratory tests, imaging tests and clinical assessment
measures) being readily available and used in UK clinical practice (and, therefore, genetic markers were
not included by the review team)
l the clinical experience of advisors in evaluating prognosis/treatment response in patients
l the initial scoping of literature in the area by the review team.
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Appendix 2 Additional details of deviations from
the final protocol
Review 1
l It was anticipated that, in the final protocol, the study types included in review 1 would probably
include published reports of cohort studies (and potentially case–control studies) that report the
associations between individual prognostic variables and outcomes. In order to maintain the feasibility
of the assessment, review 1 was restricted to the inclusion of studies that describe the development,
external validation or impact of eligible clinical prediction models in early RA. Therefore, in line with the
multivariable approach employed in prediction model research, individual prognostic factors were
not studied.
l It was necessary, because of resource and time constraints, to adopt an iterative approach to the
screening of evidence during the review 1 study selection (as described in Chapter 3, Study selection).
It was also originally intended in the final protocol that a randomly selected sample of titles/abstracts
would be checked by a second reviewer. However, in light of the iterative screening approach applied
in review 1, it was no longer considered appropriate to undertake this stage.
l It was originally intended in the final protocol that all studies would be assessed by criteria informed by
the QUIPS tool.54 However, it was necessary to revise this approach in order to allow for the quality
assessment of the included clinical prediction model and external validation studies using the most
methodologically appropriate tool (PROBAST).49
l It was stated in the review protocol that meta-analyses would be conducted using a Bayesian RE
model. However, this was modified for the final analysis because there were very few studies that
validated each clinical prediction model, thereby providing limited information with which to estimate
the between-study heterogeneity. Although it would be possible to implement a Bayesian RE analysis
using a weakly informative prior, this was not implemented because there was a lack of empirical
evidence to inform the prior distribution for the heterogeneity parameter and eliciting experts’ beliefs
was beyond the scope of this project. Although the analysis deviated slightly from the protocol, the
implemented RE model accounts for uncertainty in the between-study heterogeneity and is consistent
with the methodological recommendations.40
Review 2
Following a protocol amendment, to maintain the feasibility of the assessment, review 2 comprised:
l a systematic review of studies that describe the development, external validation or impact of eligible
clinical prediction models to predict the response to individual treatments in patients with early RA
(developed/validated in observational cohorts or experimental data sets)
l a review of primary studies (experimental or observational) to identify patient characteristics that affect
the response to individual treatments in patients with early RA.
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Appendix 3 Sample search strategy (MEDLINE)
Database: Ovid MEDLINE (R) Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations,Ovid MEDLINE (R) Daily, Ovid MEDLINE and Versions (R).
Date range searched: 1947 to September 2016.
Date searched: 27 September 2016.
Search strategy
1. exp rheumatoid arthritis/ (101,628)
2. rheumatoid arthritis.tw. (89,399)
3. 1 or 2 (129,354)
4. incidence.sh. or exp mortality/ or follow-up studies.sh. or prognos:.tw. or predict:.tw. or
course:.tw. (2,798,958)
5. exp animals/ not exp humans/ (4,320,871)
6. 4 not 5 (2,590,653)
7. predict:.mp. or scor:.tw. or observ:.mp. (4,442,632)
8. 7 not 5 (3,608,545)
9. 3 and 6 (17,646)
10. (3 and 8) not 9 (17,584)
11. (ACPA or ACPAs or anti-CCP* or antiCCP* or anti-CPA or antiCPA or ACCP*).mp. (3078)
12. (anti-cyclic citrullinated or anticyclic citrullinated).mp. (1271)
13. (anticitrullinated or anti-citrullinated).mp. (924)
14. 11 or 12 or 13 (3733)
15. (rheumat* factor* or RF).mp. (38,768)
16. exp radiography/ (707,925)
17. (radiologic* or radiograph* or x-ray* or xray*).mp. (1,010,600)
18. ((erosi* or erode*) adj3 (bone* or joint*)).mp. (3790)
19. erosion progression.mp. (57)
20. sharp score.mp. (340)
21. joint space narrowing.mp. (1373)
22. JSN.mp. (405)
23. 16 or 17 or 18 or 19 or 20 or 21 or 22 (1,262,189)
24. (disease activity score or DAS).mp. (51,082)
25. (28 joint* or twenty eight joint*).mp. (1665)
26. 24 and 25 (1509)
27. (DAS28 or DAS 28).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms] (2897)
28. 26 or 27 (3287)
29. (ESR or (erythrocyte* adj3 sediment*)).mp. or erythrocyte sedimentation rate/ (30,112)
30. C-Reactive Protein/ or (c reactive protein* or CRP or C-RP).mp. (699,592)
31. (SJC or (sw#ll* adj3 joint* adj2 (count* or number*))).mp. (1375)
32. 28 or 29 or 30 or 31 (94,961)
33. (smok* or tobacco or nicotine or cigarette* or ecig* or vape*).mp. (335,894)
34. Delayed Diagnosis/ (3879)
35. ((late or delay*) adj3 (treat* or present* or diagnos* or help-seeking or visit* or doctor* or GP* or
report* or consult* or assess*)).mp. (70,970)
36. ("time to presentation" or untreated or un-treated).mp. (154,236)
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37. disease duration.mp. (14,321)
38. 34 or 35 or 36 or 37 (250,927)
39. (BMI or body mass ind* or obes* or overweight or over-weight).mp. (410,712)
40. haq* or health assessment questionnaire*).mp. (4175)
41. exp ultrasonography/ (280,410)
42. (ultrasound or ultrasonogra* or sonogra* or doppler).mp. (408,038)
43. 41 or 42 (495,613)
44. exp Antirheumatic Agents/ (384,372)
45. (Disease-modifying antirheumatic* or Disease-modifying anti-rheumatic*).mp. (4245)
46. DMARD* or bDMARD* or cDMARD*).mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms] (3486)
47. exp Biological Therapy/ or biological therap*.mp. (395,939)
48. (biologic or biologics).mp. (57,465)
49. ciclosporin or cyclosporine or cyclophosphamide or cytophosphane or (gold adj2 (inject* or
intraven*)) or myocrisin or sodium aurothiomalate or gold sodium thiomolate or hydroxychloroquine
or HCQ or Plaquenil or leflunomide or arava or methotrexate or amethopterin or mycophenolate or
Mycophenolic acid or CellCept or Myfortic or sulfasalazine or sulphasalazine or salazopyrin or sulazine
or azulfidine or abatacept or CTLA41g or orencia or rituximab or mabthera or tocilizumab or Actemra or
RoActemra or adalimumab or humira or certolizumab pegol or cimzia or etanercept or enbrel or
golimumab or simponi or infliximab or remicade).af. (187,989)
50. (anti-TNF or antiTNF or ((TNF* or tumo?r necros#s factor*) adj3 (inhibit* or block* or antagonist* or
anti* or alpha)) or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or co-stimulation
blocker* or interleukin 6 or IL-6 or ("T lymphocyt*" adj2 activat*) or B lymphocyt* or Biosimilar*).mp.
(525,731)
51. (adalimumab or humira or d 2e7 or d2e7).af. or 331731-18-1.rn. or etanercept.af. or enbrel.af.
or 185243-69-0.rn. or infliximab.af. or remicade.af. or 170277-31-3.rn. or ta650.af. or ta 650.af. or
certolizumab pegol.af. or cimzia.af. or cdp870.af. or 428863-50-7.rn. or 1132819-27-2.rn. or czp.af.
or abatacept.af. (20,564)
52. (orencia or 213252-14-3 or 332348-12-6 or bms188667 or bms 188667 or ctla4ig or ctla 4ig or
golimumab or cnto148 or cnto 148 or simponi or 476181-74-5 or tocilizumab or atlizumab or actemra or
roactemra or 375823-41-9 or tofacitinib or xeljanz or tasocitinib or cp690550 or cp 690550 or 540737-29-9
or rituximab or rituxan or mabthera).af. or 174722-31-7.rn. (19,971)
53. atacicept.af. or 845264-92-8.rn. or unii-k3d9a0icq3.af. or uniik3d9a0icq3.af. or taci-fc5.af. or
tacifc5.af. or taci-ig.af. or taciig.af. (107)
54. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 (1,313,135)
55. 14 or 15 or 23 or 32 or 33 or 38 or 39 or 40 (2,253,817)
56. 9 and 55 (7258)
57. limit 56 to english language (6321)
58. 55 or 43 (2,627,621)
59. 3 and 8 and 58 (12,425)
60. 54 and 59 (5264)
61. limit 60 to english language (4943)
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Appendix 4 Review 1 excluded full-text studies
TABLE 21 Review 1 excluded full-text studies with rationale
First author
(date of publication) Title of publication Justification for exclusion
Akhavan (2011)122 Prevalence of and predictive factors for
sustained remission in early RA: results from
SONORA study
No measure of predictive performance
reported
Alemao (2014)123 Development and validation of a prognostic
clinical model for rapid radiographic
progression in patients with RA
Not early RA
Aletaha (2013)124 Rheumatoid factor determines structural
progression in rheumatoid arthritis dependent
and independent
of disease activity
No measure of predictive performance
reported
Alishiri (2008)125 Logistic regression models for predicting
physical and mental health-related quality of
life in rheumatoid arthritis patients
Not early RA
Allaart (2011)126 A multi-biomarker disease activity (Vectra DA)
algorithm score for rheumatoid arthritis
predicts radiographic progression in the BeSt
study
Preliminary report. No further relevant
data reported
Alves (2010)127 The ACR/EULAR 2010 criteria as well as other
predictive algorithms for rheumatoid arthritis
show good diagnostic performance
Study design
Anderson (2000)128 Factors predicting response to treatment in
rheumatoid arthritis: the importance of
disease duration
Study design
Balsa (2010)129 Prediction of functional impairment and
remission in rheumatoid arthritis patients by
biochemical variables and genetic
polymorphisms
Not early RA
Bakker (2010)130 Development of a multi-biomarker test for
rheumatoid arthritis (RA) disease activity
(Vectra DA)
Preliminary report. No further relevant
data reported
Bakker (2012)131 Performance of a multi-biomarker score
measuring rheumatoid arthritis disease activity
in the CAMERA tight control study
No measure of predictive performance
reported for radiographic progression.
Associations with DAS28 reported
(not used in prediction)
Barnabe (2014)132 Socio-demographic and health status
characteristics explain clinical outcome
trajectories in early inflammatory arthritis (EIA)
Conference abstract with no definition
of early RA. Early inflammatory
arthritis
Bedran (2013)133 Validation of a prediction rule for the
diagnosis of rheumatoid arthritis in patients
with recent onset undifferentiated arthritis
Diagnostic study
Belghomari (1999)134 Risk factors for radiographic articular
destruction of hands and wrists in rheumatoid
arthritis
Study design
Bombardier (2009)135 Which subgroups are at higher risk of rapid
radiographic progression in early rheumatoid
arthritis: results from SONORA study
Not handled as primary report of
SONORA radiographic risk model
continued
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Bombardier (2010)136 Radiographic damage and radiographic
progression are predictors for physical
function: results from SONORA study
Limited reporting and no measure of
predictive performance
Bombardier (2010)137 Sustained remission in early RA: results from
SONORA study
Limited reporting and no measure of
predictive performance
Bombardier (2010)138 Clinical prognostic factors for radiographic
damage in early rheumatoid arthritis: results
from SONORA study
Not handled as primary report of
SONORA radiographic risk model
Bøyesen (2009)139 Antibodies to cyclic citrullinated protein and
erythrocyte sedimentation rate predict hand
bone loss in patients with rheumatoid arthritis
of short duration: a longitudinal study
Study design
Breedveld (2004)140 Multiple faces of rheumatoid arthritis:
diagnostic and therapeutic algorithms
Study design
Britsemmer (2011)141 Validation of the 2010 ACR/EULAR
classification criteria for rheumatoid arthritis:
slight improvement over the 1987 ACR criteria
Study design
Brown (2007)142 Serum macrophage inhibitory cytokine 1 in
rheumatoid arthritis: a potential marker of
erosive joint destruction
Not early RA
Bruynesteyn (2002)143 Detecting radiological changes in rheumatoid
arthritis that are considered important by
clinical experts: influence of reading with or
without known sequence
Study design
Bukhari (2002)144 Rheumatoid factor is the major predictor of
increasing severity of radiographic erosions in
rheumatoid arthritis: results from the Norfolk
Arthritis Register Study, a large inception
cohort
No measure of predictive performance
reported
Carrier (2016)145 Serum levels of 14-3-3η protein supplement
C-reactive protein and rheumatoid arthritis-
associated antibodies to predict clinical and
radiographic outcomes in a prospective cohort
of patients with recent-onset inflammatory
polyarthritis
No measure of predictive performance
reported
Caruso (1990)146 Clinical, laboratory and radiographic features
in early rheumatoid arthritis
No measure of predictive performance
reported
Chalan (2013)147 Circulating CD4+CD161+ T lymphocytes are
increased in seropositive arthralgia patients
but decreased in patients with newly
diagnosed rheumatoid arthritis
No prognostic/predictive factors under
assessment
Chibnik (2011)148 Genetic risk score predicting risk of
rheumatoid arthritis phenotypes and age of
symptom onset
Unclear reporting of duration of
disease at baseline
Ciurtin (2016)149 Ultrasound-detected subclinical inflammation
was better reflected by the disease activity
score (DAS-28) in patients with suspicion of
inflammatory arthritis compared to established
rheumatoid arthritis
Not early RA
Conaghan (2010)150 Persistently moderate DAS28 is not benign:
loss of function occurs in early RA despite
step-up DMARD therapy
Study design
Conaghan (2011)151 Predicting outcomes in rheumatoid arthritis Literature review
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Corbett (1988)152 The Middlesex hospital prospective study of
early rheumatoid disease
Insufficient details available on
population characteristics and
methods
Corbett (1993)153 Factors predicting death, survival and
functional outcome in a prospective study of
early rheumatoid disease over fifteen years
Not eligible outcome
Courvoisier (2008)154 Prognostic factors of 10-year radiographic
outcome in early rheumatoid arthritis: a
prospective study
No measure of predictive performance
reported
Curtis (2010)155 Validation of a multi-biomarker test for
rheumatoid arthritis (RA) disease activity
(Vectra DA) in a multi-cohort study
Preliminary report of Curtis et al.156
Curtis (2012)156 Validation of a novel multibiomarker test to
assess rheumatoid arthritis disease activity
Symptom duration at baseline not
reported
Curtis (2015)157 A randomized trial comparing disease activity
measures for the assessment and prediction
of response in rheumatoid arthritis patients
initiating certolizumab pegol
Not early RA
Dawes (1986)158 Prediction of progressive joint damage in
patients with rheumatoid arthritis receiving
gold or D-penicillamine therapy
Duration of symptoms for total group
not reported, but data available
indicate not early RA
de Carvalho (1980)159 Radiographic progression of rheumatoid
arthritis related to some clinical and laboratory
parameters
Study design
de Punder (2015)160 Personalising treatment targets in rheumatoid
arthritis by using a simple prediction model
Prediction model includes variables
measured outside early RA definition
de Vries-Bouwstra (2008)161 Progression of joint damage in early
rheumatoid arthritis: association with HLA-
DRB1, rheumatoid factor, and anti-citrullinated
protein antibodies in relation to different
treatment strategies
No measure of predictive performance
reported
Desai (2015)162 An external validation study reporting poor
correlation between the claims-based index
for rheumatoid arthritis severity and the
disease activity score
Duration of symptoms not reported
Eastman (2012)163 Characterisation of a multiplex, 12-biomarker
test for rheumatoid arthritis
Study design
Eberhardt (1990)164 Early rheumatoid arthritis – onset, course and
outcome over 2 years
Limited reporting of predictive
performance
Eberhardt (1996)165 Associations of HLA-DRB and -DBQ genes
with two and 5 year outcome in rheumatoid
arthritis
Not eligible factor
Elshafie (2013)166 IgA rheumatoid factor is more predominant
than anti-CCP in Sudanese rheumatoid
arthritis patients, whereas IgG RF is a strong
prognostic marker and associated with early
onset
Study design
Emery (1996)167 Algorithm to predict radiological erosions in
early rheumatoid arthritis. Messages from
paper are incorrect
Letter to editor
continued
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Emery (2008)168 Clinical identification and treatment of a
rapidly progressing disease state in patients
with rheumatoid arthritis
Review
Forslind (2007)169 Sex: a major predictor of remission in early
rheumatoid arthritis?
No measure of predictive performance
reported
Fautrel (2011)170 Identification of patients who could require
early biologic therapy by developing a matrix
predicting rapid radiographic progression in
early rheumatoid arthritis patients treated by
methotrexate. A study based on the ESPOIR
cohort data
Preliminary report of included study.
No further relevant data reported
Fautrel (2012)171 Value of matrices developed to identify early
rheumatoid arthritis patients with rapid
radiographic progression despite methotrexate
therapy: a comparison of their performance in
the early rheumatoid arthritis ESPOIR cohort
Preliminary report of included study.
No further relevant data reported
Fautrel (2013)172 Performance of rapid radiographic progression
prediction matrices in the early rheumatoid
arthritis patients of the ESPOIR cohort
Preliminary report of included study.
No further relevant data reported
Fautrel (2015)173 Identifying patients with rheumatoid arthritis
with moderate disease activity at risk of
significant radiographic progression despite
methotrexate treatment
Not early RA
Fransen (2010)174 Validity of the revised ACR/EULAR
classification criteria for rheumatoid arthritis:
predicting persistent arthritis and joint
erosions after 2 years in patients with early
undifferentiated arthritis
Diagnostic study
Gardiner (2015)175 Estimating under-diagnosis of rheumatoid
arthritis in primary care data from the UK
clinical practice research datalink
Diagnostic study
Garnero (2002)102 Association of baseline levels of urinary
glucosyl-galactosyl-pyridinoline and type II
collagen C-telopeptide with progression of
joint destruction in patients with early
rheumatoid arthritis
No measure of predictive performance
reported
Goronzy (2004)176 Prognostic markers of radiographic
progression in early rheumatoid arthritis
No measure of predictive performance
reported
Graudal (2004)177 The natural history and prognosis of
rheumatoid arthritis: association of
radiographic outcome with process variables,
joint motion and immune proteins
Not eligible risk model with measure
of predictive performance
Graudal (2004)178 Scandinavian Journal of Rheumatology:
preface
No further data to Graudal et al.177
Green (2003)179 Serum MMP-3 and MMP-1 and progression of
joint damage in early rheumatoid arthritis
Limited reporting of predictive
performance
Haji (2012)180 Can sustained remission of rheumatoid
arthritis be predicted? An analysis from the
Japanese national database of rheumatic
disease (NinJa)
Disease duration at baseline not
reported
Haji (2013)181 A prediction rule for sustained remission of
rheumatoid arthritis
Disease duration at baseline not
reported
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Hambardzumyan (2013)182 A multi-biomarker disease activity blood test
(Vectra DA) correlates with radiographic
progression in early rheumatoid arthritis:
results from the SWEFOT trial
Preliminary report of included study.
No further relevant data reported
Hambardzumyan (2013)183 A multi-biomarker disease activity score
correlates with radiographic progression in
early rheumatoid arthritis: results from a
randomised trial
Preliminary report of included study.
No further relevant data reported
Hambardzumyan (2013)184 Multi-biomarker disease activity (MBDA) score
and the 12 individual biomarkers in early
rheumatoid arthritis patients relate
differentially to clinical response and
radiographic progression: results from the
SWEFOT trial
Preliminary report of included study.
No further relevant data reported
Hambardzumyan (2013)185 In early rheumatoid arthritis, the 12 individual
biomarkers that comprise the multiple
biomarker disease activity score relate
differentially to clinical response and
radiographic progression: results
from a randomised trial
Preliminary report of included study.
No further relevant data reported
Harrison (1999)186 The influence of HLA-DRB1 alleles and
rheumatoid factor on disease outcome in an
inception cohort of patients with early
inflammatory arthritis
Study design
Harrison (2001)187 The association of cigarette smoking with
disease outcome in patients with early
inflammatory polyarthritis
Mixed arthritis population (< 80%
were people with RA) and no
subgroup. No measure of predictive
performance reported
Hazes (2011)188 The epidemiology of early inflammatory arthritis Literature review
Heimans 201491 A two-step treatment strategy trial in patients
with early arthritis aimed at achieving
remission: the IMPROVED study
Study design
Hendrikx (2013)189 Moving towards personalized healthcare: a
patient reported outcome based algorithm can
aid rheumatologists and patients in monitoring
rheumatoid arthritis in daily clinical practice
Study design
Hendrikx (2015)190 Monitoring rheumatoid arthritis using an
algorithm based on patient-reported outcome
measures: a first step towards personalised
healthcare
Study design
Hirata (2013)191 A multi-biomarker score measures rheumatoid
arthritis disease activity in the BeSt study
Outcome measurement time point
unclear
Hirata (2016)192 Assessment of disease activity in rheumatoid
arthritis by multi-biomarker disease activity
(MBDA) score
Full text not in the English language
Houssien (1998)193 Rheumatoid factor isotypes, disease activity
and the outcome of rheumatoid arthritis:
comparative effects of different antigens
Not early RA. Study design
James (2004)194 Orthopaedic intervention in early rheumatoid
arthritis. Occurrence and predictive factors in
an inception cohort and 1064 patients
followed for 5 years
Not eligible outcome. Study design
continued
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Jessome (2014)195 Assessing the validity and reliability of a novel
MRI semi-automated algorithm for quantifying
bone loss in the hand
Study design
Jessome (2015)196 Early erosions in rheumatoid arthritis (EERA)
software reliably measures erosive damage on
MRI in the metacarpophalangeal joints of
rheumatoid arthritis patients
Study design
Kaarela (1985)197 Prognostic factors and diagnostic criteria in
early rheumatoid arthritis
Mixed early arthritis population and
diagnostic focus of study
Kapoor (2013)198 The impact of inflammation on metabolomic
profiles in patients with arthritis
Study design
Kastbom (2016)199 Changes in the anticitrullinated peptide
antibody response in relation to therapeutic
outcome in early rheumatoid arthritis: results
from the SWEFOT trial
No measure of predictive performance
Kaufmann (2013)200 Comparison between several prediction scores
and the new EULAR/ACR criteria for diagnosis
and prognosis of rheumatoid arthritis
Study design. Comparison of criteria
for development of RA in early
arthritis cohort
Keller (1999)201 The SF-36 Arthritis-Specific Health Index
(ASHI): II. Tests of validity in four clinical trials
Study design
Kent (2009)202 Analysis of multiple phenotypes Literature review
Kirino (2015)203 Predicting joint destruction in rheumatoid
arthritis with power Doppler, anti-citrullinated
peptide antibody, and joint swelling
Not early RA
Kita (2010)204 MRI-proven bone edema of wrist and finger
joints at entry is the strongest predictor
toward further radiographic progression in
patients with undifferentiated arthritis: results
from the prospective cohort at Nagasaki
university
Insufficient results reported
Knudsen (2008)205 Biomarkers of inflammation in patients with
unclassified polyarthritis and early rheumatoid
arthritis. Relationship to disease activity and
radiographic outcome
Study design
Kojima (2015)206 Patient-reported outcomes as assessment tools
and predictors of long-term prognosis:
a 7-year follow-up study of patients with
rheumatoid arthritis
Not early RA
Kokebie (2010)207 The role of synovial fluid markers of
catabolism and anabolism in osteoarthritis,
rheumatoid arthritis and asymptomatic organ
donors
Study design
Kooloos WM, Huizinga TWJ,
Guchelaar HJ, Klareskog L,
Padyukov L, Wessels JAM,
van Vollenhoven RF. Department
of Clinical Pharmacy and
Toxicology, and Department of
Rheumatology, Leiden University
Medical Center, Leiden,
The Netherlands; 2009
External validation of the clinical
pharmacogenetic model for predicting MTX
monotherapy efficacy using a Swedish cohort
of patients with recent-onset rheumatoid
arthritis
Not eligible outcome
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Krabben (2013)208 Risk of rheumatoid arthritis development in
patients with unclassified arthritis according to
the 2010 ACR/EULAR criteria for rheumatoid
arthritis
Not early RA. Study evaluating
progression to RA in unclassified
arthritis cohort
Kroot (2000)209 The prognostic value of anti-cyclic citrullinated
peptide antibody in patients with recent-onset
rheumatoid arthritis
Limited reporting of predictive
performance
Kvien (2000)210 Data driven attempt to create a clinical
algorithm for identification of women with
rheumatoid arthritis at high risk of
osteoporosis
Not early RA
Lahiri (2014)211 Using lifestyle factors to identify individuals at
higher risk of inflammatory polyarthritis (results
from the European Prospective Investigation of
Cancer-Norfolk and the Norfolk Arthritis
Register-the EPIC-2-NOAR Study)
Not eligible end point. Risk of
developing inflammatory polyarthritis
or RA
Lahiri (2013)212 A risk score to identify individuals at higher
risk of inflammatory polyarthritis: results from
the European prospective investigation of
cancer (Norfolk) and the Norfolk arthritis
register (the EPIC-2-NOAR study)
Not eligible end point. Risk of
developing inflammatory polyarthritis
or RA
Landewe (2007)213 Predictive markers in rapidly progressing
rheumatoid arthritis
Review
Lanfant (2008)214 An algorithm including the intrasynovial
expression of CD20 and serum biomarkers
(rheumatoid factors, anti-CCP2 and
RANK-ligand) able to predict the progression
of bone erosions in very early arthritis
Insufficient details reported
Lanfant-Weybel (2012)215 Synovium CD20 expression is a potential new
predictor of bone erosion progression in very
early arthritis treated by sequential DMARDs
monotherapy – a pilot study from the VErA
cohort
Study design
Lauwerys (2015)216 Heterogeneity of synovial molecular patterns
in patients with arthritis
Study design
Le Loët (2010)217 Serum IgA rheumatoid factor and pyridinoline
in very early arthritis as predictors of erosion(s)
at two years: a simple model of prediction from
a conservatively treated community-based
inception cohort
Study design. Study population:
≤ 80% with RA
Li (2016)218 Relationship of multi-biomarker disease
activity score and other risk factors with
radiographic progression in an observational
study of patients with rheumatoid arthritis
Not early RA
Li (2013)219 Biomarker-based estimates of risk of
radiographic progression in the Leiden early
arthritis cohort
Conference abstract of Li et al.218
Li (2013)220 Impact of a multi-biomarker disease activity
test on rheumatoid arthritis treatment
decisions and therapy use
Not available
Liao (2009)221 Clinical factors that predict erosion-free status
in rheumatoid arthritis
Not early RA
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Liao 2011222 Clinical predictors of erosion-free status in
rheumatoid arthritis: a prospective cohort
study
Available data indicate not early RA
Lillegraven (2013)223 The performance of matrix-based risk models
for rapid radiographic progression in an
observational cohort of established
rheumatoid arthritis patients
External validation cohort not early RA
Lillegraven (2013)95 Performance of matrix-based risk models for
rapid radiographic progression in a cohort of
patients with established rheumatoid arthritis
External validation cohort not early RA
Lindqvist (2002)224 Ten year outcome in a cohort of patients with
early rheumatoid arthritis: health status,
disease process, and damage
Limited reporting of predictive
performance
Lindqvist (2005)225 Prognostic laboratory markers of joint damage
in rheumatoid arthritis
No measure of predictive performance
reported
Linn-Rasker (2007)226 Arthritis of the large joints – in particular, the
knee, at first presentation is predictive for a
high level of radiological destruction of the
small joints in rheumatoid arthritis
No measure of predictive performance
reported
Lisitsyna (2014)227 Factors associated with major depressive
disorder in rheumatoid arthritis patients
No eligible end point
Lisitsyna (2015)228 Depression as a risk factor for joints
destruction in rheumatoid arthritis patients
Insufficient details reported
Liu (2009)229 Prediction of disease severity in patients with
early rheumatoid arthritis by gene expression
profiling
Study design
Løppenthin (2015)230 Physical activity and the association with
fatigue and sleep in Danish patients with
rheumatoid arthritis
Not early RA
Luukkainen (1983)231 The prediction of radiological destruction
during the early stage of rheumatoid arthritis
Not available
Ma (2014)232 Multi-biomarker disease activity score is
associated with Power Doppler ultrasound in
patients with rheumatoid arthritis in low
disease activity state
Duration of RA at baseline not
reported
Ma (2012)233 Biomarker signature in rheumatoid arthritis
patients with low disease activity: the REMIRA
study
Not available
Ma (2011)234 Investigation of a multi-biomarker disease
activity (Vectra DA) signature and algorithm
score in rheumatoid arthritis patients with low
disease activity: the REMIRA study
Not early RA
Ma (2014)235 Clinical and serological predictors of remission
in rheumatoid arthritis are dependent on
treatment regimen
Insufficient reporting of predictive
performance
Ma (2012)236 Remission in early rheumatoid arthritis:
predicting treatment response
No eligible factor included in final
model
Machold (2007)237 Very recent onset rheumatoid arthritis: clinical
and serological patient characteristics
associated with radiographic progression over
the first years of disease
Limited reporting of predictive
performance
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Mamehara (2010)238 Serum matrix metalloproteinase-3 as predictor
of joint destruction in rheumatoid arthritis,
treated with non-biological disease modifying
anti-rheumatic drugs
Not early RA
Mathsson (2008)239 Antibodies against citrullinated vimentin in
rheumatoid arthritis
Not eligible risk model with measure
of predictive performance
Mei (2007)240 Evaluating gene × gene and gene × smoking
interaction in rheumatoid arthritis using
candidate genes in GAW15
Study design
Miller (2013)241 The diagnostic accuracy of rheumatoid factor
testing in primary care
Diagnostic study
Miller (2014)242 Negative rheumatoid factor in primary care
delays referral of patients with rheumatoid
arthritis
Study design
Mierau (2006)243 Diagnosis and prognosis of early rheumatoid
arthritis, with special emphasis on laboratory
analysis
Review
Möller (2014)244 Anaemia may add information to standardised
disease activity assessment to predict
radiographic damage in rheumatoid arthritis:
a prospective cohort study
Duration of symptoms at baseline not
reported for total population but
available data indicate not early RA
Morel (2005)245 How to predict prognosis in early rheumatoid
arthritis
Review
Möttönen (1988)246 Prediction of erosiveness and rate of
development of new erosions in early
rheumatoid arthritis
Limited reporting of predictive
performance
Möttönen (1998)247 Only high disease activity and positive
rheumatoid factor indicate poor prognosis in
patients with early rheumatoid arthritis
No measure of predictive performance
reported
Nakashima (2016)248 Magnetic resonance imaging bone oedema at
enrolment predicts rapid radiographic
progression in patients with early RA: results
from the Nagasaki University early arthritis
cohort
Unclear reporting of predictive
performance
Nell (2005)249 Autoantibody profiling as early diagnostic and
prognostic tool for rheumatoid arthritis
Limited reporting of predictive
performance
Nielen (2005)250 Antibodies to citrullinated human fibrinogen
(ACF) have diagnostic and prognostic value in
early arthritis
Mixed population. Available data
indicate that < 80% of the study
population had RA and no early RA
subgroup
Nishiguchi (2014)251 Self-assessment tool of disease activity of
rheumatoid arthritis by using a smartphone
application
Study design
Nishiguchi (2016)252 Self-assessment of rheumatoid arthritis disease
activity using a smartphone application.
Development and 3-month feasibility study
Study design
Norton (2013)253 Trajectories of functional limitation in early
rheumatoid arthritis and their association with
mortality
No measure of predictive performance
reported
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Norton (2013)254 A study of baseline prevalence and cumulative
incidence of comorbidity and extra-articular
manifestations in RA and their impact on
outcome
Not eligible risk model with measure
of predictive performance
Norton (2014)255 Health Assessment Questionnaire disability
progression in early rheumatoid arthritis:
systematic review and analysis of two
inception cohorts
No measure of predictive performance
Ødegård (2006) 256 Association of early radiographic damage with
impaired physical function in rheumatoid
arthritis: a ten-year, longitudinal observational
study in 238 patients
Not early RA
Papadopoulos (2005)257 Does cigarette smoking influence disease
expression, activity and severity in early
rheumatoid arthritis?
No measure of predictive performance
reported
Park (2011)258 Patterns of radiographic outcomes in early,
seropositive rheumatoid arthritis: a baseline
analysis
Study design
Park (2014)259 Examining radiographic outcomes over time Study design
Plant (1994)260 Measurement and prediction of radiological
progression in early rheumatoid arthritis
Study design
Plant (2000)261 Relationship between time-integrated
C-reactive protein levels and radiologic
progression in patients with rheumatoid
arthritis
No measure of predictive performance
reported
Posthumus (2000)262 Serum matrix metalloproteinase 3 in early
rheumatoid arthritis is correlated with disease
activity and radiological progression
Study design
Putrik (2016)263 Less educated and older patients have
reduced access to biologic DMARDs even in a
country with highly developed social welfare
(Norway): results from Norwegian cohort
study NOR-DMARD
Not an eligible end point
Quinn (2003)264 Prognostic factors in a large cohort of patients
with early undifferentiated inflammatory
arthritis after application of a structured
management protocol
Not early RA
Quinn (2006)265 Anti-CCP antibodies measured at disease
onset help identify seronegative rheumatoid
arthritis and predict radiological and functional
outcome
Limited reporting of predictive
performance
Rech (2016)266 Prediction of disease relapses by
multibiomarker disease activity and
autoantibody status in patients with
rheumatoid arthritis on tapering DMARD
treatment
Not early RA
Rezaei (2012)267 In early rheumatoid arthritis, patients with a
good initial response to methotrexate have
excellent 2-year clinical outcomes, but
radiological progression is not fully prevented:
data from the methotrexate responders
population in the SWEFOT trial
Study design
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Rhodes (2010)268 A genetic association study of serum
acute-phase C-reactive protein levels in
rheumatoid arthritis: implications for clinical
interpretation
Study design
Saevarsdottir (2011)269 Predictors of response to methotrexate in early
DMARD naive rheumatoid arthritis: results
from the initial open-label phase of the
SWEFOT trial
No measure of predictive performance
reported
Saevarsdottir (2011)270 Patients with early rheumatoid arthritis who
smoke are less likely to respond to treatment
with methotrexate and tumor necrosis
factor inhibitors: observations from the
Epidemiological Investigation of Rheumatoid
Arthritis and the Swedish Rheumatology
Register cohorts
No measure of predictive performance
reported
Salaffi (2009)271 A predictive algorithm combining routine
assessment and power Doppler
ultrasonography for the development of
rheumatoid arthritis from an early-onset
undifferentiated arthritis
Not early RA
Scherer (2011)272 Distinct ACPA fine specificities, formed under
the influence of HLA shared epitope alleles,
have no effect on radiographic joint damage
in rheumatoid arthritis
Study design
Scott (2000)273 Prognostic factors in early rheumatoid arthritis Review
Scott (2013)274 Prediction model for rheumatoid arthritis:
modelling 46 genetic risk variants with
smoking
Study design
Semb (2014)275 Development of a transatlantic cardiovascular
risk calculator for rheumatoid arthritis
(ATACC-RA)
Study design
Semb (2015)276 Development of a transatlantic cardiovascular
risk calculator for rheumatoid arthritis
Study design
Shen (2010)277 Serum biomarkers predict progressive
structural damage in the BeSt study
Limited reporting of methods/results
Shen (2015)278 Sparse kernel machine regression for ordinal
outcomes
No measure of predictive performance
reported
Sjoblom (1984)279 Factors related to the progression and joint
destruction in rheumatoid arthritis
Not early RA
Smolen (2006)100 Predictors of joint damage in patients with
early rheumatoid arthritis treated with
high-dose methotrexate with or without
concomitant infliximab: results from the
ASPIRE trial
Study design
Smolen (2013)280 Forget personalised medicine and focus on
abating disease activity
Commentary
Solomon (2015)281 Derivation and internal validation of an
expanded cardiovascular risk prediction score
for rheumatoid arthritis: a Consortium of
Rheumatology Researchers of North America
Registry Study
Not eligible outcome
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Sparks (2013)282 Performance of prediction models for
rheumatoid arthritis serological phenotypes
among women using family history, genetics
and environmental factors
Modelling risk of RA
Stucki (1997)283 Management of rheumatoid arthritis Literature review
Suarez-Almazor (1994)284 Outcome in rheumatoid arthritis. A 1985
inception cohort
Study design
Syversen (2010)285 Prediction of radiographic progression in
rheumatoid arthritis and the role of antibodies
against mutated citrullinated vimentin: results
from a 10-year prospective study
No measure of predictive performance
reported
Tchetverikov (2003)286 Matrix metalloproteinases-3, -8, -9 as markers
of disease activity and joint damage
progression in early rheumatoid arthritis
No measure of predictive performance
reported
Teitsson (1984)287 Prospective study of early rheumatoid arthritis.
I. Prognostic value of IgA rheumatoid factor
No measure of predictive performance
reported
Ting (2008)288 Development of a health care utilisation
data-based index for rheumatoid arthritis
severity: a preliminary study
Duration of symptoms at baseline not
reported. Not an eligible outcome
Tobón (2013)289 First-year radiographic progression as a
predictor of further progression in early
arthritis: results of a large national French
cohort
≤ 80% of the study population had
RA and no early RA subgroup
available
Uhlig (2000)290 The course of rheumatoid arthritis and
predictors of psychological, physical and
radiographic outcome after 5 years of
follow-up
Does not meet early RA definition
van Beers-Tas (2015)291 How does established rheumatoid arthritis
develop, and are there possibilities for
prevention?
Literature review
van den Broek (2013)292 The clinical relevance of rapid radiological
progression in the first year of treatment
during 8 years of follow-up of early
rheumatoid arthritis patients
Conference abstract. Appears to be
linked with van den Broek et al.293
van den Broek (2012)293 Rapid radiological progression in the first year
of early rheumatoid arthritis is predictive of
disability and joint damage progression during
8 years of follow-up
Study design
van der Heijde (1992)294 Prognostic factors for radiographic damage
and physical disability in early rheumatoid
arthritis. A prospective follow-up study of
147 patients
Limited reporting of predictive
performance
van der Heide (1995)295 Prediction of progression of radiological
damage in newly diagnosed rheumatoid
arthritis
Limited reporting of predictive
performance
van der Helm-van Mil (2005)296 Antibodies to citrullinated proteins and
differences in clinical progression of
rheumatoid arthritis
Study design
van der Helm-van Mil (2008)297 Validation of a prediction rule for disease
outcome in patients with recent-onset
undifferentiated arthritis: moving towards
individualised treatment decision-making
Not early RA
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
van der Helm-van Mil (2010)298 Genetic variants in the prediction of
rheumatoid arthritis
Modelling risk of RA
van der Helm-van Mil (2013)299 An evaluation of molecular and clinical
remission in rheumatoid arthritis by assessing
radiographic progression
Measure of predictive performance
not appropriate to review question
van Jaarsveld (1999)300 The prognostic value of the antiperinuclear
factor, anti-citrullinated peptide antibodies
and rheumatoid factor in early rheumatoid
arthritis
Limited reporting of predictive
performance
van Nies (2015)301 Evaluating processes underlying the predictive
value of baseline erosions for future
radiological damage in early rheumatoid
arthritis
No measure of predictive performance
van Steenbergen (2013)302 Anaemia to predict radiographic progression
in rheumatoid arthritis
No measure of predictive performance
reported
van Zeben (1991)303 Association of HLA-DR4 with a more
progressive disease course in patients with
rheumatoid arthritis
Study design
van Zeben (1993)304 Factors predicting outcome of rheumatoid
arthritis: results of a follow up study
Symptom duration at baseline unclear
Varache (2011)305 Diagnostic accuracy of ACR/EULAR 2010
criteria for rheumatoid arthritis in a 2-year
cohort
Study design
Vastesaeger (2008)94 Matrix risk model for prediction of rapid
radiographic progression in rheumatoid
arthritis
Preliminary report of included study.
No further relevant data reported
Versteegh (2010)306 Mapping onto Eq-5 D for patients in poor
health
Study design
Vesperini (2013)307 Association of tobacco exposure and
reduction of radiographic progression in early
rheumatoid arthritis: results from a French
multicentre cohort
No measure of predictive performance
reported
Visser 2002308 How to diagnose rheumatoid arthritis early: a
prediction model for persistent (erosive)
arthritis
Study design. Mixed early arthritis
population
Visser (2009)309 The BeSt matrix model in recent-onset
rheumatoid arthritis patients: individual
prediction of rapid radiographic progression
and numbers-needed-to-treat with initial
combination therapy
Preliminary report of included study.
No further relevant data reported
Visser (2009)310 The clinical relevance of a prediction rule for
disease outcome in patients with
undifferentiated arthritis: comment on the
article by van der Helm-van Mil et al.
Letter to editor
Visvanathan (2007)311 Changes in biomarkers of inflammation and
bone turnover and associations with clinical
efficacy following infliximab plus methotrexate
therapy in patients with early rheumatoid
arthritis
No measure of predictive performance
reported
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TABLE 21 Review 1 excluded full-text studies with rationale (continued )
First author
(date of publication) Title of publication Justification for exclusion
Wessels (2007)312 A clinical pharmacogenetic model to predict
the efficacy of methotrexate monotherapy in
recent-onset rheumatoid arthritis
Not an eligible outcome. DAS not
DAS28 (borderline exclusion)
Westedt (1986)313 Serum immune complexes containing IgA
appear to predict erosive arthritis in a
longitudinal study in rheumatoid arthritis
No measure of predictive performance
reported
Weyand (1992)314 The influence of HLA-DRB1 genes on disease
severity in rheumatoid arthritis
Not early RA
Widdifield (2013)315 Accuracy of Canadian health administrative
databases in identifying patients with
rheumatoid arthritis: a validation study using
the medical records of rheumatologists
Study design
Wolfe (1998)316 Radiographic outcome of recent-onset RA: a
19-year study of radiographic progression
Limited reporting of predictive
performance
Wolfe (2000)317 A reappraisal of HAQ disability in rheumatoid
arthritis
Study design. No measure of
predictive performance reported
Wolfe (2000)318 The effect of smoking on clinical, laboratory,
and radiographic status in rheumatoid arthritis
Not early RA
Wong (2004)319 Development and evaluation of a patient self-
report case-finding method for rheumatoid
arthritis
Study design
Yamanaka (2000)320 Serum matrix metalloproteinase 3 as a
predictor of the degree of joint destruction
during the six months after measurement, in
patients with early rheumatoid arthritis
Study design. No measure of
predictive performance reported
Young (1987)321 A prospective study of early onset rheumatoid
arthritis over fifteen years: prognostic features
and outcome
Limited reporting of predictive
performance
Young (1988)322 A prognostic index for erosive changes in the
hands, feet and cervical spines in early
rheumatoid arthritis
Limited reporting of predictive
performance
Young (1997)323 Can we predict aggressive disease? Review
Young (2000)324 Socioeconomic deprivation and rheumatoid
disease: what lessons for the health service?
No measure of predictive performance
reported
Young-Min (2007)325 Biomarkers predict radiographic progression in
early rheumatoid arthritis and perform well
compared with traditional markers
No eligible factor included in baseline
model for radiographic progression.
Longitudinal model time frame
outside 2-year early RA definition
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Appendix 5 Additional calculations for
data extractions
Obtaining estimates of logit(C) and standard error
External validation studies that reported the c-statistic were considered. The logit transform is used to
put the reported value on a suitable scale for analysis. Granger et al.82 and Heimans et al.84 report the
associated CIs that can be used to obtain the standard error as follows:
n
½logit(Cub)− logit(C lb) / (2 × 1.96)
2
o2
. (14)
No appropriate estimates of uncertainty are provided in the De Cock et al.80 validation, but the standard
error was approximated from the total number of observed events, expected events and the sample size,
as described in Debray et al.40 (Appendix 6):
Var(logit(C))≈
1 +
s* (1−c)
2−c
+
s*c
1 + c
O(N−O)c(1−c)
, (15)
in which O is the total number of observed events, N is the total sample size and:
s*=
N
2
−1. (16)
Calculating the expected number of events
When possible, the expected number of events was calculated for each risk model evaluated in each
external validation population. Here, we give an example of calculating the number of expected events for
one risk model only, the Syversen model,76 chosen as it has a smaller number of risk categories than other
externally validated risk models.
For each risk category, the PR is provided in the published risk development study. The number of
individuals in the external validation study who are assigned to each risk category (N) is provided in the
external validation study (De Cock et al.80 in this example). The expected number of events in each risk
category (E) is computed by multiplying the PR and the number of individuals. The total number of
expected events is then found by summing these expected numbers over all risk categories (Table 22).
Calculating distribution of linear predictor (case mix)
For each risk category, the PR is provided in the published risk development study and the number of
individuals in the external validation study who are assigned to each risk category (N) is provided in the
external validation study. These can be used to work out the distribution of risks (Figures 8 and 9).
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TABLE 22 Calculation of expected number of events for the Syversen risk model in the De Cock et al.80 external
validation population
Risk category PR
De Cock et al.80 population
N E O
1 0.0928 0 0 0
2 0.2535 1 0.2535 0
3 0.2891 0 0 0
4 0.5744 2 1.1488 1
5 0.2460 5 1.23 1
6 0.5200 5 2.6 0
7 0.5646 3 1.6938 0
8 0.8115 5 4.0575 0
9 0.2387 1 0.2387 0
10 0.5100 4 2.04 1
11 0.5548 6 3.3288 0
12 0.8053 9 7.2477 0
13 0.5000 1 0.5 0
14 0.7685 4 3.074 0
15 0.7990 10 7.99 1
16 0.9296 17 15.8032
Total 73 51.206 4
E, expected number of events; N, number of events; O, total number of observed events.
Note
O : E is 0.078.
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FIGURE 8 Distribution of linear predictor (case mix) for risk models in the De Cock et al.80 external validation
population. (a) ASPIRE CRP; (b) ASPIRE ESR; (c) BeSt; (d) ESPOIR; (e) SWEFOT 2; and (f) Syversen. (continued )
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
220
(c)
0
0
5
10
25
20
15
Mean = 20.59
SD = 16.83
10 20 4030
Risk score (%)
F
re
q
u
e
n
cy
50 7060 0
0
5
10
25
20
15
Mean = 17.86
SD = 11.43
10 20
Risk score (%)
F
re
q
u
e
n
cy
30 40
(d)
(e)
10
0
5
10
20
15
Mean = 26.8
SD = 14.31
20 30 40
Risk score (%)
F
re
q
u
e
n
cy
6050 70 20
0
5
10
20
15
Mean = 70.15
SD = 21.01
40 60
Risk score (%)
F
re
q
u
e
n
cy
80 100
(f)
FIGURE 8 Distribution of linear predictor (case mix) for risk models in the De Cock et al.80 external validation
population. (a) ASPIRE CRP; (b) ASPIRE ESR; (c) BeSt; (d) ESPOIR; (e) SWEFOT 2; and (f) Syversen.
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FIGURE 9 Distribution of linear predictor (case mix) for the BeSt models in Heimans et al.84 external validation
population.
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Calculating risk probabilities for the Syversen model
The final risk model provided in Syversen et al.76 is given as:
log
p
1−p
 
= −2.28 + 1.38IantiCCP+ ve + 1.20 × Ifemale + 1.16 × IhighESR + 1.12 × IRF + ve. (17)
This results in the following risk matrix, which provides the risks for each combination of factors (Table 23).
TABLE 23 Risk matrix for Syversen et al.76
RF status ESR
ACPA status
ACPA– ACPA+
Male Female Male Female
RF positive High 0.5 0.7685 0.799 0.9296
Low 0.2387 0.51 0.5548 0.8053
RF negative High 0.246 0.52 0.5646 0.8115
Low 0.0928 0.2535 0.2891 0.5744
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive.
Note
Blue, 90%; light green, 80%; light blue, 50%; dark green, 20%; dark blue, 10%.
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Appendix 6 Quality assessment results for
Prediction model study Risk Of Bias Assessment
Tool domains 1, 2 and 3 (review 1)
Prediction model study Risk Of Bias Assessment Tool domain 1:
participant selection
TABLE 24 Domain 1A: risk of bias (prediction model development studies)
Name of risk model
Were appropriate
data sources used?
Were all inclusions and
exclusions of participants
appropriate?
Risk of bias introduced
by the selection of
participants
ASPIRE78 Y Y Low
Bansback58 Y Y Low
Berglin59 Y Y Low
BeSt79 Y Y Low
Brennan60 Y Y Low
Centola61 Y Y Low
Combe (A)62 Y Y Low
Combe (B)63 Y Y Low
de Punder64 Y Y Low
de Vries-Bouwstra65 Y Y Low
Degboé66 Y Y Low
Dirven67 Y Y Low
Dixey68 Y Y Low
Drossaers-Bakker56 Y PYa,b Unclear
ESPOIR69 Y Y Low
Forslind70 Y Y Low
Graell71 Y Y Low
Houseman72 Y Y Low
Sanmartí75 Y Y Low
SONORA57 Y NIb Unclear
SWEFOT73 Y Y Low
Syversen76 Y PYc Unclear
van Steenbergen77 Y Y Low
NI, no information; PY, probably yes; Y, yes.
a Females only recruited.
b Method of RA diagnosis is unclear.
c Permitted disease duration up to 4 years.
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Prediction model study Risk Of Bias Assessment Tool domain 1:
participant selection
TABLE 25 Domain 1A: risk of bias (external validation studies)
First author of external
validation study
Were appropriate data
sources used?
Were all inclusions and
exclusions of participants
appropriate?
Risk of bias introduced
by the selection of
participants
De Cock80 Y PYa Unclear
Granger82 Y Y Low
Hambardzumyan83 Y Y Low
Heimans84 Y PYb Unclear
Markusse85 Y Y Low
PY, probably yes; Y, yes.
a Method of RA diagnosis is unclear.
b c-Statistic was apparently reported for a mixed RA/undifferentiated arthritis population. Therefore, the data in this trial
relate to a mixed early arthritis population.
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Prediction model study Risk Of Bias Assessment Tool domain 2: predictors
TABLE 26 Domain 2A: risk of bias (prediction model development studies)
Name of risk model
Were predictors defined
and assessed in a similar
way for all participants?a
Were predictor
assessments made
without knowledge of
outcome data?b
Were all (final) predictors
available at the time at
which the model was
intended to be used?
Were all relevant predictors analysed
(i.e. all selected prognostic factors
analysed as candidate predictors)?
Risk of bias
introduced by
predictors or
their assessment
(low/high/unclear)c
ASPIRE78 PY Y Y No ACPA status, DAS28, smoking status,
HAQ score or early RA untreated for
≥ 12 weeks following the onset of
symptoms
Unclear
Bansback58 PY Y PY (dependent on availability
of the Carstairs index)
No ACPA status, CRP levels or smoking
status
Unclear
Berglin59 PY Y Y No early RA untreated for ≥ 12 weeks
following the onset of symptoms, HAQ
score or smoking status
Unclear
BeSt79 PY Y Y No DAS28 (DAS only) Low
Brennan60 PY Y Y No ACPA status, erosions/joint damage on
radiographic analysis, smoking status, ESR
or DAS28
Unclear
Centola61 PY PY PY [dependent on the
availability of biomarker
assay(s)]
Biomarker tests only Uncleard
Combe (A)62 PY Y PY (dependent on the
availability of SE testing)
No ACPA status, DAS28 or smoking status Unclear
Combe (B)63 PY Y Y No ACPA status, DAS28 or smoking status Unclear
de Punder64 PY Y Y No early RA untreated for ≥ 12 weeks
following the onset of symptoms or HAQ
score
Unclear
de Vries-Bouwstra65 PY Y PY (dependent on the
availability of SE testing)
No ACPA status, CRP levels, DAS28 or
smoking status
Unclear
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TABLE 26 Domain 2A: risk of bias (prediction model development studies) (continued )
Name of risk model
Were predictors defined
and assessed in a similar
way for all participants?a
Were predictor
assessments made
without knowledge of
outcome data?b
Were all (final) predictors
available at the time at
which the model was
intended to be used?
Were all relevant predictors analysed
(i.e. all selected prognostic factors
analysed as candidate predictors)?
Risk of bias
introduced by
predictors or
their assessment
(low/high/unclear)c
Degboé66 PY Y PY (dependent on the
availability of anti-MCV,
AhFibA testing)
No SJC, ESR, DAS28, smoking status or
HAQ score
Unclear
Dirven67 PY Y Y No DAS28 (DAS only) Low
Dixey68 PY Y Y No ACPA status, CRP levels, DAS28 or
smoking status
Unclear
Drossaers-Bakker56 PY Y PY (alternative models
provided with available
predictors)
No ACPA status, CRP levels, DAS28 or
smoking status
Unclear
ESPOIR69 PY Y Y No smoking status Low
Forslind70 PY Y Y No SJC, smoking status or early RA
untreated for ≥ 12 weeks following the
onset of symptoms
Unclear
Graell71 PY Y Y No smoking status Low
Houseman72 PY PY (anti-CCP measured at
8.2 years)
PY (dependent on the
availability of MMP-3
testing)
No SJC, DAS28, smoking status, HAQ score
or early RA untreated for ≥ 12 weeks
following the onset of symptoms
Unclear
Sanmartí75 PY Y PY (dependent on the
availability of HLA-DRB1*04
test)
Assumed same as for Graell et al.71 and,
therefore, no smoking status
Low
SONORA57 NI Y Y NI Unclear
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Name of risk model
Were predictors defined
and assessed in a similar
way for all participants?a
Were predictor
assessments made
without knowledge of
outcome data?b
Were all (final) predictors
available at the time at
which the model was
intended to be used?
Were all relevant predictors analysed
(i.e. all selected prognostic factors
analysed as candidate predictors)?
Risk of bias
introduced by
predictors or
their assessment
(low/high/unclear)c
SWEFOT73 PY Y Y Y Low
Syversen76 PY Y Y No SJC, DAS28, smoking status or early RA
untreated for ≥ 12 weeks following the
onset of symptoms
Unclear
van Steenbergen77 PY Y PY (dependent on the
availability of genetic tests)
No erosions at baseline, CRP levels, DAS28,
smoking status or HAQ score
Unclear
NI, no information; PY, probably yes; Y, yes.
a If not reported (but there was no evidence to the contrary), it was rated as ‘probably yes’.
b If the predictors measured at baseline and the outcomes at a subsequent time point were rated as ‘yes’.
c Rated as being unclear if two or more key candidate predictors of interest were not assessed (as the potential contribution of untested predictors to the final model is unknown).
d Although the study design focused on the inclusion of biomarkers only, the potential contribution of other characteristics of interest to the final model is unclear.
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Prediction model study Risk Of Bias Assessment Tool domain 3: outcomes
TABLE 27 Domain 2A: risk of bias (external validation studies)
First author of
external validation
study
Were predictors defined
and assessed in a similar
way for all participants?a
Were predictor assessments
made without knowledge of
the outcome data?b
Risk of bias introduced by
predictors or their assessment
(low/high/unclear)
De Cock80 PY Y Low
Granger82 PY Y Low
Hambardzumyan83 PY Y Low
Heimans84 PY Y Low
Markusse85 PY Y Low
PY, probably yes; Y, yes.
a If this is not reported, but there is no evidence to the contrary, then it is rated as ‘probably yes’.
b If the predictors measured at baseline and the outcomes at a subsequent time point are rated as ‘yes’.
TABLE 28 Domain 3A: risk of bias (prediction model development studies)
Name of risk
model
Was a prespecified
outcome definition
used?a
Was the outcome
defined and determined
in a similar way for all
participants?b
Was the outcome
determined without
knowledge of
predictor information?
Risk of bias introduced
by outcome or its
determination
(low/high/unclear)
ASPIRE78 Y PY PY Low
Bansback58 PY PY NI Unclear
Berglin59 PY PY Y Low
BeSt79 Y PY PY Low
Brennan60 PY PY NI Unclear
Centola61 PY PY NI Unclear
Combe (A)62 Y PY Y Low
Combe (B)63 PY PY NI Unclear
de Punder64 Y PY NI Unclear
de Vries-
Bouwstra65
PY PY Y Low
Degboé66 PY PY Y Low
Dirven67 Y PY PY Low
Dixey68 PY PY NI Unclear
Drossaers-
Bakker56
PY PY NI Unclear
ESPOIR69 Y PY Y Low
Forslind70 PY PY Y Low
Graell71 PY PY NI Unclear
Houseman72 PY PY PY Low
Sanmartí75 Y PY NI Unclear
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TABLE 28 Domain 3A: risk of bias (prediction model development studies) (continued )
Name of risk
model
Was a prespecified
outcome definition
used?a
Was the outcome
defined and determined
in a similar way for all
participants?b
Was the outcome
determined without
knowledge of
predictor information?
Risk of bias introduced
by outcome or its
determination
(low/high/unclear)
SONORA57 PY PY NI Unclear
SWEFOT73 Y PY NI Unclear
Syversen76 PY PY Y Low
van
Steenbergen77
PY PY Y Low
NI, no information; PY, probably yes; Y, yes.
a If a clear justification is given for the definition of the outcome, it is rated as ‘yes’. If it is not reported, but there is no
evidence to the contrary, it is rated as ‘probably yes’.
b If it is not reported, but there is no evidence to the contrary, it is rated as ‘probably yes’.
TABLE 29 Domain 3A: risk of bias (external validation studies)
Name of
external
validation study
Was a prespecified
outcome definition
used?a
Was the outcome
defined and determined
in a similar way for all
participants?b
Was the outcome
determined without
knowledge of
predictor information?
Risk of bias introduced
by outcome or its
determination
(low/high/unclear)
De Cock80 Y PY NI Unclear
Granger82 Y PY Y (blinded to clinical
evaluation)
Low
Hambardzumyan83 Y PY NI Unclear
Heimans84 Y PY PY (blinded to patient
identity)
Lowc
Markusse85 PY PY PY (blinded to patient
identity)
Low
NI, no information; PY, probably yes; Y, yes.
a If a clear justification is given for the definition of the outcome, it is rated as ‘yes’. If it is not reported, but there is no
evidence to the contrary, it is rated as ‘probably yes’.
b If it is not reported, but there is no evidence to the contrary, it is rated as ‘probably yes’.
c Note that the predicted outcome applied in the external validation differed from that in the original model
development paper.
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TABLE 30 Additional baseline population characteristics of the included risk prediction model development
and external validation studies
Name of risk
model/external
validation study
(number of baseline
characteristics
reported)
Characteristic
Age Sex HAQ score
Radiographic joint
damage ACPA/anti-CCP status
Risk model development studies
ASPIRE78
(n= 1049)
Median age: 51 years
(IQR 41–60 years)
71.1% female Median (scale 0–3):
1.5 (IQR 1.0–1.9)
Median total modified SHS:
5.0 (IQR 1.5–14.0)
82% (n= 854) of patients
with joint erosion
65.9% (n= 687) of patients
with JSN
0.3% of patients (n= 3)
with prior joint surgery
NR
Bansback58
(n= 985, NR across total
sample)
Aged 17–93 years at
disease onset (median
55 years, IQR NR)
Female: n= 654
(66%)
Median: 1.00
(IQR NR)
n= 241 (24%) had erosions
at baseline
NR
Berglin59 NR [mean age at onset of
symptoms was 54 years
(range 23–73 years)]
NR NR NR Anti-CCP: 74.8%
BeSt79
(Reported for 465/508;
NR for whole sample,
reported by treatment
group)
Mean age: 54 years across
groups (SD 13–14 years)
Female sex:
66–70% across
groups (SD
66–70%)
HAQ score of 1.4
across groups
(0.6 to 0.7)
Median erosions: 1.8–2.0
across groups (IQR 0.5–4.5)
Total median SHS: 3.3–4.0
across groups (IQR 1.5–8.5)
ACPA+: 55–64%
Brennan60
(Total population,
n= 175)
18–51 years: 32%
52–66 years: 34%
> 66 years: 34%
71% female HAQ score ≥ 1
(scale 0–3): 59%
NR NR
Centola61
(Feasibility studies I–IV,
n= 652; algorithm
training study stage 3,
n= 249 samples)
Feasibility studies I–IV
(stage 2), mean age:
59 years
Algorithm training study
(stage 3), median age:
58 years (IQR 49–67 years)
Feasibility studies
I–IV (stage 2):
77–91% female
Algorithm training
study (stage 3):
75% female
Feasibility studies
I–IV (stage 2): NR
Algorithm training
study (stage 3): NR
Feasibility studies I–IV
(stage 2): NR
Algorithm training study
(stage 3): NR
Feasibility studies I–IV
(stage 2): 61–63%
CCP positive
Algorithm training study
(stage 3): 58% anti-CCP
positive
Combe A62
(n= 191)
Mean age at diagnosis:
50.5 years (SD 14.7 years)
73.3% female Mean: 1.3 (SD 0.7) Mean Sharp score: 3.6
(SD 7.7)
NR
Combe B63
(n= 191)
Mean age: 50.5 years
(SD 14.7 years)
73% female NR
Mean: 1.3 (range
0–2.75)
NR
Erosion score, mean: 1.7
(range 0–33.0)
NR
de Punder64
(n= 425; NR for total
group)
Mean age:
l Joint damage
progressors: 54 years
(SD 14 years)
l Non-progressors:
57 years (SD 14 years)
Joint damage
progressors: 59%
Non-progressors:
66%
NR Erosions:
l Joint damage
progressors: 62%
l Non-progressors: 32%
Anti-CCP positive:
l Joint damage
progressors: 82%
l Non-progressors
mean: 53%
de Vries-Bouwstra65
(n= 152)
Median age: 66 years
(IQR 55–76 years)
68% female NR Patients with erosions in
hands or feet: 57 (38%)
NR
Degboé66
(n= 566)
Median age: 50.5 years
(IQR 40.2–57.0 years)
78.6% female NR mTSS, median: 3 (IQR 0–7) ACPA+: 333
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RF status SJC TJC ESR CRP level Smoking status
Median:= 175U/ml
(IQR 30–357U/ml)
Median: 19
(IQR 14–26)
Median: 31
(IQR 22–44)
Median: 40mm/hour
(IQR 23–61mm/hour)
Median:1.4mg/dl
(IQR 0.4–4.1mg/dl)
NR
74% (n= 730) of
patients were
seropositive at baseline
NR NR NR NR NR
IgM RF: 85.7%
IgA RF: 78.6%
IgG RF: 46.8%
NR NR NR NR NR
RF positive: 62.66% Median: 13–14 across
groups
Median: 11–14 Median: 35–38mm/hour
across groups
Median: 21–22mg/l
across groups
NR
NR NR NR NR NR NR
Feasibility studies I–IV
(stage 2): 64–97%
positive
Algorithm training study
(stage 3): 61% positive
Feasibility studies I–IV
(stage 2), median SJC28:
2.0 (IQR 0.0–10) to 16
(IQR 12–21)
Algorithm training study
(stage 3), median: 4
(IQR 0–17)
Feasibility studies I–IV
(stage 2), median TJC28:
2.0 (IQR 0–8.3) to 12
(IQR 4.8–20)
Algorithm training study
(stage 3), median: 5
(IQR 0–18)
Feasibility studies I–IV
(stage 2): NR
Algorithm training study
(stage 3): NR
Feasibility studies I–IV
(stage 2), median:
14mg/l (IQR
4.0–32mg/l) to
18mg/l (IQR
6.9–47mg/l)
Algorithm training
study (stage 3),
median: 3.8mg/l
(IQR 1.3–20.5mg/l)
Feasibility studies
I–IV (stage 2): NR
Algorithm training
study (stage 3): NR
RF positive: 80.6%
IgM RF: 68.0%
IgA RF: 75.4%
Mean: 9
(SD 5.9)
Mean: 21
(SD 10)
Mean: 40.2mm/hour
(SD 28.5mm/hour)
Mean: 34.1mg/l
(SD 43.2mg/l)
NR
IgA or IgM RF positive:
80.8%
Mean: 9.0
(SD 5.9)
Mean: 21.7
(SD 10.5)
Mean: 40.2mm/hour
(SD 28.5mm/hour)
Mean: 34.1mg/l
(SD 43.2mg/l)
NR
RF positive:
l Joint damage
progressors: 87%
l Non-progressors:
66%
SJC28:
l Joint damage
progressors, median:
11 (IQR 7–16)
l Non-progressors,
median: 10 (IQR 6–14)
TJC28:
Joint damage
progressors, median:
7 (IQR4–13)
Non-progressors,
median: 6 (IQR 2–12)
Joint damage progressors,
median: 40mm/hour
(IQR 21–59mm/hour)
Non-progressors,
median: 21mm/hour
(IQR 9–38mm/hour)
Joint damage
progressors, median:
22mg/l (IQR
7–52mg/l)
Non-progressors,
median: 3mg/l
(IQR 0–23mg/l)
Smoker status (ever):
l Joint damage
progressors:
72%
l Non-progressors:
67%
IgM RF positive: 93
(61%)
Median number swollen
joints: 6 (IQR 4–8)
NR NR NR NR
RF positive: 54.2% NR NR Median: 22mm/hour
(IQR 12–37mm/hour)
Median: 9mg/l
(IQR 0–21mg/l)
Smokers: 48.1%
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TABLE 30 Additional baseline population characteristics of the included risk prediction model development
and external validation studies (continued )
Name of risk
model/external
validation study
(number of baseline
characteristics
reported)
Characteristic
Age Sex HAQ score
Radiographic joint
damage ACPA/anti-CCP status
Dirven67
(NR for total group;
MTX mono, n= 239;
combination and
prednisone, n= 131;
combination and IFX,
n= 127)
Mean age:
l MTX monotherapy:
54 years (SD 13 years)
l Combination and
prednisone: 55 years
(SD 14 years)
l Combination and IFX:
54 years (SD 14 years)
MTX monotherapy:
70%
Combination and
prednisone: 66%
Combination and
IFX: 66%
Mean: 1.4 (SD
0.6–0.7) across
groups
Median total SHS:
l MTX monotherapy: 4.0
(IQR 1.5–8.8)
l Combination and
prednisone: 3.5
(IQR 1.5–8.5)
l Combination and IFX:
4.0 (IQR 1.5–8.8)
Erosive (≥ 1):
l MTX
monotherapy: 71%
l Combination and
prednisone: 71%
l Combination and
IFX: 73%
ACPA positive:
l MTX
monotherapy: 63%
l Combination and
prednisone: 55%
l Combination and
IFX: 66%
Dixey68
(n= 866)
l Age at onset:
< 45 years, 24%
l 45–60 years, 40%
l > 60 years, 36%
66% female NR Erosion score:
l 0, 68%
l 1, 11%
l > 1, 21%
NR
Drossaers-Bakker56
(n= 112)
Mean age: 37 years
(SD 8.4 years)
100% female Median: 0.75 (IQR
NR) (range 0–2.88)
Median SHS: 12 (IQR NR)
Presence of erosions: 22%
NR
ESPOIR69
(n= 370)
Mean age: 49.4 years
(SD 11.4 years)
73.2% female Mean HAQ score:
1.03 (SD 0.7)
18% with typical RA erosion
on radiographs
Mean vSHS 6.02 (SD 9.7)
ACPA positivity: 50%
Forslind70
(n= 379)
Median age: 55 years
(IQR 45–67 years)
65% female HAQ score (scale
0–3), median: 0.90
(IQR 0.50–1.38)
Larsen score scale range
(0–200), median: 4
(IQR 0–10)
NR
Graell71
(n= 105)
Mean age: 55 years
(SD 14.9 years)
81% female MHAQ, mean
score: 0.97
(SD 0.56)
Larsen score, mean: 1.2
(SD 2.7)
Anti-CCP positive: 70.4%
Houseman72
(n= 58)
Mean age: 53 years
(SD 11 years)
64% female Median: 1.4
(IQR 0.9–2.1)
Larsen score, median: 1
(IQR 0–2.5)
NR
Sanmartí75
(n= 105)
Mean age: 55 years
(SD 14.9 years)
81% female MHAQ, mean
score: 1 (SD 0.6)
Larsen score, mean: 1.2
(SD 2.7)
Erosion joint count, mean:
0.4 (SD 0.9)
Anti-CCP positive: 70.4%
SONORA57 (n= 994) Mean age: 53 years
(SD 14.81 years)
72% female NR Sharp score, mean: 5.49
(SD 7.85) (n= 746)
NR
SWEFOT73
(n= 269)
Median age: 57 years
(IQR 46–63 years)
28% male HAQ score: 1.1
(IQR 0.9–1.6)
SHS, median: 2 (IQR 0–6)
JSN score, median: 0
(IQR 0–3)
Erosion score, median: 0
(IQR 0–2), 42% erosions
Anti-CCP positive: 62%
Syversen76
(n= 238)
Mean age: 51.9 years
(SD 13.0 years)
73.5% female Mean: 0.9
(SD 0.6)
Erosive disease: 55.2% Anti-CCP positive: 60.5%
van Steenbergen77
(n= 426)
Mean age : 56.6 years
(SD 15.3 years)
68.1% female NR SHS, median: 5.0
(IQR 2.0–10.0)
ACPA+: 53.3%
RF status SJC TJC ESR CRP level Smoking status
RF positive:
l MTX
monotherapy: 65%
l Combination and
prednisone: 65%
l Combination and
IFX: 64%
l Median: MTX
monotherapy: 14
(IQR 10–20)
l Combination and
prednisone: 14
(IQR 10–18)
l Combination and IFX:
13 (IQR 9–17)
Median:
l MTX monotherapy:
22 (IQR 14–31)
l Combination and
prednisone: 22
(IQR 13–33)
l Combination and
IFX: 19 (IQR 12–22)
Median:
l MTX monotherapy:
38mm/hour (IQR
21–58mm/hour)
l Combination
and prednisone:
35mm/hour (IQR
17–45mm/hour)
l Combination and IFX:
36mm/hour (IQR
19–58 mm/hour)
Median:
l MTX
monotherapy:
22mg/l
(9–59mg/l)
l Combination
and
prednisone:
21mg/l
(10–57mg/l)
l Combination
and IFX: 21mg/l
(7–44mg/l)
Smoking status
(yes/no):
l MTX
monotherapy:
39%
l Combination
and
prednisone:
34%
l Combination
and IFX: 32%
RF negative: 27% NR NR NR NR NR
RF positive: 55% Median: 3.5 (IQR NR) NR Median: 27 mm/hour
(IQR NR)
NR NR
IgM RF positivity: 55.1% Mean SJC28: 7.9 (SD 5.4) Mean TJC28: 8.7
(SD 6.9)
Mean ESR: 32.7mm/first
hour (SD 25mm/first hour)
Mean CRP level:
24.8mg/l
(SD 37.7mg/l)
NR
RF positive: 61% NR NR Median: 29mm/hour
(IQR 14–50mm/hour)
Median: 19mg/l
(IQR 6–43mg/l)
Current/previous
smoker: 60%
RF positive: 73.3% SJC28, mean: 8.3 (SD 4.1) TJC28, mean: 10.1
(SD 5.9)
Mean: 39.5mm/hour
(SD 24.5mm/hour)
Mean: 2.8mg/dl
(SD 2.9mg/dl)
NR
RF positive: 77% Median: 9 (IQR 4–14) Median: 15 (IQR 6–18) Median: 28mm/hour
(IQR 14–45mm/hour)
Median: 17mg/l
(IQR 5–40mg/l)
NR
RF positive: 74.3% SJC28, mean: 8.3 (SD 4.1) TJC28, mean: 10.1
(SD5.9)
Mean: 39.6mm/hour
(SD 24.5mm/hour)
Mean: 2.8mg/dl
(SD 2.9mg/dl)
NR
NR NR NR NR NR NR
RF positive: 67%
RF and ACPA+: 49%
SJC28, median: 10
(IQR 6–14)
TJC28, median: 8
(IQR 5–13)
Median: 34mm/hour
(IQR 22–54mm/hour)
CRP level, median:
19mg/l
(IQR 9–47mg/l)
Current smokers:
24%
Past smokers: 37%
Never smoked: 39%
IgA RF positive: 37.8%
IgM RF positive: 47.9%
NR NR Median: 20.5mm/hour
(IQR 10.0–36.0mm/hour)
Median: 5.3mg/l
(IQR 1.7–13.8mg/l)
NR
IgM RF positive: 58.2% SJC66, median: 8
(IQR 4–14)
NR Median: 33.0mm/hour
(18.0–55.0mm/hour)
NR NR
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TABLE 30 Additional baseline population characteristics of the included risk prediction model development
and external validation studies (continued )
Name of risk
model/external
validation study
(number of baseline
characteristics
reported)
Characteristic
Age Sex HAQ score
Radiographic joint
damage ACPA/anti-CCP status
External validation studies
De Cock80
(n= 74)
Mean age: 52 years
(SD 16 years)
65% female Mean HAQ score
(scale 0–3): 1.10
(SD 0.76)
NR ACPA+: 71%
Granger82
(n= 370)
Mean age: 49.4 years
(SD 11.4 years)
73.2% female Mean (HAQ score:
1.0 (SD 0.7)
Typical RA erosion: 17.8%
vSHS baseline total score:
4.5 (SD 6.8)
ACPA+: 50%
Hambardzumyan83
(n= 487)
NR 70% female NR Mean SHS: 4.5 (median 2) Anti-CCP positive: 57%
Heimans84
(RA n= 479)
Mean age: 52 years
(SD 13 years)
70% female NR Median, total SHS: 0
(IQR 0–0)
Erosive: 15%
ACPA+: 68%
Markusse85
(n= 508)
NR for total group NR for total group NR for total group NR for total group NR for total group
ACPA+, anticitrullinated protein/peptide anti-body positive; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin; JSN, joint space narrowing;
mTSS, total van der Heijde-modified Sharp score; NR, not reported; SJC66, 66 swollen joint count; TJC28, 28 tender joint count; vSHS, van der Heijde-modified
Sharp score.
RF status SJC TJC ESR CRP level Smoking status
RF positive: 71%
RF: 224.7 U/ml
(281.1 U/ml)
Total SJC, mean 12.45
(SD 8.19)
SJC28, mean: 8.01
(SD 5.35)
Total TJC, mean: 14.35
(SD 10.59)
TJC28, mean: 8.28
(SD 6.38)
Mean ESR: 36.66mm/hour
(SD 24.06mm/hour)
Mean CRP level:
28.80mg/l
(33.78mg/l)
Smokers: 28%
IgM RF positive: 55.1% SJC, mean: 287.9
(SD 5.4)
TJC, mean: 288.7
(SD 6.9)
ESR, mean: 32.7mm/first
hour (SD 25mm/first hour)
Mean CRP level:
24.8mg/l
(SD 37.7mg/l)
NR
RF positive: 68% SJC28, mean: 10.8
(SD 5.28)
TJC28, mean: 9.6
(SD 6.07)
Mean: 39.9mm/hour
(SD 25.9mm/hour)
Mean: 33.8mg/l
(SD 36.81mg/l)
NR
RF positive: 69% Median SJC: 7
(IQR 3–11)
Median TJC: 7
(IQR 4–10)
NR NR NR
NR for total group NR for total group NR for total group NR for total group NR for total group NR for total group
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TABLE 31 Performance results from clinical prediction model development studies: additional performance
measures
Name of clinical prediction
model (submodels) Other performance measures (e.g. sensitivity, specificity, PPV, NPV, accuracy)
Models predicting radiographic joint damage
ASPIRE78
ESR
CRP
NR
Berglin59 Model 1: accuracy 73%
Model 2: accuracy 67%
BeSt79
ESR
CRP
PPV and NPV reported for a range of PRs. At 60% PR (100% patients classified),
PPV = 75% and NPV = 69%
Brennan60 Threshold of 0.5 PR
Prediction sample: accuracy = 76/105 (72%)
Validation sample: PPV = 76%; NPV = 80%; and accuracy = 79%
Addition of second-line drugs and/or steroids tested: PPV= 72%; NPV = 82%; and
accuracy = 79%
Combe (A)62
Two models
p= 0.50 as probability cut-off point
Model 1 (radiographic progression): sensitivity, 0.71; and specificity, 0.74
Model 2 (high Sharp score of > 4): sensitivity, 0.78; and specificity, 0.85
de Punder64
Extended
Simplified
NR
de Vries-Bouwstra65 Presence of progression of radiological damage PPV = 75.3%
Degboé66
Four models
Anti-CCP
Anti-MCV
AhFibA
High ACPA level
Anti-CCP2 (25 U/ml, 95% diagnosis specificity): PPV= 63.5%; and NPV, 57.5%
Anti-CCP2 (40 U/ml, 98% diagnosis specificity): PPV= 62.8%; and NPV, 58.4%
Anti-MCV (20 UA/ml, 95% diagnosis specificity): PPV= 64.8%; and NPV, 51.5%
Anti-MCV (35 UA/ml, 98% diagnosis specificity): PPV= 62.1%; and NPV, 57.5%
AhFibA (0.056 AU, 95% diagnosis specificity): PPV= 67.6%; and NPV, 53.4%a
AhFibA (0.119 AU, 98% diagnosis specificity): PPV= 62.8%; and NPV, 56.3%a
Dixey68
Three models
Non-erosive group at baseline (68%): correctly predicted ERO or not by 3 years in 67%
(sensitivity, 52%; specificity, 78%; and PPV, 68%). Severity of ERO predicted correctly
in 82% (sensitivity, 96%; specificity, 42%; and PPV, 77%) and Larsen score and ESR
at 1 year (90% correct; sensitivity, 98%; specificity, 52%; and PPV, 84%). Validity of
each model tested in a random 40% subset of the cohort not used in the analysis and
‘confirmed the prognostic value of these variables’ (overall: 67.30% 79.20% and 87.20%
in the test sample for the three models)
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TABLE 31 Performance results from clinical prediction model development studies: additional performance
measures (continued )
Name of clinical prediction
model (submodels) Other performance measures (e.g. sensitivity, specificity, PPV, NPV, accuracy)
Drossaers-Bakker56 Mild radiographic damage: all (SJC, RF, ERO, SE), all-over correct, 88%; PPV, 80%; and
NPV, 91%
Selected (SJC, RF, ERO): all-over correct, 87%; PPV, 87%; and NPV, 86%
Severe radiographic damage: all (SJC, RF, ERO, RAP), all-over correct, 85%; PPV, 91%;
and NPV, 80%
Selected (SJC, RF, ERO): all-over correct, 84%; PPV, 85%; and NPV, 74%
ESPOIR69 NR
Forslind70 Model 1 (radiological damage): accuracy, 78%; sensitivity, 0.79; specificity, 0.77; PPV, 0.79;
and NPV, 0.77
Model 2 (radiological progression): accuracy, 75%; sensitivity, 0.75; specificity, 0.75;
PPV, 0.77; and NPV, 0.73
Houseman72 Model for radiographic progression PPV= 81%, NPV = 85%
Model for absolute radiographic outcome PPV= 87%, NPV 64%
Sanmartí75 Sensitivity, 53.9%; specificity, 81.7%; PPV, 56%; and NPV, 80.3%
SONORA57 NR
SWEFOT73
Whole group
Whole group stratified
Anti-CCP
Sex
NR
Syversen76 Model 1 (externally validated in De Cock et al.80): sensitivity, 89.2%; specificity, 51%; and
accuracy, 73.6%
Model 2 (adjusted for baseline radiographic score): sensitivity, 81.1%; specificity, 76.5%;
and accuracy, 76.5%
Model 3 (anti-CCP as a continuous variable): sensitivity, 86.5%; specificity, 64.7%; and
accuracy, 77.6%
van Steenbergen77 NR
Models predicting HAQ/disease course
Bansback58 NR
Combe (B)63 p= 0.408 (probability of 5-year HAQ score of > 1). PPV= 46.15%, NPV = 92.71%
Dirven67 67% patients reliably classified using cut-off points of < 35% (low risk) and > 60%
(high risk); PPV = 71%; and NPV = 74%
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TABLE 31 Performance results from clinical prediction model development studies: additional performance
measures (continued )
Name of clinical prediction
model (submodels) Other performance measures (e.g. sensitivity, specificity, PPV, NPV, accuracy)
Drossaers-Bakker56 Mild HAQ score: all (HAQ score, ERO), all-over correct, 88%; PPV, 89%; and NPV, 85%
Selected (HAQ score, ERO), all-over correct, 88%; PPV, 89%; and NPV, 85%
Severe HAQ score: all (HAQ score), all-over correct, 84%; PPV, 91%; and NPV, 72%
Selected (HAQ score): all-over correct, 84%; PPV, 91%; and NPV, 72%
Severe disease course: all (SJC, HAQ, SE), all-over correct, 80%; PPV, 84%; and NPV, 76%
Selected (SJC, Ritchie score): all-over correct, 83%; PPV, 91%; and NPV, 76%
Graell71 Sensitivity, 70.1%; specificity, 64%; PPV, 83.9%; and NPV, 44.4%
Models predicting DAS28
Centola61 NR
ERO, erosive; NR, not reported; RAP, rheumatoid arthritis protected; UA, undifferentiated arthritis.
a Original publication states AU without further details.
TABLE 32 Performance results from external validation studies – additional performance measures
Name of clinical prediction
model (submodels) Other performance measures (e.g. sensitivity, specificity, PPV, NPV, accuracy)
De Cock80 NR
Hambardzumyan83 Sensitivity, 0.98; specificity, 0.17; PPV = 0.21; and NPV = 0.97
Heimans84 RA (progression of ≥ 0.5 on the SHS, based on intermediate or higher risk for progression)
PPV= 15.4%, NPV for no progression= 98.8%
Markusse85 NR
NR, not reported.
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Appendix 8 Review 2 excluded studies
TABLE 33 Review 2 excluded studies with rationale
First author (date) Title Justification for exclusion
Addimanda (2014)326 Efficacy and safety of tocilizumab in refractory rheumatoid
arthritis: a real life cohort from a single centre
Not early RA
Aga (2013)327 Clinical predictors of response to methotrexate treatment in
DMARD naive patients with early rheumatoid arthritis: results
from a longitudinal observational study
Treatment duration of
< 6 months
Ajeganova (2013)328 Association of obesity with worse disease severity in rheumatoid
arthritis as well as with comorbidities: a long-term followup
from disease onset
Not prediction of treatment
response
Akdemir (2014)329 Radiological outcomes after two years of remission steered
treatment in early arthritis patients
Early RA and UA patients,
results not separated
Akdemir (2014)330 ACPA-negative RA patients benefit from initial combination
therapy with early clinical improvement-a sub-analysis of the
best study
Not prediction of treatment
response
Akdemir (2016)331 Predictive factors of radiological progression after two years of
remission steered treatment in early arthritis patients
Early RA and UA patients,
results not separated
Akhavan (2011)122 Prevalence of and predictive factors for sustained remission in
early RA: Results from SONORA study
Not prediction of treatment
response
Akhavan (2013)332 The impact of reaching low disease activity in the first year on
future disability and damage in patients with early rheumatoid
arthritis
Not prediction of treatment
response
Akhavan (2014)333 Predictive validity of low disease activity using patient reported
measures on long-term outcomes in early rheumatoid arthritis-
results from study of new onset rheumatoid arthritis and Ontario
best practices initiative
Not prediction of treatment
response
Alemao (2016)334 Effects of achieving target measures in rheumatoid arthritis on
functional status, quality of life, and resource utilization: analysis
of clinical practice data
Not early RA
Alessandri (2004)335 Decrease of anti-cyclic citrullinated peptide antibodies and
rheumatoid factor following anti-TNFalpha therapy (infliximab) in
rheumatoid arthritis is associated with clinical improvement
Disease duration at baseline
not reported
Aletaha (2007)336 Disease activity early in the course of treatment predicts
response to therapy after one year in rheumatoid arthritis
patients
No eligible factor/end point
(DAS28 data not reported)
Aletaha (2009)337 Rheumatoid arthritis joint progression in sustained remission is
determined by disease activity levels preceding the period of
radiographic assessment
No baseline predictors
Aletaha (2013)338 Rituximab dissociates the tight link between disease activity and
joint damage in rheumatoid arthritis patients
Not prediction of treatment
response
Aletaha (2013)124 Rheumatoid factor determines structural progression of
rheumatoid arthritis dependent and independent of disease
activity
Not prediction of treatment
response
Alivernini (2014)339 Ultrasonography as useful tool to identify rheumatoid arthritis
patients in clinical remission for tapering or withdrawal TNFa
blockers without disease relapse
Disease duration at baseline
not reported
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Alivernini (2016)340 Tapering and discontinuation of TNF-alpha blockers without
disease relapse using ultrasonography as a tool to identify
patients with rheumatoid arthritis in clinical and histological
remission
Not early RA
Allaart (2006)341 Aiming at low disease activity in rheumatoid arthritis with initial
combination therapy or initial monotherapy strategies: the BeSt
study
No data on prediction of
treatment response
Allaart (2010)342 When to start which DMARDs in rheumatoid arthritis? Not possible to obtain paper
Allaart (2011)126 A multi-biomarker disease activity (Vectra DA) algorithm score
for rheumatoid arthritis predicts radiographic progression in the
BeSt study
Not prediction of treatment
response
Ammitzbøll (2012)343 M-ficolin, an activator of the complement system, predicts
DAS28 remission in early DMARD-naive rheumatoid arthritis
Not prediction of treatment
response
Ammitzbøll (2012)344 M-ficolin, an activator of the complement system, is the
strongest predictor of both DAS28 remission and low disease
activity in a cohort of 180 early DMARD naive rheumatoid
arthritis patients followed in the opera-study
Not prediction of treatment
response
Ammitzbøll (2013)345 M-ficolin, an activator of the complement system, predicts
DAS28 remission in early DMARD naive rheumatoid arthritis
Not prediction of treatment
response
Ammitzbøll (2013)346 M-ficolin levels reflect disease activity and predict remission in
early rheumatoid arthritis
Not prediction of treatment
response
Ancuta (2014)347 Correlation between time to switch and clinical response
amplitude to rituximab in second line treatment in rheumatoid
arthritis patients with treatment failure to tumor necrosis factor
inhibitors: 3-year data from repeat observational study
No relevant predictive factors
Anderson (2000)128 Factors predicting response to treatment in rheumatoid arthritis:
the importance of disease duration
Not early RA
Angwin (2006)348 Radiographic progression in the Cobra study: computer
measurements of joint space, a comparison with scoring
Not possible to obtain paper
Atzeni (2009)349 Predicting response to anti-TNF treatment in rheumatoid arthritis
patients
Not early RA
Atzeni (2014)350 Predictors of response to anti-TNF therapy in RA patients with
moderate or high DAS28 scores
Not early RA
Baddoura (2006)351 Severity of rheumatoid arthritis: the SEVERA study Not prediction of treatment
response and no eligible
predictive factor
Baer (2014)352 Does low disease activity at six months predict remission at
12 months in rheumatoid arthritis patients treated with biologics
in a real-world setting?
Not prediction of treatment
response
Baillet (2014)353 Biomarker sets predict therapeutic response to TNF-inhibitors
in rheumatoid arthritis and spondyloarthritis patients:
a theragnostic approach in a multicenter cohort
Results not reported
separately for RA patients on
relevant predictors
Bakker (2010)130 Development of a multi-biomarker test for rheumatoid arthritis
(RA) disease activity (Vectra DA)
Not prediction of treatment
response
Balogh (2013)354 Comparison of DAS-28 and 2011-ACR/EULAR remission criteria
in a biologic-treated rheumatoid arthritis patient cohort
Not early RA
Balogh (2013)355 Comparison of remission criteria in a tumour necrosis factor
inhibitor treated rheumatoid arthritis longitudinal cohort: patient
global health is a confounder
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Balsa (2010)129 Prediction of functional impairment and remission in rheumatoid
arthritis patients by biochemical variables and genetic
polymorphisms
Not early RA
Barnabe (2011)356 Predictors for remission in rheumatoid arthritis are affected by
remission definition
Not early RA
Barnabe (2012)357 Identified predictors for remission in rheumatoid arthritis depend
on remission definition
Not early RA
Barnabe (2014)358 The effect of different remission definitions on identification of
predictors of both point and sustained remission in rheumatoid
arthritis treated with anti-TNF therapy
Not early RA
Baruth (2013)359 Factors associated with disability in a sample of adults with
arthritis
Not early RA
Bathon (2005)360 Disease activity scores using CRP versus ESR and the relationship
between EULAR and ACR responses in patients with early
rheumatoid arthritis
Not prediction of treatment
response
Baumgartner
(2004)361
Etanercept (Enbrel) in patients with rheumatoid arthritis with
recent onset versus established disease: improvement in
disability
Not early RA
Bay-Jensen (2014)362 Serological biomarkers of joint tissue turnover predict
tocilizumab response at baseline
Not early RA
Bejarano (2012)363 Relationship between early bone mineral density changes and
long-term function and radiographic progression in rheumatoid
arthritis
No relevant predictive factors
Bellis (2015)364 Ultrasound-detected synovitis and tenosynovitis independently
associate with flare in patients with rheumatoid arthritis in
clinical remission
Not early RA
Ben Slama (2014)365 Comparison of activity score DAS28-ESR and DAS28-CRP in
patients with rheumatoid arthritis
Not early RA
Benedict (2010)366 Comparative effectiveness of biologic therapies for treating
rheumatoid arthritis (RA) in patients who failed an anti tumor
necrosis factor agent: a meta-regression analysis
Not early RA
Bentzon (1986)367 Influence of previous gold treatment and other patient variables
on outcome of treatment with disease modifying anti-rheumatic
drugs (DMARD) in patients with rheumatoid arthritis
Not early RA
Benucci (2010)368 Predictive factors of response to rituximab therapy in
rheumatoid arthritis: what do we know today?
Review (not systematic)
Bijlsma (2007)369 Optimal use of methotrexate: the advantages of tight control Editorial
Bingham (2012)370 Predictors of significant Disease Activity Score-28 (using CRP)
remission achieved with intravenous golimumab in patients with
active rheumatoid arthritis despite methotrexate therapy: results
of the phase 3, multicenter, double-blind, placebo-controlled
trial
Not early RA
Bingham (2013)371 Predictors of significant Disease Activity Score-28 (using
C-reactive protein) remission achieved with intravenous
golimumab in patients with active rheumatoid arthritis despite
methotrexate therapy: results of the phase III, multicentre,
double-blind, placebo-controlled trial
Not early RA
Bobbio-Pallavicini
(2007)372
High IgA rheumatoid factor levels are associated with poor
clinical response to tumour necrosis factor alpha inhibitors in
rheumatoid arthritis
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Boers (2001)373 Inflammation and damage in an individual joint predict further
damage in that joint in patients with early rheumatoid arthritis
Not prediction of treatment
response
Borangiu (2014)374 Ultrasound active synovitis can be predicted by using clinical
measures
Disease duration at baseline
not reported
Bouman (2015)375 Associations of a multi-biomarker disease activity score with
clinical and radiographic parameters in rheumatoid arthritis
Not prediction of treatment
effect
Braun (2008)376 Comparison of the clinical efficacy and safety of subcutaneous
versus oral administration of methotrexate in patients with
active rheumatoid arthritis: results of a six-month, multicenter,
randomised, double-blind, controlled, phase IV trial
No relevant outcomes
Breedveld (2005)377 Association between baseline radiographic damage and
improvement in physical function after treatment of patients
with rheumatoid arthritis
Not early RA
Brown (2002)378 Baseline clinical, functional and ultrasonographic assessment can
be used to predict subsequent remission in rheumatoid arthritis
Disease duration at baseline
not reported
Buch (2003)379 Does synovial cytokine expression predict response to tumour
necrosis factor-alpha blockade in patients with rheumatoid
arthritis?
Not prediction of treatment
response
Buchanan (2013)380 Basal metabolic rate as an indicator of rheumatoid arthritis
disease activity and predictor of remission: Australian results
from period 1 of the preserve trial
Disease duration at baseline
not reported
Burmester (2008)381 Clinical remission and/or minimal disease activity in patients
receiving adalimumab treatment in a multinational, open-label,
twelve-week study
Not early RA
Burmester (2015)382 Efficacy and safety of ascending methotrexate dose in
combination with adalimumab: the randomised CONCERTO trial
Not prediction of treatment
effect
Bykerk (2015)383 On drug and drug-free remission by baseline disease duration in
the avert trial: abatacept versus methotrexate comparison in
patients with early rheumatoid arthritis
Insufficient detail of baseline
characteristics
Callaghan (2014)384 Biological therapy for rheumatoid arthritis: is personalised
medicine possible?
Not early RA
Cañete (2011)385 Clinical significance of high levels of soluble tumour necrosis
factor-alpha receptor-2 produced by alternative splicing in
rheumatoid arthritis: a longitudinal prospective cohort study
No relevant predictive factors
Canhão (2012)386 Comparative effectiveness and predictors of response to tumour
necrosis factor inhibitor therapies in rheumatoid arthritis
Not early RA
Cantini (2016)387 Tailored first-line biologic therapy in patients with rheumatoid
arthritis, spondyloarthritis, and psoriatic arthritis
Not early RA
Capell (1993)388 Second line (disease modifying) treatment in rheumatoid
arthritis: which drug for which patient?
Not prediction of treatment
response
Castrejón (2016)389 Prediction of remission in a French early arthritis cohort by
RAPID3 and other core data set measures, but not by the
absence of rheumatoid factor, anticitrullinated protein
antibodies, or radiographic erosions
Not prediction of treatment
response
Casu (2013)390 Clinical and serological response to tocilizumab in patients with
rheumatoid arthritis
Not early RA
Cavet (2009)391 Predicting radiographic progression in rheumatoid arthritis with
ultrasound and biomarkers
Disease duration at baseline
not reported
Cazzato (2014)392 Early response indicator early predicts clinical response to
certolizumab in rheumatoid arthritis patients
Disease duration at baseline
not reported
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Chandrashekara
(2015)393
Neutrophil–lymphocyte ratio, pain perception, and disease
activity score may serve as important predictive markers for
sustained remission in rheumatoid arthritis
Not prediction of treatment
response
Chatzidionysiou
(2011)394
Seropositivity and in particular ACPA positivity is a strong
predictor of response to treatment with rituximab: pooled data
from 10 European registries
Not possible to obtain paper
Chatzidionysiou
(2013)395
Seropositivity and response to RTX: data from the cererra
collaboration
Disease duration at baseline
not reported
Chatzidionysiou
(2015)396
Smoking and response to rituximab in anti-CCP positive and
negative rheumatoid arthritis-results from an international
European collaboration
Not early RA
Chen (2013)397 Influence of adult height on rheumatoid arthritis: association
with disease activity, impairment of joint function and overall
disability
No relevant predictive factors
Chen (2014)398 Elevated serum IgG4 defines specific clinical phenotype of
rheumatoid arthritis
Not early RA
Cheung (2014)399 Are tender joints better than synovitis to predict structural
damage in rheumatoid arthritis?
Not early RA
Chitale (2012)400 Initial triple DMARD therapy predicts ACR EULAR remission in an
early rheumatoid arthritis inception cohort
Not prediction of treatment
response
Cho (2012)401 Do patients with elderly-onset rheumatoid arthritis have severe
functional disability?
Not early RA
Choquette (2010)402 Impact of disease duration on the outcome of RA patients
treated with infliximab in Canada
Not early RA
Choquette (2011)403 Comparison of disease characteristics of rheumatoid arthritis
patients in remission according to the DAS criteria versus the
new ACR/EULAR criteria in a real-world patient population
Not possible to obtain paper
Choquette (2013)404 Comparison of disease characteristics of RA patients in remission
according to the DAS criteria versus the new ACR/EULAR criteria
in a real-world patient population
Not early RA
Choquette (2013)405 What is the impact of rheumatoid factor positivity on the
real-world effectiveness of infliximab treatment in rheumatoid
arthritis?
Disease duration at baseline
not reported
Choquette (2015)406 Use of rituximab compared to anti-TNF agents as second and
third line therapy in patients with rheumatoid arthritis: 6-year
follow-up report from the rhumadata clinical database and
registry
No relevant predictive factors
or outcomes
Choquette (2015)407 Predictors of clinical response to biologics in rheumatoid
arthritis: experience from a Canadian clinic
Not early RA
Chow (2015)408 What is the effect of TNF inhibitors on employment status in
rheumatoid arthritis patients and what are the predictors of
progression to unemployment?
Disease duration at baseline
not reported
Choy (2007)409 Does the Health Assessment Questionnaire predict 5-year quality
of life in early RA?
Commentary
Choy (2013)410 Physician global assessment at three months is strongly
predictive of disease activity at 12 months in early rheumatoid
arthritis. Results from the catch cohort
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Christensen (2014)411 Temporal summation of pain and ultrasound Doppler activity as
predictors of treatment response in patients with rheumatoid
arthritis: protocol for the Frederiksberg hospitals Rheumatoid
Arthritis, pain assessment and Medical Evaluation
(FRAME-cohort) study
Protocol
Christensen (2016)412 Ultrasound Doppler but not temporal summation of pain
predicts DAS28 response in rheumatoid arthritis: a prospective
cohort study
Not early RA
Ciurtin (2015)413 Evaluating impact of risk associated outcomes on ultrasound
Doppler score of patients with inflammatory hand joint pain
using a beta-binomial model
Insufficient detail reported
Ciurtin (2016)149 Ultrasound-detected subclinical inflammation was better
reflected by the disease activity score (DAS-28) in patients with
suspicion of inflammatory arthritis compared to established
rheumatoid arthritis
Not prediction of treatment
response
Coburn (2015)414 Anti-citrullinated protein antibody and radiographic disease
progression in rheumatoid arthritis
Disease duration at baseline
not reported
Cohen (2005)415 C-reactive protein predicts treatment response to adalimumab
(HUMIRA (R)) in patients with rheumatoid arthritis
Not possible to obtain paper
Colmegna (2016)416 High rates of obesity and greater associated disability among
people with rheumatoid arthritis in Canada
Not early RA
Combe (2001)62 Prognostic factors for radiographic damage in early rheumatoid
arthritis: a multiparameter prospective study
Not prediction of treatment
response
Couderc (2013)417 Predictive factors of rituximab response in rheumatoid arthritis:
results from a French university hospital
Not early RA
Couderc (2013)417 Predictive factors for the response to rituximab in rheumatoid
arthritis: results from a French university hospital
Not early RA
Courvoisier (2016)418 Rheumatoid arthritis patients after initiation of a new biologic
agent: trajectories of disease activity in a large multinational
cohort study
Not early RA
Cuchacovich (2008)419 Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels
and a decrease in anti-CCP titres are associated with clinical
response to adalimumab in rheumatoid arthritis
Not early RA
Cuppen (2015)420 Personalized biological treatment for rheumatoid arthritis:
a systematic review with a focus on clinical applicability
Not early RA
Cuppen (2015)421 Towards individualized risk determination in RA: a prediction
model for TNFi discontinuation within the first year after start
Insufficient detail reported
Cuppen (2016)422 Exploring the inflammatory metabolomic profile to predict
response to TNF-alpha inhibitors in rheumatoid arthritis
Not early RA
Curtis (2010)155 Validation of a multi-biomarker test for rheumatoid arthritis (RA)
disease activity (Vectra DA) in a multi-cohort study
Insufficient information to
determine treatment response
Curtis (2010)423 Prediction of one-year response to etanercept and methotrexate
in rheumatoid arthritis patients in TEMPO
Not early RA
Curtis (2011)424 Derivation and preliminary validation of an administrative
claims-based algorithm for the effectiveness of medications for
rheumatoid arthritis
No relevant predictors
Curtis (2011)425 Validation of a preliminary administrative claims-based algorithm
for the effectiveness of medications for rheumatoid arthritis
No relevant predictors
Curtis (2012)426 Predicting future response to certolizumab pegol in rheumatoid
arthritis patients: features at 12 weeks associated with low
disease activity at 1 year
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Curtis (2012)156 Validation of a novel multibiomarker test to assess rheumatoid
arthritis disease activity
Treatment duration of
< 6 months
Curtis (2013)427 Clinical response within 12 weeks as a predictor of future low
disease activity in patients with early RA: results from the TEAR
Trial
No relevant predictors
Curtis (2015)157 A randomized trial comparing disease activity measures for the
assessment and prediction of response in rheumatoid arthritis
patients initiating certolizumab pegol
Not early RA
D’Agostino (2015)428 Do ultrasound (power Doppler ultrasonography) and Disease
Activity Score-28 measure different aspects of disease activity?
Analyses from an open-label study of power Doppler
ultrasonography response patients with rheumatoid arthritis
patients starting abatacept
Nothing on prediction of
treatment effect
D’Agostino (2015)429 In patients with rheumatoid arthritis and an inadequate
response to methotrexate, does body mass index influence the
efficacy of abatacept on inflammation when measured by
power Doppler ultrasonography? Results from the appraise
study
Not early RA
Dahl (2009)430 TNF-inhibitors in established rheumatoid arthritis: the effect of
age on treatment response and predictors of remission
No baseline disease duration
reported
Dai (2010)431 The clinical response to etanercept in rheumatoid arthritis is in
part dependent on pretreatment tumour necrosis factor-alpha
expression in the synovium
Not possible to obtain paper
Daïen (2014)432 Predictive factors of response to biological disease modifying
antirheumatic drugs: towards personalized medicine
Review (not systematic)
Dames (2006)433 Utility of Disease Activity Score-28 (DAS-28) for determining
need for DMARD change in veterans affairs rheumatoid arthritis
(VARA) patients: an analysis of discrepancies between DAS-28
scores and clinical stability status
Not prediction of treatment
response
da Mota (2012)434 Baseline HAQ and SF-36 questionnaire scores cannot predict
clinical remission, radiographic progression or the need for
biological therapy in a three-year prospective study of a Brazilian
early rheumatoid arthritis cohort
Not prediction of treatment
response
Danve (2015)435 Male gender and higher hemoglobin predict response to
methotrexate in rheumatoid arthritis
No relevant predictive factors
or outcomes
Darawankul (2015)436 The good EULAR response at the first year is strongly predictive
of clinical remission in rheumatoid arthritis: results from the
TARAC cohort
Not early RA
Dasgupta (2014)437 Predictors of low disease activity and remission after one dose of
golimumab in patients with rheumatoid arthritis
Not early RA
Dejaco (2010)438 Third generation anti-cyclic citrullinated peptide antibodies do
not predict anti-TNF-alpha treatment response in rheumatoid
arthritis
Disease duration unclear
de Jong (2013)439 Response to glucocorticoids at 2 weeks predicts the
effectiveness of DMARD induction therapy at 3 months: post
hoc analyses from the tREACH study
Treatment duration of
< 6 months at time of analysis
de Jong (2015)440 Effect of prednisone on type I interferon signature in
rheumatoid arthritis: consequences for response prediction to
rituximab
Not early RA
de Miguel (2015)441 Doppler ultrasound better predicts X-Ray progression in
rheumatoid arthritis than any definition of clinical remission
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
de Rooy (2011)442 Predicting arthritis outcomes-what can be learned from the
Leiden Early Arthritis Clinic?
Not prediction of treatment
response
de Vries-Bouwstra
(2006)65
Using predicted disease outcome to provide differentiated
treatment of early rheumatoid arthritis
Not prediction of treatment
response
de Vries-Bouwstra
(2008)161
Progression of joint damage in early rheumatoid arthritis:
association with HLA–DRB1, rheumatoid factor, and
anti–citrullinated protein antibodies in relation to different
treatment strategies
Time of predictor
measurement not stated and
unclear whether or not it was
within the 2-year early RA
window
Demir (2003)443 Value of wrist ultrasound in prediction of disease activity in
patients with rheumatoid arthritis
Not possible to obtain paper
Di Cicco (2014)444 Synovial ectopic lymphoneogenesis predicts primary clinical
response to certolizumab pegol in patients with rheumatoid
arthritis
Not early RA
Di Cicco (2014)445 Presence of synovial lymphocyte aggregates predicts clinical
response to DMARD therapy in patients with early rheumatoid
arthritis
Not prediction of treatment
response
Ding (2015)446 Predictors of response to TNF-α antagonist therapy in Chinese
rheumatoid arthritis
No relevant outcomes
Dirven (2009)447 Predictors of HAQ response after 3 months of treatment with
different strategies in recent onset active RA
Not prediction of treatment
response
Dougados (2007)448 Sustained efficacy along with improvements in disease activity
score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs)
with abatacept (Aba) in rheumatoid arthritis (RA) pts with an
inadequate response to anti-tumor necrosis factor (TNF) therapy:
the long-term extension (LTE) of the attain trial
Not prediction of treatment
response
Drouin (2010)449 Predictors of clinical response and radiographic progression in
patients with rheumatoid arthritis treated with methotrexate
monotherapy
Not early RA
Durez (2014)450 Baseline predictors of remission rates during golimumab
treatment for rheumatoid arthritis in the go-more study
Not early RA
Ellingsen (2009)451 The increased cc chemokine ligand 19 (CCL19) at baseline is an
independent predictor of the 5-year radiographic progression in
early steroid and DMARD-naive rheumatoid arthritis (RA)
patients
Insufficient information to
determine treatment response
Emery (2006)452 Abatacept inhibits structural damage progression, as assessed by
the Genant-modified Sharp scoring system, in Rheumatoid
Arthritis (RA) patients with an inadequate response to
Methotrexate (MTX): the aim (abatacept in inadequate
responders to MTX) trial – a sub-analysis by disease duration
Not possible to obtain paper
Emery (2011)453 Exploratory analyses of the association of MRI with clinical,
laboratory and radiographic findings in patients with rheumatoid
arthritis
Not prediction of treatment
effect
Emery (2011)454 Optimising treatment in rheumatoid arthritis: a review of
potential biological markers of response
Review (not systematic)
Emery (2011)455 Post-treatment changes in serum C-reactive protein levels and
clinical response in rheumatoid arthritis
Not early RA
Emery (2012)456 Combination etanercept and methotrexate provides better
disease control in very early (≤ 4 months) versus early
rheumatoid arthritis (> 4 months and < 2 years): post hoc
analyses from the COMET study
Does not meet criteria for the
window of opportunity
covariate (not all patients
DMARD naive)
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Emery (2012)457 Golimumab’s efficacy in patients with very active disease in
methotrexate-naive rheumatoid arthritis
Not early RA
Emery (2012)458 Predictors of radiographic progression in methotrexate-naive
patients with rheumatoid arthritis based on one-year
radiographic data from the go-before golimumab clinical trial
Not early RA
Emery (2013)459 Radiographic progression in patients with early rheumatoid
arthritis treated with etanercept: results from the prize study
Not prediction of treatment
response
Emery (2014)460 Early response to etanercept-methotrexate induction therapy
predicts sustained remission with reduced–dose combination
regimen in the prize study
Insufficient methodological
details reported
Emery (2014)461 Early response to full-dose etanercept-plus-methotrexate
induction therapy predicts sustained remission with
reduced-dose combination therapy in early rheumatoid arthritis
patients
Insufficient methodological
details reported
Emery (2014)462 Efficacy of golimumab plus methotrexate in methotrexate-naive
patients with severe active rheumatoid arthritis
Not early RA
Emery (2014)463 Predictors of drug-free remission following treatment with
abatacept (in combination with methotrexate or as
monotherapy) in early rheumatoid arthritis
No relevant outcomes
Emery (2015)464 Abatacept plus methotrexate can effectively and safely regain
the target of remission following re-treatment for flares after
drug-free withdrawal in patients with early rheumatoid arthritis
Not prediction of treatment
effect
Emery (2015)465 A European chart review study on early rheumatoid arthritis
treatment patterns, clinical outcomes, and healthcare utilization
Not early RA
Emery (2015)116 Evaluating drug-free remission with abatacept in early
rheumatoid arthritis: results from the phase 3b, multicentre,
randomised, active-controlled AVERT study of 24 months, with a
12-month, double-blind treatment period
No relevant outcome
Erickson (2014)466 Predictors of radiologic disease progression during the
rheumatoid arthritis comparison of active therapies trial
Not early RA
Eser (2012)467 Extraarticular manifestations in Turkish patients with rheumatoid
arthritis: impact of EAMs on the health-related quality of life in
terms of disease activity, functional status, severity of pain, and
social and emotional functioning
Not early RA
Not prediction of treatment
effect
Estrach (2003)468 Swollen joint count as a predictor of response to anti-tumor
necrosis factor alpha therapy in rheumatoid arthritis: comment
on the article by Sokka and Pincus (multiple letters) [3]
Not early RA
Fabricio (2015)469 Predictability to achieve low activity and/or remission with
leflunomide use in patients with rheumatoid arthritis
Insufficient methodological
details reported
Fabris (2010)470 Study on the possible role of the –174G>C IL-6 promoter
polymorphism in predicting response to rituximab in rheumatoid
arthritis
Not early RA
Fautrel (2012)471 Moderate rheumatoid arthritis despite methotrexate treatment:
risk of radiographic progression
Not early RA
Fautrel (2016)472 Step-down strategy of spacing TNF-blocker injections for
established rheumatoid arthritis in remission: results of the
multicentre non-inferiority randomised open-label controlled trial
(STRASS: Spacing of TNF-blocker injections in Rheumatoid
ArthritiS Study)
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Favalli (2013)473 Disease duration and year of publication affect the results of
studies on rheumatoid arthritis damage progression by biologic
agents: a systematic review and meta-analysis
Not prediction of treatment
response
Favalli (2014)474 The comparison of effects of biologic agents on rheumatoid
arthritis damage progression is biased by period of enrolment:
data from a systematic review and meta-analysis
Not prediction of treatment
response
Fedele (2015)475 Clinical parameters and B cell subsets as biomarkers of response
to tocilizumab in rheumatoid arthritis
Insufficient detail reported
Fedorenko (2014)476 Effects of four different treatment regimens on radiologic
progression in early rheumatoid arthritis (RA)
Insufficient detail reported on
methods and results relating
to prediction of treatment
response
Feist (2010)477 A study to evaluate the effectiveness and safety of the
interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) after 4
and 24 weeks in patients with active rheumatoid arthritis (RA)
final effectiveness results of the TAMARA study
Not prediction of treatment
response
Ferdousi (2011)478 Disease duration as a determinate factor of disease activity and
radiographic progression in rheumatoid arthritis
Pooled data from 2 trials
(not risk model)
Fernández-Nebro
(2007)479
Effectiveness, predictive response factors, and safety of
anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive
rheumatoid arthritis
Not early RA
Filer (2010)480 Utility of ultrasound joint counts as predictors of outcome in
patients with very early arthritis
Not prediction of treatment
response
Filippi (2015)481 Predictors of persistence of power Doppler ultrasound synovitis
in rheumatoid arthritis patients in clinical remission
Not early RA
Finckh (2007)482 Cigarette smoking and radiographic progression in rheumatoid
arthritis
Not early RA
Finckh (2010)483 Which subgroup of patients with rheumatoid arthritis benefits
from switching to rituximab versus alternative anti-tumor
necrosis factor (TNF) agents after previous failure of an anti-TNF
agent?
Not early RA
Finckh (2015)484 The impact of tobacco smoking on the effectiveness of
abatacept in rheumatoid arthritis: data from a pan European
analysis of RA registries
Not early RA
Fisher (2011)485 Fine specificity of anti-citrullinated peptide antibodies is
associated with response to anti-TNF agents in rheumatoid
arthritis: results from the British Society of Rheumatology
biologics register
Disease duration at baseline
not reported
Fisher (2012)486 Heterogeneity of anticitrullinated peptide antibodies and
response to anti-tumour necrosis factor agents in rheumatoid
arthritis
Not early RA
Fleischmann (2014)487 Short-term efficacy of etanercept plus methotrexate vs.
combinations of disease-modifying anti-rheumatic drugs with
methotrexate in established rheumatoid arthritis
Not early RA
Folkersen (2016)488 Integration of known DNA, RNA and protein biomarkers
provides prediction of anti-TNF response in rheumatoid arthritis:
results from the COMBINE study
No relevant predictors
Foltz (2009)489 Ultrasound and magnetic resonance imaging did not provide
early assessment of biotherapy response in patients with
rheumatoid arthritis
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Forsblad-d’Elia
(2015)490
Drug adherence, response and predictors thereof for tocilizumab
in patients with rheumatoid arthritis: results from the Swedish
biologics register
Not early RA
Forslind (2007)169 Sex: a major predictor of remission in early rheumatoid arthritis? Not prediction of treatment
response
Fransen (2012)491 Clinical pharmacogenetic model to predict response of MTX
monotherapy in patients with established rheumatoid arthritis
after DMARD failure
Not early RA
Fujimura (2014)492 Predicting future response to tumor necrosis factor inhibitors by
the distribution of affected joints in rheumatoid arthritis patients
Not early RA
Furst (2015)493 Evaluation of patient-reported outcomes by baseline disease
duration: 6-month data from two clinical trials of patients with
early rheumatoid arthritis treated with abatacept
No relevant predictive factors
Furst (2015)494 Final 10-year effectiveness and safety results from study DE020:
adalimumab treatment in patients with rheumatoid arthritis and
an inadequate response to standard therapy
Not early RA
Furuya (2013)495 Effect of TNF antagonists on the productivity of daily work of
patients with rheumatoid arthritis
Not early RA
Gardette (2013)496 High level of anti-CCP antibodies is predictive of good response
to rituximab in patients with active rheumatoid arthritis
Not early RA
Gherghe (2016)497 Association of the different types of radiographic damage with
physical function in patients with rheumatoid arthritis: analysis
of the RAPID trials
Not early RA
Giacomelli (2013)498 Mathematical model to predict the early responders in a
monocentric cohort of patients with rheumatoid arthritis treated
by anti TNFalpha
Insufficient detail reported
Glave-Testino
(1994)499
Factors associated with disease severity in Mexican patients with
rheumatoid arthritis
Not early RA
Goetz (2011)500 Review of treatment response in rheumatoid arthritis:
assessment of heterogeneity
Not early RA
Gomez (2004)501 High titres of anti-CCP antibodies at baseline and after one year
of DMARDs may predict a poor clinical response in patients with
early rheumatoid arthritis
Not possible to obtain paper
González-Alvaro
(2007)502
Baseline serum RANKL levels may serve to predict remission in
rheumatoid arthritis patients treated with TNF antagonists
Not early RA
Gonzalez-Lopez
(2014)503
Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated
citrullinated vimentin (anti-MCV) relation with extra-articular
manifestations in rheumatoid arthritis
Not early RA
No relevant outcomes
Goodman (2015)504 Body mass index is an independent risk factor for not achieving
sustained remission in early rheumatoid arthritis: results from the
catch observational study
Insufficient methods detail on
assessment of prediction of
treatment response
Goronzy (2004)176 Prognostic markers of radiographic progression in early
rheumatoid arthritis
Not prediction of treatment
response
Gottenberg (2012)505 Serum IL-6 and IL-21 are associated with markers of B cell
activation and structural progression in early rheumatoid
arthritis: results from the ESPOIR cohort
No relevant predictive factors
Graudal (2000)506 Inflammatory patterns in rheumatoid arthritis estimated by
the number of swollen and tender joints, the erythrocyte
sedimentation rate, and hemoglobin: long term course and
association to radiographic progression
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Gremese (2013)507 Very early rheumatoid arthritis as a predictor of remission:
a multicentre real life prospective study
Not prediction of treatment
response
Gremese (2015)508 Clinical and B cell subsets biomarkers of response to tocilizumab
in rheumatoid arthritis
Not early RA
Gullick (2012)509 Predicting ongoing active disease in early rheumatoid arthritis
using clinical measures
Pooled data from two trials
(not risk model)
Hall (1991)510 Rheumatoid nodules do not predict response to treatment with
slow-acting anti-rheumatic drugs
Not early RA
Hama (2012)511 Power Doppler ultrasonography is useful for assessing disease
activity and predicting joint destruction in rheumatoid arthritis
patients receiving tocilizumab-preliminary data
Not early RA
Hama (2014)512 PD signal detected by ultrasonography relates to joint
destruction in rheumatoid arthritis under biologics therapy in
real world
Not early RA
Hama (2015)513 Wrist PD signal detected by ultrasonography relates to joint
destruction in rheumatoid arthritis under biologics therapy in
real world
Not early RA
Hamann (2016)514 Factors associated with sustained remission in rheumatoid
arthritis in patients treated with anti-tumor necrosis factor
(anti-TNF)
Not early RA
Hambardzumyan
(2013)183
A multi-biomarker disease activity score correlates with
radiographic progression in early rheumatoid arthritis: results
from a randomized trial
Not prediction of treatment
response
Hambardzumyan
(2013)182
A multi-biomarker disease activity blood test (Vectra DA)
correlates with radiographic progression in early rheumatoid
arthritis: results from the SWEFOT trial
Not prediction of treatment
response
Hambardzumyan
(2013)185
In early rheumatoid arthritis, the 12 individual biomarkers that
comprise the multiple biomarker disease activity score relate
differentially to clinical response and radiographic progression:
results from a randomized trial
Not prediction of treatment
response
Hambardzumyan
(2013)184
Multi-biomarker disease activity (MBDA) score and the 12
individual biomarkers in early rheumatoid arthritis patients relate
differentially to clinical response and radiographic progression:
results from the SWEFOT trial
Not prediction of treatment
response
Hambardzumyan
(2015)515
Predictive biomarkers for response or non-response to MTX
monotherapy in early RA
No relevant predictive factors
Hammer (2010)516 A 78-joints ultrasonographic assessment is associated with
clinical assessments and is highly responsive to improvement in a
longitudinal study of patients with rheumatoid arthritis starting
adalimumab treatment
Not early RA
Hammer (2011)517 Patients with rheumatoid arthritis on anti-TNF therapy;
responders with major reduction in power Doppler activity can
be identified after one month
Not early RA
Haney (2012)518 Correlation of a multi-biomarker disease activity response
assessment to disease activity score 28 (C-reactive protein)
response assessment and OMERACT RAMRIS scores in a
placebo-controlled rheumatoid arthritis clinical trial with
abatacept (ASSET)
Treatment duration of
< 6 months
Haroon (2008)519 Tailor-made therapy in rheumatoid arthritis: fact or fiction? Review (not systematic)
Harris (2012)520 Can we improve outcomes in early rheumatoid arthritis by
determining best practices? An analysis of the Canadian early
rheumatoid arthritis cohort (CATCH)
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Harris (2013)521 Can we improve outcomes in early rheumatoid arthritis (ERA) by
determining best practices? An analysis of the Canadian era
cohort (CATCH)
Not prediction of treatment
response
Hazlewood (2015)522 Enhancing comparative effectiveness research by combining
observational and randomized trial data to personalize the
choice between methotrexate and triple therapy for
methotrexate-naive patients with early rheumatoid arthritis
No relevant outcome
Heidari (2007)523 The value of changes in CRP and ESR for predicting treatment
response in rheumatoid arthritis
Not early RA
Heimans (2011)524 Body mass index is associated with decreased response to initial
and delayed treatment with dose escalated infliximab in patients
with recent onset rheumatoid arthritis
Insufficient detail reported on
methods and results relating
to prediction of treatment
response
Heimans (2014)91 A two-step treatment strategy trial in patients with early arthritis
aimed at achieving remission: the IMPROVED study
Not prediction of treatment
response
Hernandez (2013)525 Predictive factors of response to tocilizumab in patients with
active rheumatoid arthritis
Not early RA
Herold (2015)526 Efficacy of tocilizumab monotherapy in patients with RA is not
influenced by ACPA positivity
Insufficient reporting of
results
Hetland (2010)527 Radiographic progression and remission rates in early
rheumatoid arthritis – MRI bone oedema and anti-CCP predicted
radiographic progression in the 5-year extension of the double-
blind randomised CIMESTRA trial
Not prediction of treatment
response
Hirano (2015)528 Predictors of effectiveness in golimumab treatment and efficacy
of dose-escalation of golimumab in patients with rheumatoid
arthritis-a multicenter registry study TBCR
Not early RA
Hirata (2013)529 Repeated high or low multi-biomarker disease activity (Vectra®
DA algorithm) scores associated with radiographic outcomes in
patients with rheumatoid arthritis treated with tumor necrosis
factor inhibitors
Not early RA
Hirata (2015)530 Serum 14–3–η level is associated with severity and clinical
outcomes of rheumatoid arthritis, and its pretreatment level is
predictive of DAS28 remission with tocilizumab
Not early RA
Hoekstra (2003)531 Factors associated with toxicity, final dose, and efficacy of
methotrexate in patients with rheumatoid arthritis
Not early RA
Horton (2016)532 Discordance between the predictors of clinical and imaging
remission in patients with early rheumatoid arthritis in clinical
practice: implications for the use of ultrasound within a
treatment-to-target strategy
Not prediction of treatment
response
Hoshi (2011)533 Greater physical dysfunction is a negative predictor for achieving
Boolean-based remission in patients with rheumatoid arthritis
treated with tocilizumab
Not early RA
Hu (2011)534 Population approach for exposure–response modelling of
golimumab in patients with rheumatoid arthritis
Not early RA
Huizinga (2011)535 Very early rheumatoid arthritis is the major predictor of
major outcomes: clinical ACR remission and radiographic
non-progression – commentary
Not possible to obtain paper
Iagnocco (2015)536 Power Doppler ultrasound monitoring of response to anti-tumor
necrosis factor alpha treatment in patients with rheumatoid
arthritis
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Iannaccone (2011)537 Using genetic and clinical data to understand response to
disease-modifying anti-rheumatic drug therapy: data from the
Brigham and Women’s Hospital Rheumatoid Arthritis Sequential
Study
Not early RA
Iannone (2013)538 Etanercept therapy in rheumatoid arthritis patients with
moderate or severe disease activity
Not early RA
Iannone (2015)539 Early good EULAR response predicts low/remission disease state
in rheumatoid arthritis patients on treatment with certolizumab
in real life settings. Data from Italian registry GISEA
Not early RA
Ickinger (2011)540 Predictors of joint damage in South Africans with rheumatoid
arthritis
Not early RA
Ideguchi (2006)541 Bone erosions in rheumatoid arthritis can be repaired through
reduction in disease activity with conventional disease-modifying
antirheumatic drugs
Not early RA
Inanc (2013)542 Can ultrasonographic findings predict response to tumor
necrosis factor-alpha inhibitor treatment in rheumatoid arthritis?
Not early RA
Inanc (2014)543 Ultrasonographic assessment of joint inflammation in
rheumatoid arthritis: predictive value in response to tumor
necrosis factor-a inhibitor treatment
Not early RA
Inanc (2014)544 Ultrasonographic assessment of joint inflammation in
rheumatoid arthritis: predictive value in response to tumor
necrosis factor-alpha inhibitor treatment
Not early RA
Inanc (2016)545 Predictive value of ultrasonographic assessment of disease
activity in response to tumor necrosis factor-alpha inhibitor
treatment in rheumatoid arthritis: a prospective cohort study
Not early RA
Inoue (2009)546 Preliminary study to identify the predictive factors for the
response to methotrexate therapy in patients with rheumatoid
arthritis
Not early RA
Inoue (2015)547 Effect of smoking on remission proportions differs between
male and female patients with rheumatoid arthritis: a study
based on the IORRA survey
Not early RA
Isaacs (2009)548 Autoantibody-positive rheumatoid arthritis (RA) patients (PTS)
have enhanced clinical response to rituximab (RTX) when
compared with seronegative patients
Not possible to obtain paper
Isaacs (2013)549 Effect of baseline rheumatoid factor and anticitrullinated peptide
antibody serotype on rituximab clinical response: a meta-analysis
Not early RA
Ishiguro (2016)550 Effectiveness and safety of tocilizumab in achieving clinical and
functional remission, and sustaining efficacy in biologics-naive
patients with rheumatoid arthritis: the FIRST Bio study
Not early RA
Iwamoto (2009)551 Prediction of DAS28-ESR remission at 6 months by baseline
variables in patients with rheumatoid arthritis treated with
etanercept in Japanese population
Not early RA
Iwamoto (2016)552 Evaluation of switching from intravenous to subcutaneous
formulation of tocilizumab in patients with rheumatoid arthritis
Not possible to obtain paper
Izumi (2015)553 Baseline serum osteopontin levels predict the clinical
effectiveness of tocilizumab but not infliximab in biologic-naive
patients with rheumatoid arthritis: a single-centre prospective
study at 1 year (the Keio First-Bio Cohort Study)
Not early RA
Jansen (2001)554 Predictors of radiographic joint damage in patients with early
rheumatoid arthritis
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Jawaheer (2012)555 Sex differences in response to anti-tumor necrosis factor therapy
in early and established rheumatoid arthritis – results from the
DANBIO Registry
Not prediction of treatment
response
Jayakumar (2012)556 Sustained clinical remission in rheumatoid arthritis: prevalence
and prognostic factors in an inception cohort of patients treated
with conventional DMARDS
Not prediction of treatment
response
Jessome (2015)557 Does computerized segmentation of early erosions on magnetic
resonance imaging predict functional ability in rheumatoid
arthritis?
Not early RA
Jilani (2015)558 The role of citrullinated protein antibodies in predicting erosive
disease in rheumatoid arthritis: a systematic literature review and
meta-analysis
Not prediction of treatment
response
Jones (1994)559 Factors predicting outcome in rheumatoid arthritis Insufficient detail reported
Joo (2015)560 Clinical predictors of severe radiographic damage in Korean
patients with rheumatoid arthritis
Insufficient details reported on
methods and results for
prediction of treatment
response and model
construction
Jurgens (2014)561 Contribution of the individual components of the disease activity
score (DAS28) to the total DAS28 score among responders and
non-responders to biological therapy for rheumatoid arthritis
No eligible predictive factors
Jurgens (2015)562 Contribution of the subjective components of the disease
activity score to the response to biologic treatment in
rheumatoid arthritis
No eligible predictive factors
Kameda (2013)563 Continuation/discontinuation of methotrexate and clinical
response to etanercept determine the radiographic progression/
repair in patients with rheumatoid arthritis: a subanalysis of
52-week results from the JESMR study
No relevant outcomes
Kameda (2013)564 A merged presentation of clinical and radiographic data using
probability plots in a clinical trial, the JESMR study
Not early RA
Kaneko (2013)565 Predictors of clinical remission (DAS28CRP < 2.6) in patients with
RA who were treated with abatacept
Disease duration at baseline
not reported
Kaneshita (2015)566 Highly elevated rheumatoid factor is a risk factor for abatacept
treatment failure in Japanese patients with rheumatoid arthritis
Not early RA
Kanters (2014)567 What drives the comparative effectiveness of biologics vs.
methotrexate in rheumatoid arthritis? Meta-regression and
graphical inspection of suspected clinical factors
No relevant outcome
Karateev (2015)568 Dynamics of disease activity scores during the first 12 weeks
allow to predict the necessity in combination therapy with
methotrexate and biologics within T2T strategy in patients with
early and established rheumatoid arthritis (REMARCA study)
Not prediction of treatment
effect
Kastbom (2016)199 Changes in the anticitrullinated peptide antibody response in
relation to therapeutic outcome in early rheumatoid arthritis:
results from the SWEFOT trial
Not prediction of treatment
response
Katchamart (2010)569 Predictors for remission in rheumatoid arthritis patients:
a systematic review
Not prediction of treatment
response
Kawada (2016)570 Predictors of biological antirheumatic drug discontinuation in
patients with rheumatoid arthritis while in remission
Comment (not study findings)
Kawasaki (2013)571 Shorter disease duration is important for tocilizumab to achieve
Boolean remission
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Kawashiri (2013)572 Evaluation of the efficacy of tocilizumab toward the patients
with active rheumatoid arthritis of Nagasaki Prefecture, Japan
Not early RA
Kawashiri (2014)573 Baseline low modified health assessment questionnaire (MHAQ)
predicts the state of remission estimated by clinical disease
activity index and MHAQ at 1 year in tocilizumab-treated
rheumatoid arthritis patients
Not early RA
Kay (2014)574 Clinical disease activity and acute phase reactant levels are
discordant among patients with active rheumatoid arthritis:
acute phase reactant levels contribute separately to predicting
outcome at one year
Not early RA
Kekow (2010)575 Real life treatment with rituximab in TNF blocker non-responders
is superior to treatment with a second TNF blocker
Not early RA
Khan (2012)576 Smoking and rheumatoid factor status in predicting responses
to biologics
Not early RA
Kim (2016)577 No predictive effect of body mass index on clinical response in
patients with rheumatoid arthritis after 24 weeks of biological
disease-modifying antirheumatic drugs: a single-centre study
Not early RA
Kimura (2016)578 Time lag between the initiation of adalimumab after
methotrexate correlates with the efficacy of adalimumab in
rheumatoid arthritis patients
Not early RA
Klaasen (2009)579 Is the response to infliximab influenced by body mass index in
rheumatoid arthritis patients?
Not early RA
Klaasen (2009)580 The relationship between synovial lymphocyte aggregates and
the clinical response to infliximab in rheumatoid arthritis: a
prospective study
Not early RA
Klaasen (2011)581 Body mass index and clinical response to infliximab in
rheumatoid arthritis
Not early RA
Knudsen (2008)205 Biomarkers of inflammation in patients with unclassified
polyarthritis and early rheumatoid arthritis. Relationship to
disease activity and radiographic outcome
Not prediction of treatment
response
Koike (2012)582 Safety and effectiveness responses to etanercept for rheumatoid
arthritis in Japan: a sub-analysis of a post-marketing surveillance
study focusing on the duration of rheumatoid arthritis
Not early RA
Koike (2014)583 Effectiveness and safety of tocilizumab: postmarketing
surveillance of 7901 patients with rheumatoid arthritis in Japan
Not early RA
Kojima (2011)584 Early aggressive intervention for rheumatoid arthritis increases
rate of remission defined using a Boolean approach in clinical
practice with tocilizumab
Not early RA
Kojima (2013)585 Importance of concomitant MTX use during treatment with
tocilizumab in patients with rheumatoid arthritis
Not early RA
Kojima (2013)586 Relationship between physicians’ decision to use concomitant
glucocorticoid and remission during treatment with tocilizumab
in patients with background of limited dose of MTX
Not early RA
Kojima (2014)587 Importance of methotrexate therapy concomitant with
tocilizumab treatment in achieving better clinical outcomes for
rheumatoid arthritis patients with high disease activity: an
observational cohort study
Not early RA
Kojima (2015)588 Importance of both disease activity at 12 weeks and clinical
response up to 12 weeks to predict achievement of low disease
activity at 52 weeks during abatacept treatment in biologics-
switching patients with rheumatoid arthritis: a multicenter
observational cohort study in Japan
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Kojima (2015)589 Predictive factors for achieving low disease activity at 52 weeks
after switching from tumor necrosis factor inhibitors to
abatacept: results from a multicenter observational cohort study
of Japanese patients
Not early RA
Kotak (2013)590 Characteristics of a moderate rheumatoid arthritis patient
population who lost remission or low disease activity: data from
the Consortium of Rheumatology Researchers of North America,
Inc. (CORRONA)
Not early RA
Kovalchik (2012)591 An association study of disease activity score components and
patient satisfaction with overall health for early RA patients on
non-biologic DMARD therapy
No relevant outcome measure
Kristensen (2008)592 Predictors of response to anti-TNF therapy according to ACR and
EULAR criteria in patients with established RA: results from the
South Swedish Arthritis Treatment Group Register
Not early RA
Kronisch (2016)593 Brief report: predicting functional disability: one-year results
from the Scottish early rheumatoid arthritis inception cohort
Mixed RA and UA population
with no separate analyses
Kruger (2012)594 Reduction in sickness absence in patients with rheumatoid
arthritis receiving adalimumab: data from a German
noninterventional study
Not early RA
Kumar (2002)595 Validation of an Indian version of the Health Assessment
Questionnaire in patients with rheumatoid arthritis
Not prediction of treatment
effect
Kume (2012)596 Anti-cyclic citrullinated protein antibodies as a predictor of
response to tocilizumab in patients with rheumatoid arthritis a
prospective study
No definition of duration of
RA and no full text identified
Kuriya (2014)597 Earlier time to remission predicts sustained clinical remission in
early rheumatoid arthritis – results from the Canadian Early
Arthritis Cohort (CATCH). Predictors of sustained clinical
remission in early rheumatoid arthritis-results from the Canadian
early arthritis cohort
Not prediction of treatment
response
Kuriya (2015)598 Working status and improvements in work productivity over
time in an early rheumatoid arthritis (ERA) cohort
No baseline predictors
(6 months)
Kynde (2014)599 Delay in RA diagnosis of more than 12 months is associated
with deteriorated functional status in patients in bDMARD
treatment-results from a prospective study
No definition of duration of
RA
Lard (200)600 Early versus delayed treatment in patients with recent-onset
rheumatoid arthritis: comparison of two cohorts who received
different treatment strategies
Not prediction of treatment
response
Le Blay (2014)601 Progressive spacing tocilizumab infusions after remission in
rheumatoid arthritis: the absence of erosion would be
determinant in choosing this strategy
Not early RA
Lee (2008)602 Disease Activity Score (DAS) and Health Assessment Questionnaire
(HAQ) values show similar changes from baseline to endpoint in
clinical trials of biological agents in patients with rheumatoid
arthritis (RA)
Not prediction of treatment
response
Lee (2013)603 Application of a multi-biomarker disease activity (Vectra® DA)
score for assessing rheumatoid arthritis patients with
fibromyalgia or low C-reactive protein
Not prediction of treatment
effect
Li (2015)604 Efficacy and safety results from a Phase 3, randomized, placebo-
controlled trial of subcutaneous golimumab in Chinese patients
with active rheumatoid arthritis despite methotrexate therapy
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Li (2015)218 Relationship of multi-biomarker disease activity score and other
risk factors with radiographic progression in an observational
study of patients with rheumatoid arthritis
Not prediction of treatment
response [and median disease
duration suggests not early
RA – although it was an early
RA (< 2 years) cohort]
Lie (2006)605 Predictors of response to methotrexate treatment: Results from
a longitudinal observational study of 876 patients with RA
[abstract]
Not prediction of treatment
response
Lie (2011)606 Characterization of long-term responders to first treatment
course of rituximab (RTX) results from the CERERRA
collaboration
Not early RA
Lie (2011)607 Early versus delayed retreatment with rituximab (RTX) in relation
to long term clinical response data from the CERERRA
collaboration
No definition of duration of
RA
Lie (2012)608 Effectiveness of sulfasalazine and methotrexate in 1102
DMARD-naive patients with early RA
Not prediction of treatment
effect
Lima (2013)609 The influence of clinical and genetic variables on methotrexate
effectiveness in Portuguese rheumatoid arthritis patients
Not early RA
Liu (2015)610 Impact of obesity on the disease course of rheumatoid arthritis Insufficient detail reported
Ljung (2011)611 New assay generation for antibodies against modified and
citrullinated peptides predicts poor response to TNF inhibitor
therapy
Not early RA
Loppin (2010)612 Low rate of rheumatoid arthritis remission in real life: might
predictive factors explain?
Incomplete definition of
duration of disease and
no full text identified
Lukas (2010)613 Repair of erosions occurs almost exclusively in damaged joints
without swelling
Not early RA
Lv (2014)614 The status of rheumatoid factor and anti-cyclic citrullinated
peptide antibody are not associated with the effect of anti-TNFA
agent treatment in patients with rheumatoid arthritis: a meta-
analysis
Not early RA
Ma (2009)615 HAQ and gender predict remission in early RA: experience in the
Early Rheumatoid Arthritis Network (ERAN)
Insufficient reporting of
duration of disease at baseline
Ma (2009)616 Predicting remission in trial of intensive therapy in early RA:
HAQ and gender are key factors
Insufficient details reported on
methods
Ma (2012)236 Remission in early rheumatoid arthritis: predicting treatment
response
Not prediction of treatment
response
Ma (2013)617 A multi-biomarker disease activity (Vectra™ DA algorithm) score
and components are associated with sustained clinical remission
in rheumatoid arthritis: the REMIRA study
Not early RA
Ma (2014)235 Clinical and serological predictors of remission in rheumatoid
arthritis are dependent on treatment regimen
Not prediction of treatment
response
Ma (2014)618 Multi-biomarker disease activity (Vectra® DA algorithm) score is
associated with power Doppler ultrasound in patients with
rheumatoid arthritis in low disease activity state: the REMIRA
cohort
Not early RA
Ma (2014)618 Multi-biomarker disease activity (Vectra DA algorithm) score is
associated with power Doppler ultrasound in patients with
rheumatoid arthritis in low disease activity state: The REMIRA
cohort
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Macchioni (2013)619 Ultrasonographic predictors for the development of joint
damage in rheumatoid arthritis patients: a single joint
prospective study
Not prediction of treatment
response
Machado (2012)620 Predictors of rheumatoid arthritis: quantitative and
semiquantitative sonographic measurements of peripheral joints
Not prediction of treatment
response
Makinen (2008)621 Sex: a major predictor of remission as measured by 28-joint
Disease Activity Score (DAS28) in early rheumatoid arthritis?
Not prediction of treatment
response
Mancarella (2007)622 Good clinical response, remission, and predictors of remission in
rheumatoid arthritis patients treated with tumor necrosis factor-
alpha blockers: the GISEA study
Not early RA
Manders (2013)623 Are TNF blocking agents associated with changes in work
participation in patients with RA?
Not early RA
Manders (2014)624 Determinants associated with work participation in patients with
established rheumatoid arthritis taking tumor necrosis factor
inhibitors
Not early RA
Maneiro (2013)625 Rheumatoid factor as predictor of response to abatacept,
rituximab and tocilizumab in rheumatoid arthritis: systematic
review and meta-analysis (Provisional abstract)
Not early RA
Maneiro (2013)625 Rheumatoid factor as predictor of response to abatacept,
rituximab and tocilizumab in rheumatoid arthritis: systematic
review and meta-analysis
Not early RA
Maneiro (2013) 626 Rheumatoid factor as predictor of response to non TNF
antagonist biologic therapies in rheumatoid arthritis: systematic
review and meta-analysis
Insufficient detail
Markusse (2013)627 Initial combination therapy in early rheumatoid arthritis: which
patients benefit?
No relevant predictors
Marotte (2010)628 Biomarkers for prediction of TNFalpha blockers response in
rheumatoid arthritis
Review (not systematic)
Martin (2014)629 Older age at rheumatoid arthritis onset and comorbidities
correlate with less health assessment questionnaire-disability
index and clinical disease activity index response to etanercept in
the RADIUS 2 registry
Not early RA
Martin-Mola (2016)630 Anti-citrullinated peptide antibodies and their value for
predicting responses to biologic agents: a review
Review (not systematic)
Matsushita (2016)631 Radiographic changes and factors associated with subsequent
progression of damage in weight-bearing joints of patients with
rheumatoid arthritis under TNF-blocking therapies. Three-year
observational study
Not possible to obtain paper
Matteson (2004)111 How aggressive should initial therapy for rheumatoid arthritis
be? Factors associated with response to ‘non-aggressive’
DMARD treatment and perspective from a 2-yr open label trial
Single-arm study (not able to
assess prediction of treatment
response)
Mattey (2009)632 Relationship between pack-year history of smoking and
response to tumor necrosis factor antagonists in patients with
rheumatoid arthritis
Not early RA
Miceli-Richard
(2006)633
Analysis of the shared epitope and selected pro- and anti-
inflammatory cytokine genes polymorphism as predictive factors
of response to adalimumab in rheumatoid arthritis patients
treated in the ReAct study
No baseline disease duration
reported; no relevant
predictor; no relevant
outcome
Mirpourian (2014)634 The association of body mass index with disease activity and
clinical response to combination therapy in patients with
rheumatoid arthritis
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Miwa (2013)635 Factors leading to HAQ remission after beginning biologics
treatment in patients with rheumatoid arthritis
No definition of duration of
RA reported and no full text
identified
Miyoshi (2013)636 A novel method predicting good response using only
background clinical data in RA patients treated with infliximab
Insufficient detail
Molina (2015)637 Association of socioeconomic status with treatment delays,
disease activity, joint damage, and disability in rheumatoid
arthritis
Not early RA
Moorthy (2007)638 Does smoking predict poor response to anti-TNF therapy for
rheumatoid arthritis?
Not early RA
Mottonen (2002)639 Delay to institution of therapy and induction of remission using
single drug or combination–disease-modifying antirheumatic
drug therapy in early rheumatoid arthritis
No relevant outcomes
Munro (1997)640 C-reactive protein levels correlate with functional outcome Not early RA
Nagasawa (2009)641 Improvement of the HAQ score by infliximab treatment in
patients with RA: its association with disease activity and
joint destruction
Not early RA
Nair (2016)642 A personalized approach to biological therapy using prediction
of clinical response based on MRP8/14 serum complex levels in
rheumatoid arthritis patients
Not early RA
Narvaez (2010)643 Predictors of response to rituximab in patients with active
rheumatoid arthritis and inadequate response to anti-TNF
agents or traditional DMARD
Not early RA
Narvaez (2011)644 Predictors of response to rituximab in patients with active
rheumatoid arthritis and inadequate response to anti-TNF
agents or traditional DMARDs
Not early RA
Navarro-Millan
(2013)645
Predictors and persistence of new-onset clinical remission in
rheumatoid arthritis patients
Not early RA
Nawata (2008)646 Discontinuation of infliximab in rheumatoid arthritis patients in
clinical remission
Not early RA
Nguyen (2012)647 The prevalence of the ultrasonographic positive power Doppler
synovitis is high and predicts the risk of relapse and structural
progression in rheumatoid arthritis in clinical remission:
a systematic literature review and meta analysis
Not prediction of treatment
response
Nguyen (2014)648 Prevalence of ultrasound-detected residual synovitis and risk
of relapse and structural progression in rheumatoid arthritis
patients in clinical remission: a systematic review and
meta-analysis
Not prediction of treatment
response
Nishimoto (2013)649 Drug free REmission/low disease activity after cessation of
tocilizumab (Actemra) Monotherapy (DREAM) study
Not early RA
Nishino (2015)650 Ultrasound evaluation of the efficacy of biologic and targeted
synthetic DMARDs toward rheumatoid arthritis patients:
Kyushu multicenter rheumatoid arthritis ultrasound prospective
observational cohort in Japan
No definition of duration of
RA reported and no full text
identified
Nishiyama (2013)651 To develop a regression model for predicting damage-related
HAQ: a nationwide study based on the ninja (national database
of rheumatic diseases by iR-net in Japan) 2011
Not prediction of treatment
response
Nixon (2007)652 Using mixed treatment comparisons and meta-regression to
perform indirect comparisons to estimate the efficacy of biologic
treatments in rheumatoid arthritis
Insufficient detail reported
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Nordberg (2016)653 Patients with seronegative RA have more inflammatory activity
compared with patients with seropositive RA in an inception
cohort of DMARD-naive patients classified according to the
2010 ACR/EULAR criteria
Not prediction of treatment
response
Ogawa (2015)654 Titre of anti-citrullinated peptide antibody affects the efficacy of
first biological treatment in rheumatoid arthritis
Not early RA
Oguma (2013)655 (F) good outcomes at week 24 is lead by early introduction of
tocilizumab and favorable treatment response up to week 12
Not early RA
Okada (2012)656 Characteristic of the Japanese patients with rheumatoid arthritis
(RA) of rapid radiographic progression (RRP) treated with
synthetic disease modifying anti-rheumatic drugs (DMARDs) in
daily practice: a large-scale prospective longitudinal cohort study
(the 1st report of apple survey)
No definition of duration of
RA reported and no full text
identified
Okada (2013)657 Characteristic of the Japanese patients with rheumatoid arthritis
(RA) of rapid radiographic progression (RRP) treated with
synthetic disease modifying anti-rheumatic drugs (DMARDs) in
daily practice: a large-scale prospective longitudinal cohort study
No definition of duration of
RA reported and no full text
identified
Okada (2013)658 Evaluation of the Japanese patients with rheumatoid arthritis
(RA) of rapid radiographic progression (RRP) treated with
synthetic disease modifying anti-rheumatic drugs (DMARDs) in
daily practice: a large-scale prospective longitudinal cohort study
(an interim report of Apple Survey)
No definition of duration of
RA reported and no full text
identified
Okada (2014)659 Evaluation of the Japanese patients with rheumatoid arthritis
(RA) of rapid radiographic progression (RRP) treated with
synthetic disease modifying anti-rheumatic drugs (DMARDs) in
daily practice: a large-scale prospective longitudinal cohort study
No definition of duration of
RA reported and no full text
identified
Ometto (2015)660 Self-reported flares predict radiographic progression in
rheumatoid arthritis patients in remission undergoing etanercept
tapering
Duration of disease at
baseline not reported in EN
abstract
Ono (2014)661 The impacts of disease of the joints on modified health
assessment questionnaire scores in rheumatoid arthritis patients:
a retrospective study using the national database of rheumatic
diseases by iR-net in Japan
Not early RA
Onuora (2012)662 Rheumatoid arthritis: how bad is obesity for RA? Review (not systematic)
Opris (2014)663 Serum drug level and anti-citrullinated peptide antibodies as
biomarkers that predict EULAR response in rheumatoid arthritis-
a new step to personalized medicine
Not prediction of treatment
response
Opris (2015)664 Active synovitis in rheumatoid arthritis patients while being on
SDAI remission
Not early RA
Ortiz (2014)665 Is there a difference in the effectiveness in the treatment of
rheumatoid arthritis with rituximab in patients with rheumatoid
factor positive and negative? A systematic review
Insufficient detail
Osipyants (2013)666 Associations between functional status and ultrasound-detected
synovitis and joint damage in rheumatoid arthritis during
tocilizumab treatment
Not early RA
Osipyants (2013)667 Imaging rather than clinical inflammation is associated with
radiographic progression in tocilizumab-treated rheumatoid
arthritis patients
Not early RA
Ottaviani (2015)668 Body mass index and response to infliximab in rheumatoid
arthritis
Not early RA
Pamuk (2015)669 Work productivity in rheumatoid arthritis: analysis from
multicenter Turkish study
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Papadopoulos
(2005)257
Does cigarette smoking influence disease expression, activity
and severity in early rheumatoid arthritis patients?
Not prediction of treatment
response
Pascual-Ramos
(2009)670
Hypervascular synovitis and American College of Rheumatology
Classification Criteria as predictors of radiographic damage in
early rheumatoid arthritis
Not prediction of treatment
response
Pavelka (2010)671 Prediction of radiographic progression of rheumatoid arthritis Language not English
Peltea (2014)672 Predictive factors for the EULAR response in RA patients with
rituximab treatment
No definition of duration of
RA and no full text identified
Peluso (2011)673 Clinical and ultrasonographic remission determines different
chances of relapse in early and long standing rheumatoid
arthritis
No relevant outcomes
Pers (2013)674 Multicenter retrospective study: response to tocilizumab in
clinical practice is not influenced by the number of previous
biotherapy or by association with a DMARD
Not early RA
Pers (2014)675 Predictors of response and remission in a large cohort of
rheumatoid arthritis patients treated with tocilizumab in
clinical practice
Not early RA
Pers (2014)676 TNFRII polymorphism is associated with response to TNF blockers
in rheumatoid arthritis patients seronegative for ACPA
Not early RA
Pers (2015)677 Response to tocilizumab in rheumatoid arthritis is not influenced
by the body mass index of the patient
Not early RA
Peterfy (2011)678 Baseline levels of the inflammatory biomarker C-reactive protein
are significantly correlated with magnetic resonance imaging
measures of synovitis at baseline and after 26 weeks of
treatment in patients with early rheumatoid arthritis
No eligible end point
Peterfy (2012)679 Baseline levels of the inflammatory biomarker CRP are
significantly correlated with MRI measures of synovitis at
baseline and after 26 weeks of treatment in patients with
early rheumatoid arthritis
No eligible end point
Plant (2000)261 Relationship between time-integrated C-reactive protein levels
and radiologic progression in patients with rheumatoid arthritis
Not prediction of treatment
response
Plant (2005)680 What factors influence functional ability in patients with
rheumatoid arthritis. Do they alter over time?
Not early RA
Pomirleanu (2013)681 A predictive model for remission and low disease activity in
patients with established rheumatoid arthritis receiving TNF
blockers
Not early RA
Pope (2011)682 Does C-reactive protein add value in active rheumatoid arthritis?
Results from the Optimisation of Humira Trial
Not early RA
Puolakka (2004)683 High self-esteem is associated with low HAQ score in patients
with rheumatoid arthritis
Not prediction of treatment
response
Quartuccio (2009)684 Rheumatoid factor positivity rather than anti-CCP positivity, a
lower disability and a lower number of anti-TNF agents failed
are associated with response to rituximab in rheumatoid arthritis
Not early RA
Quintana-Duque
(2016)685
Predictors of remission, erosive disease and radiographic
progression in a Colombian cohort of early onset rheumatoid
arthritis: a 3-year follow-up study
Not prediction of treatment
response
Radovits (2007)686 Influence of age and gender on the interpretation of the Disease
Activity Score-28 (DAS28) in rheumatoid arthritis
Disease duration at baseline
not reported
Ranganath (2015)687 Elevated baseline power Doppler discriminates an RA subgroup
highly responsive to therapy
No definition of duration of
RA and no full text identified
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Rantalaiho (2015)688 Vitality, presenteeism, and their determinants in patients with
early rheumatoid arthritis treated with a 6-month induction
infliximab therapy added on a triple combination therapy
No eligible end point
Rashid (2015)689 Factors and reasons associated with switching in rheumatoid
arthritis patients newly initiated on biologic DMARDs and impact
on health care resource utilization in a managed care
organization
No relevant outcomes
Rashid (2015)690 Factors and reasons associated with switching in rheumatoid
arthritis patients experienced on biologic DMARDs and impact
on health care resource utilization in an integrated healthcare
system
No relevant outcomes
Rech (2015)691 Prediction of disease relapses by multi-biomarker disease test
activity in rheumatoid arthritis patients tapering DMARD
treatment
Not early RA
Reina (2013)692 Predictive factors of response to tocilizumab in patients with
active rheumatoid arthritis
Not early RA
Rezaei (2012)267 In early rheumatoid arthritis, patients with a good initial
response to methotrexate have excellent 2-year clinical
outcomes, but radiological progression is not fully prevented:
data from the methotrexate responders population in the
SWEFOT trial
Not prediction of treatment
response
Rich (1999)693 Paucity of radiographic progression in rheumatoid arthritis
treated with methotrexate as the first disease modifying
antirheumatic drug
Not prediction of treatment
response
Rkain (2011)694 Clinical and ultrasonographic assessment of evolution in patients
with rheumatoid arthritis treated with tocilizumab
Not early RA
Rodrigues (2014)695 Obesity is a risk factor for worse treatment response in
rheumatoid arthritis patients – results from reuma.pt
Not prediction of treatment
response
Romao (2015)696 Clinical and pathological differences of elderly- and younger-
onset rheumatoid arthritis in an early arthritis cohort
Insufficient detail reported on
duration of RA and no full
text identified
Rother (1996)697 Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid
arthritis: a prospective study
Not early RA
Ruiz-Esquide (2011)698 Effects of smoking on disease activity and radiographic
progression in early rheumatoid arthritis
Not prediction of treatment
response
Russell (2012)699 Efficacy with abatacept in patients with earlier versus more
longstanding disease: insights from the AIM trial
Not early RA
Saevarsdottir (2011)74 Development of a matrix risk model to predict rapid
radiographic progression in early rheumatoid arthritis.
Results from a randomized trial population
Not prediction of treatment
response
Saevarsdottir
(2011)270
Patients with early rheumatoid arthritis who smoke are less likely
to respond to treatment with methotrexate and tumor necrosis
factor inhibitors: observations from the Epidemiological
Investigation of Rheumatoid Arthritis and the Swedish
Rheumatology Register cohorts
Low methodological quality
(overlap in treatment arms)
Saevarsdottir
(2011)700
Predicting response to treatment in patients with rheumatoid
arthritis
Not possible to obtain paper
Saevarsdottir
(2011)269
Predictors of response to methotrexate in early DMARD naïve
rheumatoid arthritis: results from the initial open-label phase of
the SWEFOT trial
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Saevarsdottir (2012)701 Predictive value of anti-CCP positivity on disease course and
response to therapy in early rheumatoid arthritis. Results from
the Swedish EIRA study
Insufficient detail on
treatment response
Sagawa (2014)702 Long-term treatment with tocilizumab (TCZ) strongly suppresses
joint destruction in biologic-naive patients with rheumatoid
arthritis (RA) regardless of inflammation status
Not early RA
Sakthiswary (2014)703 IgA rheumatoid factor as a serological predictor of poor
response to tumour necrosis factor alpha inhibitors in
rheumatoid arthritis
Not early RA
Salgado (2011)704 Influence of baseline rheumatoid factor on the response to
tumor necrosis factor antagonists of rheumatoid arthritis
patients: a systematic review and meta-analysis
Not early RA
Salgado (2013)705 Rheumatoid factor and response to TNF antagonists in
rheumatoid arthritis: systematic review and meta-analysis of
observational studies
Not early RA
Salgado (2013)706 Rheumatoid factor does not predict response to TNF antagonists
in rheumatoid arthritis: three centers experience
Not early RA
Salgado (2013)707 The effect of rheumatoid factor titre on the response to TNF
antagonists
Not early RA
Salgado (2014)708 Rheumatoid factor and response to TNF antagonists in
rheumatoid arthritis: systematic review and meta-analysis of
observational studies (provisional abstract)
Not early RA
Salgado (2015)709 Predictors of response to TNF antagonists Review (not systematic)
Sanmartí (2003)710 Radiological progression in early rheumatoid arthritis after
DMARDS: a one-year follow-up study in a clinical setting
Not prediction of treatment
response
Sanmartí (2007)75 Prognostic factors of radiographic progression in early
rheumatoid arthritis: a two year prospective study after a
structured therapeutic strategy using DMARDs and very low
doses of glucocorticoids
Not prediction of treatment
response
Sasso (2014)711 The multi-biomarker disease activity score as a predictor of
radiographic progression in a registry of patients with
rheumatoid arthritis
Not early RA
Sauer (2015)712 Effectiveness and costs of biologics in veterans with rheumatoid
arthritis
Disease duration at baseline
not reported
Schulman (2015)713 High body mass index negatively impacts time to achieving
sustained remission in early rheumatoid arthritis: results from a
multicenter early arthritis cohort study
Insufficient details reported on
assessment of prediction of
treatment response
Segaud (2014)714 Therapeutic response to tocilizumab in rheumatoid arthritis:
does body weight have an influence?
No definition of duration of
RA at baseline and no full text
identified
Sekiguchi (2015)715 Predicting factors associated with sustained clinical remission by
abatacept are different between in younger and elderly patients
with biologic-naive rheumatoid arthritis (ABROAD study)
Not early RA; no relevant
predictive factors
Sekiguchi (2016)716 Differences in predictive factors for sustained clinical remission
with abatacept between younger and elderly patients with
biologic-naive rheumatoid arthritis: results from the ABROAD
study
Not early RA
Sellam (2011)717 B cell activation biomarkers as predictive factors for the response
to rituximab in rheumatoid arthritis: a six-month, national,
multicenter, open-label study
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Sergeant (2015)718 Lifestyle, clinical and psychosocial predictors of good response to
methotrexate therapy in the rheumatoid arthritis medication
study (RAMS)
Single-arm study (not able to
assess prediction of treatment
response)
Shah (2014)719 Serum anti-CCP antibody and its correlation with disease activity
in local Pakistani rheumatoid arthritis patients
Not early RA
Sharma (2014)720 Biologic de-escalation in rheumatoid arthritis: cost savings and
clinical success
No relevant outcomes
Shen (2010)277 Serum biomarkers predict progressive structural damage in the
BeSt study
Not prediction of treatment
response
Sherrer (1987)721 Disability in rheumatoid arthritis: comparison of prognostic
factors across three populations
Not early RA
Shiozawa (2013)722 MMP-3 as a predictor that identifies a subgroup with potential
radiographic progression requiring additional biologics to halt
future progression among the rheumatoid arthritis patients
succeedingly treated with methotrexate (MTX) alone
Not early RA
Shrestha (2013)723 Effect of body mass index on clinical response to anti-TNF
therapies in rheumatoid arthritis: a retrospective study
No definition of duration of
RA at baseline and no full text
identified
Shrestha (2013)724 Effect of body mass index on clinical response to anti-TNF
therapy in rheumatoid arthritis
No definition of duration of
RA at baseline and no full text
identified
Shu (2014)725 Impact of missing anti-cyclic citrullinated peptide (CCP) antibody
serology on clinical outcomes in early rheumatoid arthritis:
results from catch (Canadian early arthritis cohort)
Not prediction of treatment
response
Sibilia (2012)726 Abatacept confers clinical efficacy regardless of baseline CRP
status in patients with rheumatoid arthritis and inadequate
response to methotrexate in the aim trial
Not early RA
Simone (2014)727 Genetic and clinical predictors of response to TNF-alpha therapy
in an Italian axial-SPA cohort
Not RA
Simone (2014)728 Genetic and clinical predictors of response to TNF blocker in an
Italian axial-SPA cohort
Not RA
Smith (2013)729 Can CD11C expression successfully predict response to
etanercept in rheumatoid arthritis patients?
Not early RA
Smolen (2011)730 Baseline predictors of remission with combination etanercept-
methotrexate therapy in moderately active rheumatoid arthritis:
Interim results of the preserve trial
Not early RA
Smolen (2012)731 Tocilizumab inhibits progression of joint damage in rheumatoid
arthritis irrespective of its anti-inflammatory effects:
disassociation of the link between inflammation and destruction
Not early RA
Smolen (2015)732 The effect of prior disease duration and prior DMARD use on
treatment outcomes in patients with early or established
rheumatoid arthritis
No eligible factor
Sockalingam (2009)733 Prevalence of anti cyclic citrullinated peptide antibodies in
Malaysian rheumatoid arthritis patients and its correlation
with disease activity
Not prediction of treatment
response
Soderlin (2011)734 Absent ‘Window of Opportunity’ in smokers with short disease
duration. Data from BARFOT, a multicenter study of early
rheumatoid arthritis
Insufficient details reported on
assessment of prediction of
treatment response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Soderlin (2012)735 The effect of smoking on response and drug survival in
rheumatoid arthritis patients treated with their first anti-TNF
drug
Not early RA
Soderlin (2013)736 Second-hand exposure to tobacco smoke and its effect on
disease activity in Swedish rheumatoid arthritis patients.
Data from BARFOT, a multicenter study of RA
No relevant predictors
Sokka (2000)737 Scores for functional disability in patients with rheumatoid
arthritis are correlated at higher levels with pain scores than
with radiographic scores
Not early RA
Solau-Gervais
(2012)738
Efficacy of rituximab in the treatment of rheumatoid arthritis.
Influence of serological status, coprescription of methotrexate
and prior TNF-alpha inhibitors exposure
Not early RA
Soliman (2011)739 Predictors of response to rituximab in patients with rheumatoid
arthritis: results from the British Society for Rheumatology
Biologics Register (BSRBR)
Not early RA
Srirangan (2013)740 Functional outcome in response to treatment with DMARDs
compared to anti-TNF agents in a cohort with rheumatoid
arthritis
Not early RA
Stagnaro (2013)741 A useful mathematical model able to predict the early response
to tocilizumab in rheumatoid arthritis
Insufficient detail reported
Stavropoulos-
Kalinoglou (2007)742
Redefining overweight and obesity in rheumatoid arthritis
patients
Not prediction of treatment
response
Steunebrink (2015)743 Superiority of initial combination-over step up therapy in
treatment to the target of remission in daily clinical practice in
early rheumatoid arthritis patients: results from the DREAM
registry
Disease duration at baseline
not reported
Strand (2012)744 Factors that impact work productivity in the preserve trial:
a randomized controlled trial of combination etanercept-
methotrexate therapy in patients with moderately active
rheumatoid arthritis
Not early RA
Strand (2013)745 Predictors of work impairment in a randomized controlled trial
of etanercept-methotrexate therapy in patients with moderate
rheumatoid arthritis
Not early RA
Strand (2015)746 The impact of rheumatoid arthritis on work and predictors of
overall work impairment from three therapeutic scenarios
Not early RA
Sauer (2015)712 Effectiveness and costs of biologics in veterans with rheumatoid
arthritis
Disease duration at baseline
not reported
Szekanecz (2015)747 Analysis of the association between cigarette smoking and
clinical response to certolizumab pegol treatment in Hungarian
patients with rheumatoid arthritis
No baseline disease duration
reported and no full text
identified
Tada (2013)748 Predictive factors for radiographic progression in low- and
standard-dose etanercept therapy for rheumatoid arthritis from
the prevention of cartilage destruction by etanercept (precept)
study
Not early RA
Tak (2012)749 A personalised medicine approach to biologic treatment of
rheumatoid arthritis: a preliminary treatment algorithm
Not a prediction model or
primary study
Takeuchi (2011)750 Clinical, radiographic and functional effectiveness of tocilizumab
for rheumatoid arthritis patients-REACTION 52-week study
Not early RA
Takeuchi (2014)751 Analysis on predictors for long-term clinical efficacies of
golimumab in patients with rheumatoid arthritis
Not early RA
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
266
TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Takeuchi (2014)752 Impact of disease duration before starting adalimumab
treatment on work productivity in Japanese patients with
rheumatoid arthritis; analysis of 24-weeks data from the
ANOUVEAU study
Not early RA
Tam (2007)753 Rapid improvement in rheumatoid arthritis patients on
combination of methotrexate and infliximab: clinical and
magnetic resonance imaging evaluation
Not early RA
Tamai (2012)754 Magnetic resonance imaging-proven osteitis at baseline predicts
the early rheumatoid arthritis patients who will develop rapid
radiographic progression: MRI is beneficial to find the window
of opportunity in early RA
No relevant predictors
Tamai (2014)755 Investigation of MRI bone changes in early-stage RA patients
achieved in sustained clinical good response: sub-analysis from
Nagasaki University early arthritis cohort
No relevant predictors
Tanaka (2008)756 Efficient management of rheumatoid arthritis significantly
reduces long-term functional disability
Not early RA
Tanaka (2012)757 Prevention of joint destruction in patients with high disease
activity or high C-reactive protein
Not early RA
Tanaka (2012)758 Structural damages disturb functional improvement in patients
with rheumatoid arthritis treated with etanercept
Not early RA
Tanaka (2013)759 Efficacy and safety of tocilizumab therapy in rheumatoid
arthritis: prevalence and predictive factors of sustained remission
Not early RA
Tanaka (2015)760 A longitudinal study of factors contributing to the worsening of
absenteeism in patients with rheumatoid arthritis based on the
IORRA cohort
Not early RA
Tanaka (2016)761 Prevention of joint destruction in patients with high disease
activity or high C-reactive protein levels: post hoc analysis of the
GO-FORTH study
Not possible to obtain paper
Teitsma (2015)762 Predicting the need for additional treatment in early rheumatoid
arthritis patients treated to target on methotrexate monotherapy
Insufficient details reported on
assessment of prediction of
treatment response
Terao (2015)763 Rheumatoid factor is associated with the distribution of hand
joint destruction in rheumatoid arthritis
Not early RA
Thorne (2014)764 Effectiveness and safety of infliximab in rheumatoid arthritis:
analysis from a Canadian multicenter prospective observational
registry
Not early RA
Tolusso (2010)765 Analysis of the association of CDA (cytidin deaminase) (K27Q),
TNF-(–308G>A) and PTPN22 R620W genetic polymorphisms
with auto-antibody seropositive RA and the response to B cell
depletion
No baseline disease duration
reported (Also no relevant
predictors)
Tony (2011)766 Predictive factors for response to rituximab in patients with
rheumatoid arthritis (FIRST)
Not possible to obtain paper
Torrente-Segarra
(2014)767
Assessment of 12-month efficacy and safety of 168
certolizumab pegol rheumatoid arthritis treated patients from a
multicenter retrospective national study in Spain
Not early RA
Torrente-Segarra
(2016)768
RENACER study: assessment of 12-month efficacy and safety of
168 certolizumab PEGol rheumatoid arthritis-treated patients
from a Spanish multicenter national database
Not early RA
Troelsen (2012)769 IgG glycosylation changes and MBL2 polymorphisms:
associations with markers of systemic inflammation and joint
destruction in rheumatoid arthritis
Not early RA
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Tsuji (2014)770 Baseline procalcitonin (PCT) level as a predictive marker for
clinical remission (DAS28-ESR, CDAI) at 52 weeks in biologic
naive rheumatoid arthritis (RA) patients treated by tocilizumab
(TCZ); a single centre retrospective study
Disease duration at baseline
not reported
Ursum (2010)771 Levels of anti-citrullinated protein antibodies and IgM
rheumatoid factor are not associated with outcome in early
arthritis patients: a cohort study
Not early RA
van den Broek
(2012)772
The association of treatment response and joint damage with
ACPA-status in recent-onset RA: a subanalysis of the 8-year
follow-up of the BeSt study
Not prediction of treatment
response
van den Broek
(2013)773
Personalized medicine: predicting responses to therapy in
patients with RA
Review (not systematic)
van der Heijde
(2005)774
Baseline CRP concentrations predict radiographic progression in
MTX-naive patients with recent-onset RA: subanalysis of the
PREMIER study [abstract]
Not prediction of treatment
response
van der Helm-van Mil
(2005)296
Antibodies to citrullinated proteins and differences in clinical
progression of rheumatoid arthritis
Not prediction of treatment
response
van der Helm-van Mil
(2008)775
A high body mass index has a protective effect on the amount
of joint destruction in small joints in early rheumatoid arthritis
Not prediction of treatment
response
van Der Horst-
Bruinsma (2011)776
Inclusion criteria based on DAS28 score: strength of
improvement is less dependent on baseline disease activity than
expected
Commentary (not a study)
van der Maas
(2014)777
Validity of OMERACT preliminary flare questions in a
randomized controlled trial, that assesses impact of disease
activity guided down-titration of anti-TNF treatment in
rheumatoid arthritis patients in low disease activity
Not early RA
van der Woude
(2009)778
Prevalence of and predictive factors for sustained disease-
modifying antirheumatic drug-free remission in rheumatoid
arthritis: results from two large early arthritis cohorts
No relevant outcome
van Gaalen (2004)779 Association between HLA class II genes and autoantibodies to
cyclic citrullinated peptides (CCPs) influences the severity of
rheumatoid arthritis
Insufficient information on
treatment response
van Jaarsveld
(1999)300
The prognostic value of the antiperinuclear factor, anti-
citrullinated peptide antibodies and rheumatoid factor in early
rheumatoid arthritis
Not prediction of treatment
response
van Laar (2007)780 Do high levels of IgA rheumatoid factor indicate a poor
response to treatment with TNF inhibitors in patients with RA?
Commentary
van Nies (2014)781 What is the evidence for the presence of a therapeutic window
of opportunity in rheumatoid arthritis? A systematic literature
review
Review – cross-checked
van Sijl (2013)782 A novel and effective prediction model of response to rituximab
in rheumatoid arthritis
Insufficient detail reported
van Vollenhoven
(2009)783
Six-month results from the collaborative European registries for
rituximab in rheumatoid arthritis (CERERRA). Efficacy of
rituximab is highest in RF-positive patients and in those who
failed at most one prior anti-TNF
Not early RA
van Vollenhoven
(2014)784
A prediction model that identifies patients most likely to benefit
from first-line therapy with adalimumab plus methotrexate in
early rheumatoid arthritis
Insufficient detail reported
Vastesaeger (2009)78 Matrix risk model for prediction of rapid radiographic
progression in rheumatoid arthritis
Not prediction of treatment
response
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Vastesaeger (2016)785 Prediction of remission and low disease activity in disease-
modifying anti-rheumatic drug-refractory patients with
rheumatoid arthritis treated with golimumab
Not early RA
Vazquez (2007)786 Prognostic markers of clinical remission in early rheumatoid
arthritis after two years of DMARDs in a clinical setting
Not prediction of treatment
response
Velloso Feijoo (2013)787 B cell depletion therapy in a cohort of patients with seropositive
and seronegative rheumatoid arthritis
Not early RA
Ven (2014)788 Can we use ultrasound to identify rheumatoid arthritis patients
in remission who can taper their medication?
Disease duration at baseline
not reported
Verschueren (2009)789 Predictors of remission, normalized physical function, and
changes in the working situation during follow-up of patients
with early rheumatoid arthritis: an observational study
Not prediction of treatment
response
Verstappen (2005)790 Working status among Dutch patients with rheumatoid arthritis:
work disability and working conditions
Not early RA
Verstappen (2009)791 Adverse events and factors associated with toxicity in patients
with early rheumatoid arthritis treated with methotrexate
(the CAMERA study)
No relevant outcomes
Verstappen (2010)792 Working status in patients with rheumatoid arthritis, ankylosing
spondylitis and psoriatic arthritis: results from the British Society
for Rheumatology Biologics Register
Not early RA
Vesperini (2013)307 Association of tobacco exposure and reduction of radiographic
progression in early rheumatoid arthritis: results from a French
multicenter cohort
Not prediction of treatment
response
Vidal (2014)793 Influence of body mass index on disease activity and
radiographic joint damage in rheumatoid arthritis: a systematic
review and meta-analysis
Not early RA
Visman (2011)794 Effect of the application of trial inclusion criteria on the efficacy
of adalimumab therapy in a rheumatoid arthritis cohort
Not early RA
Visser (2008)795 Pretreatment serum levels of anti-cyclic citrullinated peptide
antibodies are associated with the response to methotrexate in
recent-onset arthritis
Population (UA)
Visser (2010)79 A matrix risk model for the prediction of rapid radiographic
progression in patients with rheumatoid arthritis receiving
different dynamic treatment strategies: post hoc analyses from
the BeSt study
Not prediction of treatment
response
Visvanathan (2007)311 Changes in biomarkers of inflammation and bone turnover and
associations with clinical efficacy following infliximab plus
methotrexate therapy in patients with early rheumatoid arthritis
No relevant predictors
Vital (2010)796 Serum cytokine profile predicts response to rituximab therapy in
rheumatoid arthritis
Not prediction of treatment
response
Volkov (2013)797 Monitoring anti-interleukin 6 receptor antibody treatment in
rheumatoid arthritis and prediction progressive structural
damage of the wrist joints by ultrasonography
Not early RA
Vreju (2016)798 Subclinical ultrasound synovitis in a particular joint is associated
with ultrasound evidence of bone erosions in that same joint in
rheumatoid patients in clinical remission
Not early RA
Wagner (2009)799 Serum markers associated with clinical response in methotrexate
naïve rheumatoid arthritis patients treated with golimumab, a
human anti-TNFα monoclonal antibody
Not possible to obtain paper
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Wagner (2010)800 Association of serum markers with clinical response measures in
rheumatoid arthritis patients treated with golimumab, a human
anti-TNF alpha monoclonal antibody
Not possible to obtain paper
Wang (2016)801 Short-term efficacy reliably predicts long-term clinical benefit in
rheumatoid arthritis clinical trials as demonstrated by model-
based meta-analysis
No relevant outcomes
Wang (2016)802 Relationship between baseline and early changes in C-reactive
protein and interleukin-6 levels and clinical response to
tocilizumab in rheumatoid arthritis
Not early RA
Watanabe (2013)803 Tocilizumab efficiently halts radiographic progression in patients
with rheumatoid arthritis and swollen joint counts within a year
predict long-term radiographic outcomes: three year results from
Michinoku Tocilizumab Study Group
Not early RA
Weinblatt (2006)804 Predictors of poor radiographic response in rheumatoid arthritis
subjects treated with methotrexate: preliminary analysis from the
era and tempo studies
Not prediction of treatment
response
Weinblatt (2011)805 Factors associated with radiographic progression in patients with
rheumatoid arthritis who were treated with methotrexate
Not early RA
Wessels (2007)312 A clinical pharmacogenetic model to predict the efficacy of
methotrexate monotherapy in recent-onset rheumatoid arthritis
Not prediction of treatment
response
Westhoff (2013)806 Indicators of depression are stronger predictors of work disability
in early arthritis than disease activity or response to therapy
No relevant outcomes
Wevers-De Boer
(2011)807
Remission induction therapy with methotrexate and prednisone
in patients with early rheumatoid and undifferentiated arthritis
Treatment duration of
< 6 months
Wevers-De Boer
(2012)808
Extended report: remission induction therapy with methotrexate
and prednisone in patients with early rheumatoid and
undifferentiated arthritis (the IMPROVED study)
Treatment duration of
< 6 months
Wevers-De Boer
(2012)809
Remission after one year in ACPA positive and ACPA negative
patients with early arthritis
Treatment duration of
< 6 months
Wevers-De Boer
(2013)810
Early metacarpal bone mineral density loss is predictive for
radiologic joint damage progression after 1 year in patients with
early arthritis
Combined sample of RA and
UA, analyses not reported
separately in this abstract
White (2009)811 Clinical features of disease severity and body mass index predict
outcome at 6 months in a cohort of patients with early
rheumatoid arthritis
Insufficient detail reported on
methods and treatment
Wolfe (2000)318 The effect of smoking on clinical, laboratory, and radiographic
status in rheumatoid arthritis
Not early RA
Wolfe (2012)812 Effect of body mass index on mortality and clinical status in
rheumatoid arthritis
Not early RA
Xibille (2013)813 Plasma adiponectin level and body mass index (BMI) predict
response to treatment in patients with rheumatoid arthritis
Not early RA
Xibille (2013)814 Leptin and adiponectin serum levels as predictors of treatment
response in patients with rheumatoid arthritis
Not early RA
Yamanaka (2007)815 Retrospective clinical study on the notable efficacy and related
factors of infliximab therapy in a rheumatoid arthritis
management group in Japan (RECONFIRM)
Not early RA
Yamanaka (2015)816 Trend of patient characteristics and its impact on the response
to adalimumab in patients with rheumatoid arthritis: post hoc
time-course analysis of an all-case pms in Japan
Not possible to obtain paper
Yamasaki (2014)817 Predictive marker for the long-term discontinuation of infliximab
in rheumatoid arthritis with clinical remission
Disease duration at baseline
not reported
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TABLE 33 Review 2 excluded studies with rationale (continued )
First author (date) Title Justification for exclusion
Yazici (2011)818 Greater remission rates in patients with early versus long-
standing disease in biologic-naive rheumatoid arthritis patients
treated with abatacept: a post hoc analysis of randomized
clinical trial data
Not early RA
Yoshida (2015)819 Incidence and predictors of biological antirheumatic drug
discontinuation attempts among patients with rheumatoid
arthritis in remission: a CORRONA and NinJa collaborative
cohort study
Not early RA
Yoshimi (2013)820 Ultrasonography is a potent tool for the prediction of
progressive joint destruction during clinical remission of
rheumatoid arthritis
Not early RA
Yuasa (2013)821 Treatment responses and their predictors in patients with
rheumatoid arthritis treated with biological agents
Not early RA
Zeidler (2012)822 Reply to: very early rheumatoid arthritis as a predictor of
remission: a multicentre real life prospective study
No data (comment)
Zhang (2009)823 The sensitivity to change for lower disease activity is greater
than for higher disease activity in rheumatoid arthritis trials
No relevant outcomes
Zheng (2014)824 Application of high frequency color Doppler ultrasound in the
monitoring of rheumatoid arthritis treatment
Not early RA
Zhilyaev (2014)825 Efficacy of biological treatment in cohort of rheumatoid arthritis
patients in Moscow
Not early RA
Zufferey (2013)826 Disease activity in rheumatoid arthritis patients at initiation of
biologic agents and 1 year of treatment: results from the Swiss
SCQM registry
Not early RA
UA, undifferentiated arthritis.
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TABLE 34 Additional population characteristics of included primary studies at baseline
Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Garnero (2002)102 All participants 49 (SD 12) 80 1.49 (SD 0.67) SHS erosion score:
6.3 (SD 9.5)
SHS total score: 11.9
(SD 16.6)
NR 88 23 (SD 11) NR 4.2mg/dl
(SD 6.0)
NR NR
Heimans (2013)103
BeSt
All participants 55 (SD 14)
a
68
a
1.4 (SD 0.7)
a
SHS erosion score:
3.7 (SD 5.1)
SHS total score: 6.6
(SD 8.2)
57
a
65
a
NR NR NR Smoker, n: 177
(35%)
a
NR
BMI of < 25 kg/m2 53 (SD 15) 72 1.4 (SD 0.6) NR 65 69 13 (IQR 10–19) 38mm/hour (IQR
20–58mm/hour)
20mg/l
(IQR 8–55mg/l)
Smoker, n: 88
(41%)
NR
BMI of ≥ 25 kg/m2 56 (SD 13) 64 1.4 (SD 0.7) NR 59 62 14 (IQR 9–18) 34mm/hour (IQR
18–56mm/hour)
21mg/l
(IQR 9–50mg/l)
Smoker, n: 89
(31%)
NR
Sequential
monotherapy
54 (SD 13) 68 1.4 (SD 0.7)
b
SHS erosion score:
4.1 (SD 6.2)
SHS total score: 7.3
(SD 9.5)
NR 67 NR NR NR NR NR
Step-up
combination
therapy
54 (SD 13) 71 1.4 (SD 0.6)
b
SHS erosion score:
3.5 (SD 4.3)
SHS total score: 6.3
(SD 6.9)
NR 64 NR NR NR NR NR
MTX and SSZ and
tapered prednisone
55 (SD 14) 65 1.4 (SD 0.7)
b
SHS erosion score:
3.3 (SD 4.3)
SHS total score: 5.9
(SD 6.5)
NR 65 NR NR NR NR NR
MTX and IFX 54 (SD 14) 66 1.4 (SD 0.7)
b
SHS erosion score:
3.9 (SD 5.8)
SHS total score: 7.0
(SD 10.0)
NR 64 NR NR NR NR NR
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Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Huizinga (2015)104
AVERT
All participants 47.0 (SD 12.6)
c
77.8 1.4 (SD 0.66) NR 58 95.2
c
NR NR 17.5mg/l
(SD 25.0mg/l)
c
NR NR
ABT s.c. and MTX 46.4 (SD 13.2)
c
79.8
c
1.5 (SD 0.68)
c
NR 56 95
c
NR NR 18.1mg/l
(SD 28.4mg/l)
c
NR NR
ABT s.c. 45.4 (SD 11.9)
c
76.7
c
1.4 (SD 0.66)
c
NR 55 95.7
c
NR NR 16.9mg/l
(SD 23.9mg/l)
c
NR NR
MTX 49.1 (SD 12.4)
c
76.7
c
1.4 (SD 0.65)
c
NR 64 94.8
c
NR NR 17.3mg/l
(SD 22.4mg/l)
c
NR NR
Maska (2012)105
TEAR
All participants
(with serum
cotinine at baseline
and week 48)
49.6 (SD 12.2) 73 1.2 (SD 0.4) NR NR NR 12.5 (SD 5.7) 32.8mm/hour
(SD 24.0mm/
hour)
NR See below NR
Current smokers 50.1 (SD 10.8) 67 1.3 (SD 0.4) NR NR NR 12.5 (SD 5.8) 32.6mm/hour
(SD 24.3mm/
hour)
NR Current smokers:
119 (29%)
NR
Non-smokers 49.4 (SD 12.7) 75 1.2 (SD 0.4) NR NR NR 12.4 (SD 5.7) 32.9mm/hour
(SD 23.9mm/
hour)
NR Non-smokers: 293
(71%)
NR
Mustila (2011)106
FIN-RACo
All participants 47 (SD 10)
a
63
a
0.87 (SD 0.58)
a
Erosive disease: 45%
a
71
a
65
a
13 (SD 7)
a
37mm/hour
(SD 23mm/hour)
a
NR NR NR
ACPA+ NR NR NR Erosive disease: 54% 100 83 NR NR NR NR NR
ACPA– NR NR NR Erosive disease: 22% 0 22 NR NR NR NR NR
MTX and HCQ and
SSZ in a TTT
regime
46 (SD 10) 61 0.84 (SD 0.54) Erosions in hand or
foot radiographs:
42%
NR 68 13 (SD 6) 37mm/hour
(SD 24mm/hour)
NR NR NR
cDMARD
sequential
monotherapy
in a TTT regime
(starting with SSZ)
48 (SD 11) 65 0.91 (SD 0.63) Erosions in hand or
foot radiographs:
48%
NR 62 14 (SD 7) 37mm/hour
(SD 21mm/hour)
NR NR NR
continued
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TABLE 34 Additional population characteristics of included primary studies at baseline (continued )
Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Pasero (1996)107 All participants 49.6 (SD 11.6)
a
78 NR Number of patients
with erosions: 193
a
Number of patients
without erosions: 91
a
NR NR 14.8 (SD 7.7)
a
47.2mm/hour
(SD 28.0mm/
hour)
a
8.4mg/dl
(SD 17.1mg/dl)a
NR NR
Patients with joint
erosions at
baseline
NR NR NR NR NR NR NR NR NR NR NR
Patients without
joint erosions at
baseline
NR NR NR NR NR NR NR NR NR NR NR
CsA arm 48.4 (SD 11.6) 77 NR Number of patients
with erosions: 104
Number of patients
without erosions: 37
NR NR 14.9 (SD 7.5) 46.9mm/hour
(SD 25.2mm/
hour)
8.3mg/dl
(SD 16.7mg/dl)
NR NR
Other cDMARDs
arm
50.8 (SD 11.5) 78 NR Number of patients
with erosions: 89
Number of patients
without erosions: 54
NR NR 14.7 (SD 7.8) 47.5mm/hour
(SD 30.8mm/
hour)
8.5mg/dl
(SD 17.5mg/dl)
NR NR
Rau (1998)108 All participants 55.5 (SD 9.5)
a
66 NR Mean radiographic
score (0–190): 5.2
a
Number of eroded
joints (0–38): 4.4
a
NR 61 15.2 (SD 6.9)
a
40.9mm/hour
(SD 24.0mm/
hour)
a
4.4mg/dl
(SD 4.0mg/dl)
a
NR NR
MTX 54.2 (SD 8.6) 60 NR Mean radiographic
score (0–190): 5.8
Number of eroded
joints (0–38): 4.2
NR 68 15.3 (± 6.6) 41.1mm/hour
(± 24.5mm/
hour)
4.1mg/100 ml
(± 3.6mg/
100 ml)
NR NR
GSTM 56.8 (SD 10.4) 72 NR Mean radiographic
score (0–190): 4.6
Number of eroded
joints (0–38): 4.6
NR 54 15.1 (± 7.2) 40.6mm/hour
(± 23.6mm/
hour)
4.6mg/100 ml
(± 4.4mg/
100 ml)
NR NR
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Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Seegobin (2014)109
CARDERA
All participants 54 (IQR 20–89)
a,d 69 1.6 (SD 0.7) NR 48 68 NR NR NR NR NR
ACPA+ 54.0 (IQR
46.0–64.0)
67 1.62 (IQR
1.00–2.12)
Larsen score: 7.50
(IQR 2.50–21.25)
100 79
e
NR NR NR NR NR
ACPA– 55.0 (IQR
47.0–62.0)
74 1.62 (IQR
1.12–2.12)
Larsen score: 4.50
(IQR 1.00–9.50)
0 39 NR NR NR NR NR
MTX monotherapy 54 (range
21–80)
d,f
67
f
1.5 (SD 0.7)
f
Larsen score: 7
(IQR 3–15)
f
NR 66
f
NR NR NR NR NR
CsA and MTX 53 (range
20–89)
d,f
66
f
1.7 (SD 0.7)
f
Larsen score: 8
(IQR 3–23)
f
NR 65
f
NR NR NR NR NR
Prednisolone and
MTX
54 (range
27–84)
d,f
66
f
1.6 (0.7)
f
Larsen score: 6
(IQR 2–20)
f
NR 66
f
NR NR NR NR NR
Triple therapy 55 (range
20–78)
d,f
67
f
1.6 (SD 0.7) Larsen score: 5
(IQR 2–14)
f
NR 72
f
NR NR NR NR NR
Smolen
(2006)100
Vastesaeger
(2009)78
ASPIRE
All participants 50 (SD 13)
a
71 1.5 (SD 0.6) 82.5% with erosions
a
NR 72
a
22 (SD 10)
a
44mm/hour
(SD 28mm/hour)
a
3.0mg/dl
(SD 3.1mg/dl)
a
NR NR
MTX 50 (SD 13) 75 1.5 (SD 0.6)
a
80% with erosions NR 71 22 (SD 11) 43mm/hour
(SD 28mm/hour)
2.6mg/dl
(SD 2.9mg/dl)
NR NR
IFX (all doses) 50 (SD 13)
a
70 1.5 (SD 0.6) 83.5% with erosions
a
NR 72
a
22 (SD 10)
a
44mm/hour
(SD 28mm/hour)
a
3.0mg/dl
(SD 3.3mg/dl)
a
NR NR
MTX and IFX
3mg/kg
51 (SD 12) 71 1.5 (SD 0.7)
a
84% with erosions NR 71 21 (SD 10) 45mm/hour
(SD 29mm/hour)
2.9mg/dl
(SD 3.3mg/dl)
NR NR
MTX and IFX
6mg/kg
50 (SD 13) 68 1.5 (SD 0.6) 83% with erosions NR 73 22 (SD 11) 44mm/hour
(SD 27mm/hour)
3.0mg/l
(SD 3.4mg/dl)
NR NR
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
6
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
6
6
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
8
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
A
rch
er
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
2
7
7
TABLE 34 Additional population characteristics of included primary studies at baseline (continued )
Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Sokolove (2015)110
AMPLE
All patients NR NR NR NR 76 NR NR NR NR NR NR
Anti-CCP2
negative
ABT: 52
(IQR 24.0–80.0)
ADA: 58
(IQR 21.0–83.0)
ABT: 84.8
ADA: 85.2
ABT: 1.3
(IQR 0.0–2.9)
ADA: 1.4
(IQR 0.0–2.6)
NR 0 ABT: 42.4
ADA: 51.9
NR NR ABT: 0.6mg/dl
(IQR 0.0–
10.4mg/dl)
ADA: 0.6mg/dl
(IQR 0.0–
42mg/dl)
ABT:
l Never: 52%
l Past: 21%
l Current: 27%
ADA:
l Never: 57%
l Past: 30%
l Current: 13%
NR
Anti-CCP2
positive; Q1
ABT: 50
(IQR 22.0–70.0)
ADA: 50
(IQR 19.0–78.0)
ABT: 88.1
ADA: 83.6
ABT: 1.4
(IQR 0.0–2.5)
ADA: 1.3
(IQR 0.0–2.5)
NR 100 ABT: 85.7
ADA: 92.7
NR NR ABT: 0.8mg/dl
(IQR 0.1–
8.4mg/dl)
ADA: 0.6mg/dl
(IQR 0.0–
4.8mg/dl)
ABT:
l Never: 64%
l Past: 14%
l Current: 21%
ADA:
l Never: 55%
l Past: 20%
l Current: 26%
NR
Anti-CCP2
positive; Q2
ABT: 52
(IQR 21.0–78.0)
ADA: 49
(IQR 22.0–73.0)
ABT: 80.4
ADA: 87.0
ABT: 1.7
(IQR 0.0–2.8)
ADA: 1.6
(IQR 0.0–2.9)
NR 100 ABT: 98.0
ADA: 93.5
NR NR ABT: 0.9mg/dl
(IQR 0.0–
9.4mg/dl)
ADA: 1.3mg/dl
(IQR 0.1–
5.8mg/dl)
ABT:
l Never: 53%
l Past: 16%
l Current: 31%
ADA:
l Never: 59%
l Past: 20%
l Current: 22%
NR
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Author (year),
name of trial
or cohort
(if relevant)
Characteristic
Group/
treatment arm
Mean/median
age (years)
Sex
(% female)
Mean/median
HAQ score at
baseline
Mean/median
baseline erosions
on radiograph or
percentage of
erosions
ACPA
+/anti-CCP-
positive at
baseline
(%)
RF positive
at baseline
(%)
Mean/median
SJC at baseline
Mean/median
ESR at baseline
Mean/median
CRP levels at
baseline
Baseline
smoking status
Vascularity of
synovium using
PD ultrasound
Anti-CCP2 positive;
Q3
ABT: 47.5
(IQR 25.0–73.0)
ADA: 52
(IQR 26.0–78.0)
ABT: 82.6
ADA: 80.4
ABT: 1.4
(IQR 0.0–2.8)
ADA: 1.6
(IQR 0.0–3.0)
NR 100 ABT: 100.0
ADA: 96.1
NR NR ABT: 0.9mg/dl
(IQR 0.1–
11.3mg/dl)
ADA: 1.0mg/dl
(IQR 0.0–
9.0mg/dl)
ABT:
l Never: 57%
l Past: 11%
l Current: 33%
ADA:
l Never: 57%
l Past: 18%
l Current: 26%
NR
Anti-CCP2 positive;
Q4
ABT: 51.5
(IQR 19.0–70.0)
ADA: 52
(IQR 27.0–85.0)
ABT: 78.3
ADA: 72.5
ABT: 1.6
(IQR 0.0–2.9)
ADA: 1.8
(IQR 0.0–2.8)
NR 100 ABT: 95.7
ADA: 100.0
NR NR ABT: 0.9mg/dl
(IQR 0.0–
13.9mg/dl)
ADA: 0.7mg/dl
(IQR 0.0–
11.8mg/dl)
ABT:
l Never: 41%
l Past: 35%
l Current: 24%
ADA:
l Never: 57%
l Past: 16%
l Current: 28%
NR
Taylor (2004)101 All 53.3 (SD 12.9)
a
75
a
NR Total SHS: 8.1 (11.8)
a
NR NR 9.2 (SD 3.2)
a
31.6mm/hour
(SD 20.3mm/
hour)
a
18.9mg/dl
(SD 23.0mg/dl)
a
NR Total CDA: 8597
pixels (SD 6644)
a
MTX 51.4 (SD 14.0) 67
a
NR Total SHS: 7.1 (7.8) NR NR 8.8 (SD 2.7) 35.7mm/hour
(SD 21.2)
25.0mg/dl
(SD 25.4mg/dl)
NR Total CDA: 8212
pixels (SD 6479)
IFX and MTX 55.2 (SD 11.8) 83
a
NR Total SHS: 9.0 (15.9) NR NR 9.5 (SD 3.8) 27.4mm/hour
(SD 19.5mm/
hour)
12.7mg/dl
(SD 20.7mg/dl)
NR Total CDA: 9072
pixels (SD 6718)
ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/peptide anti-body positive; AMPLE, abatacept vs. adalimumab in biologic naive RA patients with background MTX; anti-CCP2, anti-cyclic citrullinated
peptide-2; AVERT, Assessing Very Early Rheumatoid arthritis Treatment; CARDERA, Combination Anti-Rheumatic Drugs in Early RA; CDA, colour Doppler area; FIN-RACo, Finnish Rheumatoid Arthritis Combination Therapy; NR, not reported;
PD, power Doppler; Q1/Q2/Q3/Q4, quartile 1/quartile 2/quartile 3/quartile 4; s.c., subcutaneous administration; TEAR, Treatment of Early Aggressive Rheumatoid arthritis.
a Calculated.
b D-HAQ (Dutch version of the Health Assessment Questionnaire).
c From Emery et al. (2015).116
d Mean (range).
e p< 0.001 vs. ACPA–.
f From Choy et al. (2008).114
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Appendix 10 Interaction between baseline
predictor and treatment figures
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FIGURE 10 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 1 year from
Mustila et al.106 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 11 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 2 years from
Mustila et al.106 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 12 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 3 years from
Mustila et al.106 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 13 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 4 years from
Mustila et al.106 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 14 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 5 years from
Mustila et al.106 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 16 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 12 months from
Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 15 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 6 months from
Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 17 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 18 months from
Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 18 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 24 months from
Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive.
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FIGURE 19 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 6 months
(CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 20 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 12 months
(CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 21 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 18 months
(CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 22 Anticitrullinated protein/peptide anti-body status–treatment interaction on erosions at 24 months
(CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 23 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 6 months
from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive.
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FIGURE 24 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 12 months
from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive.
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FIGURE 25 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 18 months
from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive.
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FIGURE 26 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 24 months
from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive.
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FIGURE 27 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at
6 months (CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 28 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at
12 months (CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 29 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at
18 months (CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 30 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at
24 months (CsA vs. placebo) from Seegobin et al.109 ACPA–, anticitrullinated protein/peptide anti-body negative;
ACPA+, anticitrullinated protein/peptide anti-body positive.
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FIGURE 31 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 6 months
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 32 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 1 year
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 33 Anticitrullinated protein/peptide anti-body status–treatment interaction on disease activity at 2 years
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 34 Anticitrullinated protein/peptide anti-body status–treatment interaction on physical function at 6 months
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated protein/
peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 35 Anticitrullinated protein/peptide anti-body status–treatment interaction on physical function at 1 year
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 36 Anticitrullinated protein/peptide anti-body status–treatment interaction on physical function at 2 years
from Sokolove et al.110 ACPA–, anticitrullinated protein/peptide anti-body negative; ACPA+, anticitrullinated
protein/peptide anti-body positive; Q, quartile; s.c., subcutaneous.
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FIGURE 37 Smoking status–treatment interaction on disease activity at 1–2 years from Maska et al.105
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FIGURE 38 Smoking status–treatment interaction on disease activity at 24 weeks from Maska et al.105
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FIGURE 39 Smoking status–treatment interaction on disease activity at 48 weeks from Maska et al.105
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FIGURE 40 Smoking status–treatment interaction on disease activity at 102 weeks from Maska et al.105
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FIGURE 41 Erosion status–treatment interaction on radiographic progression (progression in the eroded joint
count) at 12 months from Pasero et al.107 EJC, eroded joint count.
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FIGURE 42 Erosion status–treatment interaction on radiographic progression (progression in the damage score) at
12 months from Pasero et al.107
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FIGURE 43 Radiographic score tertile–treatment interaction on radiographic progression at 54 weeks from
Smolen et al.100
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FIGURE 44 C-reactive protein tertile–treatment interaction on radiographic progression at 54 weeks from
Smolen et al.100
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FIGURE 45 Erythrocyte sedimentation rate tertile–treatment interaction on radiographic progression at 54 weeks
from Smolen et al.100
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